0001821825-23-000013.txt : 20231103 0001821825-23-000013.hdr.sgml : 20231103 20231103075259 ACCESSION NUMBER: 0001821825-23-000013 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231103 DATE AS OF CHANGE: 20231103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Organon & Co. CENTRAL INDEX KEY: 0001821825 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464838035 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40235 FILM NUMBER: 231374514 BUSINESS ADDRESS: STREET 1: 30 HUDSON STREET STREET 2: FL 33 CITY: JERSEY CITY STATE: NJ ZIP: 07302 BUSINESS PHONE: 551-430-6000 MAIL ADDRESS: STREET 1: 30 HUDSON STREET STREET 2: FL 33 CITY: JERSEY CITY STATE: NJ ZIP: 07302 10-Q 1 ogn-20230930.htm 10-Q ogn-20230930
0001821825FALSE12/312023Q300018218252023-01-012023-09-3000018218252023-10-27xbrli:shares00018218252023-07-012023-09-30iso4217:USD00018218252022-07-012022-09-3000018218252022-01-012022-09-30iso4217:USDxbrli:shares00018218252023-09-3000018218252022-12-310001821825us-gaap:CommonStockMember2022-06-300001821825us-gaap:AdditionalPaidInCapitalMember2022-06-300001821825us-gaap:RetainedEarningsMember2022-06-300001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000018218252022-06-300001821825us-gaap:RetainedEarningsMember2022-07-012022-09-300001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001821825us-gaap:CommonStockMember2022-07-012022-09-300001821825us-gaap:CommonStockMember2022-09-300001821825us-gaap:AdditionalPaidInCapitalMember2022-09-300001821825us-gaap:RetainedEarningsMember2022-09-300001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000018218252022-09-300001821825us-gaap:CommonStockMember2023-06-300001821825us-gaap:AdditionalPaidInCapitalMember2023-06-300001821825us-gaap:RetainedEarningsMember2023-06-300001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000018218252023-06-300001821825us-gaap:RetainedEarningsMember2023-07-012023-09-300001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001821825us-gaap:CommonStockMember2023-07-012023-09-300001821825us-gaap:CommonStockMember2023-09-300001821825us-gaap:AdditionalPaidInCapitalMember2023-09-300001821825us-gaap:RetainedEarningsMember2023-09-300001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001821825us-gaap:CommonStockMember2021-12-310001821825us-gaap:AdditionalPaidInCapitalMember2021-12-310001821825us-gaap:RetainedEarningsMember2021-12-310001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100018218252021-12-310001821825us-gaap:RetainedEarningsMember2022-01-012022-09-300001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001821825us-gaap:CommonStockMember2022-01-012022-09-300001821825us-gaap:CommonStockMember2022-12-310001821825us-gaap:AdditionalPaidInCapitalMember2022-12-310001821825us-gaap:RetainedEarningsMember2022-12-310001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001821825us-gaap:RetainedEarningsMember2023-01-012023-09-300001821825us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001821825us-gaap:CommonStockMember2023-01-012023-09-30ogn:segmentogn:manufacturingFacility0001821825ogn:OncologyBiosimilarMember2023-09-30ogn:country0001821825ogn:ImmunologyBiosimilarMember2023-09-300001821825country:CA2023-09-30ogn:product0001821825country:US2023-09-300001821825ogn:ClariaMedicalIncMember2023-01-310001821825ogn:ClariaMedicalIncMember2023-09-300001821825us-gaap:StockCompensationPlanMember2023-07-012023-09-300001821825us-gaap:StockCompensationPlanMember2022-07-012022-09-300001821825us-gaap:StockCompensationPlanMember2023-01-012023-09-300001821825us-gaap:StockCompensationPlanMember2022-01-012022-09-300001821825country:USogn:NexplanonImplanonNXTMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:NexplanonImplanonNXTMember2023-07-012023-09-300001821825ogn:NexplanonImplanonNXTMember2023-07-012023-09-300001821825country:USogn:NexplanonImplanonNXTMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:NexplanonImplanonNXTMember2022-07-012022-09-300001821825ogn:NexplanonImplanonNXTMember2022-07-012022-09-300001821825country:USogn:NexplanonImplanonNXTMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:NexplanonImplanonNXTMember2023-01-012023-09-300001821825ogn:NexplanonImplanonNXTMember2023-01-012023-09-300001821825country:USogn:NexplanonImplanonNXTMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:NexplanonImplanonNXTMember2022-01-012022-09-300001821825ogn:NexplanonImplanonNXTMember2022-01-012022-09-300001821825country:USogn:FollistimAQMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:FollistimAQMember2023-07-012023-09-300001821825ogn:FollistimAQMember2023-07-012023-09-300001821825country:USogn:FollistimAQMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:FollistimAQMember2022-07-012022-09-300001821825ogn:FollistimAQMember2022-07-012022-09-300001821825country:USogn:FollistimAQMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:FollistimAQMember2023-01-012023-09-300001821825ogn:FollistimAQMember2023-01-012023-09-300001821825country:USogn:FollistimAQMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:FollistimAQMember2022-01-012022-09-300001821825ogn:FollistimAQMember2022-01-012022-09-300001821825country:USogn:NuvaRingMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:NuvaRingMember2023-07-012023-09-300001821825ogn:NuvaRingMember2023-07-012023-09-300001821825country:USogn:NuvaRingMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:NuvaRingMember2022-07-012022-09-300001821825ogn:NuvaRingMember2022-07-012022-09-300001821825country:USogn:NuvaRingMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:NuvaRingMember2023-01-012023-09-300001821825ogn:NuvaRingMember2023-01-012023-09-300001821825country:USogn:NuvaRingMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:NuvaRingMember2022-01-012022-09-300001821825ogn:NuvaRingMember2022-01-012022-09-300001821825country:USogn:GanirelixAcetateInjectionMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:GanirelixAcetateInjectionMember2023-07-012023-09-300001821825ogn:GanirelixAcetateInjectionMember2023-07-012023-09-300001821825country:USogn:GanirelixAcetateInjectionMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:GanirelixAcetateInjectionMember2022-07-012022-09-300001821825ogn:GanirelixAcetateInjectionMember2022-07-012022-09-300001821825country:USogn:GanirelixAcetateInjectionMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:GanirelixAcetateInjectionMember2023-01-012023-09-300001821825ogn:GanirelixAcetateInjectionMember2023-01-012023-09-300001821825country:USogn:GanirelixAcetateInjectionMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:GanirelixAcetateInjectionMember2022-01-012022-09-300001821825ogn:GanirelixAcetateInjectionMember2022-01-012022-09-300001821825country:USogn:MarvelonMercilonMember2023-07-012023-09-300001821825ogn:MarvelonMercilonMemberus-gaap:NonUsMember2023-07-012023-09-300001821825ogn:MarvelonMercilonMember2023-07-012023-09-300001821825country:USogn:MarvelonMercilonMember2022-07-012022-09-300001821825ogn:MarvelonMercilonMemberus-gaap:NonUsMember2022-07-012022-09-300001821825ogn:MarvelonMercilonMember2022-07-012022-09-300001821825country:USogn:MarvelonMercilonMember2023-01-012023-09-300001821825ogn:MarvelonMercilonMemberus-gaap:NonUsMember2023-01-012023-09-300001821825ogn:MarvelonMercilonMember2023-01-012023-09-300001821825country:USogn:MarvelonMercilonMember2022-01-012022-09-300001821825ogn:MarvelonMercilonMemberus-gaap:NonUsMember2022-01-012022-09-300001821825ogn:MarvelonMercilonMember2022-01-012022-09-300001821825country:USogn:JadaMember2023-07-012023-09-300001821825ogn:JadaMemberus-gaap:NonUsMember2023-07-012023-09-300001821825ogn:JadaMember2023-07-012023-09-300001821825country:USogn:JadaMember2022-07-012022-09-300001821825ogn:JadaMemberus-gaap:NonUsMember2022-07-012022-09-300001821825ogn:JadaMember2022-07-012022-09-300001821825country:USogn:JadaMember2023-01-012023-09-300001821825ogn:JadaMemberus-gaap:NonUsMember2023-01-012023-09-300001821825ogn:JadaMember2023-01-012023-09-300001821825country:USogn:JadaMember2022-01-012022-09-300001821825ogn:JadaMemberus-gaap:NonUsMember2022-01-012022-09-300001821825ogn:JadaMember2022-01-012022-09-300001821825country:USogn:OtherWomensHealthMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:OtherWomensHealthMember2023-07-012023-09-300001821825ogn:OtherWomensHealthMember2023-07-012023-09-300001821825country:USogn:OtherWomensHealthMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:OtherWomensHealthMember2022-07-012022-09-300001821825ogn:OtherWomensHealthMember2022-07-012022-09-300001821825country:USogn:OtherWomensHealthMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:OtherWomensHealthMember2023-01-012023-09-300001821825ogn:OtherWomensHealthMember2023-01-012023-09-300001821825country:USogn:OtherWomensHealthMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:OtherWomensHealthMember2022-01-012022-09-300001821825ogn:OtherWomensHealthMember2022-01-012022-09-300001821825country:USogn:RenflexisMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:RenflexisMember2023-07-012023-09-300001821825ogn:RenflexisMember2023-07-012023-09-300001821825country:USogn:RenflexisMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:RenflexisMember2022-07-012022-09-300001821825ogn:RenflexisMember2022-07-012022-09-300001821825country:USogn:RenflexisMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:RenflexisMember2023-01-012023-09-300001821825ogn:RenflexisMember2023-01-012023-09-300001821825country:USogn:RenflexisMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:RenflexisMember2022-01-012022-09-300001821825ogn:RenflexisMember2022-01-012022-09-300001821825country:USogn:OntruzantMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:OntruzantMember2023-07-012023-09-300001821825ogn:OntruzantMember2023-07-012023-09-300001821825country:USogn:OntruzantMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:OntruzantMember2022-07-012022-09-300001821825ogn:OntruzantMember2022-07-012022-09-300001821825country:USogn:OntruzantMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:OntruzantMember2023-01-012023-09-300001821825ogn:OntruzantMember2023-01-012023-09-300001821825country:USogn:OntruzantMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:OntruzantMember2022-01-012022-09-300001821825ogn:OntruzantMember2022-01-012022-09-300001821825country:USogn:BrenzysMember2023-07-012023-09-300001821825ogn:BrenzysMemberus-gaap:NonUsMember2023-07-012023-09-300001821825ogn:BrenzysMember2023-07-012023-09-300001821825country:USogn:BrenzysMember2022-07-012022-09-300001821825ogn:BrenzysMemberus-gaap:NonUsMember2022-07-012022-09-300001821825ogn:BrenzysMember2022-07-012022-09-300001821825country:USogn:BrenzysMember2023-01-012023-09-300001821825ogn:BrenzysMemberus-gaap:NonUsMember2023-01-012023-09-300001821825ogn:BrenzysMember2023-01-012023-09-300001821825country:USogn:BrenzysMember2022-01-012022-09-300001821825ogn:BrenzysMemberus-gaap:NonUsMember2022-01-012022-09-300001821825ogn:BrenzysMember2022-01-012022-09-300001821825country:USogn:AybintioMember2023-07-012023-09-300001821825ogn:AybintioMemberus-gaap:NonUsMember2023-07-012023-09-300001821825ogn:AybintioMember2023-07-012023-09-300001821825country:USogn:AybintioMember2022-07-012022-09-300001821825ogn:AybintioMemberus-gaap:NonUsMember2022-07-012022-09-300001821825ogn:AybintioMember2022-07-012022-09-300001821825country:USogn:AybintioMember2023-01-012023-09-300001821825ogn:AybintioMemberus-gaap:NonUsMember2023-01-012023-09-300001821825ogn:AybintioMember2023-01-012023-09-300001821825country:USogn:AybintioMember2022-01-012022-09-300001821825ogn:AybintioMemberus-gaap:NonUsMember2022-01-012022-09-300001821825ogn:AybintioMember2022-01-012022-09-300001821825country:USogn:HadlimaMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:HadlimaMember2023-07-012023-09-300001821825ogn:HadlimaMember2023-07-012023-09-300001821825country:USogn:HadlimaMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:HadlimaMember2022-07-012022-09-300001821825ogn:HadlimaMember2022-07-012022-09-300001821825country:USogn:HadlimaMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:HadlimaMember2023-01-012023-09-300001821825ogn:HadlimaMember2023-01-012023-09-300001821825country:USogn:HadlimaMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:HadlimaMember2022-01-012022-09-300001821825ogn:HadlimaMember2022-01-012022-09-300001821825country:USogn:ZetiaMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:ZetiaMember2023-07-012023-09-300001821825ogn:ZetiaMember2023-07-012023-09-300001821825country:USogn:ZetiaMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:ZetiaMember2022-07-012022-09-300001821825ogn:ZetiaMember2022-07-012022-09-300001821825country:USogn:ZetiaMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:ZetiaMember2023-01-012023-09-300001821825ogn:ZetiaMember2023-01-012023-09-300001821825country:USogn:ZetiaMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:ZetiaMember2022-01-012022-09-300001821825ogn:ZetiaMember2022-01-012022-09-300001821825country:USogn:VytorinMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:VytorinMember2023-07-012023-09-300001821825ogn:VytorinMember2023-07-012023-09-300001821825country:USogn:VytorinMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:VytorinMember2022-07-012022-09-300001821825ogn:VytorinMember2022-07-012022-09-300001821825country:USogn:VytorinMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:VytorinMember2023-01-012023-09-300001821825ogn:VytorinMember2023-01-012023-09-300001821825country:USogn:VytorinMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:VytorinMember2022-01-012022-09-300001821825ogn:VytorinMember2022-01-012022-09-300001821825country:USogn:AtozetMember2023-07-012023-09-300001821825ogn:AtozetMemberus-gaap:NonUsMember2023-07-012023-09-300001821825ogn:AtozetMember2023-07-012023-09-300001821825country:USogn:AtozetMember2022-07-012022-09-300001821825ogn:AtozetMemberus-gaap:NonUsMember2022-07-012022-09-300001821825ogn:AtozetMember2022-07-012022-09-300001821825country:USogn:AtozetMember2023-01-012023-09-300001821825ogn:AtozetMemberus-gaap:NonUsMember2023-01-012023-09-300001821825ogn:AtozetMember2023-01-012023-09-300001821825country:USogn:AtozetMember2022-01-012022-09-300001821825ogn:AtozetMemberus-gaap:NonUsMember2022-01-012022-09-300001821825ogn:AtozetMember2022-01-012022-09-300001821825country:USogn:RosuzetMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:RosuzetMember2023-07-012023-09-300001821825ogn:RosuzetMember2023-07-012023-09-300001821825country:USogn:RosuzetMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:RosuzetMember2022-07-012022-09-300001821825ogn:RosuzetMember2022-07-012022-09-300001821825country:USogn:RosuzetMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:RosuzetMember2023-01-012023-09-300001821825ogn:RosuzetMember2023-01-012023-09-300001821825country:USogn:RosuzetMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:RosuzetMember2022-01-012022-09-300001821825ogn:RosuzetMember2022-01-012022-09-300001821825country:USogn:CozaarHyzaarMember2023-07-012023-09-300001821825ogn:CozaarHyzaarMemberus-gaap:NonUsMember2023-07-012023-09-300001821825ogn:CozaarHyzaarMember2023-07-012023-09-300001821825country:USogn:CozaarHyzaarMember2022-07-012022-09-300001821825ogn:CozaarHyzaarMemberus-gaap:NonUsMember2022-07-012022-09-300001821825ogn:CozaarHyzaarMember2022-07-012022-09-300001821825country:USogn:CozaarHyzaarMember2023-01-012023-09-300001821825ogn:CozaarHyzaarMemberus-gaap:NonUsMember2023-01-012023-09-300001821825ogn:CozaarHyzaarMember2023-01-012023-09-300001821825country:USogn:CozaarHyzaarMember2022-01-012022-09-300001821825ogn:CozaarHyzaarMemberus-gaap:NonUsMember2022-01-012022-09-300001821825ogn:CozaarHyzaarMember2022-01-012022-09-300001821825country:USogn:OtherCardiovascularMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:OtherCardiovascularMember2023-07-012023-09-300001821825ogn:OtherCardiovascularMember2023-07-012023-09-300001821825country:USogn:OtherCardiovascularMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:OtherCardiovascularMember2022-07-012022-09-300001821825ogn:OtherCardiovascularMember2022-07-012022-09-300001821825country:USogn:OtherCardiovascularMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:OtherCardiovascularMember2023-01-012023-09-300001821825ogn:OtherCardiovascularMember2023-01-012023-09-300001821825country:USogn:OtherCardiovascularMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:OtherCardiovascularMember2022-01-012022-09-300001821825ogn:OtherCardiovascularMember2022-01-012022-09-300001821825country:USogn:SingulairMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:SingulairMember2023-07-012023-09-300001821825ogn:SingulairMember2023-07-012023-09-300001821825country:USogn:SingulairMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:SingulairMember2022-07-012022-09-300001821825ogn:SingulairMember2022-07-012022-09-300001821825country:USogn:SingulairMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:SingulairMember2023-01-012023-09-300001821825ogn:SingulairMember2023-01-012023-09-300001821825country:USogn:SingulairMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:SingulairMember2022-01-012022-09-300001821825ogn:SingulairMember2022-01-012022-09-300001821825country:USogn:NasonexMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:NasonexMember2023-07-012023-09-300001821825ogn:NasonexMember2023-07-012023-09-300001821825country:USogn:NasonexMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:NasonexMember2022-07-012022-09-300001821825ogn:NasonexMember2022-07-012022-09-300001821825country:USogn:NasonexMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:NasonexMember2023-01-012023-09-300001821825ogn:NasonexMember2023-01-012023-09-300001821825country:USogn:NasonexMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:NasonexMember2022-01-012022-09-300001821825ogn:NasonexMember2022-01-012022-09-300001821825country:USogn:DuleraMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:DuleraMember2023-07-012023-09-300001821825ogn:DuleraMember2023-07-012023-09-300001821825country:USogn:DuleraMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:DuleraMember2022-07-012022-09-300001821825ogn:DuleraMember2022-07-012022-09-300001821825country:USogn:DuleraMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:DuleraMember2023-01-012023-09-300001821825ogn:DuleraMember2023-01-012023-09-300001821825country:USogn:DuleraMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:DuleraMember2022-01-012022-09-300001821825ogn:DuleraMember2022-01-012022-09-300001821825country:USogn:ClarinexMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:ClarinexMember2023-07-012023-09-300001821825ogn:ClarinexMember2023-07-012023-09-300001821825country:USogn:ClarinexMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:ClarinexMember2022-07-012022-09-300001821825ogn:ClarinexMember2022-07-012022-09-300001821825country:USogn:ClarinexMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:ClarinexMember2023-01-012023-09-300001821825ogn:ClarinexMember2023-01-012023-09-300001821825country:USogn:ClarinexMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:ClarinexMember2022-01-012022-09-300001821825ogn:ClarinexMember2022-01-012022-09-300001821825country:USogn:OtherRespiratoryMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:OtherRespiratoryMember2023-07-012023-09-300001821825ogn:OtherRespiratoryMember2023-07-012023-09-300001821825country:USogn:OtherRespiratoryMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:OtherRespiratoryMember2022-07-012022-09-300001821825ogn:OtherRespiratoryMember2022-07-012022-09-300001821825country:USogn:OtherRespiratoryMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:OtherRespiratoryMember2023-01-012023-09-300001821825ogn:OtherRespiratoryMember2023-01-012023-09-300001821825country:USogn:OtherRespiratoryMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:OtherRespiratoryMember2022-01-012022-09-300001821825ogn:OtherRespiratoryMember2022-01-012022-09-300001821825country:USogn:ArcoxiaMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:ArcoxiaMember2023-07-012023-09-300001821825ogn:ArcoxiaMember2023-07-012023-09-300001821825country:USogn:ArcoxiaMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:ArcoxiaMember2022-07-012022-09-300001821825ogn:ArcoxiaMember2022-07-012022-09-300001821825country:USogn:ArcoxiaMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:ArcoxiaMember2023-01-012023-09-300001821825ogn:ArcoxiaMember2023-01-012023-09-300001821825country:USogn:ArcoxiaMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:ArcoxiaMember2022-01-012022-09-300001821825ogn:ArcoxiaMember2022-01-012022-09-300001821825country:USogn:FosamaxMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:FosamaxMember2023-07-012023-09-300001821825ogn:FosamaxMember2023-07-012023-09-300001821825country:USogn:FosamaxMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:FosamaxMember2022-07-012022-09-300001821825ogn:FosamaxMember2022-07-012022-09-300001821825country:USogn:FosamaxMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:FosamaxMember2023-01-012023-09-300001821825ogn:FosamaxMember2023-01-012023-09-300001821825country:USogn:FosamaxMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:FosamaxMember2022-01-012022-09-300001821825ogn:FosamaxMember2022-01-012022-09-300001821825country:USogn:DiprospanMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:DiprospanMember2023-07-012023-09-300001821825ogn:DiprospanMember2023-07-012023-09-300001821825country:USogn:DiprospanMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:DiprospanMember2022-07-012022-09-300001821825ogn:DiprospanMember2022-07-012022-09-300001821825country:USogn:DiprospanMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:DiprospanMember2023-01-012023-09-300001821825ogn:DiprospanMember2023-01-012023-09-300001821825country:USogn:DiprospanMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:DiprospanMember2022-01-012022-09-300001821825ogn:DiprospanMember2022-01-012022-09-300001821825country:USogn:OtherNonOpiodPainBoneAndDermatologyMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:OtherNonOpiodPainBoneAndDermatologyMember2023-07-012023-09-300001821825ogn:OtherNonOpiodPainBoneAndDermatologyMember2023-07-012023-09-300001821825country:USogn:OtherNonOpiodPainBoneAndDermatologyMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:OtherNonOpiodPainBoneAndDermatologyMember2022-07-012022-09-300001821825ogn:OtherNonOpiodPainBoneAndDermatologyMember2022-07-012022-09-300001821825country:USogn:OtherNonOpiodPainBoneAndDermatologyMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:OtherNonOpiodPainBoneAndDermatologyMember2023-01-012023-09-300001821825ogn:OtherNonOpiodPainBoneAndDermatologyMember2023-01-012023-09-300001821825country:USogn:OtherNonOpiodPainBoneAndDermatologyMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:OtherNonOpiodPainBoneAndDermatologyMember2022-01-012022-09-300001821825ogn:OtherNonOpiodPainBoneAndDermatologyMember2022-01-012022-09-300001821825country:USogn:ProscarMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:ProscarMember2023-07-012023-09-300001821825ogn:ProscarMember2023-07-012023-09-300001821825country:USogn:ProscarMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:ProscarMember2022-07-012022-09-300001821825ogn:ProscarMember2022-07-012022-09-300001821825country:USogn:ProscarMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:ProscarMember2023-01-012023-09-300001821825ogn:ProscarMember2023-01-012023-09-300001821825country:USogn:ProscarMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:ProscarMember2022-01-012022-09-300001821825ogn:ProscarMember2022-01-012022-09-300001821825country:USogn:PropeciaMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:PropeciaMember2023-07-012023-09-300001821825ogn:PropeciaMember2023-07-012023-09-300001821825country:USogn:PropeciaMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:PropeciaMember2022-07-012022-09-300001821825ogn:PropeciaMember2022-07-012022-09-300001821825country:USogn:PropeciaMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:PropeciaMember2023-01-012023-09-300001821825ogn:PropeciaMember2023-01-012023-09-300001821825country:USogn:PropeciaMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:PropeciaMember2022-01-012022-09-300001821825ogn:PropeciaMember2022-01-012022-09-300001821825country:USogn:OtherSundryEstablishedBrandsMember2023-07-012023-09-300001821825us-gaap:NonUsMemberogn:OtherSundryEstablishedBrandsMember2023-07-012023-09-300001821825ogn:OtherSundryEstablishedBrandsMember2023-07-012023-09-300001821825country:USogn:OtherSundryEstablishedBrandsMember2022-07-012022-09-300001821825us-gaap:NonUsMemberogn:OtherSundryEstablishedBrandsMember2022-07-012022-09-300001821825ogn:OtherSundryEstablishedBrandsMember2022-07-012022-09-300001821825country:USogn:OtherSundryEstablishedBrandsMember2023-01-012023-09-300001821825us-gaap:NonUsMemberogn:OtherSundryEstablishedBrandsMember2023-01-012023-09-300001821825ogn:OtherSundryEstablishedBrandsMember2023-01-012023-09-300001821825country:USogn:OtherSundryEstablishedBrandsMember2022-01-012022-09-300001821825us-gaap:NonUsMemberogn:OtherSundryEstablishedBrandsMember2022-01-012022-09-300001821825ogn:OtherSundryEstablishedBrandsMember2022-01-012022-09-300001821825country:USogn:OtherSundryProductsMember2023-07-012023-09-300001821825ogn:OtherSundryProductsMemberus-gaap:NonUsMember2023-07-012023-09-300001821825ogn:OtherSundryProductsMember2023-07-012023-09-300001821825country:USogn:OtherSundryProductsMember2022-07-012022-09-300001821825ogn:OtherSundryProductsMemberus-gaap:NonUsMember2022-07-012022-09-300001821825ogn:OtherSundryProductsMember2022-07-012022-09-300001821825country:USogn:OtherSundryProductsMember2023-01-012023-09-300001821825ogn:OtherSundryProductsMemberus-gaap:NonUsMember2023-01-012023-09-300001821825ogn:OtherSundryProductsMember2023-01-012023-09-300001821825country:USogn:OtherSundryProductsMember2022-01-012022-09-300001821825ogn:OtherSundryProductsMemberus-gaap:NonUsMember2022-01-012022-09-300001821825ogn:OtherSundryProductsMember2022-01-012022-09-300001821825country:US2023-07-012023-09-300001821825us-gaap:NonUsMember2023-07-012023-09-300001821825country:US2022-07-012022-09-300001821825us-gaap:NonUsMember2022-07-012022-09-300001821825country:US2023-01-012023-09-300001821825us-gaap:NonUsMember2023-01-012023-09-300001821825country:US2022-01-012022-09-300001821825us-gaap:NonUsMember2022-01-012022-09-300001821825ogn:EuropeAndCanadaMember2023-07-012023-09-300001821825ogn:EuropeAndCanadaMember2022-07-012022-09-300001821825ogn:EuropeAndCanadaMember2023-01-012023-09-300001821825ogn:EuropeAndCanadaMember2022-01-012022-09-300001821825ogn:AsiaPacificAndJapanMember2023-07-012023-09-300001821825ogn:AsiaPacificAndJapanMember2022-07-012022-09-300001821825ogn:AsiaPacificAndJapanMember2023-01-012023-09-300001821825ogn:AsiaPacificAndJapanMember2022-01-012022-09-300001821825country:CN2023-07-012023-09-300001821825country:CN2022-07-012022-09-300001821825country:CN2023-01-012023-09-300001821825country:CN2022-01-012022-09-300001821825ogn:LatinAmericaMiddleEastRussiaAndAfricaMember2023-07-012023-09-300001821825ogn:LatinAmericaMiddleEastRussiaAndAfricaMember2022-07-012022-09-300001821825ogn:LatinAmericaMiddleEastRussiaAndAfricaMember2023-01-012023-09-300001821825ogn:LatinAmericaMiddleEastRussiaAndAfricaMember2022-01-012022-09-300001821825ogn:OtherCountriesMember2023-07-012023-09-300001821825ogn:OtherCountriesMember2022-07-012022-09-300001821825ogn:OtherCountriesMember2023-01-012023-09-300001821825ogn:OtherCountriesMember2022-01-012022-09-300001821825us-gaap:PerformanceSharesMember2023-01-012023-09-300001821825us-gaap:CostOfSalesMember2023-07-012023-09-300001821825us-gaap:CostOfSalesMember2022-07-012022-09-300001821825us-gaap:CostOfSalesMember2023-01-012023-09-300001821825us-gaap:CostOfSalesMember2022-01-012022-09-300001821825us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001821825us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001821825us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001821825us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001821825us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001821825us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001821825us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001821825us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-30xbrli:pure0001821825us-gaap:RestrictedStockMember2022-12-310001821825us-gaap:PerformanceSharesMember2022-12-310001821825us-gaap:RestrictedStockMember2023-01-012023-09-300001821825us-gaap:RestrictedStockMember2023-09-300001821825us-gaap:PerformanceSharesMember2023-09-30ogn:position0001821825srt:ScenarioForecastMember2023-12-310001821825srt:ScenarioForecastMembersrt:MinimumMember2023-10-012023-12-310001821825srt:ScenarioForecastMembersrt:MaximumMember2023-10-012023-12-310001821825us-gaap:ForeignExchangeForwardMember2023-09-300001821825us-gaap:ForeignExchangeForwardMember2022-12-310001821825us-gaap:FairValueInputsLevel2Member2023-09-300001821825us-gaap:FairValueInputsLevel2Member2022-12-310001821825us-gaap:SeniorNotesMemberogn:EuroDenominatedTermLoansMember2023-09-30iso4217:EUR0001821825us-gaap:SeniorNotesMemberogn:EuroDenominatedTermLoanBFacilityMember2023-09-300001821825us-gaap:SeniorNotesMemberogn:OrganonFinance1LLCMemberogn:A2875SeniorSecuredNotesDue2028Member2023-09-300001821825us-gaap:SeniorNotesMemberogn:EuroDenominatedTermLoansMember2023-07-012023-09-300001821825us-gaap:SeniorNotesMemberogn:EuroDenominatedTermLoansMember2022-07-012022-09-300001821825us-gaap:SeniorNotesMemberogn:EuroDenominatedTermLoansMember2023-01-012023-09-300001821825us-gaap:SeniorNotesMemberogn:EuroDenominatedTermLoansMember2022-01-012022-09-300001821825us-gaap:OtherOperatingIncomeExpenseMember2023-07-012023-09-300001821825us-gaap:OtherOperatingIncomeExpenseMember2022-07-012022-09-300001821825us-gaap:OtherOperatingIncomeExpenseMember2023-01-012023-09-300001821825us-gaap:OtherOperatingIncomeExpenseMember2022-01-012022-09-300001821825us-gaap:SeniorNotesMemberogn:TermLoanBFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-01-012023-09-300001821825us-gaap:SeniorNotesMemberogn:TermLoanBFacilityMember2023-09-300001821825us-gaap:SeniorNotesMemberogn:TermLoanBFacilityMember2022-12-310001821825us-gaap:SeniorNotesMemberogn:EuroInterbankOfferedRateMemberogn:EuroDenominatedSeniorSecuredTrancheBTermLoanMember2023-01-012023-09-300001821825us-gaap:SeniorNotesMemberogn:EuroDenominatedSeniorSecuredTrancheBTermLoanMember2023-09-300001821825us-gaap:SeniorNotesMemberogn:EuroDenominatedSeniorSecuredTrancheBTermLoanMember2022-12-310001821825us-gaap:SeniorNotesMemberogn:OrganonFinance1LLCMemberogn:A4125SeniorSecuredNotesDue2028Member2023-09-300001821825us-gaap:SeniorNotesMemberogn:A4125SeniorSecuredNotesDue2028Member2023-09-300001821825us-gaap:SeniorNotesMemberogn:A4125SeniorSecuredNotesDue2028Member2022-12-310001821825us-gaap:SeniorNotesMemberogn:A2875SeniorSecuredNotesDue2028Member2023-09-300001821825us-gaap:SeniorNotesMemberogn:A2875SeniorSecuredNotesDue2028Member2022-12-310001821825us-gaap:SeniorNotesMemberogn:OrganonFinance1LLCMemberogn:A5125SeniorUnsecuredNotesDue2031Member2023-09-300001821825us-gaap:SeniorNotesMemberogn:A5125SeniorUnsecuredNotesDue2031Member2023-09-300001821825us-gaap:SeniorNotesMemberogn:A5125SeniorUnsecuredNotesDue2031Member2022-12-310001821825us-gaap:NotesPayableOtherPayablesMember2023-09-300001821825us-gaap:NotesPayableOtherPayablesMember2022-12-310001821825us-gaap:SeniorNotesMemberogn:TermLoanBFacilityMemberogn:SecuredOvernightFinancingRateSOFROneMonthInterestPeriodMember2023-01-012023-09-300001821825us-gaap:SeniorNotesMemberogn:TermLoanBFacilityMemberogn:UsSecuredOvernightFinancingRateSOFRThreeMonthInterestPeriodMember2023-01-012023-09-300001821825us-gaap:SeniorNotesMemberogn:TermLoanBFacilityMemberogn:SecuredOvernightFinancingRateSOFRSixMonthInterestPeriodMember2023-01-012023-09-300001821825us-gaap:SeniorNotesMemberogn:TermLoanBFacilityMember2023-03-302023-03-300001821825us-gaap:RevolvingCreditFacilityMember2023-06-212023-06-210001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300001821825us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300001821825us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300001821825us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300001821825us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300001821825us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300001821825us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001821825us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300001821825us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001821825us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001821825us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300001821825us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300001821825ogn:SamsungBioepisCoLtdMember2023-01-012023-09-300001821825ogn:SamsungBioepisCoLtdMembercountry:BR2023-09-300001821825country:BR2023-09-300001821825ogn:SamsungBioepisCoLtdMember2023-09-300001821825ogn:SamsungBioepisCoLtdMember2023-07-012023-09-300001821825ogn:SamsungBioepisCoLtdMember2022-07-012022-09-300001821825ogn:SamsungBioepisCoLtdMember2022-01-012022-09-300001821825ogn:SamsungBioepisCoLtdMember2022-12-310001821825srt:AffiliatedEntityMember2021-06-032021-06-030001821825srt:AffiliatedEntityMember2023-09-300001821825srt:AffiliatedEntityMember2022-12-310001821825srt:AffiliatedEntityMember2023-07-012023-09-300001821825srt:AffiliatedEntityMember2022-07-012022-09-300001821825srt:AffiliatedEntityMember2023-01-012023-09-300001821825srt:AffiliatedEntityMember2022-01-012022-09-300001821825ogn:FosamaxMember2023-09-30ogn:case0001821825ogn:FederalMemberogn:FosamaxMemberogn:FemurFractureLitigationMember2014-03-012014-03-310001821825ogn:FederalMemberogn:FosamaxMemberogn:FemurFractureLitigationMember2022-12-160001821825ogn:FederalMemberogn:FosamaxMemberogn:FemurFractureLitigationMember2022-12-150001821825ogn:FosamaxMemberogn:NewJerseyStateCourtMemberogn:FemurFractureLitigationMember2023-09-300001821825ogn:CaliforniaStateCourtMemberogn:FosamaxMemberogn:FemurFractureLitigationMember2023-09-300001821825ogn:OtherStateCourtsMemberogn:FosamaxMemberogn:FemurFractureLitigationMember2023-09-300001821825ogn:NorthernDistrictOfOhioMemberogn:ImplanonMember2023-09-300001821825us-gaap:NonUsMemberogn:NexplanonImplanonNXTMember2023-09-300001821825us-gaap:NonUsMemberogn:ImplanonMember2023-09-300001821825us-gaap:NonUsMemberogn:NexplanonMember2023-09-300001821825country:USogn:PropeciaProscarMember2023-09-300001821825us-gaap:NonUsMemberogn:PropeciaProscarMember2023-09-300001821825country:ES2022-10-012022-10-310001821825ogn:NexplanonMemberus-gaap:SubsequentEventMember2023-10-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 10-Q
________________
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 001-40235
Organon & Co.
(Exact name of registrant as specified in its charter)
Delaware
46-4838035
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
30 Hudson Street, Floor 33
Jersey City,
New Jersey
07302
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (551) 430-6900
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock ($0.01 par value)
OGN
New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares of common stock outstanding as of the close of business on October 27, 2023: 255,606,461


Table of Contents

-2-
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements

Organon & Co.
Condensed Consolidated Statements of Income
(Unaudited, $ in millions except shares in thousands and per share amounts)
 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Revenues$1,519 $1,537 $4,665 $4,689 
Costs, Expenses and Other
Cost of sales612 551 1,832 1,700 
Selling, general and administrative538 440 1,424 1,234 
Research and development137 127 394 329 
Acquired in-process research and development and milestones— 10 8 107 
Restructuring costs— 11 4 11 
Interest expense134 108 398 303 
Exchange losses (gains)14 4 25 (21)
Other expense, net4 4 11 15 
1,439 1,255 4,096 3,678 
Income Before Income Taxes80 282 569 1,011 
Taxes on income22 55 92 202 
Net Income$58 $227 $477 $809 
Earnings per Share:
Basic$0.23 $0.89 $1.87 $3.19 
Diluted$0.23 $0.89 $1.86 $3.17 
Weighted Average Shares Outstanding:
Basic255,588 254,348 255,112 253,986 
Diluted256,349 255,067 256,162 255,094 

The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.
-3-
Organon & Co.
Condensed Consolidated Statements of Comprehensive Income
(Unaudited, $ in millions)
 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Net income$58 $227 $477 $809 
Other Comprehensive Income, Net of Taxes:
Benefit plan net loss and prior service cost, net of amortization
— — (1)— 
Cumulative translation adjustment
(43)(97)(11)(173)
 (43)(97)(12)(173)
Comprehensive income$15 $130 $465 $636 

The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.
-4-
Organon & Co.
Condensed Consolidated Balance Sheets
(Unaudited, $ in millions except shares in thousands and per share amounts)
September 30, 2023December 31, 2022
Assets
Current Assets:
Cash and cash equivalents$414 $706 
Accounts receivable (net of allowance for doubtful accounts of $9 in
2023 and $9 in 2022)
1,648 1,475 
Inventories (excludes inventories of $95 in 2023 and $148 in 2022 classified in Other assets)
1,186 1,003 
Other current assets802 747 
Total Current Assets4,050 3,931 
Property, plant and equipment, net1,096 1,018 
Goodwill4,603 4,603 
Intangibles, net561 649 
Other assets702 754 
Total Assets$11,012 $10,955 
Liabilities and Equity
Current Liabilities:
Current portion of long-term debt$8 $8 
Trade accounts payable1,067 1,132 
Accrued and other current liabilities1,255 1,188 
Income taxes payable161 184 
Total Current Liabilities2,491 2,512 
Long-term debt8,646 8,905 
Deferred income taxes43 19 
Other noncurrent liabilities421 411 
Total Liabilities11,601 11,847 
Contingencies (Note 15)
Organon & Co. Stockholders' Deficit:
Common stock, $0.01 par value
Authorized - 500,000
Issued and outstanding - 255,606 in 2023 and 254,370 in 2022
3 3 
Accumulated deficit(16)(331)
Accumulated other comprehensive loss(576)(564)
Total Stockholders' Deficit(589)(892)
Total Liabilities and Stockholders' Deficit$11,012 $10,955 
The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.
-5-
Organon & Co.
Condensed Consolidated Statements of Stockholders' Equity (Deficit)
(Unaudited, $ in millions, except shares in thousands and per share amounts)

Common StockAdditional Paid-In CapitalAccumulated Deficit
Accumulated
Other
Comprehensive
Loss
Total
SharesPar Value
Balance at July 1, 2022254,321 $3 $— $(551)$(589)$(1,137)
Net income— — — 227 — 227 
Other comprehensive loss, net of taxes— — — — (97)(97)
Cash dividends declared on common stock ($0.28 per share)
— — — (74)— (74)
Stock-based compensation plans and other43 — — 15 — 15 
Net transfers from Merck & Co., Inc., including Separation Adjustments— — — — — — 
Balance at September 30, 2022254,364 $3 $— $(383)$(686)$(1,066)
Balance at July 1, 2023255,568 $3 $— $(25)$(533)$(555)
Net income— — — 58 — 58 
Other comprehensive loss, net of taxes
— — — — (43)(43)
Cash dividends declared on common stock ($0.28 per share)
— — — (74)— (74)
Stock-based compensation plans and other38 — — 25 — 25 
Balance at September 30, 2023255,606 $3 $— $(16)$(576)$(589)
Balance at January 1, 2022
253,550 $3 $— $(998)$(513)$(1,508)
Net income— — — 809 — 809 
Other comprehensive loss, net of taxes— — — — (173)(173)
Cash dividends declared on common stock ($0.84 per share)
— — — (218)— (218)
Stock-based compensation plans and other814 — — 41 — 41 
Net transfers to Merck & Co., Inc. including Separation Adjustments
— — — (17)— (17)
Balance at September 30, 2022254,364 $3 $— $(383)$(686)$(1,066)
Balance at January 1, 2023
254,370 $3 $— $(331)$(564)$(892)
Net income— — — 477 — 477 
Other comprehensive loss, net of taxes
— — — — (12)(12)
Cash dividends declared on common stock ($0.84 per share)
— — — (221)— (221)
Stock-based compensation plans and other1,236 — 59 — 59 
Balance at September 30, 2023255,606 $3 $— $(16)$(576)$(589)
The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.
-6-
Organon & Co.
Condensed Consolidated Statements of Cash Flows
(Unaudited, $ in millions)
Nine Months Ended
September 30,
 20232022
Cash Flows from Operating Activities
Net income$477 $809 
Adjustments to reconcile net income to net cash flows provided by operating activities:
Depreciation88 72 
Amortization88 88 
Impairment of assets— 9 
Acquired in-process research and development and milestones8 107 
Deferred income taxes4 (18)
Stock-based compensation74 52 
Unrealized foreign exchange loss (gain)19 (45)
Other24 24 
Net changes in assets and liabilities
Accounts receivable(185)(119)
Inventories(137)(134)
Other current assets(56)(76)
Trade accounts payable(68)(323)
Accrued and other current liabilities34 108 
Income taxes payable(21)45 
Other53 (8)
Net Cash Flows Provided by Operating Activities402 591 
Cash Flows from Investing Activities
Capital expenditures(172)(133)
Proceeds from sale of property, plant and equipment1 3 
Acquired in-process research and development and milestones(8)(105)
Purchase of product rights and asset acquisition, net of cash acquired— (124)
Net Cash Flows Used in Investing Activities(179)(359)
Cash Flows from Financing Activities
Proceeds from debt80 — 
Repayments of debt(336)(106)
Net transfers to Merck & Co., Inc.— (17)
Employee withholding taxes related to stock-based awards(15)(11)
Dividend payments(221)(217)
Net Cash Flows Used in Financing Activities(492)(351)
Effect of Exchange Rate Changes on Cash and Cash Equivalents(23)(119)
Net Decrease in Cash and Cash Equivalents(292)(238)
Cash and Cash Equivalents, Beginning of Period706 737 
Cash and Cash Equivalents, End of Period$414 $499 
 The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.
-7-

Notes to Condensed Consolidated Financial Statements (unaudited)

1. Background and Nature of Operations

Organon & Co. ("Organon" or the "Company") is a global health care company with a focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.

The Company's operations include the following product portfolios:

•Women's Health: Organon's women's health products are sold by prescription primarily in two therapeutic areas, contraception, with key brands such as Nexplanon® (etonogestrel implant) (sold as Implanon NXT™ in some countries outside the United States) and NuvaRing® (etonogestrel / ethinyl estradiol vaginal ring), and fertility, with key brands such as Follistim AQ® (follitropin beta injection) (marketed in most countries outside the United States as Puregon™). Nexplanon is a long-acting reversible contraceptive, which is a class of contraceptives that is recognized as one of the most effective types of hormonal contraception available to patients with a low long-term average cost. Other women’s health products include the Jada® System, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted and a license from Daré Biosciences for the global commercial rights to Xaciato™ (clindamycin phosphate vaginal gel, 2%), an FDA-approved medication for the treatment of bacterial vaginosis ("BV") in females 12 years of age and older. In October 2023, Xaciato was launched in the United States.

•Biosimilars: Organon's current portfolio spans across immunology and oncology treatments. Organon's oncology biosimilars have been launched in more than 20 countries and Organon's immunology biosimilars have been launched in five countries. All five biosimilars in Organon's portfolio have launched in Canada, and three biosimilars; Ontruzant® (trastuzumab-dttb), Renflexis® (infliximab-abda) and Hadlima™ (adalimumab-bwwd) have been launched in the United States.

•Established Brands: Organon has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management. A number of Organon's established brands lost exclusivity years ago and have faced generic competition for some time.

2. Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company's opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon's Annual Report on Form 10-K for the year ended December 31, 2022.

Use of Estimates

The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2022. Accordingly, actual results could differ materially from management's estimates and assumptions.

The Company was impacted by COVID-19 during the first half of 2023, specifically, in the Company's operations in China. The Company does not anticipate a continued impact from COVID-19. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the
-8-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
information reasonably available to the Company as of September 30, 2023 and through the date of this report which are difficult to predict.

Recently Adopted Accounting Standards

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 and December 31, 2022; the sunset date was subsequently deferred to December 31, 2024 based on the amendment issued in December 2022 under ASU 2022-06, Reference Rate Reform (Topic 848). The Company applied this guidance to our Senior Credit Agreement, as amended on June 30, 2023. The impact to the Consolidated Financial Statements as a result of the application of the reference rate reform guidance is not material. See Note 11 "Long-Term Debt" for additional details.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance became effective for the Company on January 1, 2023 and its amendments will be applied prospectively to business combinations occurring on or after the effective date of the guidance. The adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.

3. Acquisitions and Licensing Arrangements

Claria Medical, Inc. ("Claria")

In January 2023, the Company made a strategic investment in Claria, a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy. Under the terms of the agreement, Organon paid $8 million upfront and has the option to acquire Claria for an additional $47 million, payable if and when the option is exercised. The $8 million was expensed as Acquired in-process research and development and milestones in our Condensed Consolidated Statement of Income for the nine months ended September 30, 2023.

4. Earnings per Share ("EPS")

The calculations of basic and diluted earnings per common share are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions and shares in thousands, except per share amounts)2023202220232022
Net income$58 $227 $477 $809 
Basic weighted average number of shares outstanding255,588254,348255,112253,986
Stock awards and equity units (share equivalent)761 719 1,0501,108
Diluted weighted average common shares outstanding256,349255,067256,162255,094
EPS:
Basic$0.23 $0.89 $1.87 $3.19 
Diluted$0.23 $0.89 $1.86 $3.17 
Anti-dilutive shares excluded from the calculation of EPS10,390 6,313 9,833 4,432 

Diluted EPS was computed using the treasury stock method for stock option awards, performance share units and restricted share units. The computation of diluted EPS excludes the effect of the potential exercise of stock-based awards when the effect of the potential exercise would be anti-dilutive.
-9-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
5. Product and Geographic Information

The Company's operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies within women's health, biosimilars and established brands.

Revenues of the Company's products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int'lTotalU.S.Int'lTotal
Women's Health
Nexplanon/Implanon NXT$146 $74 $220 $151 $78 $229 $418 $181 $599 $401 $194 $595 
Follistim AQ22 32 54 27 33 60 74 105 179 79 100 179 
NuvaRing
18 20 37 27 23 50 50 67 117 65 68 133 
Ganirelix Acetate Injection
4 21 25 6 30 36 15 74 88 20 77 97 
Marvelon/Mercilon
— 30 30 — 31 31 — 97 97 — 85 85 
Jada12 — 13 5 — 5 30 — 31 12 — 12 
Other Women's Health (1)
16 22 39 19 23 42 52 74 126 68 70 138 
Biosimilars
Renflexis57 12 69 54 7 60 172 29 201 145 20 166 
Ontruzant11 28 40 15 14 29 36 57 93 35 52 87 
Brenzys— 13 13 — 24 24 — 45 45 — 52 52 
Aybintio— 12 12 — 10 10 — 34 34 — 29 29 
Hadlima2 6 8 — 6 6 2 18 20 — 14 14 
Established Brands
Cardiovascular
Zetia2 65 66 2 85 87 5 234 239 7 280 287 
Vytorin2 31 33 1 30 31 5 95 100 6 98 104 
Atozet— 126 126 — 109 109 — 397 397 — 350 350 
Rosuzet— 17 17 — 17 17 — 52 52 — 55 55 
Cozaar/Hyzaar3 65 68 2 68 70 8 217 225 11 244 256 
Other Cardiovascular (1)
1 42 44 1 34 35 2 124 126 3 117 120 
Respiratory
Singulair3 88 91 3 92 94 8 282 290 8 308 316 
Nasonex— 54 55 — 49 49 — 187 188 9 173 182 
Dulera40 9 49 31 9 40 116 28 144 98 30 127 
Clarinex2 26 28 — 25 26 4 103 107 3 96 99 
Other Respiratory (1)
17 9 25 11 10 21 42 20 61 34 32 66 
Non-Opioid Pain, Bone and Dermatology
Arcoxia— 64 64 — 64 64 — 207 207 — 185 185 
Fosamax1 40 41 1 35 36 2 121 123 2 115 117 
Diprospan— 31 31 — 28 28 — 58 58 — 91 91 
Other Non-Opioid Pain, Bone and Dermatology (1)
4 70 74 2 63 65 11 196 207 10 200 210 
Other
Proscar— 25 25 — 26 27 1 76 77 1 76 77 
Propecia2 21 22 2 28 30 5 86 92 5 90 95 
Other (1)
5 72 76 6 81 87 10 231 240 21 230 251 
Other (2)
— 24 24 — 39 39 (1)103 102 — 115 116 
Revenues$370 $1,149 $1,519 $366 $1,171 $1,537 $1,067 $3,598 $4,665 $1,043 $3,646 $4,689 
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately. Revenues from Marvelon and Mercilon and Jada were previously reported as part of Other Women's Health. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.
(2) Includes manufacturing sales to Merck & Co., Inc. ("Merck") and third parties for current and prior periods.

-10-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Revenues by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Europe and Canada$392 $363 $1,259 $1,243 
United States370 366 1,067 1,043 
Asia Pacific and Japan284 283 869 888 
China202 241 661 721 
Latin America, Middle East, Russia, and Africa
239 236 687 665 
Other (1)
32 48 122 129 
Revenues$1,519 $1,537 $4,665 $4,689 
(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods.

6. Stock-Based Compensation Plans

The Company grants stock option awards, performance share units ("PSUs") and restricted share units ("RSUs") pursuant to its 2021 Incentive Stock Plan.

The PSU awards are based on the following performance factors:
•total stockholder return of the Company relative to an index of peer companies ("relative TSR") specified in the awards; and
•the results of the cumulative free cash flow ("FCF") of the Company over a three-year period.

Stock-based compensation expenses incurred by the Company were as follows:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Stock-based compensation expense recognized in:
Cost of sales$5 $3 $13 $9 
Selling, general and administrative 18 12 50 35 
Research and development4 3 11 8 
Total$27 $18 $74 $52 
Income tax benefits$6 $3 $16 $11 

The weighted average fair value of options granted was determined using the following assumptions:

Nine Months Ended
September 30,
20232022
Expected dividend yield4.82 %3.12 %
Risk-free interest rate3.56 2.47 
Expected volatility42.30 43.43 
Expected life (years)5.895.89
-11-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

A summary of the equity award transactions for the nine months ended September 30, 2023 is as follows:

Stock OptionsRestricted Share UnitsPerformance Share Units
(shares in thousands)SharesWeighted average exercise priceWeighted average grant date fair valueSharesWeighted average grant date fair valueSharesWeighted average grant date fair value
Outstanding as of January 1, 20234,729 $34.34 $8.91 5,048 $33.27 486 $46.72 
Granted1,124 23.52 6.55 3,867 23.51 636 23.30 
Vested/Exercised— — — (1,930)33.93 — — 
Forfeited/Cancelled(89)36.12 8.70 (459)30.79 — — 
Outstanding as of September 30, 2023
5,764 $32.21 $8.45 6,526 $27.47 1,122 $33.44 

The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2023:

Equity Awards Vested and Expected to VestEquity Awards That are Exercisable
(awards in thousands; aggregate intrinsic value in millions)
AwardsWeighted Average Exercise PriceAggregate Intrinsic Value
Remaining
Term
(in years)
AwardsWeighted Average Exercise PriceAggregate Intrinsic Value
Remaining
Term
(in years)
Stock Options5,591 $32.21 $— 7.043,311 $33.79 $— 5.87
Restricted Share Units6,071 114 1.98
Performance Share Units629 12 1.82

The amount of unrecognized compensation costs as of September 30, 2023 was $170 million, which will be recognized in operating expense ratably over the weighted average vesting period of 1.93 years.

7. Restructuring

In 2022, Organon initiated restructuring activities to optimize its internal operations by reducing headcount through selected markets and functions. As a result of this program, the Company restructured approximately 130 positions, with the majority of the position eliminations occurring in selected markets outside of the United States in our commercial organizations. During the nine months ended September 30, 2023, $15 million of restructuring charges have been paid, with the remaining severance payments to be paid by the end of the 2023 fiscal year. For the nine months ended September 30, 2023, the Company recorded restructuring charges of $4 million, which relate to severance costs for eliminated positions.

Liabilities for costs associated with restructuring activities were $10 million and $20 million at September 30, 2023 and December 31, 2022, respectively, and are included primarily in Accrued and other current liabilities.

In the fourth quarter of 2023, Organon will implement additional restructuring activities to optimize its internal operations by reducing headcount in certain markets and functions. As a result of these activities, the Company expects to restructure approximately 3% of the Company's headcount, which is expected to result in a charge of approximately $60 million to $70 million primarily representing severance and severance related costs in the fourth of quarter of 2023. These amounts will be paid over the next twelve months.

8. Taxes on Income

The effective income tax rates were 27.0% and 19.6% for the three months ended September 30, 2023 and 2022, respectively, and 16.1% and 20.0% for the nine months ended September 30, 2023 and 2022, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense. The 2023 year-to-date effective tax rate favorable impact is primarily attributable to a reduced tax rate arrangement that was agreed to in Switzerland for an active entity.

-12-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2023 results. The Company will continue to assess future impacts of this legislation.

9. Inventories

Inventories consisted of:
($ in millions)September 30, 2023December 31, 2022
Finished goods$496 $482 
Raw materials
128 44 
Work in process606 601 
Supplies57 44 
Total (approximates current cost)$1,287 $1,171 
Decrease to LIFO costs(6)(20)
 $1,281 $1,151 
Recognized as:
Inventories$1,186 $1,003 
Other assets95 148 
Inventories valued under the last in, first out ("LIFO") method85 77 

Amounts recognized as Other assets are comprised primarily of raw materials and work in process inventories and are not expected to be converted to finished goods that will be sold within one year. The Company has a long-term vendor supply contract that includes certain annual minimum purchase commitments.

10. Financial Instruments

Foreign Currency Risk Management

The Company has a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates.

The Company uses a balance sheet risk management program to partially mitigate the exposure of net monetary assets of its subsidiaries that are denominated in a currency other than a subsidiary's functional currency from the effects of volatility in foreign exchange. In these instances, Organon principally utilizes forward exchange contracts to partially offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Swiss franc, and Japanese yen. For exposures in developing country currencies, the Company enters into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument.

Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Exchange losses (gains). The forward contracts are not designated as hedges and are marked to market through Exchange losses (gains). Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year. The notional amount of forward contracts was $1.0 billion and $1.5 billion as of September 30, 2023 and December 31, 2022, respectively. The cash flows and the related gains and losses from these contracts are reported as operating activities in the Condensed Consolidated Statements of Cash Flows.

-13-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of our assets and liabilities were as follows:
($ in millions)Fair Value Measurement Level September 30, 2023December 31, 2022
Forward contracts in Other current assets
2$17 $6 
Forward contracts in Accrued and other current liabilities
212 24 

Foreign exchange risk is also managed through the use of economic hedges on foreign currency balances. See Note 11 "Long-Term Debt" for additional details. €1.983 billion in the aggregate of both the euro-denominated term loan (€733 million) and the 2.875% euro-denominated secured notes (€1.25 billion) has been designated and is effective as an economic hedge of the net investment in euro-denominated subsidiaries.

Foreign currency gains due to spot rate fluctuations on the euro-denominated debt instruments included in foreign currency translation adjustments resulting from hedge designation were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Foreign currency gains in Other comprehensive income
$79 $176 $21 $303 

The Condensed Consolidated Statements of Income include the impact of actual net (gains) and losses of Organon's derivative financial instruments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Foreign exchange loss (gain) in Exchange losses (gains)
$14 $4 $25 $(21)

Organon has established accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. Under these agreements, Organon factored $55 million and $43 million of accounts receivable as of September 30, 2023 and December 31, 2022, respectively, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statements of Cash Flows.

-14-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
11. Long-Term Debt

The following is a summary of Organon's total debt:
($ in millions)September 30, 2023December 31, 2022
Term Loan B Facility:
SOFR plus 300 bps plus SOFR adjustment1 term loan due 2028
$2,543 $2,793 
EURIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)
773 787 
4.125% secured notes due 2028
2,100 2,100 
2.875% euro-denominated secured notes due 2028 (€1.25 billion)
1,318 1,331 
5.125% notes due 2031
2,000 2,000 
Other borrowings7 7 
Other (discounts and debt issuance costs)(87)(105)
Total principal long-term debt$8,654 $8,913 
Less: Current portion of long-term debt8 8 
Total Long-term debt, net of current portion$8,646 $8,905 
1.The SOFR adjustment is an additional interest amount per annum of 11.448 bps for a one-month interest period, 26.161 bps for a three-month interest period, or 42.826 bps for a six-month interest period, at our option.

The nature and terms of our Senior Credit Agreement, Notes and Other borrowings are described in detail in Note 11 "Long-Term Debt and Leases" in the 2022 Annual Report on Form 10-K for the year ended December 31, 2022.

On June 30, 2023, the Company entered into Amendment No. 1 to the Senior Credit Agreement. Amendment No. 1 replaces LIBOR-based rates with Adjusted Term Secured Overnight Financing Rate ("SOFR")-based rates and updates certain other provisions of the Senior Credit Agreement to reflect the transition from LIBOR to the Adjusted Term SOFR. The impact of the rate transition was not material to the Condensed Consolidated Financial Statements.

Long-term debt was recorded at the carrying amount. The estimated fair value of long-term debt (including current portion) is as follows:
($ in millions)September 30, 2023December 31, 2022
Long-term debt
$7,853 $8,294 

Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy.

The Company made interest payments related to its debt instruments of $311 million for the nine months ended September 30, 2023. The average maturity of the Company's long-term debt as of September 30, 2023 is approximately 5.3 years and the weighted-average interest rate on total borrowings as of September 30, 2023 is 5.7%.

-15-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

On March 30, 2023, the Company made a discretionary prepayment of $250 million on the U.S. Dollar-denominated term loan.

On June 21, 2023, the Company borrowed $80 million on the Revolving Credit Facility and subsequently repaid the amount on June 30, 2023.

The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows:
($ in millions)
2023$2 
20249 
20259 
20269 
20279 
Thereafter8,703 

The Senior Credit Agreement contains customary financial covenants, including a total leverage ratio covenant, which measures the ratio of (i) consolidated total debt to (ii) consolidated earnings before interest, taxes, depreciation, and amortization, and subject to other adjustments, that must meet certain defined limits which are tested on a quarterly basis. In addition, the Senior Credit Agreement contains covenants that limit, among other things, Organon’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem, or repurchase equity interests, and create or become subject to liens. As of September 30, 2023, the Company is in compliance with all financial covenants and no default or event of default has occurred.

-16-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
12. Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated other comprehensive income (loss) by component are as follows:
($ in millions)Employee
Benefit
Plans		Cumulative
Translation
Adjustment
Accumulated Other
Comprehensive
Loss
Balance at July 1, 2022, net of taxes$(13)$(576)$(589)
Other comprehensive loss, pretax— (97)(97)
Tax— — — 
Other comprehensive loss, net of taxes— (97)(97)
Balance at September 30, 2022, net of taxes$(13)$(673)$(686)
Balance at July 1, 2023, net of taxes$9 $(542)$(533)
Other comprehensive loss, pretax
— (43)(43)
Tax— — — 
Other comprehensive loss, net of taxes
— (43)(43)
Balance at September 30, 2023, net of taxes$9 $(585)$(576)
Balance at January 1, 2022, net of taxes$(13)$(500)$(513)
Other comprehensive loss, pretax(1)(173)(174)
Tax1 — 1 
Other comprehensive loss, net of taxes— (173)(173)
Balance at September 30, 2022, net of taxes$(13)$(673)$(686)
Balance at January 1, 2023, net of taxes$10 $(574)$(564)
Other comprehensive loss, pretax
(1)(11)(12)
Tax— — — 
Other comprehensive loss, net of taxes
(1)(11)(12)
Balance at September 30, 2023, net of taxes$9 $(585)$(576)

13. Samsung Collaboration

The Company has an agreement with Samsung Bioepis Co., Ltd. ("Samsung Bioepis") to develop and commercialize multiple pre-specified biosimilar candidates, which have since launched and are part of the Company's product portfolio. Under the agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis. The Company's access rights to each product under the agreement last for 10 years from each product's launch date on a market-by-market basis. Gross profits are shared equally in all markets with the exception of certain markets in Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to the Company. Since the Company is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Generally, profit sharing adjustments are recorded either to Cost of sales (after commercialization) or Selling, general and administrative expenses (prior to commercialization).

Samsung Bioepis is eligible for additional payments associated with pre-specified clinical and regulatory milestones. As of September 30, 2023, potential future regulatory milestone payments of $25 million remain under the agreement.

In July 2023, the Company began selling Hadlima, a biosimilar referencing Humira1 (adalimumab), in the United States.

-17-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Sales$143 $129 $394 $346 
Cost of sales98 86 272 221 
Selling, general and administrative17 18 53 60 

($ in millions)September 30, 2023December 31, 2022
Receivables from Samsung included in Other current assets
$8 $21 
Payables to Samsung included in Trade accounts payable
62 72 

14. Third-Party Arrangements

On June 2, 2021, Organon and Merck entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the "Separation").

The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation, including, but not limited to a tax matters agreement, an employee matters agreement, Interim Operating Model Agreements ("IOM Agreements"), Manufacturing and Supply Agreements, Intellectual Property License Agreements, Regulatory Agreements and a transition services agreement (the "Transition Service Agreement" or "TSA").

Following the Separation, certain functions continue to be provided by Merck under the TSA or are being performed using the Company's own resources or third-party service providers. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of certain services under the TSA expired as of July 2, 2023, however, certain services have been extended to at least 35 months. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate, and Merck manufactures certain products for the Company, or its applicable affiliate. For details on the rights and responsibilities of the parties under the agreements, refer to Note 18 "Third-Party Arrangements and Related Party Disclosures" to the audited Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

For the three and nine months ended September 30, 2023, material transactions occurred in connection with the IOM Agreements.

The amounts due under such agreements were:
($ in millions)September 30, 2023December 31, 2022
Due from Merck in Accounts receivable
$467 $374 
Due to Merck in Accounts payable
601 543 

Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Sales $28 $38 $95 $104 
Cost of sales 25 31 88 91 

-18-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
15. Contingencies

Organon is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters.

Organon records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.

Given the nature of the litigation discussed in this note and the complexities involved in these matters, Organon is unable to reasonably estimate a possible loss or range of possible loss for such matters until Organon knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation, and (v) any other factors that may have a material effect on the litigation.

Organon's decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. Organon has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.

Reference is made below to certain litigation in which Merck, but not Organon, is named as a defendant. Pursuant to the Separation and Distribution Agreement, Organon is required to indemnify Merck for liabilities relating to, arising from, or resulting from such litigation.

Product Liability Litigation

Fosamax

Merck is a defendant in product liability lawsuits in the United States involving Fosamax® (alendronate sodium) (the "Fosamax Litigation"). As of September 30, 2023, approximately 3,130 cases comprising the Fosamax Litigation are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries ("Femur Fractures") in association with the use of Fosamax.

All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey ("Femur Fracture MDL"). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck's favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck's motion for judgment as a matter of law in the Glynn case and held that the plaintiff's failure to warn claim was preempted by federal law.

In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court's preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit ("Third Circuit"). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court's preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court's opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs' state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck's motion and ruled that plaintiffs' failure to warn claims are preempted as a matter of law to the extent they assert that Merck should have added a Warning or Precaution regarding atypical femur fractures prior to October 2010. On July 11, 2022, the District Court entered an Order to Show Cause as to why the Court should not dismiss either with prejudice or conditionally all of plaintiffs' claims that are not dependent on the preempted failure to warn claims. On November 18, 2022, as a result of the Order to Show Cause, the District Court entered a Final Judgment resulting in the dismissal with prejudice of all plaintiffs in the MDL. On
-19-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
December 16, 2022, those plaintiffs filed their Notice of Appeal to the Third Circuit challenging the District Court's preemption ruling. 974 of the 975 cases previously pending in the Femur Fracture MDL have either been dismissed or are on appeal to the Third Circuit. Plaintiff's motion to remand one case back to its transferor court is pending.

As of September 30, 2023, approximately 1,880 cases alleging Femur Fractures have been filed in New Jersey state court and are pending in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck continued to select additional cases to be reviewed.

As of September 30, 2023, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been consolidated before a single judge in Orange County, California.

Additionally, there are four Femur Fracture cases pending in other state courts.

Discovery is presently stayed in the Femur Fracture MDL and in the state court in California.

Nexplanon/Implanon

Merck is a defendant in lawsuits brought by individuals relating to the use of Nexplanon and Implanon™ (etonogestrel implant). There are two filed product liability actions involving Implanon, both of which are pending in the Northern District of Ohio as well as 56 unfiled cases involving Implanon alleging similar injuries, which have been tolled under a written tolling agreement. As of September 30, 2023, Merck had 18 cases pending outside the United States, of which 12 relate to Implanon and six relate to Nexplanon.

Propecia/Proscar

As of September 30, 2023, one case involving Proscar® (finasteride) remains pending in the United States in the United States District Court for the Eastern District of California in which Merck's motion to dismiss was granted by the District Court, but the plaintiff can appeal the decision. The Company is also defending 14 product liability cases involving Propecia® (finasteride) outside the United States, two of which are class actions and three of which are putative class actions.

Governmental Proceedings

From time to time, Organon's subsidiaries may receive inquiries and may be the subject of preliminary investigation activities from competition and/or other governmental authorities, including in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to Organon, monetary fines and/or remedial undertakings may be required. Subject to certain exceptions specified in the Separation and Distribution Agreement, Organon assumed liability for all pending and threatened legal matters related to products transferred to Organon, including competition investigations resulting from enforcement activity concerning Merck's conduct involving Organon's products. Organon could be obligated to indemnify Merck for fines or penalties, or a portion thereof, resulting from such investigations. In one such enforcement matter in Spain concerning NuvaRing, in October 2022, the National Commission on Markets and Competition ("CNMC") imposed a fine on Merck in the amount of €39 million for abuse of a dominant position in the market for contraceptive vaginal rings from June 2017 to April 2018. The CNMC decision to impose the fine has been appealed to the National High Court in Spain. If the fine ultimately stands, Organon could be obligated to indemnify Merck for a portion thereof.

Hadlima

In July 2021, Organon received a Civil Investigation Demand ("CID") from the Office of the Attorney General for the State of Washington. The CID requests answers to interrogatories, as well as various documents, regarding certain activities related to adalimumab and adalimumab biosimilars. Organon is cooperating with the government's investigation and has produced information in response to the CID.

-20-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Patent Litigation

From time to time, generic manufacturers of pharmaceutical products file Abbreviated New Drug Applications with the FDA seeking to market generic forms of Organon's products prior to the expiration of relevant patents owned by Organon. To protect its patent rights, Organon may file patent infringement lawsuits against such generic companies. Similar lawsuits defending Organon's patent rights may exist in other countries. Organon intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products, potential payment of damages and legal fees, and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.

Nexplanon

In June 2017, Microspherix LLC ("Microspherix") sued Organon in the U.S. District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of Nexplanon infringed several of Microspherix's patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until the patents expired in May 2021. Organon brought Inter Partes Review proceedings in the United States Patent and Trademark Office ("USPTO") and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against Organon. Organon appealed the decisions that found claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO's decisions. The matter is no longer stayed in the district court, and Organon is currently litigating the invalidity and non-infringement of the remaining asserted claims. A claim construction hearing was held on March 2, 2022, and a claim construction order issued on February 27, 2023. This case was scheduled for trial before a jury in Camden, New Jersey starting on October 16, 2023; however, on October 13, 2023, a status conference was held during which the parties informed the district court that an agreement in principle of the key terms of a settlement was reached. The proceedings were stayed for 60 days to allow time for the parties to execute a settlement agreement. Organon reserved $80 million to cover the settlement.

Other Litigation

In addition to the matters described above, there are various other pending legal proceedings involving Organon, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of Organon as of September 30, 2023, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to Organon's financial condition, results of operations or cash flows either individually or in the aggregate.

Legal Defense Reserves

Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by Organon; the development of Organon's legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against Organon; and the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The legal defense reserve as of September 30, 2023 and December 31, 2022 was $23 million and $17 million, respectively, and represented Organon's best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by Organon. Organon will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.

-21-
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue." These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include, but are not limited to, pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general; an inability to fully execute on our product development and commercialization plans in the United States, Europe, and elsewhere internationally; an inability to adapt to the industry-wide trend toward highly discounted channels; changes in tax laws or other tax guidance which could adversely affect our cash tax liability, effective tax rates, and results of operations and lead to greater audit scrutiny; expanded brand and class competition in the markets in which Organon operates; global tensions, which may result in disruptions in the broader global economic environment; uncertainty regarding the U.S. federal budget and debt ceiling, and the impact of a potential U.S. federal government shutdown; governmental initiatives that adversely impact our marketing activities, particularly in China; volatility in Organon’s stock price; political and social pressures, or regulatory developments, that adversely impact demand for, availability of, or patient access to contraception or fertility products; difficulties with performance of third parties Organon relies on for its business growth; the failure of any supplier to provide substances, materials, or services as agreed; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties; competition from generic products as Organon's products lose patent protection; expiration of current patents or loss of patent protection for Organon's products; difficulties implementing or executing on Organon's acquisition strategy or failure to recognize the benefits of such acquisitions; and other factors discussed in Organon's most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

General

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to assist in understanding the Company’s financial condition and results of operations. The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and with our audited financial statements, including the accompanying notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022. Operating results discussed herein are not necessarily indicative of the results of any future period.

Organon & Co. ("Organon" or the "Company") is a global health care company with a focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.

Recent Developments

Business Development

Claria Medical, Inc. ("Claria")

In January 2023, the Company made a strategic investment in Claria, a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy. Under the terms of the agreement, Organon paid $8 million upfront and has the option to acquire Claria for an additional $47 million, payable if and when the option is exercised. The $8 million was expensed as Acquired in-process research and development and milestones in our Condensed Consolidated Statement of Income for the nine months ended September 30, 2023.

-22-
COVID-19 Update

COVID-19 related disruptions, including patients' inability to access health care providers, prioritization of COVID-19 patients, as well as social distancing measures, negatively affected our results during 2022 and the first half of 2023, specifically, in China. During 2022 and to a lesser extent in the first half of 2023, our business was impacted by previous lockdowns in selective cities across China. The China economy has had a slower recovery post-COVID which has impacted the retail business.


Operating Results

Sales Overview
Three Months Ended September 30,% Change% Change Excluding Foreign ExchangeNine Months Ended September 30,% Change% Change Excluding Foreign Exchange
($ in millions)2023202220232022
United States$370 $366 1 %1 %$1,067 $1,043 2 %2 %
International1,149 1,171 (2)(1)3,598 3,646 (1)2 
Total$1,519 $1,537 (1)%(1)%$4,665 $4,689 (1)%2 %

Worldwide sales were $1.5 billion for the three months ended September 30, 2023, a decrease of 1% compared with the same period in 2022. Worldwide sales were negatively impacted by approximately $10 million, due to unfavorable foreign exchange. Excluding foreign exchange, sales decreases primarily reflect Zetia® (ezetimibe) (marketed in most countries outside of the United States as Ezetrol™) and Vytorin® (ezetimibe/simvastatin) (marketed outside of the United States as Inegy™) driven by the impact of volume-based procurement ("VBP") in China, the Fertility portfolio mainly due to the negative impact of unfavorable discount rates in the United States, NuvaRing due to ongoing generic competition in the United States, Brenzys™ (etanercept) primarily driven by the timing of tenders in Brazil and Nexplanon due to unfavorable discount rates in the United States and decreased volume from the tender process in Mexico. This was offset by sales increases in Atozet™ (ezetimibe and atorvastatin calcium) (marketed outside of the United States) due to increased demand in France, Ontruzant driven by increased demand and the timing of tenders in Brazil and Renflexis driven primarily by continued demand growth in the United States and Canada.

Worldwide sales were $4.7 billion for the nine months ended September 30, 2023, consistent with 2022. Worldwide sales were negatively impacted by approximately 3%, or $119 million, due to unfavorable foreign exchange. Excluding foreign exchange, sales increases primarily reflect the performance of Atozet, due to increased demand in France and the timing of customers' buying patterns in the Middle East, Korea and Mexico, Renflexis driven primarily by continued demand growth in the United States and Canada, Arcoxia™ (etoricoxib) (marketed outside of the United States) primarily due to customers buying patterns in various international regions and higher demand in China, Jada due to continued uptake in the United States following the launch in February 2022, Dulera® (formoterol/fumarate dihydrate) primarily due to the favorable impact from discount rates and price in the United States and Marvelon™ (desogestrel and ethinyl estradiol pill) and Mercilon™ (desogestrel and ethinyl estradiol pill), resulting from the transaction with Bayer Healthcare where Organon gained full rights in selected territories in Southeast Asia and China during 2022. This performance was offset by Zetia and Vytorin driven by the impact of VBP in China, the impact of the Diprospan™ (betamethasone) regulatory inspection finding at the Heist manufacturing location that impacted the manufacturing of selected injectable steroid brands (the "Market Action") and decreased sales of Cozaar® (losartan potassium) and Hyzaar® (a combination of losartan potassium and hydrochlorothiazide that is marketed in Japan as Preminent™), primarily due to ongoing generic competition.

The loss of exclusivity negatively impacted sales by approximately $7 million and $9 million during the three and nine months ended September 30, 2023, compared to the three and nine months ended September 30, 2022, based on the decrease in volume period over period, mainly impacting NuvaRing in the United States. VBP in China had a $31 million and $83 million negative impact on sales during the three and nine months ended September 30, 2023, compared to the three and nine months ended September 30, 2022. Organon expects VBP to impact the Company's established brands product portfolio for the next several quarters.

Organon's operations include a portfolio of products. Highlights of the sales of Organon's products for the three and nine months ended September 30, 2023 and 2022 are provided below. See Note 5 "Product and Geographic Information" to the Condensed Consolidated Financial Statements for further details on sales of our products.

-23-
Women's Health
Three Months Ended September 30,% Change% Change Excluding Foreign ExchangeNine Months Ended September 30,% Change% Change Excluding Foreign Exchange
($ in millions)2023202220232022
Nexplanon/Implanon NXT$220 $229 (4)%(3)%$599 $595 1 %2 %
NuvaRing37 50 (26)(23)117 133 (12)(10)
Marvelon/Mercilon30 31 (3)(2)97 85 13 17 
Follistim AQ54 60 (10)(8)179 179 — 3 
Ganirelix Acetate Injection25 36 (30)(29)88 97 (9)(7)
Jada
13 5 134 134 31 12 150 150 

Contraception

Worldwide sales of Nexplanon, a single-rod subdermal contraceptive implant, decreased 4% for the three months ended September 30, 2023, compared to 2022 due to unfavorable discount rates in the United States and decreased volume from the tender process in Mexico. Sales of Nexplanon increased 1% for the nine months ended September 30, 2023, compared to 2022, primarily due to price increases, the impact of the timing of tenders in various international markets and the impact of distributors' buying patterns in prior periods in the United States, offset by unfavorable discount rates in the United States.

Worldwide sales of NuvaRing, a vaginal contraceptive product, declined 26% and 12% for the three and nine months ended September 30, 2023, respectively, compared to 2022, due to ongoing generic competition in the United States. We expect a continued decline in NuvaRing sales as a result of generic competition.

Worldwide sales of Marvelon and Mercilon, combined oral hormonal daily contraceptive pills not approved or marketed in the United States but available in certain countries outside the United States, remained consistent for the three months ended September 30, 2023, compared to 2022. Sales of Marvelon and Mercilon increased 13% for the nine months ended September 30, 2023, compared to 2022, as a result of the transaction with Bayer Healthcare where Organon gained full rights in selected territories in Southeast Asia and China during 2022.

Fertility

Worldwide sales of Follistim AQ, a fertility treatment, declined 10% for the three months ended September 30, 2023, compared to 2022, due to the negative impact of unfavorable discount rates in the United States offset by increased demand. Sales of Follistim AQ remained consistent for the nine months ended September 30, 2023, compared to 2022, due to volume recovery in China related to the COVID-19 negative impact during the first half of the year, offset by the negative impact of unfavorable discount rates in the United States.

Worldwide sales of Ganirelix Acetate Injection (marketed in certain countries outside the United States as Orgalutran™), a fertility treatment, declined 30% and 9% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily due to unfavorable discount rates in the United States and the impact of distributors' buying patterns in several markets.

Other Women's Health

Worldwide sales of Jada, a device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted, increased 134% and 150% for the three and nine months ended September 30, 2023, respectively, compared to 2022. The sales increase in both periods is due to continued uptake in the United States following the Jada launch.

-24-
Biosimilars
Three Months Ended September 30,% Change% Change Excluding Foreign ExchangeNine Months Ended September 30,% Change% Change Excluding Foreign Exchange
($ in millions)2023202220232022
Renflexis$69 $60 15 %15 %$201 $166 22 %22 %
Ontruzant40 29 36 34 93 87 8 7 
Brenzys13 24 (43)(41)45 52 (13)(8)
Hadlima8 6 38 42 20 14 48 55 

Renflexis is a biosimilar to Remicade1 (infliximab) for the treatment of certain inflammatory diseases. Sales growth of 15% and 22% for the three and nine months ended September 30, 2023, respectively, compared to 2022, was driven primarily by continued demand growth in the United States and Canada. We have commercialization rights to Renflexis in countries outside Europe, Korea, China, Turkey, and Russia.

Ontruzant is a biosimilar to Herceptin1 (trastuzumab) for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Sales in the three and nine months ended September 30, 2023, compared to 2022, increased 36% and 8%, respectively, driven by increased demand and the timing of tenders in Brazil partially offset by the competitive pressures in Europe. We have commercialization rights to Ontruzant in countries outside of Korea and China.

Brenzys is a biosimilar to Enbrel1 (etanercept) for the treatment of certain inflammatory diseases. Sales in the three and nine months ended September 30, 2023, compared to 2022, declined 43% and 13%, respectively, primarily driven by the timing of tenders in Brazil. We have commercialization rights to Brenzys in countries outside of the United States, Europe, Korea, China, and Japan.

Hadlima is a biosimilar to Humira1 (adalimumab) for the treatment of certain inflammatory diseases. We have commercialization rights to Hadlima in countries outside of the EU, Korea, China, Turkey, and Russia. Hadlima is currently approved in the United States, Australia, Canada, and Israel. We recorded sales of $8 million and $20 million during the three and nine months ended September 30, 2023, respectively, reflecting an increase from modest sales during 2022 in markets outside of the United States and the launch in the United States in July 2023.

Established Brands

Established brands represents a broad portfolio of well-known brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management, for which generic competition varies by market.

Cardiovascular
Three Months Ended September 30,% Change% Change Excluding Foreign ExchangeNine Months Ended September 30,% Change% Change Excluding Foreign Exchange
($ in millions)2023202220232022
Zetia/Vytorin$99 $118 (16)%(16)%$339 $390 (13)%(11)%
Atozet126 109 16 10 397 350 14 14 
Cozaar/Hyzaar68 70 (2)2 225 256 (12)(7)

Combined global sales of Zetia and Vytorin, medicines for lowering LDL cholesterol, declined 16% and 13% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily driven by the impact of VBP in China.

Sales of Atozet, a medicine for lowering LDL cholesterol, increased 16% and 14% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily due to increased demand in France and the timing of customers' buying patterns in the Middle East, Korea, and Mexico.

Combined global sales of Cozaar and Hyzaar, medicines for the treatment of hypertension, declined 2% and 12% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily due to ongoing generic competition.

-25-

Respiratory
Three Months Ended September 30,% Change% Change Excluding Foreign ExchangeNine Months Ended September 30,% Change% Change Excluding Foreign Exchange
($ in millions)2023202220232022
Singulair$91 $94 (4)%— %$290 $316 (8)%(3)%
Nasonex55 49 10 16 188 182 3 7 
Dulera49 40 24 24 144 127 13 14 

Worldwide sales of Singulair® (montelukast sodium), a once-a-day oral medicine for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis, remained consistent during the three months ended September 30, 2023 compared to 2022. Sales of Singulair declined 8% during the nine months ended September 30, 2023, compared to 2022, due to increased pricing pressures in China related to renewal contracts for hospital tenders and the alleviation of our competitors' supply disruptions in Japan during 2022, which had positively impacted demand for Singulair in 2022.

Global sales of Nasonex® (mometasone), an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, increased 10% and 3% during the three and nine months ended September 30, 2023, compared to 2022, due to increased demand across several markets partially offset by a $10 million milestone payment related to a regulatory approval received during the first quarter of 2022.

Global sales of Dulera, a combination medicine for the treatment of asthma, increased 24% and 13% for the three and nine months ended September 30, 2023, respectively, compared to 2022, primarily due to the favorable impact from discount rates and price in the United States.

Non-Opioid Pain, Bone and Dermatology
Three Months Ended September 30,% Change% Change Excluding Foreign ExchangeNine Months Ended September 30,% Change% Change Excluding Foreign Exchange
($ in millions)2023202220232022
Arcoxia$64 $64 — %5 %$207 $185 12 %16 %
Diprospan31 28 10 11 58 91 (37)(36)

Sales of Arcoxia, a medicine for the treatment of arthritis and pain, remained consistent during the three months ended September 30, 2023 compared to 2022. Sales of Arcoxia increased 12% during the nine months ended September 30, 2023, compared to 2022, primarily due to customers buying patterns in various international regions and higher demand in China.

Sales of Diprospan, a corticosteroid approved for treatment of wide range of inflammatory conditions, increased 10% during the three months ended September 30, 2023 compared to 2022 as the Company replenishes supply from the Market Action. Sales of Diprospan declined 37% during the nine months ended September 30, 2023, compared to 2022, due to the Market Action. In the first quarter of 202

3, we resolved the regulatory inspection findings. The Company expects sales recovery to continue to occur over the next twelve months.

Other
Three Months Ended September 30,% Change% Change Excluding Foreign ExchangeNine Months Ended September 30,% Change% Change Excluding Foreign Exchange
($ in millions)2023202220232022
Proscar$25 $27 (6)%(2)%$77 $77 — %6 %

Worldwide sales of Proscar, a medicine for the treatment of symptomatic benign prostate enlargement, for the three and nine months ended September 30, 2023 were substantially consistent with sales for the corresponding periods in 2022.

-26-
Costs, Expenses and Other
Three Months Ended September 30,% ChangeNine Months Ended September 30,% Change
($ in millions)2023202220232022
Cost of sales$612 $551 11 %$1,832 $1,700 8 %
Selling, general and administrative538 440 22 1,424 1,234 15 
Research and development137 127 8 394 329 20 
Acquired in-process research and development and milestones— 10 (100)8 107 (93)
Restructuring costs— 11 (100)4 11 (64)
Interest expense134 108 24 398 303 31 
Exchange losses (gains)14 4 *25 (21)*
Other expense, net4 4 — 11 15 (27)
$1,439 $1,255 15 %$4,096 $3,678 11 %
* Calculation not meaningful.

Cost of Sales

Cost of sales increased 11% and 8% for the three and nine months ended September 30, 2023, respectively, compared to the same periods in 2022, primarily due to foreign exchange translation, higher employee-related costs and distribution related costs, which increased as a result of inflationary pressures, and product mix. During the nine months ended September 30, 2022, the Company recorded an impairment charge of $9 million related to a product right for a biosimilar product.

Selling, General and Administrative

Selling, general and administrative expenses increased 22% and 15% for the three and nine months ended September 30, 2023, respectively, compared to the same period in 2022, due to higher employee-related costs, costs incurred in connection with the separation from Merck, which includes the implementation of the enterprise resource planning system, and the $80 million charge related to the Microspherix legal matter as discussed in Note 15. "Contingencies" to the Condensed Consolidated Financial Statements.

Research and Development

Research and development expenses increased 8% and 20% for the three and nine months ended September 30, 2023, respectively, compared to the same period in 2022, primarily due to higher costs associated with the Company's recent acquisitions of clinical stage assets, increased clinical study activity and higher employee-related costs.

Acquired In-Process Research and Development and Milestones

For the nine months ended September 30, 2023, acquired in-process research and development and milestones of $8 million related to the Claria transaction. For the three months ended September 30, 2022, acquired in-process research and development and milestones represents the upfront milestones related to the Cirqle transaction. For the nine months ended September 30, 2022 acquired in-process research and development and milestones represents the upfront and development milestones related to both the Cirqle and Henlius transactions.

Restructuring Costs

For the nine months ended September 30, 2023, the Company incurred $4 million of headcount related restructuring expense as part of the restructuring activities which were initiated during 2022 to optimize its internal operations.

Interest Expense

For the three months ended September 30, 2023, interest expense increased due to increased interest rates on our term loans. For the nine months ended September 30, 2023, interest expense increased due to increased interest rates, unamortized debt fees and discounts expensed as part of the prepayment on the U.S. Dollar-denominated term loan and the impact of exchange rates.

-27-
Exchange Losses (Gains)

For the three and nine months ended September 30, 2023, the change in exchanges losses (gains) was driven by foreign currency translation losses as well as the impact of the portion of Euro-denominated debt not designated as a net investment hedge in the prior year period.

Other Expense, net

For the three and nine months ended September 30, 2023, other expense, net, remained relatively consistent with the prior year.

Taxes on Income

The effective income tax rates were 27.0% and 19.6% for the three months ended September 30, 2023 and 2022, respectively, and 16.1% and 20.0% for the nine months ended September 30, 2023 and 2022, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense. The 2023 quarter-to-date and year-to-date effective tax rate favorable impact is primarily attributable to a reduced tax rate arrangement that was agreed to in Switzerland for an active entity.

On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2023 results. The Company will continue to assess future impacts of this legislation.

Liquidity and Capital Resources

As of September 30, 2023, Organon had cash and cash equivalents of $414 million.

Working capital was $1.6 billion and $1.4 billion as of September 30, 2023 and December 31, 2022, respectively. The increase in working capital was primarily driven by an increase in inventory and the timing of collection of receivables.

Net cash provided by operating activities was $402 million for the nine months ended September 30, 2023 compared to $591 million for the same period in the prior year. The decrease in cash provided by operating activities was primarily attributable to lower net income partially offset by the changes in working capital balances.

Net cash used in investing activities was $179 million for the nine months ended September 30, 2023 compared to $359 million for the same period in the prior year, primarily reflecting lower investment in business development transactions in the nine months ended September 30, 2023 compared to the same period in the prior year, partially offset by an increase in capital expenditures.

Net cash used in financing activities was $492 million for the nine months ended September 30, 2023 compared to $351 million for the same period in the prior year. The increase in cash used in financing activities was driven by the $250 million voluntary prepayment on the U.S. Dollar-denominated term loan in the first quarter of 2023.

Organon will continue to monitor the impacts of the Ukraine-Russia war and the Hamas-Israel war, which may negatively impact Organon's operations, financial position, or cash flows. For the three and nine months ended September 30, 2023 and 2022, Organon's combined revenues from Ukraine, Russia and Israel were approximately 2% of total revenues. As of September 30, 2023, the Company's assets in Ukraine, Russia and Israel are not material.

Our contractual obligations as of September 30, 2023, which require material cash requirements in the future, consist of contractual milestones, purchase obligations and lease obligations. In addition, Organon is responsible for settlement of certain tax matters that the Company expects to pay during 2023. Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2022 for further details. The Company has terminated the ebopiprant license agreement and development program; as a result, the Company will not owe the previously disclosed $25 million milestone payment or other milestone payments under the ebopiprant license agreement. As of September 30, 2023, there have been no material changes to our contractual obligations, or settlements of tax matters outside the ordinary course of business.

-28-
During the third quarter of 2023, Organon paid cash dividends of $0.28 per share. On November 2, 2023, the Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 14, 2023, to stockholders of record at the close of business on November 13, 2023.

The Company has historically generated and expects to continue to generate positive cash flow from operations. Our ability to fund our operations and anticipated capital needs is reliant upon the generation of cash from operations, supplemented as necessary by periodic utilization of our Revolving Credit Facility. Our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures, repayment of borrowings, payment of dividends and strategic business development transactions. We believe that our financing arrangements, future cash from operations, and access to capital markets will provide adequate resources to fund our future cash flow needs.

Critical Accounting Estimates

Our significant accounting policies, which include management’s best estimates and judgments, are included in Note 3 "Summary of Accounting Policies" to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. See Note 2 "Basis of Presentation" to the Condensed Consolidated Financial Statements for information on the adoption of new accounting standards during 2023. There have been no changes to our accounting policies as of September 30, 2023. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Organon's Annual Report on Form 10-K for the year ended December 31, 2022.

Recently Issued Accounting Standards

For a discussion of recently issued accounting standards, see Note 2 "Basis of Presentation" to the Condensed Consolidated Financial Statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency Risk

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely affected by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to forecasted transactions and net assets denominated in the euro, Swiss franc, and Japanese yen. We established a balance sheet risk management program and a net investment hedge to mitigate against volatility of changes in foreign exchange rates. See Note 10 "Financial Instruments" to the Condensed Consolidated Financial Statements included elsewhere in this report for further information on Organon’s risk management.

Interest Rate Risk

Our long-term debt portfolio consists of both fixed and variable-rate instruments. For any variable rate debt, interest rate changes in the underlying index rates will impact future interest expense. We do not hold any derivative contracts that hedge our interest rate risk; however, we may consider entering into such contracts in the future.

There have been no changes to Organon’s market risk during the quarter ended September 30, 2023. For a discussion of our exposure to market risk, refer to our market risk disclosures set forth under Item 7A.—Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4. Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the period ending September 30, 2023. Based upon that evaluation, our CEO and our CFO concluded that, as of September 30, 2023, the end of the period covered by this report, the Company's disclosure controls and procedures were effective and provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the applicable rules and forms, and that it is accumulated and communicated to our management, including our CEO and our CFO, as appropriate, to allow timely decisions regarding required disclosure.

-29-
The Company began an implementation of an enterprise resource planning ("ERP") system, which will replace the existing core financial system. The ERP system is designed to accurately maintain the Company's financial records used to report operating results. The implementation of the consolidated financial reporting module will be completed during Q4 of the 2023 fiscal year. The implementation of the general ledger modules is in progress and occurring in phases and is expected to be completed by the first half of 2024. The changes in process under the new ERP will continue to be subject to our evaluation of the operating effectiveness of internal control over financial reporting.

Except for the implementation of an ERP system, there was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The information called for by this Item is incorporated herein by reference to Note 15 "Contingencies" included in Part I, Item. 1.

Item 1A. Risk Factors

There have been no material changes in the Company's risk factors from those disclosed in Item 1A. Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.

Item 5. Other Information

During the three months ended September 30, 2023, no director or officer of the company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
-30-
Item 6. Exhibits
Number
Description
10.1
*31.1
—
*31.2
—
**32.1
—
**32.2
—
101.INS
—
XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH
—
XBRL Taxonomy Extension Schema Document.
101.CAL
—
XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
—
XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
—
XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
—
XBRL Taxonomy Extension Presentation Linkbase Document.
104
—
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
*Filed herewith
**Furnished herewith

1 Indicates, in this Form 10-Q for Quarter Ending September 30, 2023, brand names of products, which are trademarks not owned by the Company or its subsidiaries. Humira is a trademark registered in the United States in the name of AbbVie Biotechnology Ltd.; Enbrel is a trademark registered in the United States in the name of Immunex Corporation; Remicade is a trademark registered in the United States in the name of Janssen Biotech, Inc.; and Herceptin is a trademark registered in the United States in the name of Genentech, Inc. Brand names of products that are in all italicized letters, without the footnote, are trademarks of, or are otherwise licensed by, Organon and/or one of its subsidiaries.

-31-
Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ORGANON & CO.
Date: November 3, 2023
/s/ Kathryn DiMarco
Kathryn DiMarco
Senior Vice President Finance - Corporate Controller
Date: November 3, 2023
/s/ Matthew Walsh
Matthew Walsh
Chief Financial Officer



















 EX-31.1 2 ogn09302023-exhibit311.htm EX-31.1 Document

Exhibit 31.1


CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin Ali, certify that:

1. I have reviewed this Form 10-Q of Organon & Co;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. the registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


November 3, 2023
/s/ Kevin Ali
Kevin Ali
Chief Executive Officer

 EX-31.2 3 ogn09302023-exhibit312.htm EX-31.2 Document


Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew Walsh, certify that:

1. I have reviewed this Form 10-Q of Organon & Co;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. the registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 3, 2023
/s/ Matthew Walsh
Matthew Walsh
Chief Financial Officer


 EX-32.1 4 ogn09302023-exhibit321.htm EX-32.1 Document

Exhibit 32.1


CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. § 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C.§ 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended September 30, 2023 of Organon & Co. fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.§ 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Organon & Co.

November 3, 2023
/s/ Kevin Ali
Kevin Ali
Chief Executive Officer




 EX-32.2 5 ogn09302023-exhibit322.htm EX-32.2 Document


Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. § 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C.§ 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended September 30, 2023 of Organon & Co. fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.§ 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Organon & Co.

November 3, 2023
/s/ Matthew Walsh
Matthew Walsh
Chief Financial Officer


 EX-101.SCH 6 ogn-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Background and Nature of Operations link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Acquisitions and Licensing Arrangements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Earnings per Share ("EPS") link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Product and Geographic Information link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Stock-Based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Taxes on Income link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Samsung Collaboration link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Third-Party Arrangements link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Earnings per Share ("EPS") (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Product and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Stock-Based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Samsung Collaboration (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Third-Party Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Background and Nature of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Acquisitions and Licensing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Earnings per Share ("EPS") (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Product and Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Product and Geographic Information - Sales of Company's Products (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Product and Geographic Information - Revenues by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Stock-Based Compensation Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Stock-Based Compensation Plans - Stock-based Compensation Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Stock-Based Compensation Plans - Stock Option Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Stock-Based Compensation Plans - Equity Award Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Stock-Based Compensation Plans - Equity Awards Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Financial Instruments - Schedule of Financial Instruments Recorded at Estimated Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Financial Instruments - Schedule of Long-term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Financial Instruments - Schedule of (Gain) Loss on Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Long-Term Debt - Summary of Long-term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Long-Term Debt - Summary of Long-term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Long-Term Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Long-Term Debt - Schedule of Maturities on Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Samsung Collaboration - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Samsung Collaboration - Summary of Information Related to Collaboration (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Third-Party Arrangements - Accounts Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Third-Party Arrangements - Sales and Cost of Sales Resulting from the Manufacturing and Supply Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ogn-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ogn-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ogn-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Net changes in assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Schedule of Sales of Company's Products Revenue from External Customers by Products and Services [Table Text Block] Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Marvelon/Mercilon Marvelon/Mercilon [Member] Marvelon/Mercilon Statement of Stockholders' Equity [Abstract] Average maturity of long-term debt Debt Instrument, Average Maturity Debt Instrument, Average Maturity Revolving Credit Facility Revolving Credit Facility [Member] Accounts receivables factored Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Effect of Exchange Rate Changes on Cash and Cash Equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Propecia/ Proscar Propecia/ Proscar [Member] Propecia/ Proscar Restricted Stock, Remaining Term Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Deferred income taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] PSU's Performance Share Units Performance Shares [Member] Segment Reporting [Abstract] Trade accounts payable Payables to Samsung included in Trade accounts payable Due to Merck in Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Number of pending claims Loss Contingency, Pending Claims, Number Contingencies (Note 15) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Number of countries product sold in Number Of Countries Product Sold In Number Of Countries Product Sold In Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Vested/Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stock Options, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Geographical [Axis] Geographical [Axis] Taxes on Income Income Tax Disclosure [Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Number of pending putative class actions Loss Contingency, Pending Claims, Number of Pending Putative Class Actions Loss Contingency, Pending Claims, Number of Pending Putative Class Actions Current Liabilities: Liabilities, Current [Abstract] Acquired in-process research and development and milestones Payments to Acquire in Process Research and Development Provision of services extension period Separation And Distribution Agreement, Provision Of Services Extension Period Separation And Distribution Agreement, Provision Of Services Extension Period Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Brenzys Brenzys [Member] Brenzys Recognized as: Inventory, Net [Abstract] Forfeited/Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted (in dollars per share) Earnings Per Share, Diluted Number of medicines and products Number Of Medicines And Products Number Of Medicines And Products Net transfers to Merck & Co., Inc. Net Financing Transfers Net Financing Transfers PEO Total Compensation Amount PEO Total Compensation Amount Other Other Sundry Products [Member] Other Sundry Products Accounts receivable (net of allowance for doubtful accounts of $9 in 2023 and $9 in 2022) Receivables from Samsung included in Other current assets Due from Merck in Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Secured Overnight Financing Rate (SOFR) Six Month Interest Period Secured Overnight Financing Rate (SOFR) Six Month Interest Period [Member] Secured Overnight Financing Rate (SOFR) Six Month Interest Period Aybintio Aybintio [Member] Aybintio Stock Options, Weighted Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Implanon Implanon [Member] Implanon Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] us-Secured Overnight Financing Rate (SOFR) Three Month Interest Period us-Secured Overnight Financing Rate (SOFR) Three Month Interest Period [Member] us-Secured Overnight Financing Rate (SOFR) Three Month Interest Period Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Amount of legal defense reserves Estimated Litigation Liability 2.875% Senior Secured Notes Due 2028 2.875% Senior Secured Notes Due 2028 [Member] 2.875% Senior Secured Notes Due 2028 Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Long-term debt Long-Term Debt, Fair Value Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Propecia Propecia [Member] Propecia Tax Other Comprehensive Income (Loss), Tax Net Income Net income Net income Net Income (Loss) Total Current Liabilities Liabilities, Current Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Derivative Contract [Domain] Derivative Contract [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Costs, Expenses and Other Cost of Revenue [Abstract] Liabilities and Equity Liabilities and Equity [Abstract] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Organon & Co. Stockholders' Deficit: Equity, Attributable to Parent [Abstract] Vested/Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Total (approximates current cost) Inventory, Gross Schedule of Basic and Diluted Earnings Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of sales Cost of sales Cost of Goods and Services Sold Clarinex Clarinex [Member] Clarinex Samsung Bioepis Samsung Bioepis Co., Ltd. [Member] Samsung Bioepis Co., Ltd. Schedule of Inventory, Noncurrent Schedule of Inventory, Noncurrent [Table Text Block] Executive Category: Executive Category [Axis] Follistim AQ Follistim AQ [Member] Follistim AQ Vested/Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Benefit plan net loss and prior service cost, net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Name Measure Name Name Forgone Recovery, Individual Name Cozaar/Hyzaar Cozaar/Hyzaar [Member] Cozaar/Hyzaar Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities Decrease to LIFO costs Inventory, LIFO Reserve 2024 Long-Term Debt, Maturity, Year Two Asset Acquisition [Domain] Asset Acquisition [Domain] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Commercial milestone payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Unrealized foreign exchange loss (gain) Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Forecast Forecast [Member] Notional amount Derivative, Notional Amount Selling, general and administrative Selling, General and Administrative Expenses [Member] Common stock dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Other State Courts Other State Courts [Member] Other State Courts Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Schedule of Long-term Debt Instruments Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Northern District of Ohio Northern District of Ohio [Member] Northern District of Ohio Income Statement Location [Axis] Income Statement Location [Axis] Summary of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Other (discounts and debt issuance costs) Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Foreign Exchange Forward Foreign Exchange Forward [Member] Income taxes payable Accrued Income Taxes, Current Revenues Sales Sales Revenues Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Restructuring activities Restructuring Reserve Award Type [Axis] Award Type [Axis] Anti-dilutive shares excluded from the calculation of EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Diprospan Diprospan [Member] Diprospan Interest expense Interest Expense Acquired in-process research and development and milestones Acquired in-process research and development and milestones Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Latin America, Middle East, Russia, and Africa Latin America, Middle East, Russia and Africa [Member] Latin America, Middle East, Russia and Africa Notes Payable, Other Payables Notes Payable, Other Payables [Member] Trading Arrangement: Trading Arrangement [Axis] Collaboration agreement period Collaboration Arrangement Agreement Period Collaboration Arrangement Agreement Period Third-Party Arrangements Related Party Transactions Disclosure [Text Block] Number of unfiled claims Loss Contingency, Unfiled Claims, Number Loss Contingency, Unfiled Claims, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Inventories valued under the last in, first out ("LIFO") method LIFO Inventory Amount 2025 Long-Term Debt, Maturity, Year Three Upfront payments Collaborative Arrangement, Rights and Obligations, Upfront Payment Collaborative Arrangement, Rights and Obligations, Upfront Payment Entity Shell Company Entity Shell Company Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Intangibles, net Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Other (Income) Expense Other Operating Income (Expense) [Member] Derivative Gain Statement of Income or Comprehensive Income [Extensible Enumeration] DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag Income taxes payable Increase (Decrease) in Income Taxes Payable Other Women's Health Other Womens Health [Member] Other Womens Health Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, issued (in shares) Common Stock, Shares, Issued Vested/Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Stock Option Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Total principal long-term debt Long-Term Debt Net transfers to Merck & Co., Inc. including Separation Adjustments Consideration Paid in Connection With the Separation Consideration Paid in Connection With the Separation Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expense 2026 Long-Term Debt, Maturity, Year Four Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Samsung Collaboration Collaborative Arrangement Disclosure [Text Block] Employee Stock Option Employee Stock Option [Member] Cumulative Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Amount of unrecognized compensation costs period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Asset Acquisition [Table] Asset Acquisition [Table] Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Term Loan B Facility Term Loan B Facility [Member] Term Loan B Facility Amount of unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Thereafter Long-Term Debt, Maturity, after Year Five Acquisitions and Licensing Arrangements Asset Acquisition [Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Other Cardiovascular Other Cardiovascular [Member] Other Cardiovascular Stock-Based Compensation Plans Share-Based Payment Arrangement [Text Block] Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Other Other Noncash Income (Expense) Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Nasonex Nasonex [Member] Nasonex Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Subsequent event Subsequent Event [Member] Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Number of manufacturing facilities Number of Manufacturing Facilities Number of Manufacturing Facilities Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Related Party [Domain] Related Party, Type [Domain] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Hadlima Hadlima [Member] Hadlima Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Award performance period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Equity Awards Vested and Expected to Vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Financial Instruments Financial Instruments Disclosure [Text Block] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventories (excludes inventories of $95 in 2023 and $148 in 2022 classified in Other assets) Inventories Inventory, Net Forward contracts in Accrued and other current liabilities Fair Value Hedge Liabilities Statistical Measurement [Axis] Statistical Measurement [Axis] Spain SPAIN Inventories classified in other assets Other assets Inventory, Noncurrent Other current assets Increase (Decrease) in Other Current Assets Total, costs expenses and other Costs Expenses And Other Costs Expenses And Other Restricted Stock, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total Shareholder Return Amount Total Shareholder Return Amount Number of claims on appeal Loss Contingency, Claims on Appeal, Number Loss Contingency, Claims on Appeal, Number Singulair Singulair [Member] Singulair Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Face amount of debt Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 4.125% Senior Secured Notes Due 2028 4.125% Senior Secured Notes Due 2028 [Member] 4.125% Senior Secured Notes Due 2028 Current Assets: Assets, Current [Abstract] Euro Interbank Offered Rate Euro Interbank Offered Rate [Member] Euro Interbank Offered Rate Number of pending class actions Loss Contingency, Pending Claims, Number of Pending Class Actions Loss Contingency, Pending Claims, Number of Pending Class Actions Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Carrying Values and Estimated Fair Values of Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Early repayment of senior debt Early Repayment of Senior Debt Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Nexplanon Nexplanon [Member] Nexplanon Earnings per Share: EPS: Earnings Per Share, Basic [Abstract] PEO PEO [Member] Other Other Sundry Established Brands [Member] Other Sundry Established Brands Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net Cash Flows Used in Investing Activities Net Cash Provided by (Used in) Investing Activities Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Asia Pacific and Japan Asia Pacific and Japan [Member] Asia Pacific and Japan Debt Instrument [Axis] Debt Instrument [Axis] Net income Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Fosamax Fosamax [Member] Fosamax Stock Options, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Credit Facility [Axis] Credit Facility [Axis] Schedule of Maturities on Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total Liabilities Liabilities Summary of Equity Awards Outstanding Share-Based Payment Arrangement, Activity [Table Text Block] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Asset Acquisition [Axis] Asset Acquisition [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Stock Options, Weighted Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Brazil BRAZIL All Executive Categories All Executive Categories [Member] Oncology Biosimilar Oncology Biosimilar [Member] Oncology Biosimilar Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] CANADA CANADA Income tax benefits Share-Based Payment Arrangement, Expense, Tax Benefit Earnings Per Share [Abstract] Basis of Presentation Basis of Accounting [Text Block] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Related Party Affiliated Entity [Member] Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 255,606 in 2023 and 254,370 in 2022 Common Stock, Value, Issued China CHINA Organization, Consolidation and Presentation of Financial Statements [Abstract] Weighted Average Shares Outstanding: Earnings Per Share, Diluted, Other Disclosure [Abstract] Accrued and other current liabilities Accrued and Other Liabilities, Current Accrued and Other Liabilities, Current Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total Current Assets Assets, Current Impairment of assets Asset Impairment Charges Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] California State Court California State Court [Member] California State Court Litigation Case [Domain] Litigation Case [Domain] Amortization Amortization Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Number of positions Restructuring and Related Cost, Number of Positions Eliminated PEO Name PEO Name Schedule of Product Information [Table] Schedule of Product Information [Table] Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Net Cash Flows Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Other assets Deferred Income Taxes and Other Assets, Noncurrent Background and Nature of Operations Nature of Operations [Text Block] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Jada Jada [Member] Jada Long-Term Debt Debt Disclosure and Lessee, Operating Leases [Text Block] Debt Disclosure and Lessee, Operating Leases Business Combination and Asset Acquisition [Abstract] Total Stockholders' Deficit Beginning balance Ending balance Equity, Attributable to Parent Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Restricted Share Units Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Number of claims dismissed Loss Contingency, Claims Dismissed, Number Expected life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Income Before Income Taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Purchase of product rights and asset acquisition, net of cash acquired Payments to Acquire Intangible Assets Europe and Canada Europe and Canada [Member] Europe and Canada Restructuring Restructuring and Related Activities Disclosure [Text Block] Level 2 Fair Value, Inputs, Level 2 [Member] Debt instrument interest payments Debt Instrument, Interest Payments Debt Instrument, Interest Payments Entity Emerging Growth Company Entity Emerging Growth Company Supplies Other Inventory, Supplies, Gross Finished goods Inventory, Finished Goods, Gross Schedule of (Gain) Loss on Derivative Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Ganirelix Acetate Injection Ganirelix Acetate Injection [Member] Ganirelix Acetate Injection Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Share-based Compensation Plans Share-Based Payment Arrangement [Member] Title Trading Arrangement, Individual Title Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Schedule of Consolidated Revenues by Geographic Area Revenue from External Customers by Geographic Areas [Table Text Block] Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Inventory Inventory Net And Inventory Noncurrent Inventory Net And Inventory Noncurrent Product and Service [Axis] Product and Service [Axis] Earnings per Share ("EPS") Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Atozet Atozet [Member] Atozet Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Other expense, net Other Operating and Nonoperating Income (Expense) Other Operating and Nonoperating Income (Expense) Summary of Information Related to Collaboration Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Proscar Proscar [Member] Proscar Minimum Minimum [Member] Property, plant and equipment, net Property, Plant and Equipment, Net Exercise Price Award Exercise Price Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Other comprehensive income (loss) Other comprehensive loss, net of taxes Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Cash dividends declared on common stock Dividends, Common Stock, Cash Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Proceeds from debt Proceeds from Issuance of Long-Term Debt Exchange losses (gains) Gain (Loss), Foreign Currency Transaction, before Tax Employee withholding taxes related to stock-based awards Payment, Tax Withholding, Share-Based Payment Arrangement Vytorin Vytorin [Member] Vytorin Net Cash Flows Used in Financing Activities Net Cash Provided by (Used in) Financing Activities Secured Overnight Financing Rate (SOFR) One Month Interest Period Secured Overnight Financing Rate (SOFR) One Month Interest Period [Member] Secured Overnight Financing Rate (SOFR) One Month Interest Period 5.125% Senior Unsecured Notes Due 2031 5.125% Senior Unsecured Notes Due 2031 [Member] 5.125% Senior Unsecured Notes Due 2031 Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Current portion of long-term debt Less: Current portion of long-term debt Long-Term Debt, Current Maturities Schedule of Stock-based Compensation Expenses Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total Liabilities and Stockholders' Deficit Liabilities and Equity Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Euro Denominated Term Loan B Euro Denominated Senior Secured Tranche B Term Loan [Member] Euro Denominated Senior Secured Tranche B Term Loan Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Stock Options, Remaining Term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Stock Options, Awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Gross profit sharing arrangement percentage Collaboration Arrangement, Profit Sharing Arrangement, Percentage Collaboration Arrangement, Profit Sharing Arrangement, Percentage Restructuring costs Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Term Loan B Facility Euro Denominated Term Loan B Facility [Member] Euro Denominated Term Loan B Facility Federal Federal [Member] Federal Termination Date Trading Arrangement Termination Date Forward contracts in Other current assets Fair Value Hedge Assets Common stock, authorized (in shares) Common Stock, Shares Authorized Immunology Biosimilar Immunology Biosimilar [Member] Immunology Biosimilar Raw materials Inventory, Raw Materials, Gross Ontruzant Ontruzant [Member] Ontruzant New Jersey State Court New Jersey State Court [Member] New Jersey State Court Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt Long-Term Debt, Gross Adjustments to reconcile net income to net cash flows provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Rosuzet Rosuzet [Member] Rosuzet Compensation Amount Outstanding Recovery Compensation Amount Claria Medical, Inc. Claria Medical, Inc. [Member] Claria Medical, Inc. Other Comprehensive Income, Net of Taxes: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Forfeited/Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income taxes Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Work in process Inventory, Work in Process, Gross Forfeited/Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] 2023 Long-Term Debt, Maturity, Year One Number of biosimilar products Number Of Biosimilar Products Number Of Biosimilar Products Related Party [Axis] Related Party, Type [Axis] Stock-based compensation plans and other (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Stock awards and equity units (share equivalent) (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Cost of sales Cost of Sales [Member] Payments for restructuring Payments for Restructuring Document Period End Date Document Period End Date Organon Finance 1 LLC Organon Finance 1 LLC [Member] Organon Finance 1 LLC Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Schedule of Financial Instruments Recorded at Estimated Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Forfeited/Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Repayments of debt Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Gains on derivatives Derivative, Gain (Loss) on Derivative, Net Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Taxes on income Income Tax Expense (Benefit) Int’l Non-US [Member] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Other comprehensive loss, net of taxes Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Femur Fracture Litigation Femur Fracture Litigation [Member] Femur Fracture Litigation Equity [Abstract] Inventories Inventory Disclosure [Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Other Non-Opiod Pain, Bone and Dermatology Other Non-Opiod Pain, Bone and Dermatology [Member] Other Non-Opiod Pain, Bone and Dermatology Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Restricted stock, Awards (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Amendment Flag Amendment Flag Summary of Equity Award Transactions Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Credit Facility [Domain] Credit Facility [Domain] Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Equity Awards Vested and Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest Other Other Countries [Member] Other Countries Spread on variable rate Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Governmental fine Loss Contingency, Damages Sought, Value Long-term debt Total Long-term debt, net of current portion Long-Term Debt, Excluding Current Maturities Diluted (in shares) Diluted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Dulera Dulera [Member] Dulera Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Capital expenditures Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-In Capital Additional Paid-in Capital [Member] Total Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Other Respiratory Other Respiratory [Member] Other Respiratory Stock Options, Remaining Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Stock-based compensation plans and other APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 2027 Long-Term Debt, Maturity, Year Five U.S. United States UNITED STATES Restructuring and Related Activities [Abstract] Dividend payments Payments of Dividends Other noncurrent liabilities Other Liabilities, Noncurrent Vested/Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Forfeited/Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Headcount reductions, percent Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent Other comprehensive loss, pretax Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Weighted-average interest rate of debt Long-Term Debt, Weighted Average Interest Rate, over Time Potential future regulatory milestone payments Collaboration Agreement, Potential Contractual Obligation Collaboration Agreement, Potential Contractual Obligation Product and Geographic Information Segment Reporting Disclosure [Text Block] Net Decrease in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Nexplanon/Implanon NXT Nexplanon/Implanon NXT [Member] Nexplanon/Implanon NXT Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Zetia Zetia [Member] Zetia Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Scenario [Axis] Scenario [Axis] Arcoxia Arcoxia [Member] Arcoxia Basic (in shares) Basic weighted average number of shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status NuvaRing NuvaRing [Member] NuvaRing Renflexis Renflexis [Member] Renflexis Product Information [Line Items] Product Information [Line Items] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Net transfers from Merck & Co., Inc., including Separation Adjustments Net Transfers in Connection with Separation Net Transfers in Connection with Separation Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Stock Options, Awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Scenario [Domain] Scenario [Domain] Equity Awards That are Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Proceeds from revolving credit facility Proceeds from Long-Term Lines of Credit Euro Denominated Term Loan Euro Denominated Term Loans [Member] Euro Denominated Term Loans EX-101.PRE 10 ogn-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Oct. 27, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-40235  
Entity Registrant Name Organon & Co.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 46-4838035  
Entity Address, Address Line One 30 Hudson Street, Floor 33  
Entity Address, City or Town Jersey City,  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07302  
City Area Code (551)  
Local Phone Number 430-6900  
Title of 12(b) Security Common Stock ($0.01 par value)  
Trading Symbol OGN  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   255,606,461
Entity Central Index Key 0001821825  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Revenues $ 1,519 $ 1,537 $ 4,665 $ 4,689
Costs, Expenses and Other        
Cost of sales 612 551 1,832 1,700
Selling, general and administrative 538 440 1,424 1,234
Research and development 137 127 394 329
Acquired in-process research and development and milestones 0 10 8 107
Restructuring costs 0 11 4 11
Interest expense 134 108 398 303
Exchange losses (gains) 14 4 25 (21)
Other expense, net 4 4 11 15
Total, costs expenses and other 1,439 1,255 4,096 3,678
Income Before Income Taxes 80 282 569 1,011
Taxes on income 22 55 92 202
Net Income $ 58 $ 227 $ 477 $ 809
Earnings per Share:        
Basic (in dollars per share) $ 0.23 $ 0.89 $ 1.87 $ 3.19
Diluted (in dollars per share) $ 0.23 $ 0.89 $ 1.86 $ 3.17
Weighted Average Shares Outstanding:        
Basic (in shares) 255,588 254,348 255,112 253,986
Diluted (in shares) 256,349 255,067 256,162 255,094
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net income $ 58 $ 227 $ 477 $ 809
Other Comprehensive Income, Net of Taxes:        
Benefit plan net loss and prior service cost, net of amortization 0 0 (1) 0
Cumulative translation adjustment (43) (97) (11) (173)
Other comprehensive income (loss) (43) (97) (12) (173)
Comprehensive income $ 15 $ 130 $ 465 $ 636
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current Assets:    
Cash and cash equivalents $ 414 $ 706
Accounts receivable (net of allowance for doubtful accounts of $9 in 2023 and $9 in 2022) 1,648 1,475
Inventories (excludes inventories of $95 in 2023 and $148 in 2022 classified in Other assets) 1,186 1,003
Other current assets 802 747
Total Current Assets 4,050 3,931
Property, plant and equipment, net 1,096 1,018
Goodwill 4,603 4,603
Intangibles, net 561 649
Other assets 702 754
Total Assets 11,012 10,955
Current Liabilities:    
Current portion of long-term debt 8 8
Trade accounts payable 1,067 1,132
Accrued and other current liabilities 1,255 1,188
Income taxes payable 161 184
Total Current Liabilities 2,491 2,512
Long-term debt 8,646 8,905
Deferred income taxes 43 19
Other noncurrent liabilities 421 411
Total Liabilities 11,601 11,847
Contingencies (Note 15)
Organon & Co. Stockholders' Deficit:    
Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 255,606 in 2023 and 254,370 in 2022 3 3
Accumulated deficit (16) (331)
Accumulated other comprehensive loss (576) (564)
Total Stockholders' Deficit (589) (892)
Total Liabilities and Stockholders' Deficit $ 11,012 $ 10,955
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 9 $ 9
Inventories classified in other assets $ 95 $ 148
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 500,000,000 500,000,000
Common stock, issued (in shares) 255,606,000 254,370,000
Common stock, outstanding (in shares) 255,606,000 254,370,000
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021   253,550,000      
Beginning balance at Dec. 31, 2021 $ (1,508) $ 3 $ 0 $ (998) $ (513)
Stockholders' Equity [Roll Forward]          
Net income 809     809  
Other comprehensive loss, net of taxes (173)       (173)
Cash dividends declared on common stock (218)     (218)  
Stock-based compensation plans and other (in shares)   814,000      
Stock-based compensation plans and other 41     41  
Net transfers to Merck & Co., Inc. including Separation Adjustments (17)     (17) 0
Ending balance (in shares) at Sep. 30, 2022   254,364,000      
Ending balance at Sep. 30, 2022 (1,066) $ 3 0 (383) (686)
Beginning balance (in shares) at Jun. 30, 2022   254,321,000      
Beginning balance at Jun. 30, 2022 (1,137) $ 3 0 (551) (589)
Stockholders' Equity [Roll Forward]          
Net income 227     227  
Other comprehensive loss, net of taxes (97)       (97)
Cash dividends declared on common stock (74)     (74)  
Stock-based compensation plans and other (in shares)   43,000      
Stock-based compensation plans and other 15     15  
Net transfers from Merck & Co., Inc., including Separation Adjustments 0     0  
Ending balance (in shares) at Sep. 30, 2022   254,364,000      
Ending balance at Sep. 30, 2022 (1,066) $ 3 0 (383) (686)
Beginning balance (in shares) at Dec. 31, 2022   254,370,000      
Beginning balance at Dec. 31, 2022 (892) $ 3 0 (331) (564)
Stockholders' Equity [Roll Forward]          
Net income 477     477  
Other comprehensive loss, net of taxes (12)       (12)
Cash dividends declared on common stock (221)     (221)  
Stock-based compensation plans and other (in shares)   1,236,000      
Stock-based compensation plans and other 59     59  
Ending balance (in shares) at Sep. 30, 2023   255,606,000      
Ending balance at Sep. 30, 2023 (589) $ 3 0 (16) (576)
Beginning balance (in shares) at Jun. 30, 2023   255,568,000      
Beginning balance at Jun. 30, 2023 (555) $ 3 0 (25) (533)
Stockholders' Equity [Roll Forward]          
Net income 58     58  
Other comprehensive loss, net of taxes (43)       (43)
Cash dividends declared on common stock (74)     (74)  
Stock-based compensation plans and other (in shares)   38,000      
Stock-based compensation plans and other 25     25  
Ending balance (in shares) at Sep. 30, 2023   255,606,000      
Ending balance at Sep. 30, 2023 $ (589) $ 3 $ 0 $ (16) $ (576)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Stockholders' Equity [Abstract]        
Common stock dividends declared (in dollars per share) $ 0.28 $ 0.28 $ 0.84 $ 0.84
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flows from Operating Activities    
Net income $ 477 $ 809
Adjustments to reconcile net income to net cash flows provided by operating activities:    
Depreciation 88 72
Amortization 88 88
Impairment of assets 0 9
Acquired in-process research and development and milestones 8 107
Deferred income taxes 4 (18)
Stock-based compensation 74 52
Unrealized foreign exchange loss (gain) 19 (45)
Other 24 24
Net changes in assets and liabilities    
Accounts receivable (185) (119)
Inventories (137) (134)
Other current assets (56) (76)
Trade accounts payable (68) (323)
Accrued and other current liabilities 34 108
Income taxes payable (21) 45
Other 53 (8)
Net Cash Flows Provided by Operating Activities 402 591
Cash Flows from Investing Activities    
Capital expenditures (172) (133)
Proceeds from sale of property, plant and equipment 1 3
Acquired in-process research and development and milestones (8) (105)
Purchase of product rights and asset acquisition, net of cash acquired 0 (124)
Net Cash Flows Used in Investing Activities (179) (359)
Cash Flows from Financing Activities    
Proceeds from debt 80 0
Repayments of debt (336) (106)
Net transfers to Merck & Co., Inc. 0 (17)
Employee withholding taxes related to stock-based awards (15) (11)
Dividend payments (221) (217)
Net Cash Flows Used in Financing Activities (492) (351)
Effect of Exchange Rate Changes on Cash and Cash Equivalents (23) (119)
Net Decrease in Cash and Cash Equivalents (292) (238)
Cash and Cash Equivalents, Beginning of Period 706 737
Cash and Cash Equivalents, End of Period $ 414 $ 499
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Background and Nature of Operations
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Background and Nature of Operations Background and Nature of Operations
Organon & Co. ("Organon" or the "Company") is a global health care company with a focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.

The Company's operations include the following product portfolios:

•Women's Health: Organon's women's health products are sold by prescription primarily in two therapeutic areas, contraception, with key brands such as Nexplanon® (etonogestrel implant) (sold as Implanon NXT™ in some countries outside the United States) and NuvaRing® (etonogestrel / ethinyl estradiol vaginal ring), and fertility, with key brands such as Follistim AQ® (follitropin beta injection) (marketed in most countries outside the United States as Puregon™). Nexplanon is a long-acting reversible contraceptive, which is a class of contraceptives that is recognized as one of the most effective types of hormonal contraception available to patients with a low long-term average cost. Other women’s health products include the Jada® System, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted and a license from Daré Biosciences for the global commercial rights to Xaciato™ (clindamycin phosphate vaginal gel, 2%), an FDA-approved medication for the treatment of bacterial vaginosis ("BV") in females 12 years of age and older. In October 2023, Xaciato was launched in the United States.

•Biosimilars: Organon's current portfolio spans across immunology and oncology treatments. Organon's oncology biosimilars have been launched in more than 20 countries and Organon's immunology biosimilars have been launched in five countries. All five biosimilars in Organon's portfolio have launched in Canada, and three biosimilars; Ontruzant® (trastuzumab-dttb), Renflexis® (infliximab-abda) and Hadlima™ (adalimumab-bwwd) have been launched in the United States.

•Established Brands: Organon has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management. A number of Organon's established brands lost exclusivity years ago and have faced generic competition for some time.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company's opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon's Annual Report on Form 10-K for the year ended December 31, 2022.

Use of Estimates

The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2022. Accordingly, actual results could differ materially from management's estimates and assumptions.

The Company was impacted by COVID-19 during the first half of 2023, specifically, in the Company's operations in China. The Company does not anticipate a continued impact from COVID-19. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the
information reasonably available to the Company as of September 30, 2023 and through the date of this report which are difficult to predict.

Recently Adopted Accounting Standards

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 and December 31, 2022; the sunset date was subsequently deferred to December 31, 2024 based on the amendment issued in December 2022 under ASU 2022-06, Reference Rate Reform (Topic 848). The Company applied this guidance to our Senior Credit Agreement, as amended on June 30, 2023. The impact to the Consolidated Financial Statements as a result of the application of the reference rate reform guidance is not material. See Note 11 "Long-Term Debt" for additional details.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance became effective for the Company on January 1, 2023 and its amendments will be applied prospectively to business combinations occurring on or after the effective date of the guidance. The adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions and Licensing Arrangements
 9 Months Ended
Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions and Licensing Arrangements Acquisitions and Licensing ArrangementsClaria Medical, Inc. ("Claria")In January 2023, the Company made a strategic investment in Claria, a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy. Under the terms of the agreement, Organon paid $8 million upfront and has the option to acquire Claria for an additional $47 million, payable if and when the option is exercised. The $8 million was expensed as Acquired in-process research and development and milestones in our Condensed Consolidated Statement of Income for the nine months ended September 30, 2023.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings per Share ("EPS")
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Earnings per Share ("EPS") Earnings per Share ("EPS")
The calculations of basic and diluted earnings per common share are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions and shares in thousands, except per share amounts)2023202220232022
Net income$58 $227 $477 $809 
Basic weighted average number of shares outstanding255,588254,348255,112253,986
Stock awards and equity units (share equivalent)761 719 1,0501,108
Diluted weighted average common shares outstanding256,349255,067256,162255,094
EPS:
Basic$0.23 $0.89 $1.87 $3.19 
Diluted$0.23 $0.89 $1.86 $3.17 
Anti-dilutive shares excluded from the calculation of EPS10,390 6,313 9,833 4,432 
Diluted EPS was computed using the treasury stock method for stock option awards, performance share units and restricted share units. The computation of diluted EPS excludes the effect of the potential exercise of stock-based awards when the effect of the potential exercise would be anti-dilutive.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Product and Geographic Information
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Product and Geographic Information Product and Geographic Information
The Company's operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies within women's health, biosimilars and established brands.

Revenues of the Company's products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int'lTotalU.S.Int'lTotal
Women's Health
Nexplanon/Implanon NXT$146 $74 $220 $151 $78 $229 $418 $181 $599 $401 $194 $595 
Follistim AQ22 32 54 27 33 60 74 105 179 79 100 179 
NuvaRing
18 20 37 27 23 50 50 67 117 65 68 133 
Ganirelix Acetate Injection
4 21 25 6 30 36 15 74 88 20 77 97 
Marvelon/Mercilon
— 30 30 — 31 31 — 97 97 — 85 85 
Jada12 — 13 5 — 5 30 — 31 12 — 12 
Other Women's Health (1)
16 22 39 19 23 42 52 74 126 68 70 138 
Biosimilars
Renflexis57 12 69 54 7 60 172 29 201 145 20 166 
Ontruzant11 28 40 15 14 29 36 57 93 35 52 87 
Brenzys— 13 13 — 24 24 — 45 45 — 52 52 
Aybintio— 12 12 — 10 10 — 34 34 — 29 29 
Hadlima2 6 8 — 6 6 2 18 20 — 14 14 
Established Brands
Cardiovascular
Zetia2 65 66 2 85 87 5 234 239 7 280 287 
Vytorin2 31 33 1 30 31 5 95 100 6 98 104 
Atozet— 126 126 — 109 109 — 397 397 — 350 350 
Rosuzet— 17 17 — 17 17 — 52 52 — 55 55 
Cozaar/Hyzaar3 65 68 2 68 70 8 217 225 11 244 256 
Other Cardiovascular (1)
1 42 44 1 34 35 2 124 126 3 117 120 
Respiratory
Singulair3 88 91 3 92 94 8 282 290 8 308 316 
Nasonex— 54 55 — 49 49 — 187 188 9 173 182 
Dulera40 9 49 31 9 40 116 28 144 98 30 127 
Clarinex2 26 28 — 25 26 4 103 107 3 96 99 
Other Respiratory (1)
17 9 25 11 10 21 42 20 61 34 32 66 
Non-Opioid Pain, Bone and Dermatology
Arcoxia— 64 64 — 64 64 — 207 207 — 185 185 
Fosamax1 40 41 1 35 36 2 121 123 2 115 117 
Diprospan— 31 31 — 28 28 — 58 58 — 91 91 
Other Non-Opioid Pain, Bone and Dermatology (1)
4 70 74 2 63 65 11 196 207 10 200 210 
Other
Proscar— 25 25 — 26 27 1 76 77 1 76 77 
Propecia2 21 22 2 28 30 5 86 92 5 90 95 
Other (1)
5 72 76 6 81 87 10 231 240 21 230 251 
Other (2)
— 24 24 — 39 39 (1)103 102 — 115 116 
Revenues$370 $1,149 $1,519 $366 $1,171 $1,537 $1,067 $3,598 $4,665 $1,043 $3,646 $4,689 
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately. Revenues from Marvelon and Mercilon and Jada were previously reported as part of Other Women's Health. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.
(2) Includes manufacturing sales to Merck & Co., Inc. ("Merck") and third parties for current and prior periods.
Revenues by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Europe and Canada$392 $363 $1,259 $1,243 
United States370 366 1,067 1,043 
Asia Pacific and Japan284 283 869 888 
China202 241 661 721 
Latin America, Middle East, Russia, and Africa
239 236 687 665 
Other (1)
32 48 122 129 
Revenues$1,519 $1,537 $4,665 $4,689 
(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation Plans
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Plans Stock-Based Compensation Plans
The Company grants stock option awards, performance share units ("PSUs") and restricted share units ("RSUs") pursuant to its 2021 Incentive Stock Plan.

The PSU awards are based on the following performance factors:
•total stockholder return of the Company relative to an index of peer companies ("relative TSR") specified in the awards; and
•the results of the cumulative free cash flow ("FCF") of the Company over a three-year period.

Stock-based compensation expenses incurred by the Company were as follows:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Stock-based compensation expense recognized in:
Cost of sales$5 $3 $13 $9 
Selling, general and administrative 18 12 50 35 
Research and development4 3 11 8 
Total$27 $18 $74 $52 
Income tax benefits$6 $3 $16 $11 

The weighted average fair value of options granted was determined using the following assumptions:

Nine Months Ended
September 30,
20232022
Expected dividend yield4.82 %3.12 %
Risk-free interest rate3.56 2.47 
Expected volatility42.30 43.43 
Expected life (years)5.895.89
A summary of the equity award transactions for the nine months ended September 30, 2023 is as follows:

Stock OptionsRestricted Share UnitsPerformance Share Units
(shares in thousands)SharesWeighted average exercise priceWeighted average grant date fair valueSharesWeighted average grant date fair valueSharesWeighted average grant date fair value
Outstanding as of January 1, 20234,729 $34.34 $8.91 5,048 $33.27 486 $46.72 
Granted1,124 23.52 6.55 3,867 23.51 636 23.30 
Vested/Exercised— — — (1,930)33.93 — — 
Forfeited/Cancelled(89)36.12 8.70 (459)30.79 — — 
Outstanding as of September 30, 2023
5,764 $32.21 $8.45 6,526 $27.47 1,122 $33.44 

The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2023:

Equity Awards Vested and Expected to VestEquity Awards That are Exercisable
(awards in thousands; aggregate intrinsic value in millions)
AwardsWeighted Average Exercise PriceAggregate Intrinsic Value
Remaining
Term
(in years)
AwardsWeighted Average Exercise PriceAggregate Intrinsic Value
Remaining
Term
(in years)
Stock Options5,591 $32.21 $— 7.043,311 $33.79 $— 5.87
Restricted Share Units6,071 114 1.98
Performance Share Units629 12 1.82

The amount of unrecognized compensation costs as of September 30, 2023 was $170 million, which will be recognized in operating expense ratably over the weighted average vesting period of 1.93 years.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring
 9 Months Ended
Sep. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In 2022, Organon initiated restructuring activities to optimize its internal operations by reducing headcount through selected markets and functions. As a result of this program, the Company restructured approximately 130 positions, with the majority of the position eliminations occurring in selected markets outside of the United States in our commercial organizations. During the nine months ended September 30, 2023, $15 million of restructuring charges have been paid, with the remaining severance payments to be paid by the end of the 2023 fiscal year. For the nine months ended September 30, 2023, the Company recorded restructuring charges of $4 million, which relate to severance costs for eliminated positions.

Liabilities for costs associated with restructuring activities were $10 million and $20 million at September 30, 2023 and December 31, 2022, respectively, and are included primarily in Accrued and other current liabilities.

In the fourth quarter of 2023, Organon will implement additional restructuring activities to optimize its internal operations by reducing headcount in certain markets and functions. As a result of these activities, the Company expects to restructure approximately 3% of the Company's headcount, which is expected to result in a charge of approximately $60 million to $70 million primarily representing severance and severance related costs in the fourth of quarter of 2023. These amounts will be paid over the next twelve months.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Taxes on Income
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Taxes on Income Taxes on IncomeThe effective income tax rates were 27.0% and 19.6% for the three months ended September 30, 2023 and 2022, respectively, and 16.1% and 20.0% for the nine months ended September 30, 2023 and 2022, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense. The 2023 year-to-date effective tax rate favorable impact is primarily attributable to a reduced tax rate arrangement that was agreed to in Switzerland for an active entity.On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2023 results. The Company will continue to assess future impacts of this legislation.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of:
($ in millions)September 30, 2023December 31, 2022
Finished goods$496 $482 
Raw materials
128 44 
Work in process606 601 
Supplies57 44 
Total (approximates current cost)$1,287 $1,171 
Decrease to LIFO costs(6)(20)
 $1,281 $1,151 
Recognized as:
Inventories$1,186 $1,003 
Other assets95 148 
Inventories valued under the last in, first out ("LIFO") method85 77 
Amounts recognized as Other assets are comprised primarily of raw materials and work in process inventories and are not expected to be converted to finished goods that will be sold within one year. The Company has a long-term vendor supply contract that includes certain annual minimum purchase commitments.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Foreign Currency Risk Management

The Company has a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates.

The Company uses a balance sheet risk management program to partially mitigate the exposure of net monetary assets of its subsidiaries that are denominated in a currency other than a subsidiary's functional currency from the effects of volatility in foreign exchange. In these instances, Organon principally utilizes forward exchange contracts to partially offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Swiss franc, and Japanese yen. For exposures in developing country currencies, the Company enters into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument.

Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Exchange losses (gains). The forward contracts are not designated as hedges and are marked to market through Exchange losses (gains). Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year. The notional amount of forward contracts was $1.0 billion and $1.5 billion as of September 30, 2023 and December 31, 2022, respectively. The cash flows and the related gains and losses from these contracts are reported as operating activities in the Condensed Consolidated Statements of Cash Flows.
The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of our assets and liabilities were as follows:
($ in millions)Fair Value Measurement Level September 30, 2023December 31, 2022
Forward contracts in Other current assets
2$17 $6 
Forward contracts in Accrued and other current liabilities
212 24 

Foreign exchange risk is also managed through the use of economic hedges on foreign currency balances. See Note 11 "Long-Term Debt" for additional details. €1.983 billion in the aggregate of both the euro-denominated term loan (€733 million) and the 2.875% euro-denominated secured notes (€1.25 billion) has been designated and is effective as an economic hedge of the net investment in euro-denominated subsidiaries.

Foreign currency gains due to spot rate fluctuations on the euro-denominated debt instruments included in foreign currency translation adjustments resulting from hedge designation were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Foreign currency gains in Other comprehensive income
$79 $176 $21 $303 

The Condensed Consolidated Statements of Income include the impact of actual net (gains) and losses of Organon's derivative financial instruments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Foreign exchange loss (gain) in Exchange losses (gains)
$14 $4 $25 $(21)

Organon has established accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. Under these agreements, Organon factored $55 million and $43 million of accounts receivable as of September 30, 2023 and December 31, 2022, respectively, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statements of Cash Flows.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Long-Term Debt Long-Term Debt
The following is a summary of Organon's total debt:
($ in millions)September 30, 2023December 31, 2022
Term Loan B Facility:
SOFR plus 300 bps plus SOFR adjustment1 term loan due 2028
$2,543 $2,793 
EURIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)
773 787 
4.125% secured notes due 2028
2,100 2,100 
2.875% euro-denominated secured notes due 2028 (€1.25 billion)
1,318 1,331 
5.125% notes due 2031
2,000 2,000 
Other borrowings7 7 
Other (discounts and debt issuance costs)(87)(105)
Total principal long-term debt$8,654 $8,913 
Less: Current portion of long-term debt8 8 
Total Long-term debt, net of current portion$8,646 $8,905 
1.The SOFR adjustment is an additional interest amount per annum of 11.448 bps for a one-month interest period, 26.161 bps for a three-month interest period, or 42.826 bps for a six-month interest period, at our option.

The nature and terms of our Senior Credit Agreement, Notes and Other borrowings are described in detail in Note 11 "Long-Term Debt and Leases" in the 2022 Annual Report on Form 10-K for the year ended December 31, 2022.

On June 30, 2023, the Company entered into Amendment No. 1 to the Senior Credit Agreement. Amendment No. 1 replaces LIBOR-based rates with Adjusted Term Secured Overnight Financing Rate ("SOFR")-based rates and updates certain other provisions of the Senior Credit Agreement to reflect the transition from LIBOR to the Adjusted Term SOFR. The impact of the rate transition was not material to the Condensed Consolidated Financial Statements.

Long-term debt was recorded at the carrying amount. The estimated fair value of long-term debt (including current portion) is as follows:
($ in millions)September 30, 2023December 31, 2022
Long-term debt
$7,853 $8,294 

Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy.

The Company made interest payments related to its debt instruments of $311 million for the nine months ended September 30, 2023. The average maturity of the Company's long-term debt as of September 30, 2023 is approximately 5.3 years and the weighted-average interest rate on total borrowings as of September 30, 2023 is 5.7%.
On March 30, 2023, the Company made a discretionary prepayment of $250 million on the U.S. Dollar-denominated term loan.

On June 21, 2023, the Company borrowed $80 million on the Revolving Credit Facility and subsequently repaid the amount on June 30, 2023.

The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows:
($ in millions)
2023$2 
20249 
20259 
20269 
20279 
Thereafter8,703 

The Senior Credit Agreement contains customary financial covenants, including a total leverage ratio covenant, which measures the ratio of (i) consolidated total debt to (ii) consolidated earnings before interest, taxes, depreciation, and amortization, and subject to other adjustments, that must meet certain defined limits which are tested on a quarterly basis. In addition, the Senior Credit Agreement contains covenants that limit, among other things, Organon’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem, or repurchase equity interests, and create or become subject to liens. As of September 30, 2023, the Company is in compliance with all financial covenants and no default or event of default has occurred.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
Changes in Accumulated other comprehensive income (loss) by component are as follows:
($ in millions)Employee
Benefit
Plans		Cumulative
Translation
Adjustment
Accumulated Other
Comprehensive
Loss
Balance at July 1, 2022, net of taxes$(13)$(576)$(589)
Other comprehensive loss, pretax— (97)(97)
Tax— — — 
Other comprehensive loss, net of taxes— (97)(97)
Balance at September 30, 2022, net of taxes$(13)$(673)$(686)
Balance at July 1, 2023, net of taxes$9 $(542)$(533)
Other comprehensive loss, pretax
— (43)(43)
Tax— — — 
Other comprehensive loss, net of taxes
— (43)(43)
Balance at September 30, 2023, net of taxes$9 $(585)$(576)
Balance at January 1, 2022, net of taxes$(13)$(500)$(513)
Other comprehensive loss, pretax(1)(173)(174)
Tax1 — 1 
Other comprehensive loss, net of taxes— (173)(173)
Balance at September 30, 2022, net of taxes$(13)$(673)$(686)
Balance at January 1, 2023, net of taxes$10 $(574)$(564)
Other comprehensive loss, pretax
(1)(11)(12)
Tax— — — 
Other comprehensive loss, net of taxes
(1)(11)(12)
Balance at September 30, 2023, net of taxes$9 $(585)$(576)
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Samsung Collaboration
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Samsung Collaboration Samsung Collaboration
The Company has an agreement with Samsung Bioepis Co., Ltd. ("Samsung Bioepis") to develop and commercialize multiple pre-specified biosimilar candidates, which have since launched and are part of the Company's product portfolio. Under the agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis. The Company's access rights to each product under the agreement last for 10 years from each product's launch date on a market-by-market basis. Gross profits are shared equally in all markets with the exception of certain markets in Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to the Company. Since the Company is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Generally, profit sharing adjustments are recorded either to Cost of sales (after commercialization) or Selling, general and administrative expenses (prior to commercialization).

Samsung Bioepis is eligible for additional payments associated with pre-specified clinical and regulatory milestones. As of September 30, 2023, potential future regulatory milestone payments of $25 million remain under the agreement.

In July 2023, the Company began selling Hadlima, a biosimilar referencing Humira1 (adalimumab), in the United States.
Summarized information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Sales$143 $129 $394 $346 
Cost of sales98 86 272 221 
Selling, general and administrative17 18 53 60 

($ in millions)September 30, 2023December 31, 2022
Receivables from Samsung included in Other current assets
$8 $21 
Payables to Samsung included in Trade accounts payable
62 72 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Third-Party Arrangements
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Third-Party Arrangements Third-Party Arrangements
On June 2, 2021, Organon and Merck entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the "Separation").

The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation, including, but not limited to a tax matters agreement, an employee matters agreement, Interim Operating Model Agreements ("IOM Agreements"), Manufacturing and Supply Agreements, Intellectual Property License Agreements, Regulatory Agreements and a transition services agreement (the "Transition Service Agreement" or "TSA").

Following the Separation, certain functions continue to be provided by Merck under the TSA or are being performed using the Company's own resources or third-party service providers. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of certain services under the TSA expired as of July 2, 2023, however, certain services have been extended to at least 35 months. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate, and Merck manufactures certain products for the Company, or its applicable affiliate. For details on the rights and responsibilities of the parties under the agreements, refer to Note 18 "Third-Party Arrangements and Related Party Disclosures" to the audited Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

For the three and nine months ended September 30, 2023, material transactions occurred in connection with the IOM Agreements.

The amounts due under such agreements were:
($ in millions)September 30, 2023December 31, 2022
Due from Merck in Accounts receivable
$467 $374 
Due to Merck in Accounts payable
601 543 

Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Sales $28 $38 $95 $104 
Cost of sales 25 31 88 91 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
Organon is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters.

Organon records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.

Given the nature of the litigation discussed in this note and the complexities involved in these matters, Organon is unable to reasonably estimate a possible loss or range of possible loss for such matters until Organon knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation, and (v) any other factors that may have a material effect on the litigation.

Organon's decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. Organon has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.

Reference is made below to certain litigation in which Merck, but not Organon, is named as a defendant. Pursuant to the Separation and Distribution Agreement, Organon is required to indemnify Merck for liabilities relating to, arising from, or resulting from such litigation.

Product Liability Litigation

Fosamax

Merck is a defendant in product liability lawsuits in the United States involving Fosamax® (alendronate sodium) (the "Fosamax Litigation"). As of September 30, 2023, approximately 3,130 cases comprising the Fosamax Litigation are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries ("Femur Fractures") in association with the use of Fosamax.

All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey ("Femur Fracture MDL"). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck's favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck's motion for judgment as a matter of law in the Glynn case and held that the plaintiff's failure to warn claim was preempted by federal law.

In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court's preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit ("Third Circuit"). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court's preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court's opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs' state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck's motion and ruled that plaintiffs' failure to warn claims are preempted as a matter of law to the extent they assert that Merck should have added a Warning or Precaution regarding atypical femur fractures prior to October 2010. On July 11, 2022, the District Court entered an Order to Show Cause as to why the Court should not dismiss either with prejudice or conditionally all of plaintiffs' claims that are not dependent on the preempted failure to warn claims. On November 18, 2022, as a result of the Order to Show Cause, the District Court entered a Final Judgment resulting in the dismissal with prejudice of all plaintiffs in the MDL. On
December 16, 2022, those plaintiffs filed their Notice of Appeal to the Third Circuit challenging the District Court's preemption ruling. 974 of the 975 cases previously pending in the Femur Fracture MDL have either been dismissed or are on appeal to the Third Circuit. Plaintiff's motion to remand one case back to its transferor court is pending.

As of September 30, 2023, approximately 1,880 cases alleging Femur Fractures have been filed in New Jersey state court and are pending in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck continued to select additional cases to be reviewed.

As of September 30, 2023, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been consolidated before a single judge in Orange County, California.

Additionally, there are four Femur Fracture cases pending in other state courts.

Discovery is presently stayed in the Femur Fracture MDL and in the state court in California.

Nexplanon/Implanon

Merck is a defendant in lawsuits brought by individuals relating to the use of Nexplanon and Implanon™ (etonogestrel implant). There are two filed product liability actions involving Implanon, both of which are pending in the Northern District of Ohio as well as 56 unfiled cases involving Implanon alleging similar injuries, which have been tolled under a written tolling agreement. As of September 30, 2023, Merck had 18 cases pending outside the United States, of which 12 relate to Implanon and six relate to Nexplanon.

Propecia/Proscar

As of September 30, 2023, one case involving Proscar® (finasteride) remains pending in the United States in the United States District Court for the Eastern District of California in which Merck's motion to dismiss was granted by the District Court, but the plaintiff can appeal the decision. The Company is also defending 14 product liability cases involving Propecia® (finasteride) outside the United States, two of which are class actions and three of which are putative class actions.

Governmental Proceedings

From time to time, Organon's subsidiaries may receive inquiries and may be the subject of preliminary investigation activities from competition and/or other governmental authorities, including in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to Organon, monetary fines and/or remedial undertakings may be required. Subject to certain exceptions specified in the Separation and Distribution Agreement, Organon assumed liability for all pending and threatened legal matters related to products transferred to Organon, including competition investigations resulting from enforcement activity concerning Merck's conduct involving Organon's products. Organon could be obligated to indemnify Merck for fines or penalties, or a portion thereof, resulting from such investigations. In one such enforcement matter in Spain concerning NuvaRing, in October 2022, the National Commission on Markets and Competition ("CNMC") imposed a fine on Merck in the amount of €39 million for abuse of a dominant position in the market for contraceptive vaginal rings from June 2017 to April 2018. The CNMC decision to impose the fine has been appealed to the National High Court in Spain. If the fine ultimately stands, Organon could be obligated to indemnify Merck for a portion thereof.

Hadlima

In July 2021, Organon received a Civil Investigation Demand ("CID") from the Office of the Attorney General for the State of Washington. The CID requests answers to interrogatories, as well as various documents, regarding certain activities related to adalimumab and adalimumab biosimilars. Organon is cooperating with the government's investigation and has produced information in response to the CID.
Patent Litigation

From time to time, generic manufacturers of pharmaceutical products file Abbreviated New Drug Applications with the FDA seeking to market generic forms of Organon's products prior to the expiration of relevant patents owned by Organon. To protect its patent rights, Organon may file patent infringement lawsuits against such generic companies. Similar lawsuits defending Organon's patent rights may exist in other countries. Organon intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products, potential payment of damages and legal fees, and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.

Nexplanon

In June 2017, Microspherix LLC ("Microspherix") sued Organon in the U.S. District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of Nexplanon infringed several of Microspherix's patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until the patents expired in May 2021. Organon brought Inter Partes Review proceedings in the United States Patent and Trademark Office ("USPTO") and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against Organon. Organon appealed the decisions that found claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO's decisions. The matter is no longer stayed in the district court, and Organon is currently litigating the invalidity and non-infringement of the remaining asserted claims. A claim construction hearing was held on March 2, 2022, and a claim construction order issued on February 27, 2023. This case was scheduled for trial before a jury in Camden, New Jersey starting on October 16, 2023; however, on October 13, 2023, a status conference was held during which the parties informed the district court that an agreement in principle of the key terms of a settlement was reached. The proceedings were stayed for 60 days to allow time for the parties to execute a settlement agreement. Organon reserved $80 million to cover the settlement.

Other Litigation

In addition to the matters described above, there are various other pending legal proceedings involving Organon, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of Organon as of September 30, 2023, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to Organon's financial condition, results of operations or cash flows either individually or in the aggregate.

Legal Defense Reserves

Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by Organon; the development of Organon's legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against Organon; and the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The legal defense reserve as of September 30, 2023 and December 31, 2022 was $23 million and $17 million, respectively, and represented Organon's best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by Organon. Organon will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure        
Net income $ 58 $ 227 $ 477 $ 809
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Accounting The accompanying unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company's opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon's Annual Report on Form 10-K for the year ended December 31, 2022.
Use of Estimates
Use of Estimates

The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2022. Accordingly, actual results could differ materially from management's estimates and assumptions.

The Company was impacted by COVID-19 during the first half of 2023, specifically, in the Company's operations in China. The Company does not anticipate a continued impact from COVID-19. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the
information reasonably available to the Company as of September 30, 2023 and through the date of this report which are difficult to predict.
Recently Adopted Accounting Standards
Recently Adopted Accounting Standards

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 and December 31, 2022; the sunset date was subsequently deferred to December 31, 2024 based on the amendment issued in December 2022 under ASU 2022-06, Reference Rate Reform (Topic 848). The Company applied this guidance to our Senior Credit Agreement, as amended on June 30, 2023. The impact to the Consolidated Financial Statements as a result of the application of the reference rate reform guidance is not material. See Note 11 "Long-Term Debt" for additional details.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance became effective for the Company on January 1, 2023 and its amendments will be applied prospectively to business combinations occurring on or after the effective date of the guidance. The adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings per Share ("EPS") (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Per Common Share
The calculations of basic and diluted earnings per common share are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions and shares in thousands, except per share amounts)2023202220232022
Net income$58 $227 $477 $809 
Basic weighted average number of shares outstanding255,588254,348255,112253,986
Stock awards and equity units (share equivalent)761 719 1,0501,108
Diluted weighted average common shares outstanding256,349255,067256,162255,094
EPS:
Basic$0.23 $0.89 $1.87 $3.19 
Diluted$0.23 $0.89 $1.86 $3.17 
Anti-dilutive shares excluded from the calculation of EPS10,390 6,313 9,833 4,432 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Product and Geographic Information (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Sales of Company's Products
Revenues of the Company's products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int'lTotalU.S.Int'lTotal
Women's Health
Nexplanon/Implanon NXT$146 $74 $220 $151 $78 $229 $418 $181 $599 $401 $194 $595 
Follistim AQ22 32 54 27 33 60 74 105 179 79 100 179 
NuvaRing
18 20 37 27 23 50 50 67 117 65 68 133 
Ganirelix Acetate Injection
4 21 25 6 30 36 15 74 88 20 77 97 
Marvelon/Mercilon
— 30 30 — 31 31 — 97 97 — 85 85 
Jada12 — 13 5 — 5 30 — 31 12 — 12 
Other Women's Health (1)
16 22 39 19 23 42 52 74 126 68 70 138 
Biosimilars
Renflexis57 12 69 54 7 60 172 29 201 145 20 166 
Ontruzant11 28 40 15 14 29 36 57 93 35 52 87 
Brenzys— 13 13 — 24 24 — 45 45 — 52 52 
Aybintio— 12 12 — 10 10 — 34 34 — 29 29 
Hadlima2 6 8 — 6 6 2 18 20 — 14 14 
Established Brands
Cardiovascular
Zetia2 65 66 2 85 87 5 234 239 7 280 287 
Vytorin2 31 33 1 30 31 5 95 100 6 98 104 
Atozet— 126 126 — 109 109 — 397 397 — 350 350 
Rosuzet— 17 17 — 17 17 — 52 52 — 55 55 
Cozaar/Hyzaar3 65 68 2 68 70 8 217 225 11 244 256 
Other Cardiovascular (1)
1 42 44 1 34 35 2 124 126 3 117 120 
Respiratory
Singulair3 88 91 3 92 94 8 282 290 8 308 316 
Nasonex— 54 55 — 49 49 — 187 188 9 173 182 
Dulera40 9 49 31 9 40 116 28 144 98 30 127 
Clarinex2 26 28 — 25 26 4 103 107 3 96 99 
Other Respiratory (1)
17 9 25 11 10 21 42 20 61 34 32 66 
Non-Opioid Pain, Bone and Dermatology
Arcoxia— 64 64 — 64 64 — 207 207 — 185 185 
Fosamax1 40 41 1 35 36 2 121 123 2 115 117 
Diprospan— 31 31 — 28 28 — 58 58 — 91 91 
Other Non-Opioid Pain, Bone and Dermatology (1)
4 70 74 2 63 65 11 196 207 10 200 210 
Other
Proscar— 25 25 — 26 27 1 76 77 1 76 77 
Propecia2 21 22 2 28 30 5 86 92 5 90 95 
Other (1)
5 72 76 6 81 87 10 231 240 21 230 251 
Other (2)
— 24 24 — 39 39 (1)103 102 — 115 116 
Revenues$370 $1,149 $1,519 $366 $1,171 $1,537 $1,067 $3,598 $4,665 $1,043 $3,646 $4,689 
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately. Revenues from Marvelon and Mercilon and Jada were previously reported as part of Other Women's Health. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.
(2) Includes manufacturing sales to Merck & Co., Inc. ("Merck") and third parties for current and prior periods.
Schedule of Consolidated Revenues by Geographic Area
Revenues by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Europe and Canada$392 $363 $1,259 $1,243 
United States370 366 1,067 1,043 
Asia Pacific and Japan284 283 869 888 
China202 241 661 721 
Latin America, Middle East, Russia, and Africa
239 236 687 665 
Other (1)
32 48 122 129 
Revenues$1,519 $1,537 $4,665 $4,689 
(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods.
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation Plans (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expenses
Stock-based compensation expenses incurred by the Company were as follows:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Stock-based compensation expense recognized in:
Cost of sales$5 $3 $13 $9 
Selling, general and administrative 18 12 50 35 
Research and development4 3 11 8 
Total$27 $18 $74 $52 
Income tax benefits$6 $3 $16 $11 
Schedule of Stock Option Valuation Assumptions
The weighted average fair value of options granted was determined using the following assumptions:

Nine Months Ended
September 30,
20232022
Expected dividend yield4.82 %3.12 %
Risk-free interest rate3.56 2.47 
Expected volatility42.30 43.43 
Expected life (years)5.895.89
Summary of Equity Award Transactions
A summary of the equity award transactions for the nine months ended September 30, 2023 is as follows:

Stock OptionsRestricted Share UnitsPerformance Share Units
(shares in thousands)SharesWeighted average exercise priceWeighted average grant date fair valueSharesWeighted average grant date fair valueSharesWeighted average grant date fair value
Outstanding as of January 1, 20234,729 $34.34 $8.91 5,048 $33.27 486 $46.72 
Granted1,124 23.52 6.55 3,867 23.51 636 23.30 
Vested/Exercised— — — (1,930)33.93 — — 
Forfeited/Cancelled(89)36.12 8.70 (459)30.79 — — 
Outstanding as of September 30, 2023
5,764 $32.21 $8.45 6,526 $27.47 1,122 $33.44 
Summary of Equity Awards Outstanding
The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2023:

Equity Awards Vested and Expected to VestEquity Awards That are Exercisable
(awards in thousands; aggregate intrinsic value in millions)
AwardsWeighted Average Exercise PriceAggregate Intrinsic Value
Remaining
Term
(in years)
AwardsWeighted Average Exercise PriceAggregate Intrinsic Value
Remaining
Term
(in years)
Stock Options5,591 $32.21 $— 7.043,311 $33.79 $— 5.87
Restricted Share Units6,071 114 1.98
Performance Share Units629 12 1.82
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory
Inventories consisted of:
($ in millions)September 30, 2023December 31, 2022
Finished goods$496 $482 
Raw materials
128 44 
Work in process606 601 
Supplies57 44 
Total (approximates current cost)$1,287 $1,171 
Decrease to LIFO costs(6)(20)
 $1,281 $1,151 
Recognized as:
Inventories$1,186 $1,003 
Other assets95 148 
Inventories valued under the last in, first out ("LIFO") method85 77 
Schedule of Inventory, Noncurrent
Inventories consisted of:
($ in millions)September 30, 2023December 31, 2022
Finished goods$496 $482 
Raw materials
128 44 
Work in process606 601 
Supplies57 44 
Total (approximates current cost)$1,287 $1,171 
Decrease to LIFO costs(6)(20)
 $1,281 $1,151 
Recognized as:
Inventories$1,186 $1,003 
Other assets95 148 
Inventories valued under the last in, first out ("LIFO") method85 77 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Financial Instruments Recorded at Estimated Fair Value
The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of our assets and liabilities were as follows:
($ in millions)Fair Value Measurement Level September 30, 2023December 31, 2022
Forward contracts in Other current assets
2$17 $6 
Forward contracts in Accrued and other current liabilities
212 24 
Schedule of Long-term Debt Instruments due to spot rate fluctuations on the euro-denominated debt instruments included in foreign currency translation adjustments resulting from hedge designation were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Foreign currency gains in Other comprehensive income
$79 $176 $21 $303 
Schedule of (Gain) Loss on Derivative Instruments
The Condensed Consolidated Statements of Income include the impact of actual net (gains) and losses of Organon's derivative financial instruments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Foreign exchange loss (gain) in Exchange losses (gains)
$14 $4 $25 $(21)
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Summary of Long-term Debt Instruments
The following is a summary of Organon's total debt:
($ in millions)September 30, 2023December 31, 2022
Term Loan B Facility:
SOFR plus 300 bps plus SOFR adjustment1 term loan due 2028
$2,543 $2,793 
EURIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)
773 787 
4.125% secured notes due 2028
2,100 2,100 
2.875% euro-denominated secured notes due 2028 (€1.25 billion)
1,318 1,331 
5.125% notes due 2031
2,000 2,000 
Other borrowings7 7 
Other (discounts and debt issuance costs)(87)(105)
Total principal long-term debt$8,654 $8,913 
Less: Current portion of long-term debt8 8 
Total Long-term debt, net of current portion$8,646 $8,905 
1.The SOFR adjustment is an additional interest amount per annum of 11.448 bps for a one-month interest period, 26.161 bps for a three-month interest period, or 42.826 bps for a six-month interest period, at our option.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments
Long-term debt was recorded at the carrying amount. The estimated fair value of long-term debt (including current portion) is as follows:
($ in millions)September 30, 2023December 31, 2022
Long-term debt
$7,853 $8,294 
Schedule of Maturities on Long-term Debt
The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows:
($ in millions)
2023$2 
20249 
20259 
20269 
20279 
Thereafter8,703 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component
Changes in Accumulated other comprehensive income (loss) by component are as follows:
($ in millions)Employee
Benefit
Plans		Cumulative
Translation
Adjustment
Accumulated Other
Comprehensive
Loss
Balance at July 1, 2022, net of taxes$(13)$(576)$(589)
Other comprehensive loss, pretax— (97)(97)
Tax— — — 
Other comprehensive loss, net of taxes— (97)(97)
Balance at September 30, 2022, net of taxes$(13)$(673)$(686)
Balance at July 1, 2023, net of taxes$9 $(542)$(533)
Other comprehensive loss, pretax
— (43)(43)
Tax— — — 
Other comprehensive loss, net of taxes
— (43)(43)
Balance at September 30, 2023, net of taxes$9 $(585)$(576)
Balance at January 1, 2022, net of taxes$(13)$(500)$(513)
Other comprehensive loss, pretax(1)(173)(174)
Tax1 — 1 
Other comprehensive loss, net of taxes— (173)(173)
Balance at September 30, 2022, net of taxes$(13)$(673)$(686)
Balance at January 1, 2023, net of taxes$10 $(574)$(564)
Other comprehensive loss, pretax
(1)(11)(12)
Tax— — — 
Other comprehensive loss, net of taxes
(1)(11)(12)
Balance at September 30, 2023, net of taxes$9 $(585)$(576)
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Samsung Collaboration (Tables)
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Summary of Information Related to Collaboration
Summarized information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Sales$143 $129 $394 $346 
Cost of sales98 86 272 221 
Selling, general and administrative17 18 53 60 

($ in millions)September 30, 2023December 31, 2022
Receivables from Samsung included in Other current assets
$8 $21 
Payables to Samsung included in Trade accounts payable
62 72 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Third-Party Arrangements (Tables)
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
The amounts due under such agreements were:
($ in millions)September 30, 2023December 31, 2022
Due from Merck in Accounts receivable
$467 $374 
Due to Merck in Accounts payable
601 543 

Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Sales $28 $38 $95 $104 
Cost of sales 25 31 88 91 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Background and Nature of Operations (Details)
Sep. 30, 2023
manufacturingFacility
country
segment
product
Product Information [Line Items]  
Number of medicines and products | segment 60
Number of manufacturing facilities | manufacturingFacility 6
CANADA  
Product Information [Line Items]  
Number of biosimilar products | product 5
U.S.  
Product Information [Line Items]  
Number of biosimilar products | product 3
Oncology Biosimilar  
Product Information [Line Items]  
Number of countries product sold in | country 20
Immunology Biosimilar  
Product Information [Line Items]  
Number of countries product sold in | country 5
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions and Licensing Arrangements (Details) - Claria Medical, Inc. - USD ($)
$ in Millions
Sep. 30, 2023
Jan. 31, 2023
Asset Acquisition [Line Items]    
Upfront payments   $ 8
Commercial milestone payments $ 47  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings per Share ("EPS") (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Net income $ 58 $ 227 $ 477 $ 809
Basic weighted average number of shares outstanding (in shares) 255,588 254,348 255,112 253,986
Stock awards and equity units (share equivalent) (in shares) 761 719 1,050 1,108
Diluted weighted average common shares outstanding (in shares) 256,349 255,067 256,162 255,094
EPS:        
Basic (in dollars per share) $ 0.23 $ 0.89 $ 1.87 $ 3.19
Diluted (in dollars per share) $ 0.23 $ 0.89 $ 1.86 $ 3.17
Share-based Compensation Plans        
EPS:        
Anti-dilutive shares excluded from the calculation of EPS (in shares) 10,390 6,313 9,833 4,432
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Product and Geographic Information - Narrative (Details)
 9 Months Ended
Sep. 30, 2023
segment
Segment Reporting [Abstract]  
Number of operating segments 1
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Product and Geographic Information - Sales of Company's Products (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue from External Customer [Line Items]        
Revenues $ 1,519 $ 1,537 $ 4,665 $ 4,689
Nexplanon/Implanon NXT        
Revenue from External Customer [Line Items]        
Revenues 220 229 599 595
Follistim AQ        
Revenue from External Customer [Line Items]        
Revenues 54 60 179 179
NuvaRing        
Revenue from External Customer [Line Items]        
Revenues 37 50 117 133
Ganirelix Acetate Injection        
Revenue from External Customer [Line Items]        
Revenues 25 36 88 97
Marvelon/Mercilon        
Revenue from External Customer [Line Items]        
Revenues 30 31 97 85
Jada        
Revenue from External Customer [Line Items]        
Revenues 13 5 31 12
Other Women's Health        
Revenue from External Customer [Line Items]        
Revenues 39 42 126 138
Renflexis        
Revenue from External Customer [Line Items]        
Revenues 69 60 201 166
Ontruzant        
Revenue from External Customer [Line Items]        
Revenues 40 29 93 87
Brenzys        
Revenue from External Customer [Line Items]        
Revenues 13 24 45 52
Aybintio        
Revenue from External Customer [Line Items]        
Revenues 12 10 34 29
Hadlima        
Revenue from External Customer [Line Items]        
Revenues 8 6 20 14
Zetia        
Revenue from External Customer [Line Items]        
Revenues 66 87 239 287
Vytorin        
Revenue from External Customer [Line Items]        
Revenues 33 31 100 104
Atozet        
Revenue from External Customer [Line Items]        
Revenues 126 109 397 350
Rosuzet        
Revenue from External Customer [Line Items]        
Revenues 17 17 52 55
Cozaar/Hyzaar        
Revenue from External Customer [Line Items]        
Revenues 68 70 225 256
Other Cardiovascular        
Revenue from External Customer [Line Items]        
Revenues 44 35 126 120
Singulair        
Revenue from External Customer [Line Items]        
Revenues 91 94 290 316
Nasonex        
Revenue from External Customer [Line Items]        
Revenues 55 49 188 182
Dulera        
Revenue from External Customer [Line Items]        
Revenues 49 40 144 127
Clarinex        
Revenue from External Customer [Line Items]        
Revenues 28 26 107 99
Other Respiratory        
Revenue from External Customer [Line Items]        
Revenues 25 21 61 66
Arcoxia        
Revenue from External Customer [Line Items]        
Revenues 64 64 207 185
Fosamax        
Revenue from External Customer [Line Items]        
Revenues 41 36 123 117
Diprospan        
Revenue from External Customer [Line Items]        
Revenues 31 28 58 91
Other Non-Opiod Pain, Bone and Dermatology        
Revenue from External Customer [Line Items]        
Revenues 74 65 207 210
Proscar        
Revenue from External Customer [Line Items]        
Revenues 25 27 77 77
Propecia        
Revenue from External Customer [Line Items]        
Revenues 22 30 92 95
Other        
Revenue from External Customer [Line Items]        
Revenues 76 87 240 251
Other        
Revenue from External Customer [Line Items]        
Revenues 24 39 102 116
U.S.        
Revenue from External Customer [Line Items]        
Revenues 370 366 1,067 1,043
U.S. | Nexplanon/Implanon NXT        
Revenue from External Customer [Line Items]        
Revenues 146 151 418 401
U.S. | Follistim AQ        
Revenue from External Customer [Line Items]        
Revenues 22 27 74 79
U.S. | NuvaRing        
Revenue from External Customer [Line Items]        
Revenues 18 27 50 65
U.S. | Ganirelix Acetate Injection        
Revenue from External Customer [Line Items]        
Revenues 4 6 15 20
U.S. | Marvelon/Mercilon        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 0
U.S. | Jada        
Revenue from External Customer [Line Items]        
Revenues 12 5 30 12
U.S. | Other Women's Health        
Revenue from External Customer [Line Items]        
Revenues 16 19 52 68
U.S. | Renflexis        
Revenue from External Customer [Line Items]        
Revenues 57 54 172 145
U.S. | Ontruzant        
Revenue from External Customer [Line Items]        
Revenues 11 15 36 35
U.S. | Brenzys        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 0
U.S. | Aybintio        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 0
U.S. | Hadlima        
Revenue from External Customer [Line Items]        
Revenues 2 0 2 0
U.S. | Zetia        
Revenue from External Customer [Line Items]        
Revenues 2 2 5 7
U.S. | Vytorin        
Revenue from External Customer [Line Items]        
Revenues 2 1 5 6
U.S. | Atozet        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 0
U.S. | Rosuzet        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 0
U.S. | Cozaar/Hyzaar        
Revenue from External Customer [Line Items]        
Revenues 3 2 8 11
U.S. | Other Cardiovascular        
Revenue from External Customer [Line Items]        
Revenues 1 1 2 3
U.S. | Singulair        
Revenue from External Customer [Line Items]        
Revenues 3 3 8 8
U.S. | Nasonex        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 9
U.S. | Dulera        
Revenue from External Customer [Line Items]        
Revenues 40 31 116 98
U.S. | Clarinex        
Revenue from External Customer [Line Items]        
Revenues 2 0 4 3
U.S. | Other Respiratory        
Revenue from External Customer [Line Items]        
Revenues 17 11 42 34
U.S. | Arcoxia        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 0
U.S. | Fosamax        
Revenue from External Customer [Line Items]        
Revenues 1 1 2 2
U.S. | Diprospan        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 0
U.S. | Other Non-Opiod Pain, Bone and Dermatology        
Revenue from External Customer [Line Items]        
Revenues 4 2 11 10
U.S. | Proscar        
Revenue from External Customer [Line Items]        
Revenues 0 0 1 1
U.S. | Propecia        
Revenue from External Customer [Line Items]        
Revenues 2 2 5 5
U.S. | Other        
Revenue from External Customer [Line Items]        
Revenues 5 6 10 21
U.S. | Other        
Revenue from External Customer [Line Items]        
Revenues 0 0 (1) 0
Int’l        
Revenue from External Customer [Line Items]        
Revenues 1,149 1,171 3,598 3,646
Int’l | Nexplanon/Implanon NXT        
Revenue from External Customer [Line Items]        
Revenues 74 78 181 194
Int’l | Follistim AQ        
Revenue from External Customer [Line Items]        
Revenues 32 33 105 100
Int’l | NuvaRing        
Revenue from External Customer [Line Items]        
Revenues 20 23 67 68
Int’l | Ganirelix Acetate Injection        
Revenue from External Customer [Line Items]        
Revenues 21 30 74 77
Int’l | Marvelon/Mercilon        
Revenue from External Customer [Line Items]        
Revenues 30 31 97 85
Int’l | Jada        
Revenue from External Customer [Line Items]        
Revenues 0 0 0 0
Int’l | Other Women's Health        
Revenue from External Customer [Line Items]        
Revenues 22 23 74 70
Int’l | Renflexis        
Revenue from External Customer [Line Items]        
Revenues 12 7 29 20
Int’l | Ontruzant        
Revenue from External Customer [Line Items]        
Revenues 28 14 57 52
Int’l | Brenzys        
Revenue from External Customer [Line Items]        
Revenues 13 24 45 52
Int’l | Aybintio        
Revenue from External Customer [Line Items]        
Revenues 12 10 34 29
Int’l | Hadlima        
Revenue from External Customer [Line Items]        
Revenues 6 6 18 14
Int’l | Zetia        
Revenue from External Customer [Line Items]        
Revenues 65 85 234 280
Int’l | Vytorin        
Revenue from External Customer [Line Items]        
Revenues 31 30 95 98
Int’l | Atozet        
Revenue from External Customer [Line Items]        
Revenues 126 109 397 350
Int’l | Rosuzet        
Revenue from External Customer [Line Items]        
Revenues 17 17 52 55
Int’l | Cozaar/Hyzaar        
Revenue from External Customer [Line Items]        
Revenues 65 68 217 244
Int’l | Other Cardiovascular        
Revenue from External Customer [Line Items]        
Revenues 42 34 124 117
Int’l | Singulair        
Revenue from External Customer [Line Items]        
Revenues 88 92 282 308
Int’l | Nasonex        
Revenue from External Customer [Line Items]        
Revenues 54 49 187 173
Int’l | Dulera        
Revenue from External Customer [Line Items]        
Revenues 9 9 28 30
Int’l | Clarinex        
Revenue from External Customer [Line Items]        
Revenues 26 25 103 96
Int’l | Other Respiratory        
Revenue from External Customer [Line Items]        
Revenues 9 10 20 32
Int’l | Arcoxia        
Revenue from External Customer [Line Items]        
Revenues 64 64 207 185
Int’l | Fosamax        
Revenue from External Customer [Line Items]        
Revenues 40 35 121 115
Int’l | Diprospan        
Revenue from External Customer [Line Items]        
Revenues 31 28 58 91
Int’l | Other Non-Opiod Pain, Bone and Dermatology        
Revenue from External Customer [Line Items]        
Revenues 70 63 196 200
Int’l | Proscar        
Revenue from External Customer [Line Items]        
Revenues 25 26 76 76
Int’l | Propecia        
Revenue from External Customer [Line Items]        
Revenues 21 28 86 90
Int’l | Other        
Revenue from External Customer [Line Items]        
Revenues 72 81 231 230
Int’l | Other        
Revenue from External Customer [Line Items]        
Revenues $ 24 $ 39 $ 103 $ 115
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Product and Geographic Information - Revenues by Geographic Area (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue from External Customer [Line Items]        
Revenues $ 1,519 $ 1,537 $ 4,665 $ 4,689
Europe and Canada        
Revenue from External Customer [Line Items]        
Revenues 392 363 1,259 1,243
United States        
Revenue from External Customer [Line Items]        
Revenues 370 366 1,067 1,043
Asia Pacific and Japan        
Revenue from External Customer [Line Items]        
Revenues 284 283 869 888
China        
Revenue from External Customer [Line Items]        
Revenues 202 241 661 721
Latin America, Middle East, Russia, and Africa        
Revenue from External Customer [Line Items]        
Revenues 239 236 687 665
Other        
Revenue from External Customer [Line Items]        
Revenues $ 32 $ 48 $ 122 $ 129
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation Plans - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Amount of unrecognized compensation costs $ 170
Amount of unrecognized compensation costs period for recognition 1 year 11 months 4 days
PSU's  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award performance period 3 years
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation Plans - Stock-based Compensation Expenses (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 27 $ 18 $ 74 $ 52
Income tax benefits 6 3 16 11
Cost of sales        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 5 3 13 9
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 18 12 50 35
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 4 $ 3 $ 11 $ 8
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation Plans - Stock Option Valuation Assumptions (Details)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]    
Expected dividend yield 4.82% 3.12%
Risk-free interest rate 3.56% 2.47%
Expected volatility 42.30% 43.43%
Expected life (years) 5 years 10 months 20 days 5 years 10 months 20 days
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation Plans - Equity Award Transactions (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2023
$ / shares
shares
Stock Options  
Outstanding, beginning balance (in shares) | shares 4,729,000
Granted (in shares) | shares 1,124,000
Vested/Exercised (in shares) | shares 0
Forfeited/Cancelled (in shares) | shares (89,000)
Outstanding, ending balance (in shares) | shares 5,764,000
Weighted average exercise price  
Outstanding, beginning balance (in dollars per share) $ 34.34
Granted (in dollars per share) 23.52
Vested/Exercised (in dollars per share) 0
Forfeited/Cancelled (in dollars per share) 36.12
Outstanding, ending balance (in dollars per share) 32.21
Weighted average grant date fair value  
Outstanding, beginning balance (in dollars per share) 8.91
Granted (in dollars per share) 6.55
Vested/Exercised (in dollars per share) 0
Forfeited/Cancelled (in dollars per share) 8.70
Outstanding, ending balance (in dollars per share) $ 8.45
Restricted Share Units  
Shares  
Outstanding, beginning balance (in shares) | shares 5,048,000
Granted (in shares) | shares 3,867,000
Vested/Exercised (in shares) | shares (1,930,000)
Forfeited/Cancelled (in shares) | shares (459,000)
Outstanding, ending balance (in shares) | shares 6,526,000
Weighted average grant date fair value  
Outstanding, beginning balance (in dollars per share) $ 33.27
Granted (in dollars per share) 23.51
Vested/Exercised (in dollars per share) 33.93
Forfeited/Cancelled (in dollars per share) 30.79
Outstanding, ending balance (in dollars per share) $ 27.47
Performance Share Units  
Shares  
Outstanding, beginning balance (in shares) | shares 486,000
Granted (in shares) | shares 636,000
Vested/Exercised (in shares) | shares 0
Forfeited/Cancelled (in shares) | shares 0
Outstanding, ending balance (in shares) | shares 1,122,000
Weighted average grant date fair value  
Outstanding, beginning balance (in dollars per share) $ 46.72
Granted (in dollars per share) 23.30
Vested/Exercised (in dollars per share) 0
Forfeited/Cancelled (in dollars per share) 0
Outstanding, ending balance (in dollars per share) $ 33.44
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation Plans - Equity Awards Outstanding (Details)
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
$ / shares
shares
Equity Awards Vested and Expected to Vest  
Stock Options, Awards (in shares) | shares 5,591,000,000
Stock Options, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 32.21
Stock Options, Aggregate Intrinsic Value | $ $ 0
Stock Options, Remaining Term (in years) 7 years 14 days
Equity Awards That are Exercisable  
Stock Options, Awards (in shares) | shares 3,311,000,000
Stock Options, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 33.79
Stock Options, Aggregate Intrinsic Value | $ $ 0
Stock Options, Remaining Term 5 years 10 months 13 days
Restricted Share Units  
Equity Awards Vested and Expected to Vest  
Restricted stock, Awards (in shares) | shares 6,071,000,000
Restricted Stock, Aggregate Intrinsic Value | $ $ 114
Restricted Stock, Remaining Term 1 year 11 months 23 days
Performance Share Units  
Equity Awards Vested and Expected to Vest  
Restricted stock, Awards (in shares) | shares 629,000,000
Restricted Stock, Aggregate Intrinsic Value | $ $ 12
Restricted Stock, Remaining Term 1 year 9 months 25 days
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
position
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Restructuring Cost and Reserve [Line Items]            
Number of positions | position       130    
Payments for restructuring       $ 15    
Restructuring costs   $ 0 $ 11 4 $ 11  
Restructuring activities   $ 10   $ 10   $ 20
Forecast            
Restructuring Cost and Reserve [Line Items]            
Headcount reductions, percent 3.00%          
Minimum | Forecast            
Restructuring Cost and Reserve [Line Items]            
Restructuring costs $ 60          
Maximum | Forecast            
Restructuring Cost and Reserve [Line Items]            
Restructuring costs $ 70          
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Taxes on Income (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]        
Effective income tax rate 27.00% 19.60% 16.10% 20.00%
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Finished goods $ 496 $ 482
Raw materials 128 44
Work in process 606 601
Supplies 57 44
Total (approximates current cost) 1,287 1,171
Decrease to LIFO costs (6) (20)
Inventory 1,281 1,151
Recognized as:    
Inventories 1,186 1,003
Other assets 95 148
Inventories valued under the last in, first out ("LIFO") method $ 85 $ 77
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments - Narrative (Details)
€ in Millions, $ in Millions
Sep. 30, 2023
USD ($)
Sep. 30, 2023
EUR (€)
Dec. 31, 2022
USD ($)
Derivative Instruments, Gain (Loss) [Line Items]      
Accounts receivables factored | $ $ 55   $ 43
Euro Denominated Term Loan | Senior Notes      
Derivative Instruments, Gain (Loss) [Line Items]      
Face amount of debt   € 1,983  
Term Loan B Facility | Senior Notes      
Derivative Instruments, Gain (Loss) [Line Items]      
Face amount of debt   733  
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC      
Derivative Instruments, Gain (Loss) [Line Items]      
Face amount of debt   € 1,250  
Stated interest rate 2.875% 2.875%  
Foreign Exchange Forward      
Derivative Instruments, Gain (Loss) [Line Items]      
Notional amount | $ $ 1,000   $ 1,500
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments - Schedule of Financial Instruments Recorded at Estimated Fair Value (Details) - Level 2 - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]    
Forward contracts in Other current assets $ 17 $ 6
Forward contracts in Accrued and other current liabilities $ 12 $ 24
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments - Schedule of Long-term Debt Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative Gain Statement of Income or Comprehensive Income [Extensible Enumeration]     Foreign currency gains in Other comprehensive income Foreign currency gains in Other comprehensive income
Euro Denominated Term Loan | Senior Notes        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains on derivatives $ 79 $ 176 $ 21 $ 303
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments - Schedule of (Gain) Loss on Derivative Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]        
Exchange losses (gains) $ 14 $ 4 $ 25 $ (21)
Other (Income) Expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Exchange losses (gains) $ 14 $ 4 $ 25 $ (21)
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt - Summary of Long-term Debt Instruments (Details)
€ in Millions, $ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2023
EUR (€)
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]      
Other (discounts and debt issuance costs) $ (87)   $ (105)
Total principal long-term debt 8,654   8,913
Less: Current portion of long-term debt 8   8
Total Long-term debt, net of current portion 8,646   8,905
Notes Payable, Other Payables      
Debt Instrument [Line Items]      
Long-term debt 7   7
Term Loan B Facility | Senior Notes      
Debt Instrument [Line Items]      
Long-term debt $ 2,543   2,793
Term Loan B Facility | Senior Notes | Secured Overnight Financing Rate (SOFR)      
Debt Instrument [Line Items]      
Spread on variable rate 3.00%    
Term Loan B Facility | Senior Notes | Secured Overnight Financing Rate (SOFR) One Month Interest Period      
Debt Instrument [Line Items]      
Spread on variable rate 0.11448%    
Term Loan B Facility | Senior Notes | us-Secured Overnight Financing Rate (SOFR) Three Month Interest Period      
Debt Instrument [Line Items]      
Spread on variable rate 0.26161%    
Term Loan B Facility | Senior Notes | Secured Overnight Financing Rate (SOFR) Six Month Interest Period      
Debt Instrument [Line Items]      
Spread on variable rate 0.42826%    
Euro Denominated Term Loan B | Senior Notes      
Debt Instrument [Line Items]      
Long-term debt $ 773   787
Face amount of debt | €   € 750  
Euro Denominated Term Loan B | Senior Notes | Euro Interbank Offered Rate      
Debt Instrument [Line Items]      
Spread on variable rate 3.00%    
4.125% Senior Secured Notes Due 2028 | Senior Notes      
Debt Instrument [Line Items]      
Long-term debt $ 2,100   2,100
4.125% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC      
Debt Instrument [Line Items]      
Stated interest rate 4.125% 4.125%  
2.875% Senior Secured Notes Due 2028 | Senior Notes      
Debt Instrument [Line Items]      
Long-term debt $ 1,318   1,331
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC      
Debt Instrument [Line Items]      
Face amount of debt | €   € 1,250  
Stated interest rate 2.875% 2.875%  
5.125% Senior Unsecured Notes Due 2031 | Senior Notes      
Debt Instrument [Line Items]      
Long-term debt $ 2,000   $ 2,000
5.125% Senior Unsecured Notes Due 2031 | Senior Notes | Organon Finance 1 LLC      
Debt Instrument [Line Items]      
Stated interest rate 5.125% 5.125%  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
Long-term debt $ 7,853 $ 8,294
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Jun. 21, 2023
Mar. 30, 2023
Sep. 30, 2023
Debt Instrument [Line Items]      
Debt instrument interest payments     $ 311
Average maturity of long-term debt     5 years 3 months 18 days
Weighted-average interest rate of debt     5.70%
Revolving Credit Facility      
Debt Instrument [Line Items]      
Proceeds from revolving credit facility $ 80    
Term Loan B Facility | Senior Notes      
Debt Instrument [Line Items]      
Early repayment of senior debt   $ 250  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt - Schedule of Maturities on Long-term Debt (Details)
$ in Millions
Sep. 30, 2023
USD ($)
Debt Disclosure [Abstract]  
2023 $ 2
2024 9
2025 9
2026 9
2027 9
Thereafter $ 8,703
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance $ (555) $ (1,137) $ (892) $ (1,508)
Other comprehensive loss, pretax (43) (97) (12) (174)
Tax 0 0 0 1
Other comprehensive loss, net of taxes (43) (97) (12) (173)
Ending balance (589) (1,066) (589) (1,066)
Accumulated Other Comprehensive Loss        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance (533) (589) (564) (513)
Ending balance (576) (686) (576) (686)
Employee Benefit Plans        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance 9 (13) 10 (13)
Other comprehensive loss, pretax 0 0 (1) (1)
Tax 0 0 0 1
Other comprehensive loss, net of taxes 0 0 (1) 0
Ending balance 9 (13) 9 (13)
Cumulative Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance (542) (576) (574) (500)
Other comprehensive loss, pretax (43) (97) (11) (173)
Tax 0 0 0 0
Other comprehensive loss, net of taxes (43) (97) (11) (173)
Ending balance $ (585) $ (673) $ (585) $ (673)
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Samsung Collaboration - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Brazil  
Disaggregation of Revenue [Line Items]  
Gross profit sharing arrangement percentage 35.00%
Samsung Bioepis  
Disaggregation of Revenue [Line Items]  
Collaboration agreement period 10 years
Potential future regulatory milestone payments $ 25
Samsung Bioepis | Brazil  
Disaggregation of Revenue [Line Items]  
Gross profit sharing arrangement percentage 65.00%
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Samsung Collaboration - Summary of Information Related to Collaboration (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Disaggregation of Revenue [Line Items]          
Sales $ 1,519 $ 1,537 $ 4,665 $ 4,689  
Cost of sales 612 551 1,832 1,700  
Selling, general and administrative 538 440 1,424 1,234  
Receivables from Samsung included in Other current assets 1,648   1,648   $ 1,475
Payables to Samsung included in Trade accounts payable 1,067   1,067   1,132
Samsung Bioepis          
Disaggregation of Revenue [Line Items]          
Sales 143 129 394 346  
Cost of sales 98 86 272 221  
Selling, general and administrative 17 $ 18 53 $ 60  
Receivables from Samsung included in Other current assets 8   8   21
Payables to Samsung included in Trade accounts payable $ 62   $ 62   $ 72
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Third-Party Arrangements - Accounts Receivables (Details) - USD ($)
$ in Millions
Jun. 03, 2021
Sep. 30, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]      
Due from Merck in Accounts receivable   $ 1,648 $ 1,475
Due to Merck in Accounts payable   1,067 1,132
Related Party      
Related Party Transaction [Line Items]      
Provision of services extension period 35 months    
Due from Merck in Accounts receivable   467 374
Due to Merck in Accounts payable   $ 601 $ 543
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Third-Party Arrangements - Sales and Cost of Sales Resulting from the Manufacturing and Supply Agreements (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Related Party Transaction [Line Items]        
Sales $ 1,519 $ 1,537 $ 4,665 $ 4,689
Cost of sales 612 551 1,832 1,700
Related Party        
Related Party Transaction [Line Items]        
Sales 28 38 95 104
Cost of sales $ 25 $ 31 $ 88 $ 91
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Contingencies (Details)
€ in Millions, $ in Millions
 1 Months Ended
Oct. 31, 2022
EUR (€)
Mar. 31, 2014
case
Oct. 16, 2023
USD ($)
Sep. 30, 2023
USD ($)
case
Dec. 31, 2022
USD ($)
Dec. 16, 2022
case
Dec. 15, 2022
case
Loss Contingencies [Line Items]              
Amount of legal defense reserves | $       $ 23 $ 17    
Spain              
Loss Contingencies [Line Items]              
Governmental fine | € € 39            
Fosamax              
Loss Contingencies [Line Items]              
Number of pending claims       3,130      
Fosamax | Femur Fracture Litigation | Federal              
Loss Contingencies [Line Items]              
Number of pending claims           974 975
Number of claims dismissed   650          
Number of claims on appeal   515          
Fosamax | Femur Fracture Litigation | New Jersey State Court              
Loss Contingencies [Line Items]              
Number of pending claims       1,880      
Fosamax | Femur Fracture Litigation | California State Court              
Loss Contingencies [Line Items]              
Number of pending claims       275      
Fosamax | Femur Fracture Litigation | Other State Courts              
Loss Contingencies [Line Items]              
Number of pending claims       4      
Implanon | Int’l              
Loss Contingencies [Line Items]              
Number of pending claims       12      
Implanon | Northern District of Ohio              
Loss Contingencies [Line Items]              
Number of pending claims       2      
Number of unfiled claims       56      
Nexplanon/Implanon NXT | Int’l              
Loss Contingencies [Line Items]              
Number of pending claims       18      
Nexplanon | Subsequent event              
Loss Contingencies [Line Items]              
Amount of legal defense reserves | $     $ 80        
Nexplanon | Int’l              
Loss Contingencies [Line Items]              
Number of pending claims       6      
Propecia/ Proscar | U.S.              
Loss Contingencies [Line Items]              
Number of pending claims       1      
Propecia/ Proscar | Int’l              
Loss Contingencies [Line Items]              
Number of pending claims       14      
Number of pending class actions       2      
Number of pending putative class actions       3      
XML 74 ogn-20230930_htm.xml IDEA: XBRL DOCUMENT 0001821825 2023-01-01 2023-09-30 0001821825 2023-10-27 0001821825 2023-07-01 2023-09-30 0001821825 2022-07-01 2022-09-30 0001821825 2022-01-01 2022-09-30 0001821825 2023-09-30 0001821825 2022-12-31 0001821825 us-gaap:CommonStockMember 2022-06-30 0001821825 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001821825 us-gaap:RetainedEarningsMember 2022-06-30 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001821825 2022-06-30 0001821825 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001821825 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001821825 us-gaap:CommonStockMember 2022-09-30 0001821825 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001821825 us-gaap:RetainedEarningsMember 2022-09-30 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001821825 2022-09-30 0001821825 us-gaap:CommonStockMember 2023-06-30 0001821825 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001821825 us-gaap:RetainedEarningsMember 2023-06-30 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001821825 2023-06-30 0001821825 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001821825 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001821825 us-gaap:CommonStockMember 2023-09-30 0001821825 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001821825 us-gaap:RetainedEarningsMember 2023-09-30 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001821825 us-gaap:CommonStockMember 2021-12-31 0001821825 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001821825 us-gaap:RetainedEarningsMember 2021-12-31 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001821825 2021-12-31 0001821825 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001821825 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001821825 us-gaap:CommonStockMember 2022-12-31 0001821825 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001821825 us-gaap:RetainedEarningsMember 2022-12-31 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001821825 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001821825 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001821825 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001821825 ogn:OncologyBiosimilarMember 2023-09-30 0001821825 ogn:ImmunologyBiosimilarMember 2023-09-30 0001821825 country:CA 2023-09-30 0001821825 country:US 2023-09-30 0001821825 ogn:ClariaMedicalIncMember 2023-01-31 0001821825 ogn:ClariaMedicalIncMember 2023-09-30 0001821825 us-gaap:StockCompensationPlanMember 2023-07-01 2023-09-30 0001821825 us-gaap:StockCompensationPlanMember 2022-07-01 2022-09-30 0001821825 us-gaap:StockCompensationPlanMember 2023-01-01 2023-09-30 0001821825 us-gaap:StockCompensationPlanMember 2022-01-01 2022-09-30 0001821825 ogn:NexplanonImplanonNXTMember country:US 2023-07-01 2023-09-30 0001821825 ogn:NexplanonImplanonNXTMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:NexplanonImplanonNXTMember 2023-07-01 2023-09-30 0001821825 ogn:NexplanonImplanonNXTMember country:US 2022-07-01 2022-09-30 0001821825 ogn:NexplanonImplanonNXTMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:NexplanonImplanonNXTMember 2022-07-01 2022-09-30 0001821825 ogn:NexplanonImplanonNXTMember country:US 2023-01-01 2023-09-30 0001821825 ogn:NexplanonImplanonNXTMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:NexplanonImplanonNXTMember 2023-01-01 2023-09-30 0001821825 ogn:NexplanonImplanonNXTMember country:US 2022-01-01 2022-09-30 0001821825 ogn:NexplanonImplanonNXTMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:NexplanonImplanonNXTMember 2022-01-01 2022-09-30 0001821825 ogn:FollistimAQMember country:US 2023-07-01 2023-09-30 0001821825 ogn:FollistimAQMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:FollistimAQMember 2023-07-01 2023-09-30 0001821825 ogn:FollistimAQMember country:US 2022-07-01 2022-09-30 0001821825 ogn:FollistimAQMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:FollistimAQMember 2022-07-01 2022-09-30 0001821825 ogn:FollistimAQMember country:US 2023-01-01 2023-09-30 0001821825 ogn:FollistimAQMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:FollistimAQMember 2023-01-01 2023-09-30 0001821825 ogn:FollistimAQMember country:US 2022-01-01 2022-09-30 0001821825 ogn:FollistimAQMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:FollistimAQMember 2022-01-01 2022-09-30 0001821825 ogn:NuvaRingMember country:US 2023-07-01 2023-09-30 0001821825 ogn:NuvaRingMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:NuvaRingMember 2023-07-01 2023-09-30 0001821825 ogn:NuvaRingMember country:US 2022-07-01 2022-09-30 0001821825 ogn:NuvaRingMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:NuvaRingMember 2022-07-01 2022-09-30 0001821825 ogn:NuvaRingMember country:US 2023-01-01 2023-09-30 0001821825 ogn:NuvaRingMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:NuvaRingMember 2023-01-01 2023-09-30 0001821825 ogn:NuvaRingMember country:US 2022-01-01 2022-09-30 0001821825 ogn:NuvaRingMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:NuvaRingMember 2022-01-01 2022-09-30 0001821825 ogn:GanirelixAcetateInjectionMember country:US 2023-07-01 2023-09-30 0001821825 ogn:GanirelixAcetateInjectionMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:GanirelixAcetateInjectionMember 2023-07-01 2023-09-30 0001821825 ogn:GanirelixAcetateInjectionMember country:US 2022-07-01 2022-09-30 0001821825 ogn:GanirelixAcetateInjectionMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:GanirelixAcetateInjectionMember 2022-07-01 2022-09-30 0001821825 ogn:GanirelixAcetateInjectionMember country:US 2023-01-01 2023-09-30 0001821825 ogn:GanirelixAcetateInjectionMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:GanirelixAcetateInjectionMember 2023-01-01 2023-09-30 0001821825 ogn:GanirelixAcetateInjectionMember country:US 2022-01-01 2022-09-30 0001821825 ogn:GanirelixAcetateInjectionMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:GanirelixAcetateInjectionMember 2022-01-01 2022-09-30 0001821825 ogn:MarvelonMercilonMember country:US 2023-07-01 2023-09-30 0001821825 ogn:MarvelonMercilonMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:MarvelonMercilonMember 2023-07-01 2023-09-30 0001821825 ogn:MarvelonMercilonMember country:US 2022-07-01 2022-09-30 0001821825 ogn:MarvelonMercilonMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:MarvelonMercilonMember 2022-07-01 2022-09-30 0001821825 ogn:MarvelonMercilonMember country:US 2023-01-01 2023-09-30 0001821825 ogn:MarvelonMercilonMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:MarvelonMercilonMember 2023-01-01 2023-09-30 0001821825 ogn:MarvelonMercilonMember country:US 2022-01-01 2022-09-30 0001821825 ogn:MarvelonMercilonMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:MarvelonMercilonMember 2022-01-01 2022-09-30 0001821825 ogn:JadaMember country:US 2023-07-01 2023-09-30 0001821825 ogn:JadaMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:JadaMember 2023-07-01 2023-09-30 0001821825 ogn:JadaMember country:US 2022-07-01 2022-09-30 0001821825 ogn:JadaMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:JadaMember 2022-07-01 2022-09-30 0001821825 ogn:JadaMember country:US 2023-01-01 2023-09-30 0001821825 ogn:JadaMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:JadaMember 2023-01-01 2023-09-30 0001821825 ogn:JadaMember country:US 2022-01-01 2022-09-30 0001821825 ogn:JadaMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:JadaMember 2022-01-01 2022-09-30 0001821825 ogn:OtherWomensHealthMember country:US 2023-07-01 2023-09-30 0001821825 ogn:OtherWomensHealthMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:OtherWomensHealthMember 2023-07-01 2023-09-30 0001821825 ogn:OtherWomensHealthMember country:US 2022-07-01 2022-09-30 0001821825 ogn:OtherWomensHealthMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:OtherWomensHealthMember 2022-07-01 2022-09-30 0001821825 ogn:OtherWomensHealthMember country:US 2023-01-01 2023-09-30 0001821825 ogn:OtherWomensHealthMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:OtherWomensHealthMember 2023-01-01 2023-09-30 0001821825 ogn:OtherWomensHealthMember country:US 2022-01-01 2022-09-30 0001821825 ogn:OtherWomensHealthMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:OtherWomensHealthMember 2022-01-01 2022-09-30 0001821825 ogn:RenflexisMember country:US 2023-07-01 2023-09-30 0001821825 ogn:RenflexisMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:RenflexisMember 2023-07-01 2023-09-30 0001821825 ogn:RenflexisMember country:US 2022-07-01 2022-09-30 0001821825 ogn:RenflexisMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:RenflexisMember 2022-07-01 2022-09-30 0001821825 ogn:RenflexisMember country:US 2023-01-01 2023-09-30 0001821825 ogn:RenflexisMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:RenflexisMember 2023-01-01 2023-09-30 0001821825 ogn:RenflexisMember country:US 2022-01-01 2022-09-30 0001821825 ogn:RenflexisMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:RenflexisMember 2022-01-01 2022-09-30 0001821825 ogn:OntruzantMember country:US 2023-07-01 2023-09-30 0001821825 ogn:OntruzantMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:OntruzantMember 2023-07-01 2023-09-30 0001821825 ogn:OntruzantMember country:US 2022-07-01 2022-09-30 0001821825 ogn:OntruzantMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:OntruzantMember 2022-07-01 2022-09-30 0001821825 ogn:OntruzantMember country:US 2023-01-01 2023-09-30 0001821825 ogn:OntruzantMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:OntruzantMember 2023-01-01 2023-09-30 0001821825 ogn:OntruzantMember country:US 2022-01-01 2022-09-30 0001821825 ogn:OntruzantMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:OntruzantMember 2022-01-01 2022-09-30 0001821825 ogn:BrenzysMember country:US 2023-07-01 2023-09-30 0001821825 ogn:BrenzysMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:BrenzysMember 2023-07-01 2023-09-30 0001821825 ogn:BrenzysMember country:US 2022-07-01 2022-09-30 0001821825 ogn:BrenzysMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:BrenzysMember 2022-07-01 2022-09-30 0001821825 ogn:BrenzysMember country:US 2023-01-01 2023-09-30 0001821825 ogn:BrenzysMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:BrenzysMember 2023-01-01 2023-09-30 0001821825 ogn:BrenzysMember country:US 2022-01-01 2022-09-30 0001821825 ogn:BrenzysMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:BrenzysMember 2022-01-01 2022-09-30 0001821825 ogn:AybintioMember country:US 2023-07-01 2023-09-30 0001821825 ogn:AybintioMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:AybintioMember 2023-07-01 2023-09-30 0001821825 ogn:AybintioMember country:US 2022-07-01 2022-09-30 0001821825 ogn:AybintioMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:AybintioMember 2022-07-01 2022-09-30 0001821825 ogn:AybintioMember country:US 2023-01-01 2023-09-30 0001821825 ogn:AybintioMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:AybintioMember 2023-01-01 2023-09-30 0001821825 ogn:AybintioMember country:US 2022-01-01 2022-09-30 0001821825 ogn:AybintioMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:AybintioMember 2022-01-01 2022-09-30 0001821825 ogn:HadlimaMember country:US 2023-07-01 2023-09-30 0001821825 ogn:HadlimaMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:HadlimaMember 2023-07-01 2023-09-30 0001821825 ogn:HadlimaMember country:US 2022-07-01 2022-09-30 0001821825 ogn:HadlimaMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:HadlimaMember 2022-07-01 2022-09-30 0001821825 ogn:HadlimaMember country:US 2023-01-01 2023-09-30 0001821825 ogn:HadlimaMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:HadlimaMember 2023-01-01 2023-09-30 0001821825 ogn:HadlimaMember country:US 2022-01-01 2022-09-30 0001821825 ogn:HadlimaMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:HadlimaMember 2022-01-01 2022-09-30 0001821825 ogn:ZetiaMember country:US 2023-07-01 2023-09-30 0001821825 ogn:ZetiaMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:ZetiaMember 2023-07-01 2023-09-30 0001821825 ogn:ZetiaMember country:US 2022-07-01 2022-09-30 0001821825 ogn:ZetiaMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:ZetiaMember 2022-07-01 2022-09-30 0001821825 ogn:ZetiaMember country:US 2023-01-01 2023-09-30 0001821825 ogn:ZetiaMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:ZetiaMember 2023-01-01 2023-09-30 0001821825 ogn:ZetiaMember country:US 2022-01-01 2022-09-30 0001821825 ogn:ZetiaMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:ZetiaMember 2022-01-01 2022-09-30 0001821825 ogn:VytorinMember country:US 2023-07-01 2023-09-30 0001821825 ogn:VytorinMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:VytorinMember 2023-07-01 2023-09-30 0001821825 ogn:VytorinMember country:US 2022-07-01 2022-09-30 0001821825 ogn:VytorinMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:VytorinMember 2022-07-01 2022-09-30 0001821825 ogn:VytorinMember country:US 2023-01-01 2023-09-30 0001821825 ogn:VytorinMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:VytorinMember 2023-01-01 2023-09-30 0001821825 ogn:VytorinMember country:US 2022-01-01 2022-09-30 0001821825 ogn:VytorinMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:VytorinMember 2022-01-01 2022-09-30 0001821825 ogn:AtozetMember country:US 2023-07-01 2023-09-30 0001821825 ogn:AtozetMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:AtozetMember 2023-07-01 2023-09-30 0001821825 ogn:AtozetMember country:US 2022-07-01 2022-09-30 0001821825 ogn:AtozetMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:AtozetMember 2022-07-01 2022-09-30 0001821825 ogn:AtozetMember country:US 2023-01-01 2023-09-30 0001821825 ogn:AtozetMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:AtozetMember 2023-01-01 2023-09-30 0001821825 ogn:AtozetMember country:US 2022-01-01 2022-09-30 0001821825 ogn:AtozetMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:AtozetMember 2022-01-01 2022-09-30 0001821825 ogn:RosuzetMember country:US 2023-07-01 2023-09-30 0001821825 ogn:RosuzetMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:RosuzetMember 2023-07-01 2023-09-30 0001821825 ogn:RosuzetMember country:US 2022-07-01 2022-09-30 0001821825 ogn:RosuzetMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:RosuzetMember 2022-07-01 2022-09-30 0001821825 ogn:RosuzetMember country:US 2023-01-01 2023-09-30 0001821825 ogn:RosuzetMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:RosuzetMember 2023-01-01 2023-09-30 0001821825 ogn:RosuzetMember country:US 2022-01-01 2022-09-30 0001821825 ogn:RosuzetMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:RosuzetMember 2022-01-01 2022-09-30 0001821825 ogn:CozaarHyzaarMember country:US 2023-07-01 2023-09-30 0001821825 ogn:CozaarHyzaarMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:CozaarHyzaarMember 2023-07-01 2023-09-30 0001821825 ogn:CozaarHyzaarMember country:US 2022-07-01 2022-09-30 0001821825 ogn:CozaarHyzaarMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:CozaarHyzaarMember 2022-07-01 2022-09-30 0001821825 ogn:CozaarHyzaarMember country:US 2023-01-01 2023-09-30 0001821825 ogn:CozaarHyzaarMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:CozaarHyzaarMember 2023-01-01 2023-09-30 0001821825 ogn:CozaarHyzaarMember country:US 2022-01-01 2022-09-30 0001821825 ogn:CozaarHyzaarMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:CozaarHyzaarMember 2022-01-01 2022-09-30 0001821825 ogn:OtherCardiovascularMember country:US 2023-07-01 2023-09-30 0001821825 ogn:OtherCardiovascularMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:OtherCardiovascularMember 2023-07-01 2023-09-30 0001821825 ogn:OtherCardiovascularMember country:US 2022-07-01 2022-09-30 0001821825 ogn:OtherCardiovascularMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:OtherCardiovascularMember 2022-07-01 2022-09-30 0001821825 ogn:OtherCardiovascularMember country:US 2023-01-01 2023-09-30 0001821825 ogn:OtherCardiovascularMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:OtherCardiovascularMember 2023-01-01 2023-09-30 0001821825 ogn:OtherCardiovascularMember country:US 2022-01-01 2022-09-30 0001821825 ogn:OtherCardiovascularMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:OtherCardiovascularMember 2022-01-01 2022-09-30 0001821825 ogn:SingulairMember country:US 2023-07-01 2023-09-30 0001821825 ogn:SingulairMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:SingulairMember 2023-07-01 2023-09-30 0001821825 ogn:SingulairMember country:US 2022-07-01 2022-09-30 0001821825 ogn:SingulairMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:SingulairMember 2022-07-01 2022-09-30 0001821825 ogn:SingulairMember country:US 2023-01-01 2023-09-30 0001821825 ogn:SingulairMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:SingulairMember 2023-01-01 2023-09-30 0001821825 ogn:SingulairMember country:US 2022-01-01 2022-09-30 0001821825 ogn:SingulairMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:SingulairMember 2022-01-01 2022-09-30 0001821825 ogn:NasonexMember country:US 2023-07-01 2023-09-30 0001821825 ogn:NasonexMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:NasonexMember 2023-07-01 2023-09-30 0001821825 ogn:NasonexMember country:US 2022-07-01 2022-09-30 0001821825 ogn:NasonexMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:NasonexMember 2022-07-01 2022-09-30 0001821825 ogn:NasonexMember country:US 2023-01-01 2023-09-30 0001821825 ogn:NasonexMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:NasonexMember 2023-01-01 2023-09-30 0001821825 ogn:NasonexMember country:US 2022-01-01 2022-09-30 0001821825 ogn:NasonexMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:NasonexMember 2022-01-01 2022-09-30 0001821825 ogn:DuleraMember country:US 2023-07-01 2023-09-30 0001821825 ogn:DuleraMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:DuleraMember 2023-07-01 2023-09-30 0001821825 ogn:DuleraMember country:US 2022-07-01 2022-09-30 0001821825 ogn:DuleraMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:DuleraMember 2022-07-01 2022-09-30 0001821825 ogn:DuleraMember country:US 2023-01-01 2023-09-30 0001821825 ogn:DuleraMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:DuleraMember 2023-01-01 2023-09-30 0001821825 ogn:DuleraMember country:US 2022-01-01 2022-09-30 0001821825 ogn:DuleraMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:DuleraMember 2022-01-01 2022-09-30 0001821825 ogn:ClarinexMember country:US 2023-07-01 2023-09-30 0001821825 ogn:ClarinexMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:ClarinexMember 2023-07-01 2023-09-30 0001821825 ogn:ClarinexMember country:US 2022-07-01 2022-09-30 0001821825 ogn:ClarinexMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:ClarinexMember 2022-07-01 2022-09-30 0001821825 ogn:ClarinexMember country:US 2023-01-01 2023-09-30 0001821825 ogn:ClarinexMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:ClarinexMember 2023-01-01 2023-09-30 0001821825 ogn:ClarinexMember country:US 2022-01-01 2022-09-30 0001821825 ogn:ClarinexMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:ClarinexMember 2022-01-01 2022-09-30 0001821825 ogn:OtherRespiratoryMember country:US 2023-07-01 2023-09-30 0001821825 ogn:OtherRespiratoryMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:OtherRespiratoryMember 2023-07-01 2023-09-30 0001821825 ogn:OtherRespiratoryMember country:US 2022-07-01 2022-09-30 0001821825 ogn:OtherRespiratoryMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:OtherRespiratoryMember 2022-07-01 2022-09-30 0001821825 ogn:OtherRespiratoryMember country:US 2023-01-01 2023-09-30 0001821825 ogn:OtherRespiratoryMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:OtherRespiratoryMember 2023-01-01 2023-09-30 0001821825 ogn:OtherRespiratoryMember country:US 2022-01-01 2022-09-30 0001821825 ogn:OtherRespiratoryMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:OtherRespiratoryMember 2022-01-01 2022-09-30 0001821825 ogn:ArcoxiaMember country:US 2023-07-01 2023-09-30 0001821825 ogn:ArcoxiaMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:ArcoxiaMember 2023-07-01 2023-09-30 0001821825 ogn:ArcoxiaMember country:US 2022-07-01 2022-09-30 0001821825 ogn:ArcoxiaMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:ArcoxiaMember 2022-07-01 2022-09-30 0001821825 ogn:ArcoxiaMember country:US 2023-01-01 2023-09-30 0001821825 ogn:ArcoxiaMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:ArcoxiaMember 2023-01-01 2023-09-30 0001821825 ogn:ArcoxiaMember country:US 2022-01-01 2022-09-30 0001821825 ogn:ArcoxiaMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:ArcoxiaMember 2022-01-01 2022-09-30 0001821825 ogn:FosamaxMember country:US 2023-07-01 2023-09-30 0001821825 ogn:FosamaxMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:FosamaxMember 2023-07-01 2023-09-30 0001821825 ogn:FosamaxMember country:US 2022-07-01 2022-09-30 0001821825 ogn:FosamaxMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:FosamaxMember 2022-07-01 2022-09-30 0001821825 ogn:FosamaxMember country:US 2023-01-01 2023-09-30 0001821825 ogn:FosamaxMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:FosamaxMember 2023-01-01 2023-09-30 0001821825 ogn:FosamaxMember country:US 2022-01-01 2022-09-30 0001821825 ogn:FosamaxMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:FosamaxMember 2022-01-01 2022-09-30 0001821825 ogn:DiprospanMember country:US 2023-07-01 2023-09-30 0001821825 ogn:DiprospanMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:DiprospanMember 2023-07-01 2023-09-30 0001821825 ogn:DiprospanMember country:US 2022-07-01 2022-09-30 0001821825 ogn:DiprospanMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:DiprospanMember 2022-07-01 2022-09-30 0001821825 ogn:DiprospanMember country:US 2023-01-01 2023-09-30 0001821825 ogn:DiprospanMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:DiprospanMember 2023-01-01 2023-09-30 0001821825 ogn:DiprospanMember country:US 2022-01-01 2022-09-30 0001821825 ogn:DiprospanMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:DiprospanMember 2022-01-01 2022-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember country:US 2023-07-01 2023-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember 2023-07-01 2023-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember country:US 2022-07-01 2022-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember 2022-07-01 2022-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember country:US 2023-01-01 2023-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember 2023-01-01 2023-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember country:US 2022-01-01 2022-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:OtherNonOpiodPainBoneAndDermatologyMember 2022-01-01 2022-09-30 0001821825 ogn:ProscarMember country:US 2023-07-01 2023-09-30 0001821825 ogn:ProscarMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:ProscarMember 2023-07-01 2023-09-30 0001821825 ogn:ProscarMember country:US 2022-07-01 2022-09-30 0001821825 ogn:ProscarMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:ProscarMember 2022-07-01 2022-09-30 0001821825 ogn:ProscarMember country:US 2023-01-01 2023-09-30 0001821825 ogn:ProscarMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:ProscarMember 2023-01-01 2023-09-30 0001821825 ogn:ProscarMember country:US 2022-01-01 2022-09-30 0001821825 ogn:ProscarMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:ProscarMember 2022-01-01 2022-09-30 0001821825 ogn:PropeciaMember country:US 2023-07-01 2023-09-30 0001821825 ogn:PropeciaMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:PropeciaMember 2023-07-01 2023-09-30 0001821825 ogn:PropeciaMember country:US 2022-07-01 2022-09-30 0001821825 ogn:PropeciaMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:PropeciaMember 2022-07-01 2022-09-30 0001821825 ogn:PropeciaMember country:US 2023-01-01 2023-09-30 0001821825 ogn:PropeciaMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:PropeciaMember 2023-01-01 2023-09-30 0001821825 ogn:PropeciaMember country:US 2022-01-01 2022-09-30 0001821825 ogn:PropeciaMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:PropeciaMember 2022-01-01 2022-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember country:US 2023-07-01 2023-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember 2023-07-01 2023-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember country:US 2022-07-01 2022-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember 2022-07-01 2022-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember country:US 2023-01-01 2023-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember 2023-01-01 2023-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember country:US 2022-01-01 2022-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:OtherSundryEstablishedBrandsMember 2022-01-01 2022-09-30 0001821825 ogn:OtherSundryProductsMember country:US 2023-07-01 2023-09-30 0001821825 ogn:OtherSundryProductsMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 ogn:OtherSundryProductsMember 2023-07-01 2023-09-30 0001821825 ogn:OtherSundryProductsMember country:US 2022-07-01 2022-09-30 0001821825 ogn:OtherSundryProductsMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 ogn:OtherSundryProductsMember 2022-07-01 2022-09-30 0001821825 ogn:OtherSundryProductsMember country:US 2023-01-01 2023-09-30 0001821825 ogn:OtherSundryProductsMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 ogn:OtherSundryProductsMember 2023-01-01 2023-09-30 0001821825 ogn:OtherSundryProductsMember country:US 2022-01-01 2022-09-30 0001821825 ogn:OtherSundryProductsMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:OtherSundryProductsMember 2022-01-01 2022-09-30 0001821825 country:US 2023-07-01 2023-09-30 0001821825 us-gaap:NonUsMember 2023-07-01 2023-09-30 0001821825 country:US 2022-07-01 2022-09-30 0001821825 us-gaap:NonUsMember 2022-07-01 2022-09-30 0001821825 country:US 2023-01-01 2023-09-30 0001821825 us-gaap:NonUsMember 2023-01-01 2023-09-30 0001821825 country:US 2022-01-01 2022-09-30 0001821825 us-gaap:NonUsMember 2022-01-01 2022-09-30 0001821825 ogn:EuropeAndCanadaMember 2023-07-01 2023-09-30 0001821825 ogn:EuropeAndCanadaMember 2022-07-01 2022-09-30 0001821825 ogn:EuropeAndCanadaMember 2023-01-01 2023-09-30 0001821825 ogn:EuropeAndCanadaMember 2022-01-01 2022-09-30 0001821825 ogn:AsiaPacificAndJapanMember 2023-07-01 2023-09-30 0001821825 ogn:AsiaPacificAndJapanMember 2022-07-01 2022-09-30 0001821825 ogn:AsiaPacificAndJapanMember 2023-01-01 2023-09-30 0001821825 ogn:AsiaPacificAndJapanMember 2022-01-01 2022-09-30 0001821825 country:CN 2023-07-01 2023-09-30 0001821825 country:CN 2022-07-01 2022-09-30 0001821825 country:CN 2023-01-01 2023-09-30 0001821825 country:CN 2022-01-01 2022-09-30 0001821825 ogn:LatinAmericaMiddleEastRussiaAndAfricaMember 2023-07-01 2023-09-30 0001821825 ogn:LatinAmericaMiddleEastRussiaAndAfricaMember 2022-07-01 2022-09-30 0001821825 ogn:LatinAmericaMiddleEastRussiaAndAfricaMember 2023-01-01 2023-09-30 0001821825 ogn:LatinAmericaMiddleEastRussiaAndAfricaMember 2022-01-01 2022-09-30 0001821825 ogn:OtherCountriesMember 2023-07-01 2023-09-30 0001821825 ogn:OtherCountriesMember 2022-07-01 2022-09-30 0001821825 ogn:OtherCountriesMember 2023-01-01 2023-09-30 0001821825 ogn:OtherCountriesMember 2022-01-01 2022-09-30 0001821825 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0001821825 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001821825 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0001821825 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001821825 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0001821825 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001821825 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001821825 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001821825 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001821825 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001821825 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001821825 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001821825 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001821825 us-gaap:RestrictedStockMember 2022-12-31 0001821825 us-gaap:PerformanceSharesMember 2022-12-31 0001821825 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001821825 us-gaap:RestrictedStockMember 2023-09-30 0001821825 us-gaap:PerformanceSharesMember 2023-09-30 0001821825 srt:ScenarioForecastMember 2023-12-31 0001821825 srt:MinimumMember srt:ScenarioForecastMember 2023-10-01 2023-12-31 0001821825 srt:MaximumMember srt:ScenarioForecastMember 2023-10-01 2023-12-31 0001821825 us-gaap:ForeignExchangeForwardMember 2023-09-30 0001821825 us-gaap:ForeignExchangeForwardMember 2022-12-31 0001821825 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001821825 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001821825 ogn:EuroDenominatedTermLoansMember us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:EuroDenominatedTermLoanBFacilityMember us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:OrganonFinance1LLCMember ogn:A2875SeniorSecuredNotesDue2028Member us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:EuroDenominatedTermLoansMember us-gaap:SeniorNotesMember 2023-07-01 2023-09-30 0001821825 ogn:EuroDenominatedTermLoansMember us-gaap:SeniorNotesMember 2022-07-01 2022-09-30 0001821825 ogn:EuroDenominatedTermLoansMember us-gaap:SeniorNotesMember 2023-01-01 2023-09-30 0001821825 ogn:EuroDenominatedTermLoansMember us-gaap:SeniorNotesMember 2022-01-01 2022-09-30 0001821825 us-gaap:OtherOperatingIncomeExpenseMember 2023-07-01 2023-09-30 0001821825 us-gaap:OtherOperatingIncomeExpenseMember 2022-07-01 2022-09-30 0001821825 us-gaap:OtherOperatingIncomeExpenseMember 2023-01-01 2023-09-30 0001821825 us-gaap:OtherOperatingIncomeExpenseMember 2022-01-01 2022-09-30 0001821825 ogn:TermLoanBFacilityMember us-gaap:SeniorNotesMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-01-01 2023-09-30 0001821825 ogn:TermLoanBFacilityMember us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:TermLoanBFacilityMember us-gaap:SeniorNotesMember 2022-12-31 0001821825 ogn:EuroDenominatedSeniorSecuredTrancheBTermLoanMember us-gaap:SeniorNotesMember ogn:EuroInterbankOfferedRateMember 2023-01-01 2023-09-30 0001821825 ogn:EuroDenominatedSeniorSecuredTrancheBTermLoanMember us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:EuroDenominatedSeniorSecuredTrancheBTermLoanMember us-gaap:SeniorNotesMember 2022-12-31 0001821825 ogn:OrganonFinance1LLCMember ogn:A4125SeniorSecuredNotesDue2028Member us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:A4125SeniorSecuredNotesDue2028Member us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:A4125SeniorSecuredNotesDue2028Member us-gaap:SeniorNotesMember 2022-12-31 0001821825 ogn:A2875SeniorSecuredNotesDue2028Member us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:A2875SeniorSecuredNotesDue2028Member us-gaap:SeniorNotesMember 2022-12-31 0001821825 ogn:OrganonFinance1LLCMember ogn:A5125SeniorUnsecuredNotesDue2031Member us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:A5125SeniorUnsecuredNotesDue2031Member us-gaap:SeniorNotesMember 2023-09-30 0001821825 ogn:A5125SeniorUnsecuredNotesDue2031Member us-gaap:SeniorNotesMember 2022-12-31 0001821825 us-gaap:NotesPayableOtherPayablesMember 2023-09-30 0001821825 us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001821825 ogn:TermLoanBFacilityMember us-gaap:SeniorNotesMember ogn:SecuredOvernightFinancingRateSOFROneMonthInterestPeriodMember 2023-01-01 2023-09-30 0001821825 ogn:TermLoanBFacilityMember us-gaap:SeniorNotesMember ogn:UsSecuredOvernightFinancingRateSOFRThreeMonthInterestPeriodMember 2023-01-01 2023-09-30 0001821825 ogn:TermLoanBFacilityMember us-gaap:SeniorNotesMember ogn:SecuredOvernightFinancingRateSOFRSixMonthInterestPeriodMember 2023-01-01 2023-09-30 0001821825 ogn:TermLoanBFacilityMember us-gaap:SeniorNotesMember 2023-03-30 2023-03-30 0001821825 us-gaap:RevolvingCreditFacilityMember 2023-06-21 2023-06-21 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-01 2023-09-30 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-09-30 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001821825 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0001821825 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0001821825 ogn:SamsungBioepisCoLtdMember 2023-01-01 2023-09-30 0001821825 ogn:SamsungBioepisCoLtdMember country:BR 2023-09-30 0001821825 country:BR 2023-09-30 0001821825 ogn:SamsungBioepisCoLtdMember 2023-09-30 0001821825 ogn:SamsungBioepisCoLtdMember 2023-07-01 2023-09-30 0001821825 ogn:SamsungBioepisCoLtdMember 2022-07-01 2022-09-30 0001821825 ogn:SamsungBioepisCoLtdMember 2022-01-01 2022-09-30 0001821825 ogn:SamsungBioepisCoLtdMember 2022-12-31 0001821825 srt:AffiliatedEntityMember 2021-06-03 2021-06-03 0001821825 srt:AffiliatedEntityMember 2023-09-30 0001821825 srt:AffiliatedEntityMember 2022-12-31 0001821825 srt:AffiliatedEntityMember 2023-07-01 2023-09-30 0001821825 srt:AffiliatedEntityMember 2022-07-01 2022-09-30 0001821825 srt:AffiliatedEntityMember 2023-01-01 2023-09-30 0001821825 srt:AffiliatedEntityMember 2022-01-01 2022-09-30 0001821825 ogn:FosamaxMember 2023-09-30 0001821825 ogn:FederalMember ogn:FosamaxMember ogn:FemurFractureLitigationMember 2014-03-01 2014-03-31 0001821825 ogn:FederalMember ogn:FosamaxMember ogn:FemurFractureLitigationMember 2022-12-16 0001821825 ogn:FederalMember ogn:FosamaxMember ogn:FemurFractureLitigationMember 2022-12-15 0001821825 ogn:NewJerseyStateCourtMember ogn:FosamaxMember ogn:FemurFractureLitigationMember 2023-09-30 0001821825 ogn:CaliforniaStateCourtMember ogn:FosamaxMember ogn:FemurFractureLitigationMember 2023-09-30 0001821825 ogn:OtherStateCourtsMember ogn:FosamaxMember ogn:FemurFractureLitigationMember 2023-09-30 0001821825 ogn:NorthernDistrictOfOhioMember ogn:ImplanonMember 2023-09-30 0001821825 ogn:NexplanonImplanonNXTMember us-gaap:NonUsMember 2023-09-30 0001821825 ogn:ImplanonMember us-gaap:NonUsMember 2023-09-30 0001821825 ogn:NexplanonMember us-gaap:NonUsMember 2023-09-30 0001821825 ogn:PropeciaProscarMember country:US 2023-09-30 0001821825 ogn:PropeciaProscarMember us-gaap:NonUsMember 2023-09-30 0001821825 country:ES 2022-10-01 2022-10-31 0001821825 ogn:NexplanonMember us-gaap:SubsequentEventMember 2023-10-16 shares iso4217:USD iso4217:USD shares ogn:segment ogn:manufacturingFacility ogn:country ogn:product pure ogn:position iso4217:EUR ogn:case 0001821825 false --12-31 2023 Q3 10-Q true 2023-09-30 false 001-40235 Organon & Co. DE 46-4838035 30 Hudson Street, Floor 33 Jersey City, NJ 07302 (551) 430-6900 Common Stock ($0.01 par value) OGN NYSE Yes Yes Large Accelerated Filer false false false 255606461 1519000000 1537000000 4665000000 4689000000 612000000 551000000 1832000000 1700000000 538000000 440000000 1424000000 1234000000 137000000 127000000 394000000 329000000 0 10000000 8000000 107000000 0 11000000 4000000 11000000 134000000 108000000 398000000 303000000 -14000000 -4000000 -25000000 21000000 -4000000 -4000000 -11000000 -15000000 1439000000 1255000000 4096000000 3678000000 80000000 282000000 569000000 1011000000 22000000 55000000 92000000 202000000 58000000 227000000 477000000 809000000 0.23 0.89 1.87 3.19 0.23 0.89 1.86 3.17 255588000 254348000 255112000 253986000 256349000 255067000 256162000 255094000 58000000 227000000 477000000 809000000 0 0 1000000 0 -43000000 -97000000 -11000000 -173000000 -43000000 -97000000 -12000000 -173000000 15000000 130000000 465000000 636000000 414000000 706000000 9000000 9000000 1648000000 1475000000 95000000 148000000 1186000000 1003000000 802000000 747000000 4050000000 3931000000 1096000000 1018000000 4603000000 4603000000 561000000 649000000 702000000 754000000 11012000000 10955000000 8000000 8000000 1067000000 1132000000 1255000000 1188000000 161000000 184000000 2491000000 2512000000 8646000000 8905000000 43000000 19000000 421000000 411000000 11601000000 11847000000 0.01 0.01 500000000 500000000 255606000 255606000 254370000 254370000 3000000 3000000 -16000000 -331000000 -576000000 -564000000 -589000000 -892000000 11012000000 10955000000 254321000 3000000 0 -551000000 -589000000 -1137000000 227000000 227000000 -97000000 -97000000 0.28 74000000 74000000 43000 15000000 15000000 0 0 254364000 3000000 0 -383000000 -686000000 -1066000000 255568000 3000000 0 -25000000 -533000000 -555000000 58000000 58000000 -43000000 -43000000 0.28 74000000 74000000 38000 25000000 25000000 255606000 3000000 0 -16000000 -576000000 -589000000 253550000 3000000 0 -998000000 -513000000 -1508000000 809000000 809000000 -173000000 -173000000 0.84 218000000 218000000 814000 41000000 41000000 17000000 0 17000000 254364000 3000000 0 -383000000 -686000000 -1066000000 254370000 3000000 0 -331000000 -564000000 -892000000 477000000 477000000 -12000000 -12000000 0.84 221000000 221000000 1236000 59000000 59000000 255606000 3000000 0 -16000000 -576000000 -589000000 477000000 809000000 88000000 72000000 88000000 88000000 0 9000000 8000000 107000000 4000000 -18000000 74000000 52000000 -19000000 45000000 -24000000 -24000000 185000000 119000000 137000000 134000000 56000000 76000000 -68000000 -323000000 34000000 108000000 -21000000 45000000 -53000000 8000000 402000000 591000000 172000000 133000000 1000000 3000000 8000000 105000000 0 124000000 -179000000 -359000000 80000000 0 336000000 106000000 0 17000000 15000000 11000000 221000000 217000000 -492000000 -351000000 -23000000 -119000000 -292000000 -238000000 706000000 737000000 414000000 499000000 Background and Nature of Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon &amp; Co. ("Organon" or the "Company") is a global health care company with a focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations include the following product portfolios:</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Women's Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: Organon's women's health products are sold by prescription primarily in two therapeutic areas, contraception, with key brands such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Nexplanon®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (etonogestrel implant) (sold as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Implanon NXT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">™ in some countries outside the United States) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">NuvaRing® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(etonogestrel / ethinyl estradiol vaginal ring), and fertility, with key brands such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Follistim AQ®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (follitropin beta injection) (marketed in most countries outside the United States as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Puregon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">™). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is a long-acting reversible contraceptive, which is a class of contraceptives that is recognized as one of the most effective types of hormonal contraception available to patients with a low long-term average cost. Other women’s health products include the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Jada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">® System, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted and a license from Daré Biosciences for the global commercial rights to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Xaciato</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">™ (clindamycin phosphate vaginal gel, 2%), an FDA-approved medication for the treatment of bacterial vaginosis ("BV") in females 12 years of age and older. In October 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Xaciato </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">was launched in the United States.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Organon's current portfolio spans across immunology and oncology treatments. Organon's oncology biosimilars have been launched in more than 20 countries and Organon's immunology biosimilars have been launched in five countries. All five biosimilars in Organon's portfolio have launched in Canada, and three biosimilars;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ontruzant® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(trastuzumab-dttb), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renflexis® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(infliximab-abda) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hadlima™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (adalimumab-bwwd) have been launched in the United States.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Established Brands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Organon has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management. A number of Organon's established brands lost exclusivity years ago and have faced generic competition for some time.</span></div> 60 6 20 5 5 3 Basis of Presentation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company's opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon's Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2022. Accordingly, actual results could differ materially from management's estimates and assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was impacted by COVID-19 during the first half of 2023, specifically, in the Company's operations in China. The Company does not anticipate a continued impact from COVID-19. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information reasonably available to the Company as of September 30, 2023 and through the date of this report which are difficult to predict.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 and December 31, 2022; the sunset date was subsequently deferred to December 31, 2024 based on the amendment issued in December 2022 under ASU 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Company applied this guidance to our Senior Credit Agreement, as amended on June 30, 2023. The impact to the Consolidated Financial Statements as a result of the application of the reference rate reform guidance is not material. See Note 11 "Long-Term Debt" for additional details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance became effective for the Company on January 1, 2023 and its amendments will be applied prospectively to business combinations occurring on or after the effective date of the guidance. The adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div> The accompanying unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company's opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon's Annual Report on Form 10-K for the year ended December 31, 2022. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2022. Accordingly, actual results could differ materially from management's estimates and assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was impacted by COVID-19 during the first half of 2023, specifically, in the Company's operations in China. The Company does not anticipate a continued impact from COVID-19. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the </span></div>information reasonably available to the Company as of September 30, 2023 and through the date of this report which are difficult to predict. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 and December 31, 2022; the sunset date was subsequently deferred to December 31, 2024 based on the amendment issued in December 2022 under ASU 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Company applied this guidance to our Senior Credit Agreement, as amended on June 30, 2023. The impact to the Consolidated Financial Statements as a result of the application of the reference rate reform guidance is not material. See Note 11 "Long-Term Debt" for additional details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance became effective for the Company on January 1, 2023 and its amendments will be applied prospectively to business combinations occurring on or after the effective date of the guidance. The adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div> Acquisitions and Licensing ArrangementsClaria Medical, Inc. ("Claria")<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company made a strategic investment in Claria, a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy. Under the terms of the agreement, Organon paid $8 million upfront and has the option to acquire Claria for an additional $47 million, payable if and when the option is exercised. The $8 million was expensed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development and milestones</span> in our Condensed Consolidated Statement of Income for the nine months ended September 30, 2023. 8000000 47000000 8000000 Earnings per Share ("EPS")<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted earnings per common share are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions and shares in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,588</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,348</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,986</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards and equity units (share equivalent)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,349</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,067</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,162</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from the calculation of EPS</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,390 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,313 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,432 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>Diluted EPS was computed using the treasury stock method for stock option awards, performance share units and restricted share units. The computation of diluted EPS excludes the effect of the potential exercise of stock-based awards when the effect of the potential exercise would be anti-dilutive. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted earnings per common share are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions and shares in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,588</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,348</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,986</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards and equity units (share equivalent)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,349</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,067</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,162</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from the calculation of EPS</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,390 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,313 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,432 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 58000000 227000000 477000000 809000000 255588000 254348000 255112000 253986000 761000 719000 1050000 1108000 256349000 255067000 256162000 255094000 0.23 0.89 1.87 3.19 0.23 0.89 1.86 3.17 10390000 6313000 9833000 4432000 Product and Geographic Information<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies within women's health, biosimilars and established brands.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues of the Company's products were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.740%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Nexplanon/Implanon NXT</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ganirelix Acetate Injection</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Marvelon/Mercilon</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Jada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Women's Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biosimilars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Renflexis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Ontruzant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Brenzys</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Aybintio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Hadlima</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Established Brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Rosuzet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Cardiovascular</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Respiratory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Dulera</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Clarinex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Respiratory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Opioid Pain, Bone and Dermatology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Fosamax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Diprospan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Non-Opioid Pain, Bone and Dermatology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Proscar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Propecia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,519 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,598 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,665 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,646 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,689 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes sales of products not listed separately. Revenues from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Marvelon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Mercilon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Jada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> were previously reported as part of Other Women's Health. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes manufacturing sales to Merck &amp; Co., Inc. ("Merck") and third parties for current and prior periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic area where derived are as follows:</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific and Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America, Middle East, Russia, and Africa</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,665 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,689 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primarily reflects manufacturing sales to Merck and third parties for current and prior periods.</span></div> 1 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues of the Company's products were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.740%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Nexplanon/Implanon NXT</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ganirelix Acetate Injection</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Marvelon/Mercilon</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Jada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Women's Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biosimilars</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Renflexis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Ontruzant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Brenzys</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Aybintio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Hadlima</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Established Brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Rosuzet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Cardiovascular</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Respiratory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Dulera</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Clarinex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Respiratory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Opioid Pain, Bone and Dermatology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Fosamax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Diprospan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Non-Opioid Pain, Bone and Dermatology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Proscar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Propecia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,519 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,598 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,665 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,646 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,689 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes sales of products not listed separately. Revenues from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Marvelon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Mercilon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Jada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> were previously reported as part of Other Women's Health. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes manufacturing sales to Merck &amp; Co., Inc. ("Merck") and third parties for current and prior periods.</span></div> 146000000 74000000 220000000 151000000 78000000 229000000 418000000 181000000 599000000 401000000 194000000 595000000 22000000 32000000 54000000 27000000 33000000 60000000 74000000 105000000 179000000 79000000 100000000 179000000 18000000 20000000 37000000 27000000 23000000 50000000 50000000 67000000 117000000 65000000 68000000 133000000 4000000 21000000 25000000 6000000 30000000 36000000 15000000 74000000 88000000 20000000 77000000 97000000 0 30000000 30000000 0 31000000 31000000 0 97000000 97000000 0 85000000 85000000 12000000 0 13000000 5000000 0 5000000 30000000 0 31000000 12000000 0 12000000 16000000 22000000 39000000 19000000 23000000 42000000 52000000 74000000 126000000 68000000 70000000 138000000 57000000 12000000 69000000 54000000 7000000 60000000 172000000 29000000 201000000 145000000 20000000 166000000 11000000 28000000 40000000 15000000 14000000 29000000 36000000 57000000 93000000 35000000 52000000 87000000 0 13000000 13000000 0 24000000 24000000 0 45000000 45000000 0 52000000 52000000 0 12000000 12000000 0 10000000 10000000 0 34000000 34000000 0 29000000 29000000 2000000 6000000 8000000 0 6000000 6000000 2000000 18000000 20000000 0 14000000 14000000 2000000 65000000 66000000 2000000 85000000 87000000 5000000 234000000 239000000 7000000 280000000 287000000 2000000 31000000 33000000 1000000 30000000 31000000 5000000 95000000 100000000 6000000 98000000 104000000 0 126000000 126000000 0 109000000 109000000 0 397000000 397000000 0 350000000 350000000 0 17000000 17000000 0 17000000 17000000 0 52000000 52000000 0 55000000 55000000 3000000 65000000 68000000 2000000 68000000 70000000 8000000 217000000 225000000 11000000 244000000 256000000 1000000 42000000 44000000 1000000 34000000 35000000 2000000 124000000 126000000 3000000 117000000 120000000 3000000 88000000 91000000 3000000 92000000 94000000 8000000 282000000 290000000 8000000 308000000 316000000 0 54000000 55000000 0 49000000 49000000 0 187000000 188000000 9000000 173000000 182000000 40000000 9000000 49000000 31000000 9000000 40000000 116000000 28000000 144000000 98000000 30000000 127000000 2000000 26000000 28000000 0 25000000 26000000 4000000 103000000 107000000 3000000 96000000 99000000 17000000 9000000 25000000 11000000 10000000 21000000 42000000 20000000 61000000 34000000 32000000 66000000 0 64000000 64000000 0 64000000 64000000 0 207000000 207000000 0 185000000 185000000 1000000 40000000 41000000 1000000 35000000 36000000 2000000 121000000 123000000 2000000 115000000 117000000 0 31000000 31000000 0 28000000 28000000 0 58000000 58000000 0 91000000 91000000 4000000 70000000 74000000 2000000 63000000 65000000 11000000 196000000 207000000 10000000 200000000 210000000 0 25000000 25000000 0 26000000 27000000 1000000 76000000 77000000 1000000 76000000 77000000 2000000 21000000 22000000 2000000 28000000 30000000 5000000 86000000 92000000 5000000 90000000 95000000 5000000 72000000 76000000 6000000 81000000 87000000 10000000 231000000 240000000 21000000 230000000 251000000 0 24000000 24000000 0 39000000 39000000 -1000000 103000000 102000000 0 115000000 116000000 370000000 1149000000 1519000000 366000000 1171000000 1537000000 1067000000 3598000000 4665000000 1043000000 3646000000 4689000000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic area where derived are as follows:</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific and Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America, Middle East, Russia, and Africa</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,665 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,689 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primarily reflects manufacturing sales to Merck and third parties for current and prior periods.</span></div> 392000000 363000000 1259000000 1243000000 370000000 366000000 1067000000 1043000000 284000000 283000000 869000000 888000000 202000000 241000000 661000000 721000000 239000000 236000000 687000000 665000000 32000000 48000000 122000000 129000000 1519000000 1537000000 4665000000 4689000000 Stock-Based Compensation Plans<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock option awards, performance share units ("PSUs") and restricted share units ("RSUs") pursuant to its 2021 Incentive Stock Plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PSU awards are based on the following performance factors:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">total stockholder return of the Company relative to an index of peer companies ("relative TSR") specified in the awards; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the results of the cumulative free cash flow ("FCF") of the Company over a three-year period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses incurred by the Company were as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense recognized in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of options granted was determined using the following assumptions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the equity award transactions for the nine months ended September 30, 2023 is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Share Units</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(shares in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested/Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of September 30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.21 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.45 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.47 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.44 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Awards Vested and Expected to Vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Awards That are Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(awards in thousands; aggregate intrinsic value in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Share Units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Share Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized compensation costs as of September 30, 2023 was $170 million, which will be recognized in operating expense ratably over the weighted average vesting period of 1.93 years.</span></div> P3Y <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expenses incurred by the Company were as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense recognized in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 5000000 3000000 13000000 9000000 18000000 12000000 50000000 35000000 4000000 3000000 11000000 8000000 27000000 18000000 74000000 52000000 6000000 3000000 16000000 11000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of options granted was determined using the following assumptions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.89</span></td></tr></table></div> 0.0482 0.0312 0.0356 0.0247 0.4230 0.4343 P5Y10M20D P5Y10M20D <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the equity award transactions for the nine months ended September 30, 2023 is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Share Units</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(shares in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested/Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of September 30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.21 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.45 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.47 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.44 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4729000000 34.34 8.91 5048000000 33.27 486000000 46.72 1124000000 23.52 6.55 3867000000 23.51 636000000 23.30 0 0 0 1930000000 33.93 0 0 89000000 36.12 8.70 459000000 30.79 0 0 5764000000 32.21 8.45 6526000000 27.47 1122000000 33.44 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Awards Vested and Expected to Vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Awards That are Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(awards in thousands; aggregate intrinsic value in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Share Units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Share Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 5591000000 32.21 0 P7Y14D 3311000000 33.79 0 P5Y10M13D 6071000000 114000000 P1Y11M23D 629000000 12000000 P1Y9M25D 170000000 P1Y11M4D Restructuring<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2022, Organon initiated restructuring activities to optimize its internal operations by reducing headcount through selected markets and functions. As a result of this program, the Company restructured approximately 130 positions, with the majority of the position eliminations occurring in selected markets outside of the United States in our commercial organizations. During the nine months ended September 30, 2023, $15 million of restructuring charges have been paid, with the remaining severance payments to be paid by the end of the 2023 fiscal year. For the nine months ended September 30, 2023, the Company recorded restructuring charges of $4 million, which relate to severance costs for eliminated positions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Liabilities for costs associated with restructuring activities were $10 million and $20 million at September 30, 2023 and December 31, 2022, respectively, and are included primarily in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the fourth quarter of 2023, Organon will implement additional restructuring activities to optimize its internal operations by reducing headcount in certain markets and functions. As a result of these activities, the Company expects to restructure approximately 3% of the Company's headcount, which is expected to result in a charge of approximately $60 million to $70 million primarily representing severance and severance related costs in the fourth of quarter of 2023. These amounts will be paid over the next twelve months.</span></div> 130 15000000 4000000 10000000 20000000 0.03 60000000 70000000 Taxes on IncomeThe effective income tax rates were 27.0% and 19.6% for the three months ended September 30, 2023 and 2022, respectively, and 16.1% and 20.0% for the nine months ended September 30, 2023 and 2022, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense. The 2023 year-to-date effective tax rate favorable impact is primarily attributable to a reduced tax rate arrangement that was agreed to in Switzerland for an active entity.On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2023 results. The Company will continue to assess future impacts of this legislation. 0.270 0.196 0.161 0.200 Inventories<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories valued under the last in, first out ("LIFO") method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span> are comprised primarily of raw materials and work in process inventories and are not expected to be converted to finished goods that will be sold within one year. The Company has a long-term vendor supply contract that includes certain annual minimum purchase commitments. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories valued under the last in, first out ("LIFO") method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories valued under the last in, first out ("LIFO") method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 496000000 482000000 128000000 44000000 606000000 601000000 57000000 44000000 1287000000 1171000000 6000000 20000000 1281000000 1151000000 1186000000 1003000000 95000000 148000000 85000000 77000000 Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a balance sheet risk management program to partially mitigate the exposure of net monetary assets of its subsidiaries that are denominated in a currency other than a subsidiary's functional currency from the effects of volatility in foreign exchange. In these instances, Organon principally utilizes forward exchange contracts to partially offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Swiss franc, and Japanese yen. For exposures in developing country currencies, the Company enters into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange losses (gains).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The forward contracts are not designated as hedges and are marked to market through</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Exchange losses (gains).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year. The notional amount of forward contracts was $1.0 billion and $1.5 billion as of September 30, 2023 and December 31, 2022, respectively. The cash flows and the related gains and losses from these contracts are reported as operating activities in the Condensed Consolidated Statements of Cash Flows.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of our assets and liabilities were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Measurement Level </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of economic hedges on foreign currency balances. See Note 11 "Long-Term Debt" for additional details. €1.983 billion in the aggregate of both the euro-denominated term loan (€733 million) and the 2.875% euro-denominated secured notes (€1.25 billion) has been designated and is effective as an economic hedge of the net investment in euro-denominated subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency gains due to spot rate fluctuations on the euro-denominated debt instruments included in foreign currency translation adjustments resulting from hedge designation were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency gains in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other comprehensive income </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Statements of Income include the impact of actual net (gains) and losses of Organon's derivative financial instruments:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange loss (gain) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exchange losses (gains)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon has established accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. Under these agreements, Organon factored $55 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $43 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of accounts receivable as of September 30, 2023 and December 31, 2022, respectively, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statements of Cash Flows.</span></div> 1000000000 1500000000 <div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of our assets and liabilities were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Measurement Level </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000000 6000000 12000000 24000000 1983000000 733000000 0.02875 1250000000 due to spot rate fluctuations on the euro-denominated debt instruments included in foreign currency translation adjustments resulting from hedge designation were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency gains in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other comprehensive income </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Foreign currency gains in Other comprehensive income Foreign currency gains in Other comprehensive income 79000000 176000000 21000000 303000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Statements of Income include the impact of actual net (gains) and losses of Organon's derivative financial instruments:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange loss (gain) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exchange losses (gains)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -14000000 -4000000 -25000000 21000000 55000000 43000000 Long-Term Debt<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of Organon's total debt:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B Facility:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOFR plus 300 bps plus SOFR adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> term loan due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EURIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.125% secured notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.875% euro-denominated secured notes due 2028 (€1.25 billion)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.125% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (discounts and debt issuance costs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total principal long-term debt</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,654 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,913 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total Long-term debt, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,646 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,905 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:5.1pt">The SOFR adjustment is an additional interest amount per annum of 11.448 bps for a one-month interest period, 26.161 bps for a three-month interest period, or 42.826 bps for a six-month interest period, at our option.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature and terms of our Senior Credit Agreement, Notes and Other borrowings are described in detail in Note 11 "Long-Term Debt and Leases" in the 2022 Annual Report on Form 10-K for the year ended December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, the Company entered into Amendment No. 1 to the Senior Credit Agreement. Amendment No. 1 replaces LIBOR-based rates with Adjusted Term Secured Overnight Financing Rate ("SOFR")-based rates and updates certain other provisions of the Senior Credit Agreement to reflect the transition from LIBOR to the Adjusted Term SOFR. The impact of the rate transition was not material to the Condensed Consolidated Financial Statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was recorded at the carrying amount. The estimated fair value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including current portion) is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made interest payments related to its debt instruments of $311 million for the nine months ended September 30, 2023. The average maturity of the Company's long-term debt as of September 30, 2023 is approximately 5.3 years and the weighted-average interest rate on total borrowings as of September 30, 2023 is 5.7%. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 30, 2023, the Company made a discretionary prepayment of $250 million on the U.S. Dollar-denominated term loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2023, the Company borrowed $80 million on the Revolving Credit Facility and subsequently repaid the amount on June 30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Credit Agreement contains customary financial covenants, including a total leverage ratio covenant, which measures the ratio of (i) consolidated total debt to (ii) consolidated earnings before interest, taxes, depreciation, and amortization, and subject to other adjustments, that must meet certain defined limits which are tested on a quarterly basis. In addition, the Senior Credit Agreement contains covenants that limit, among other things, Organon’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem, or repurchase equity interests, and create or become subject to liens. As of September 30, 2023, the Company is in compliance with all financial covenants and no default or event of default has occurred.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of Organon's total debt:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B Facility:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOFR plus 300 bps plus SOFR adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> term loan due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EURIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.125% secured notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.875% euro-denominated secured notes due 2028 (€1.25 billion)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.125% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (discounts and debt issuance costs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total principal long-term debt</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,654 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,913 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total Long-term debt, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,646 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,905 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:5.1pt">The SOFR adjustment is an additional interest amount per annum of 11.448 bps for a one-month interest period, 26.161 bps for a three-month interest period, or 42.826 bps for a six-month interest period, at our option.</span></div> 0.0300 2543000000 2793000000 0.0300 750000000 773000000 787000000 0.04125 2100000000 2100000000 0.02875 1250000000 1318000000 1331000000 0.05125 2000000000 2000000000 7000000 7000000 87000000 105000000 8654000000 8913000000 8000000 8000000 8646000000 8905000000 0.0011448 0.0026161 0.0042826 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was recorded at the carrying amount. The estimated fair value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including current portion) is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7853000000 8294000000 311000000 P5Y3M18D 0.057 250000000 80000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2000000 9000000 9000000 9000000 9000000 8703000000 Accumulated Other Comprehensive Income (Loss)<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2023, net of taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, pretax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023, net of taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, pretax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2023, net of taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, pretax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023, net of taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, pretax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -13000000 -576000000 -589000000 0 -97000000 -97000000 0 0 0 0 -97000000 -97000000 -13000000 -673000000 -686000000 9000000 -542000000 -533000000 0 -43000000 -43000000 0 0 0 0 -43000000 -43000000 9000000 -585000000 -576000000 -13000000 -500000000 -513000000 -1000000 -173000000 -174000000 -1000000 0 -1000000 0 -173000000 -173000000 -13000000 -673000000 -686000000 10000000 -574000000 -564000000 -1000000 -11000000 -12000000 0 0 0 -1000000 -11000000 -12000000 9000000 -585000000 -576000000 Samsung Collaboration<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an agreement with Samsung Bioepis Co., Ltd. ("Samsung Bioepis") to develop and commercialize multiple pre-specified biosimilar candidates, which have since launched and are part of the Company's product portfolio. Under the agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis. The Company's access rights to each product under the agreement last for 10 years from each product's launch date on a market-by-market basis. Gross profits are shared equally in all markets with the exception of certain markets in Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to the Company. Since the Company is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Generally, profit sharing adjustments are recorded either to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (after commercialization) or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses (prior to commercialization).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Samsung Bioepis is eligible for additional payments associated with pre-specified clinical and regulatory milestones. As of September 30, 2023, potential future regulatory milestone payments of $25 million remain under the agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company began selling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hadlima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a biosimilar referencing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (adalimumab), in the United States.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information related to this collaboration is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Samsung included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Samsung included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P10Y 0.65 0.35 25000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information related to this collaboration is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Samsung included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Samsung included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 143000000 129000000 394000000 346000000 98000000 86000000 272000000 221000000 17000000 18000000 53000000 60000000 8000000 21000000 62000000 72000000 Third-Party Arrangements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Organon and Merck entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the "Separation"). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation, including, but not limited to a tax matters agreement, an employee matters agreement, Interim Operating Model Agreements ("IOM Agreements"), Manufacturing and Supply Agreements, Intellectual Property License Agreements, Regulatory Agreements and a transition services agreement (the "Transition Service Agreement" or "TSA"). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Separation, certain functions continue to be provided by Merck under the TSA or are being performed using the Company's own resources or third-party service providers. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of certain services under the TSA expired as of July 2, 2023, however, certain services have been extended to at least 35 months. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate, and Merck manufactures certain products for the Company, or its applicable affiliate. For details on the rights and responsibilities of the parties under the agreements, refer to Note 18 "Third-Party Arrangements and Related Party Disclosures" to the audited Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, material transactions occurred in connection with the IOM Agreements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts due under such agreements were:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due from Merck in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to Merck in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P35M <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts due under such agreements were:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due from Merck in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to Merck in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 467000000 374000000 601000000 543000000 28000000 38000000 95000000 104000000 25000000 31000000 88000000 91000000 Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed in this note and the complexities involved in these matters, Organon is unable to reasonably estimate a possible loss or range of possible loss for such matters until Organon knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation, and (v) any other factors that may have a material effect on the litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon's decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. Organon has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made below to certain litigation in which Merck, but not Organon, is named as a defendant. Pursuant to the Separation and Distribution Agreement, Organon is required to indemnify Merck for liabilities relating to, arising from, or resulting from such litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (alendronate sodium) (the "Fosamax Litigation"). As of September 30, 2023, approximately 3,130 cases comprising the Fosamax Litigation are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries ("Femur Fractures") in association with the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey ("Femur Fracture MDL"). In the only bellwether case tried to date in the Femur Fracture MDL, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn v. Merck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the jury returned a verdict in Merck's favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck's motion for judgment as a matter of law in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case and held that the plaintiff's failure to warn claim was preempted by federal law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court's preemption decision in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit ("Third Circuit"). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court's preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court's opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs' state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck's motion and ruled that plaintiffs' failure to warn claims are preempted as a matter of law to the extent they assert that Merck should have added a Warning or Precaution regarding atypical femur fractures prior to October 2010. On July 11, 2022, the District Court entered an Order to Show Cause as to why the Court should not dismiss either with prejudice or conditionally all of plaintiffs' claims that are not dependent on the preempted failure to warn claims. On November 18, 2022, as a result of the Order to Show Cause, the District Court entered a Final Judgment resulting in the dismissal with prejudice of all plaintiffs in the MDL. On </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 16, 2022, those plaintiffs filed their Notice of Appeal to the Third Circuit challenging the District Court's preemption ruling. 974 of the 975 cases previously pending in the Femur Fracture MDL have either been dismissed or are on appeal to the Third Circuit. Plaintiff's motion to remand one case back to its transferor court is pending. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, approximately 1,880 cases alleging Femur Fractures have been filed in New Jersey state court and are pending in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck continued to select additional cases to be reviewed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been consolidated before a single judge in Orange County, California.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are four Femur Fracture cases pending in other state courts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL and in the state court in California.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon/Implanon</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck is a defendant in lawsuits brought by individuals relating to the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon™ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(etonogestrel implant). There are two filed product liability actions involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, both of which are pending in the Northern District of Ohio as well as 56 unfiled cases involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alleging similar injuries, which have been tolled under a written tolling agreement. As of September 30, 2023, Merck had 18 cases pending outside the United States, of which 12 relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and six relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Propecia/Proscar</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2023, one case involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proscar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">® (finasteride) remains pending in the United States in the United States District Court for the Eastern District of California in which Merck's motion to dismiss was granted by the District Court, but the plaintiff can appeal the decision. The Company is also defending 14 product liability cases involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Propecia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">® (finasteride) outside the United States, two of which are class actions and three of which are putative class actions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, Organon's subsidiaries may receive inquiries and may be the subject of preliminary investigation activities from competition and/or other governmental authorities, including in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to Organon, monetary fines and/or remedial undertakings may be required. Subject to certain exceptions specified in the Separation and Distribution Agreement, Organon assumed liability for all pending and threatened legal matters related to products transferred to Organon, including competition investigations resulting from enforcement activity concerning Merck's conduct involving Organon's products. Organon could be obligated to indemnify Merck for fines or penalties, or a portion thereof, resulting from such investigations. In one such enforcement matter in Spain concerning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in October 2022, the National Commission on Markets and Competition ("CNMC") imposed a fine on Merck in the amount of €39 million for abuse of a dominant position in the market for contraceptive vaginal rings from June 2017 to April 2018. The CNMC decision to impose the fine has been appealed to the National High Court in Spain. If the fine ultimately stands, Organon could be obligated to indemnify Merck for a portion thereof. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hadlima</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Organon received a Civil Investigation Demand ("CID") from the Office of the Attorney General for the State of Washington. The CID requests answers to interrogatories, as well as various documents, regarding certain activities related to adalimumab and adalimumab biosimilars. Organon is cooperating with the government's investigation and has produced information in response to the CID.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file Abbreviated New Drug Applications with the FDA seeking to market generic forms of Organon's products prior to the expiration of relevant patents owned by Organon. To protect its patent rights, Organon may file patent infringement lawsuits against such generic companies. Similar lawsuits defending Organon's patent rights may exist in other countries. Organon intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products, potential payment of damages and legal fees, and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2017, Microspherix LLC ("Microspherix") sued Organon in the U.S. District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of Nexplanon infringed several of Microspherix's patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until the patents expired in May 2021. Organon brought Inter Partes Review proceedings in the United States Patent and Trademark Office ("USPTO") and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against Organon. Organon appealed the decisions that found claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO's decisions. The matter is no longer stayed in the district court, and Organon is currently litigating the invalidity and non-infringement of the remaining asserted claims. A claim construction hearing was held on March 2, 2022, and a claim construction order issued on February 27, 2023. This case was scheduled for trial before a jury in Camden, New Jersey starting on October 16, 2023; however, on October 13, 2023, a status conference was held during which the parties informed the district court that an agreement in principle of the key terms of a settlement was reached. The proceedings were stayed for 60 days to allow time for the parties to execute a settlement agreement. Organon reserved $80 million to cover the settlement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the matters described above, there are various other pending legal proceedings involving Organon, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of Organon as of September 30, 2023, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to Organon's financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by Organon; the development of Organon's legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against Organon; and the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The legal defense reserve as of September 30, 2023 and December 31, 2022 was $23 million and $17 million, respectively, and represented Organon's best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by Organon. Organon will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div> 3130 650 515 974 975 1880 275 4 2 56 18 12 6 1 14 2 3 39000000 80000000 23000000 17000000 false false false false EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

($5 @:9M@1L;@=X ,8LR&C\[IA> MOZ5-/!^?Z%]=[::6/5;P(-@O2G29>!\\1"#'#=-;JRC1SE]J7LM#1/JJ"DP>Q2U2UTKIM&*!QL)_>C\^UT9*(6O]_R*WN,##'3,& V+07FPYRO@M^?X/<,/0M MN5DO-[OIU)Y FJ\(7W$;9K[E-N_=YCJGW_6'RJ0A>N""F6BX;IM M%?UJWVB7;7_Y&]YVZ4U-#[@:@@ )(5 9 M>&PO=V]R:W-H965T-?O^V1!2^U[>4$63V:Y6^J GV[>]X4CG##S1> ; M_>O+0L_ID<*7XM[A5[^QDIHE66]RJQS-KCKCX;N;,WY?7OC-T+-?NU8=\XY*::;++#SDSW^E*IY3MI?DF9=_U7/U[J"CDM*'?%DMA@=+8^/_ M^J7"X5L6C*H%(_$[;B1>OM=!7U^Z_%DY?AO6^$)"E=5PSEA.RF-P>&JP+ES? M:&^\RF?JWI$G&[1@=7"?9R8QY \O^P&[\+O]I+)X$RV.WK#XH_HEMV'AU0>; M4KJYO@_O&A='M8LWH[T&'ZGHJ>-!5XT&H^,]]HZ;D(_%WO$;]N[<7%OS'XFT MJR:Y]0@VC8%KFVXB 60^&JMM8G2F'G&34)'!JW^-ISXXU-2_=R$4'3C9[0#S M[)TO=$)7G8+W"=->"?[K+<9'2=)7MI@['R7B_N-?%X0 M")/DRT+;%2RHTNHR-8%2-6O@\"T<"_U$:DID%2(JM,-[QHH%E^)M0E6'A?K2 M>^RIG\B2TUFV8@>I8).MIP#?P'B1D5<'WW]W/AH-+GX:C^_E M&HL9G%G#X>_;,G>[H46V:KKDK( M!0@8#$:9JTLA-3[)%4Q0AD%PD5=1F]!!%"4S0/V M2+(2S% +=H8LI20]]J9C%]) M3:)9X'A1>-,B^\Q/9V66J15IUU.W5NY,8JY_P(K"6*$&DJ1T^CM$*$90;[@2 M,UK-M'%MA-7&GAI_=]9'$S[CRZ%PD(@'L&=RSU%2.L>U8'4 \D@5_!";53TJ M$,]Z7>5=[,0"\E(:R*-0'#ELMZ7,0#TY.P+X;B_](B\S))C1TU+!2.OOI8T- MI"F[O4Q@=Y =%$S@!*,JFXA;QX#RV-H2*Q^HR!VPLTWQ_JU)$N='$:NH>@_H MEU-R426.AR*&H]X>N3AMY.)T+]._>$G!!Q\,"I_\+JW8:V&WG&V;E2HOMI0U ME@L4.$671Y23=1+ME-TZV8TN1:ACIIB[)JS6M89Y6A$77=-BS)!215:6^BLI M:MP3PQZC25&IR4('I6A$BC0U<,XI]MX9D=.9RY=K0:+&W@POBDY%>?6,4 PNDQ#5 M;7+WV^W[H^&/*BV%AR(8QOD /F4S3AQWXJ[R!25F!MW)V$OS6D<:V<&S"7BI M-_=- HI0"+1"4H&4WR*<=4^10L(!4I4JTZMWKIM(X@:N,2X MU]U4!@!23&N^[7 -<%TPK.DFK8+@C9 [2K3?Y/YZSZ@PX!#HI59$M8>E9PU+ MS_:R] $E8@/WS#3?;IF@ATVU2W=2]_]@ECO$+]HE"TX[QC .Z>/X\489%!2O M>?PB3XX&)UV4/*J2N.,_<#KQDRO_X#.:2J+.3\X/WZF/.C&9V5 !]4%2XF.C MWF6!.=1 'GG%3G9196P'-^>EB:,&R$V8T\5N 7E .'@\+5TJ[6>]3)B,!_B+ MM.9SS(1UM5/CSB&?/"I_'/OC&G_:$G"-/U)OY=2C@B*P%49)ACX]$\72*-M4 MU"S6=LF#& 5]Y MQ*$EVO)6#(S!+CS$,:HL +)B*J,Q"SL/$3A;XNWPS./!SQJ"C<$F"O! K+V2 MY0M!QI?H54%QDQ+EW$AWRM&X&/3V^A,Y/J:U[C1U4-<(2K-9PMMAYH;XU/0: M'0W.OH%>:E-B:R@P%?D-AN2E4X^$.<^I"?PU08WGCJ1Q2&L3[Z*S/Y>6FO-7 M-%\I,^Q$!?W3MHT_E;S6C!?/D@T1V,VT]>1SLZ@[7@_^D_H["*Z&0]5!P3BH1JC!Y5$;>Y]\GH*6L?3M956ZLI&X>6B1SXN7%U-[(% MO"$.D9E;\E637GIBM5]S+]O>3R?5(<;1$X&*K69$!Y+& 19*B&85?M*&OZ5: MP!B)13L&PY^PD *EYB N96B<=ID%34I4B1F7;2W+@1M6R=?Q8$Q MH]"K.,(AU3%:&,$YI&WJ+2&;*&M]C_--NX7;"H9U:4EK&E-/:S6?\FVI.(X! M!K^FZX 2)Y8U(5K3(&@$Z^$.7*'[27WR82A0OK- ;JT?L4,B.Q5?:K>KF2B- M>AF?KM,]-7(DB:VL*14L+@@/R+A]<3T3578.X]&_;7O9"CRN7P-E(':AOC) MK+G;?' OQ:R4&(C18KS*:8>F@]Q>&<:A[$83@) M:E8);[5P:QNU6LC6\$K@1H%NZYJI;VOD\KCT(N^T\*4ZE,8N!*M%PPZX1?-; MLU$T"P:4HJI1Z$H*4+A?>H_1?)U:>V?P>X5'?38&JV0GY:N=_%HLO= 20HZY ML0B,NC=\0LXM$-'XVF-Z0TCK>#X^H7]TVDG+CFE\DOR/JC#ETLL\*'#/6FZ^ MR.,OV.L96[Q<:N-K'MG8E!7HNO9>[\/9PY9^!V'N'>('>\N MD&/Y@1FV6BAY!&6M"0J80]E:Q3]K M>]YLO0>X?V$[COIA$1@*9,V#O ===Z#Q=T!G\$D*4VIX%@46E_X!$1Q8QB>6 MZ_@FX!:;$22A#W$8)S?PDD%UXO"2_U.]&53_^;C31E&2_'5-;P>77H>S%V>N M&Y;CTJ.;H5&]H;?Z\8=H$OY\@VPZD$UOH:^V=!&+EB/(/:R9KG)@HH /%6\- M%G AY4G6-:6Z4W1-QLU UV6\E @YXWG+F;U&VK+8#2R*G@6>IU'>L=!N7]VG M82\YW7\]AY=2(5[D!WPF'I5B09[0T65 M"41;[R@$*>]94'73ABB09(C'8W^<9=2G?I)F;AY%%'><^+-L ELC\U=@1Z:* M3@E^;2OS#5I1&0WW'6^[]L8X"O, TTD$TV@&D1^.0VJC,!M.^S_4SO?ZW[PF MQ&?F^(23J9M'D[B;SU*@2S[O!=]!.*)-LETVHRX:979'DA&Q.$6^8C/I;*;P M*$SUDTL%JK G+G0VO+6'N5>RID.[2".[ET0 HM!/9B$0TRB!F9\E":1^FL1P M[=X$9V6N1G5PQ5S3%M"1=Q5O6!W>B\>N3/YCWCTVGY@Z5)19'/?D&HZF8P]4 M5\"[B9&-*YH[::@$NV%);QXJ:T#_]U*:T\0&&%[1U=]02P,$% @ FSYC M5]?U!3DK" 1A( !D !X;"]W;W)K&ULK5AM M;]LX$OXK V_1;8%<+%%O5IL$<-)VV\,US2;M[N$.]X&Q:)M76=225!+WU^\S ME*VHO33=#P?0EDB1PYEGGAF.='1K[&>W5LK3W:9NW/%D[7W[8CIUB[7:2'=H M6M7@R=+8C?3HVM74M5;)*BS:U%,11?ET(W4S.3D*8Q?VY,ATOM:-NK#DNLU& MVNVIJLWM\22>[ 6!Z!*Q0JI6"\\2)"XWZDS5-0N"&G_L9$Z& M+7GA^'XO_4VP';9<2Z?.3/V[KOSZ>#*;4*66LJO]I;E]JW;V! 47IG;AGV[[ MN5DRH47GO-GL%D.#C6[ZJ[S;X3!:,(N^LT#L%HB@=[]1T/*5]/+DR)I;LCP; MTO@FF!I60SG=L%.NO,53C77^Y,*:JEMXDDU%ORBSLK)=ZP6]:WI_,W#//LKK M6KGG1U./#7G9=+$3?MH+%]\17M)[T_BUH]=-I:JOUT^AZ*"MV&M[*AX5>*7: M0TJB Q*12!Z1EPS6)T%>\EUY*Q#,TZ5JC?6Z6=&_Y]?.6W#E/P^9VTM+'Y;& M\?/"M7*ACB<($*?LC9J7ZN1S'8GDVZ5520=+4V-*'8OZ./:*O65 M=PF^\6ISK6QPT#DV>>PY.Y#_Q.CNV1/2#4A>UZ"=>TZ?#J\.P43_]*>9B(N7 M-7TT7M8_&O[YNP._&S@;9KU5LO9K.E=W;2T;TTS?;?H;.O_G1WI"<9KCOTCQ M)T3$ UG, [,P4.(_C?D^GO%P5H:1B._C,@TC&;T!4MIYO:'YKUA$B: L)5%0 MDE >L? XRB@N2D*+HRC@I\UK'^O[$+C MA@*@XF58$=WW8F[[7AG6[GNSC-O?924I%L-H#(V'3O:-K/$\01] ./NM8YY1 M_)SB/, &<$J&( 5^(L FZTHZQ@V7G)D!<, M=UR 9Y #)\5IQAC$>4X?&F^[+Q+Q'P.K&7S(,,4I3P5DD%(FE&2\\:R@4ZN: M+ULWMA)MWQ,IMWT/>Z0C"(+N\^VU;N";L?EC,")N U IMT%XR>VMK&J]D03+ M:#8\ QH8Z0DSR$JYO78>B5OC;*B@/!*\HS-I*VUNI%MT@(S^I;P.\L 3EL+N M+. Q@;T%H ?Y9A%^!?VV]<8B.$6@ RP/)(DQ%UQG^N94@I112G-OOJ"6N#W9 RWZ(F8A(B, ?VEH43P4JF;I@(EY2!QQP^< BT+GDKZ%C0&0S2O!54"(\'?F4\P"D) M0J."U84_RQTB8],"'(@+ZJ$#8T5 !PCD/3R"J71NFK]]:+71%5V@,#R@4Y@8 M:HQ7BLL*4YO5EN9V8>Y P('**;>'>P)J\>\>B2S\WA@G40ZQCR*D9?91QL'+ M/N)DD_ =1S6T?J5QH.& ;L;Y:)3;Q&P,2C;C-N2]F%L/R%^SCJ%*F6Q(6@ E M4) A [1L"$,7,7S13BH.<+< X\9.N>^O6-.J18AA3O>"K\'= M".2<.8?XC#A$^RU8)9P#@E)^%,<=7Z.4/6=$V%0#RDCU96>)/!6P[) MME4< RN2U^9&<;FA(4$O\ @5CK^?:98'9&P8[1P2*(0!$,S$^XBBZ^U!*)4^ MV%6H&U;8K>7Z:1%J)ZW<80#G7;.HNPH@N'W!-I14K"]7")#M5"L17ZK>'M[# MMK1F,YS1@5S#.$GB,A824:I!I.<-'SIAAVWZ71 0 MTN* 6*E0#*/R#\:QSBQAI1IE\4Z@O&G,2J$\5O54^;5NMC5Q5R)AUG0C5[I! ME17@Q2&L>]LK!OEA)9A> T(;V71+U-U=6-_C!3>RT9_IJ=RT+Y'3#P]X 59. MPOCD>< "JM@J&*P9.*B_Z*QE4_AI:S5&6IA@*G?X2"&>#85X]I<+\3,4JJ;6 ME634!]]=;\?O4G.\+#]4E3^^RUC8ZEX8" F_K]GQ("1>:*O T1_4YO];C7]; M:S]4C[_N.+T$$,]DPX1#_"&I<.PF(29%UD>T0&Q^:C2#<,6%J LQSQ'>QW,? MO7.'3'4A%WK)A@02UU5<,%KZ?P!778.H@^"S/F2)X3R121<*J( S,<)$"=4BI-1\ E1 MCM/4/C'M4]$^]?2IAI=>6-1?5H=(6_)WA1_0]O]!SNGHW1[&K\(7#(=$TS6^ M?\T?1H>/)//^V\#]]/X+"[()0M11K998&AT68*#MOUKT'6_:\*7@VGAO-N%V MK9 2+4_ <\ZO^PYO,'PZ.OD34$L#!!0 ( )L^8U=8V'O&PO=V]R:W-H965T W5_?W9.010QDVFD_($[W\NS>[O.L M[LZWI7K0"T0#C\N\T!>=A3&KLWY?IPM<"NV4*RQH9%:JI3#TJN9]O5(H,KMH MF?=]UXW[2R&+SNC<]MVHT7FY-KDL\$:!7B^70CU=8EYN+SI>9]=Q*^<+PQW] MT?E*S/$.S9?5C:*W?H.2R2466I8%*)Q==,;>V67"\^V$>XE;W6H#[V1:E@_\ M\C&[Z+CL$.:8&D80]+?!*\QS!B(WOM68G<8D+VRW=^@?[-YI+U.A\:K,O\K, M+"XZ@PYD.!/KW-R6VU^QWD_$>&F9:_N$;34W3#J0KK4IE_5B\F IB^I?/-9Q M:"T8N$<6^/4"W_I=&;)>_BR,&)VK<@N*9Q,:-^Q6[6IR3A:JWYWU#QGA)/ZV!+RM@_PCP$#Z5 MA5EHN"XRS/;7]\G)QE-_Y^FE?Q+P#E<.!&X/?--$AJ6A4&^R,WKSR M8O?]"<_#QO/P%/KHCI29K7.$<@95_J8O\W?]R&W4AYP_"7_8^;:=M&T':SL@ MBW2M% U/G\ LT'HCBB?8HD(0&F9E3A5 G\%DH1#WV &_DPO[/=W7!$B$SW,R MHM_:I//#;[5^Y!,5C;2<%_(O&I?%&7FD#<=,"Z(TO(:(?@']/'X,X8Y*@RSF M/9AC@4KD((H,1$:BDTP$KA[@#<#S(7(AB."68B-4NK#S,MQ0@5M9YH2$ZGDP M@$EI".8U^ E;&= C"=FN#Q\+8DK69-.Q0O'.(&X1P@BM1PY7HGW$% M/J]LC.Y%OJZB-=94D6WG0;*V]%&0Q8;B-D>8":E@0P:LV;+"ACEI MBV=MB0P9&E0467I=:PJZ94S%$'X3SRZ='2#',P68Y2F#9G(C,Z1$/$G,,PB= M@0\_0>!X_'HFIH,4N_I MO$TWS6HQ2MH8VLH+7PHF_0TJ>[(H4MSK[VI^X:I"]LNU)HU1P.^JSJ_?$PX? M4:62%+\B$_ARW%(/,LYYBYO'T/Z+V9_71AMRNF(S!_HW4:PYYEX=K;"7^$,6 M?.@$7!4&SM"#J.>&7">"P*&B$0ZX$(2QD_CP2ZT>K^?Y(?A$71]B)XH@Z WB MQ'9X$ /-JX'O^^Q?_7:\W#-RW;'$8O!BED\\,)2-= M<8KRG$OS8$C38Y;6P$E12>5K3,0AA@/6QL)NU'!G=5R)2VN^K\,40M#^O.L2R'^V>S MURVSW/W=S,G.S'7+3+?VIZW?]R#FMG[V-? C=3&M=1V M;(8;*_-Q@_:Q0;NW:+?(]Q&.P80^,] E]+ID_X_0^_4NZD5#KT7JG2(2QZ7S M02_PO(K.R; U2-^2Y%BEC'MNXM&I( 3/&0Z.%LZ8B@HITZ,/X"&9]%M7A26J MN;T0:3H^K0M3W1J:WN;.-:ZN&L_3JPO;)Z'F%!G(<49+2?YT4E#5):AZ,>7* M7CRFI:%KC&TNZ-Z(BB?0^*PLS>Z%#30WT='?4$L#!!0 ( )L^8U>LR43Z M#@, ' ( 9 >&PO=V]R:W-H965TT\%0(:29!;FTY"D.3YE@PGIV-56<$EWFDP55$P_7R.0JTG01QL)^[Y,K=N M(IR.2[;$&=K/Y9VF4=BP9+Q :;B2H'$Q"<[BT7G/X3W@"\>UV>F#RV2NU*,; M7&>3('*"4&!J'0.C9H47*(0C(AD_-IQ!LZ4+W.UOV:]\[I3+G!F\4.(KSVP^ M"88!9+A@E;#W:OT!-_EX@:D2QO_#NL9VN@&DE;&JV 23@H++NF5/F^>P$S", M7@E(-@&)UUUOY%5>,LNF8ZW6H!V:V%S'I^JC21R7[E!F5M,JIS@[O98KE%9I MC@9:#VPNT+3'H25FMQZF&Y;SFB5YA>44;I2TN8'W,L/L97Q(BAI9R5;6>7*0 M<(;E"72B8TBBI'. K].DV?%\G3^D^0R7W*1"F4HC?#N;&ZO)%]_W95P3=O<3 MNKLR,B5+<1+093"H5QA,W[Z)^]&[ W*[C=SN(?;IC.Y>5@D$M8!&^CZ1!VGV MB]P]\531[3(6,]IH!*TCX)),)@3=%],&.@2+Q1QUEF)O8S"5QQRT[_Z'"=RS-5G5HN9,&(B3(72[\)4NJ=NFU"I%8Z ?]>D7PZPJ M2^$T]08.]J L$]!B)>&>N&,AM976))U4&]NF/>+C9#CP;3R(G31Z*QD$J^#C M]=6MAY&I^VUH)=$6']?X7@SWF*JEY#]).C,CV'TL'C+L^S:*.G!K-J#N#M\@5\Q41%-1>;70%@0S%A*\A@67%./7H;0"IRHH T%VEQE,.S!8 ' MO-)KO-+[>Z\U^(;I)9<&!"XH-#H9D%]T7=_J@56EKRES9:E"^6Y.GP2H'8#6%TK9 M[&PO=V]R M:W-H965T*]$C*3O_[W5&*JK2*T9<]F"8IWL?O[CX>N=@9^]F5B!X> M*Z7=,BJ]WYS$L4M+K(0[-!O4]"4WMA*>AK:(W<:BR()1I>)D/)['E9 Z6BW" MW*U=+4SME=1X:\'5527LES-49K>,)M'3Q)TL2L\3\6JQ$07>H_]CGDY&S.Z\."3Q)WKM<']F1MS&<>7&?+:,R$4&'J&4'0WQ;/ M42D&(AK_MIA1MR4;]OM/Z%?!=_)E+1R>&_6GS'RYC-Y&D&$N:N7OS.X]MOX< M,5YJE LM[)JU'L'!P]BK="- M%K&G/7AEG+9X9PU>\@+>.[@QVI<.+G6&V7/[F+AU!),G@F?)7L![W!S"=/P: MDG$RW8,W[1R>!KSI"W@7:.56L!2>>2QT!N\Q*Z0NX)25(KU$!Q?2IBTFPZ&]Z43]:)VX@4EQ$='8=VB]'JYY\F\_&O>UR:=2[-]J&O M[NFD9K5",#D,Y_,.4V,I'R \7#HO2A:ASR:.^>PQX]E BY4730 M.8QY1T7VJ.R08FE[?'R)1 ,[5CFSVC*K0V! 6EM;&P"[+U"AX*0P)'MM:@O" M.6P3J:182]5D,.PG7,O+G<#!*^)#1TDIJ@INU(L"W/10/^ 6%9#Z/%9KM)T$ MX0+3=F829A*@\K 3-H.4E,\"<;S!1_++ E-GM)9< J]@0Q8&W-FPRUH6(7]) QF;Z"I$Y5S>*A@-&M1'57 MMV%*OP#%4CLEFHJ?_4,%M#$B$E2G@XJLJ8"\+I"@'1DWB[_3R4-I$9]5,_B= MO'P^\ZV8@D*"*+[VKK[E6-!=V=>(J2A&)5]T5)3(.U,A2>3X71#+G-ID0LUT M/-V7\7F7\?D/9_S@-V(RHL2[$/[ATCB4_/U;\*D]-Q0?[2A$U'-&R2PD\][3 M7Y,1VO^Z\;5-:$B_K$@UX4P+EH8"30^3@Q"Q47.VB2P&ZX^V$-KH7QSEL2,^ M6'3^AV3B8UH*31IB/@W!$5M?]N?1==0IE3-J^)<<47.03$9#V8Q[5WF%M@@/ M%D<:J;5O;O5NMGL3G39/@:_+FP?5C; %"TUA3J;CPV,ZLK9YI#0#;S;A8; V MGIX9H5O2NPXM+Z#ON3'^:< ;="_%U7]02P,$% @ FSYC5VN4[:&3! M/0L !D !X;"]W;W)K&ULG59M;^(X$/XK([:W M1R4*>24IVR+U55NI5:NVN_?A=!],,H!O$SMK.Z7]]S=V(*4<<*L34AP[,\_, M^'D\^&0AU0\]1S3P6A9"GW;FQE2CP4!GU/A$UJ;@ A\4Z+HLF7H[QT(N3CM^9[7PR&=S8Q<& MXY.*S? )S;?J0=%LT*+DO$2AN12@<'K:.?-'YT-K[PR^PE4RD_&$G M-_EIQ[,)88&9L0B,AA>\P**P0)3&SR5FIPUI'=??5^C7KG:J9<(T7LCB#YZ; M^6DG[4".4U87YE$NON*RGMCB9;+0[@F+QC:).I#5VLARZ4P9E%PT(WM=[L.: M0^KM< B6#H'+NPGDLKQDAHU/E%R LM:$9E]# R!6Y-!M@0Z;X""'4#'<">%F6NX$CGF'_T'E%2; M6;#*[#S8"_B$51]"KP>!%X1[\,*VTM#AA3OP7'V77&>%U+5"^/-LHHTB5?RU MK=@&*]J.94_*2%JV+O#!E5M8][Q&BYC" 02]. K=F!R';\ M?@,.:R6/ZNJ#B%)0DC2!**^'\2_@<:,])&# MD ;UNVO0\RG0\ME/$[+\5\0=KJNH?C^(8;(*Z_="/[7/T(>X";WN1ZM!SW,A M[?/>S&F/)U(IQY^&A'[-8C$5O1:LQYWD :6\81VX\]D.X1:U'<%$K9>FII'+=E!2SX9?2KX&^ M_?"A!X+^6\@^VX!P@:)A$\B+P>^#E>BF(*Q0J7OG.;=>!,\%8:,VP$I;-%2T M!4R(NK1!?+\?1:G3 _UCD<2EP*/2=J9W/W+@,B>Q#OO^T%^S-7.%.ZW)(B+> M@^&:@^:ON\P9U5PKD)7-NK^G*\1M5XCW=P7Z/\[K FV5%TRI-WN*O[.BQH;V M*VUXZ51XS;A:?2'C7^D<>T-O;W+S;/+7+JDCR+.K?>&\(Y=)+0RUZF_V>3NMU4?=)+X]"),3B.8 ]APY:P MX2\3=L=,K4C EA&QT=6W\;$7>3L?=F_U6LCW UZQ-T<\\?.SYK8_40X;VVWU M;"D3^$H3NBC!&S+5*,LV&613,OZOG7=[34W:OD1P;(>X&8;-D-#P_ Z7]A(O MW+K7@[4K38EJYBYN&ER;:VXW[6I[-SQKKD3OYLW%\HZI&1<:"IR2J]=/2.RJ MN:PU$R,K=T&:2$/7+?2VO)R8@.T-^;Q/U!+ P04 " "; M/F-7[:1=X2@# "+"0 &0 'AL+W=O8R<- M[=W:;< 7OY_G/,]C)_9H)=5WG2,:N"NYT&,O-Z8Z]WV=YE@R?2PK%#2SD*ID MAKIJZ>M*(*U UV7)U'J*7*[&7NAM M!CX6R]S8 7\RJM@2;]#\5UTKZOD=2E:4*'0A!2A<"5WJK M#5;)7,KOMG.5C;W $D*.J;$(C*I;G"'G%HAH_&@QO2ZE#=QN;]#?.NVD9(/5,<3!$41!%!_ BSLC8H<7 M[\&[_%$79@U?+^;:*#HKWQ[2V$ D#T/8[^=<5RS%L4<.:E2WZ$U>O0@'P>L# M!)..8'((?7)#WV-6MX'SM9N6 H5Y2.!A"GO22ITRE50=3 MQIE("=S ^YJO(72'(SH"03\WF@J8=G_19U5X0E?P0T M0)'PZL4P"J/7T#L[[3?%IZW1_]?[X7;(W ?=$D%'W& Y)YSVG.^7,CAMZ^&@ MO\>'^%[PF1.?1(T)LB$?3J&)[\V==L!)FJZ;1X_#$'0 MU.%3?.B%Q#2TIE.9-"Z$G9#PVG)QZHYNIO.D96[KJ=2T.7MVOF]%I"91?0_$)*L^G8!-W[:_(34$L# M!!0 ( )L^8U>"[\!>]0( (H& 9 >&PO=V]R:W-H965TQZMB9 M[4"[OWYG&RAHE(*Z$-,.HM+;NQ[')2ZR8N50U M2OJR4+IBEHYZ&9M:(RN\427B+$DZ<<6XC$8#+YOHT4 U5G")$PVFJ2JF7\8H MU'H8I=%6,.7+TCI!/!K4;(DSM-_KB:93O$,I>(72<"5!XV(8W:3]<=OI>X4? M'-=F;P\NDKE23^YP7PRCQ!%"@;EU"(Q>*[Q%(1P0T?BSP8QV+IWA_GZ+_MG' M3K',F<%;)7[RPI;#J!M!@0O6"#M5ZR^XB>?*X>5*&+_".NBV23EOC%75QI@8 M5%R&-WO>Y&'/H)N\89!M##+/.SCR+.^89:.!5FO03IO0W,:'ZJV)')?N4F96 MTU=.=G8T8Y5IY!(H*L'F2C.?J_-'-A=H/@QB2SZ<9IQO\,8!+WL#KP0"LB1KG;S6&WA37*%L$!9: M512UM)H*@Y)N2[CUZ48-OV[FQLM_'TM P&\?QW=-U#T.A6^LRX[Q6KTN=#N079-]EL*,>I_+Y04L M4:)F I@L@!745=Q=MQL/D%Y#VH6K%G22_]A0*5JLYE0@VWJ$.\PWDO0BT)N2 MA*]\^X0:VW88E[EH"I]"^&9+LLD;K5%:2I-!ZT+JTD,\)^PEV%-BCUD_:E8@ MS;-<-9+LZJ .G0PHT&-%%N_-!ZKOI9^"[K[(/HR*G70W:&_"?'E5#U/Z@>DE MEP8$+L@TN;R^BD"'R1<.5M5^VLR5I6;RVY)^%JB= GU?*&6W!^=@]_L9_0-0 M2P,$% @ FSYC5UY-OB7= @ :08 !D !X;"]W;W)K&UL?57?;]HP$/Y73EDUM=+6A! H,(@$[:;MH1,J;'N8]F"2RP_5 MB3/;*>6_W]D)*4S BV.?[SY_W_E\F6Z%?%89HH;7@I=JYF1:5Q/755&&!5.W MHL*2=A(A"Z9I*5-751)9;(,*[OJ>-W0+EI=..+6VI0RGHM8\+W$I0=5%P>1N M@5QL9T[/V1N>\C33QN"&TXJEN$+]HUI*6KD=2IP76*I+9++[%,\Y($W@XWZ-_ ML=I)RX8IO!?\5Q[K;.:,'(@Q83773V+[%5L] X,7":[L"-O&MS]V(*J5%D4; M3 R*O&R^[+7-PT' R#L3X+3X35;$(9PZ]#X7R!9WP_;O> MT/MT@730D0XNH8HYQS1%$ N<%G&)]$?^O#!XP:BT]:_'A@4 3*0IX1!D] M&X!Y%#7G27+.7TSQP14$PSL:^W>!C=#BA'_%=M9YZ/5@$/1AQ:AL@94Q1$)I MDRYE+22.7FI>ILW!FB06K*P3REPMC=F$J+JJ^.Y(9*ZS]M1&[SJCO:,2A^^4 MTV/+_TFQ:;#*WV8-T2OP1T:B&<8#&GI> /='S/T!)0Y&(QCWX%0EN0?/OT"9 MVB:GP.:GZ02=M>NC\Z9]O+DW3?B1R32G=\ QH5#O]F[@@&P:6[/0HK+-9",T MM28[S>A?@-(XT'XBA-XOS '=WR7\!U!+ P04 " ";/F-7ANP5JA@# !\ M# &0 'AL+W=OYCV8)(;L!K'F>U D?;QLY,0,C5D",$#Q$Y\SSW7 MQ\YQ1ALN7N0*0*%7%B=R;*V42J]M6P8K8$1V> J)?A)QP8C27;&T92J A'D0 MBVW7<3R;$9I8_BB_-Q/^B&8L\$Y".^4]C(6AN94A:9*Z*=4QRE_2H*7I>!9 M$B*B?P]$90(0C]!C"H*8B9/HPRTH0F/Y<60KG=($VD$)/RW@W0/P9H'Z-YFMZZJ* K'7C&CVR+5,20!C2V\""6(- MEO_^'?:EG!&)_NPFJ8EY@=W/L,[+7#7QZ%9_>L7SJRJ&HD(Z"8=0H:A._WEM^S?3Z%;U^*[V;R62,AH345]QC=NQH#UXHVB_6=&KBLM5 M*Y?GSKS3E*@UZL3Y&5:*O#YO0)?PBSPWBWPL7916*AY'Y?:(LGC$-%$JUW: M:R/_MY;A'K ,O/<,W&X:]XQER5&"M^*<.GM[\\#]\PM^"6/!>V?!K49P!L&] M_[ZQ[=I9TIS+OQ&QI/H0&$.D8YS.0 >+XJA;=!1/\^/E@BM]6,V;*_UY ,(, MT,\CSM6N8TZLU0>'_Q=02P,$% @ FSYC5]BPE_9@ @ &@8 !D !X M;"]W;W)K&ULK57;3MM $/V5D8LJD&CLV.8BZEB" MH*I4("$BVH>J#XL]25;LQ>QN$OC[SJZ-E:HF*E)?[+W,.7O.K&=<;+1YM$M$ M!\]2*#N)ELXU9W%LJR5*9D>Z044[O"W=\L71^(2Z+ABUPANZ^N34TBWN6 MFDM4EFL%!N>3Z'Q\-LU]? CXSG%CM\;@G3QH_>@G5_4D2KP@%%@YS\#HM<8I M"N&)2,93QQGU1WK@]OB5_4OP3EX>F,6I%C]X[9:3Z#2"&N=L)=R=WGS%SL^1 MYZNTL.$)FRXVB:!:6:=E!R8%DJOVS9Z[/&P!QOD;@+0#I/\*R#I %HRVRH*M M2^9861B] >.CB4PA<.93VUY"]EB\?YO-5>68;5N$DHK*S:-88E1\_ MC(^3ST-F_Q/9']:SWGJVB[V\;^9&*P<->PD?P9#9G0SO-=N2'0#J9823<69H-H12-5$-[?+3OZ7@ORDE]"*W'GB>V\DWJI&ULK5C;;N,V$/T50@V*!-A8=UE.;0.)I447: ICW;0/11\8 MB;:)E40O2=G9OR])*8HMT8J;ZL66J#.',X?#X65Z(/0;VR+$P4N>%6QF;#G? MW9DF2[8HAVQ$=J@07]:$YI"+5[HQV8XBF"JC/#,=RPK,'.+"F$]5VY+.IZ3D M&2[0D@)6YCFD/QY01@XSPS9>&[[BS9;+!G,^W<$-6B'^M%M2\68V+"G.4<$P M*0!%ZYEQ;]_%MBL-%.)/C [LZ!G(4)X)^29?OJ0SPY(>H0PE7%) \;='"Y1E MDDGX\;TF-9H^I>'Q\RO[9Q6\".89,K0@V5\XY=N9$1H@16M89OPK.?R*ZH!\ MR9>0C*E?<*BQE@&2DG&2U\;"@QP7U3]\J84X,A \>@.G-G#:!MX9 [?CAK^V)*2P2(5C5?R_1%GF4@'-C6Y\%7V:":U7P^57\X9OUSP2 J^92 N M4I1J[*-^^TF/O2DT:H1R7H5Z<'H)5V@W J[U"3B6XVK\65QN[NC"^7^]QQ_N M_40,M\D:5_&Y9_CN"XY3G)5RDH,52DJ*.18I$+\D62GT!FM*F]D#7TCNU@@F:&*)(,T3TRYC__9 ?6 M+[H!&I(L&I(L'HCL9"B]9BB]/O;Y[V(QPD5"U6(BDA'M$Q>('BC)_ M%BDH4K*N7&(!95R4+9&=X%J4K:KY1B=(U:%_'*WO^V%;%!W,<[T6+-*RV;;3 MDD8'M59<9)\ _ :X7BOBA0[F6T%[%FG9[*"=+7JVB:<7)VS$"7M+OM@3W.E"#(QC8\2P!K)7<-)SNE M87LJ=D'V*&P7[B[('=EG*K=MO>U+K8LFX^5AUX3OQ*U%=0+7H$3D02MR#4J$ M/CX3^M&6W.XOS#+$6WG\2=4>2AS+JDW4,H-G]M*]A/]U%@[*%@W*%@_%=CHT MSMO0.!^J@K794 ,P)%LT*%L\%-OI +P=/.S>S; Z>=PV1X]Z148GQPZ^%2LV MS)(R>SMZ+%?O+=5UOZ?;#G=BM(;M2M"A-[DK+@U8FM:6UN;N[5?46K_<&^6]B:]DC>]*C+A#?ZZIKH$=(- M+AC(T%IT98W&PE5:W;Q4+YSLU-7",^&L("&0H$G3=H.21&HW&'O85+4"'A /;G)) MK#EVL"_-^._QCS04:>U+XK/O^^Z[\YV37JHG70,@>6ZXT&E0([;+,-1Y#0W5 M$]F",">E5 U%8ZHJU*T"6CA0P\,XBJ["AC(19(G;VZ@LD1UR)F"CB.Z:AJH_ M:^"R3X-I<-S8LJI&NQ%F24LKV %^:S?*6.'(4K &A&92$ 5E&JRFR_7<^CN' M[PQZ?;(F-I.]E$_6N"_2(+*"@$..EH&:WP%N@'-+9&3\'CB#,:0%GJZ/[%]< M[B:7/=5P(_D/5F"=!A\"4D!).XY;V7^%(9^%YN^[N Y(WFF4S0 V M"AHF_)\^#W4X <3Q&4 \ &*GVP=R*F\ITBQ1LB?*>ALVNW"I.K01QX2]E!TJ M<\H,#K.-DD67(Z&B('<@*T7;FN7D7OC[MH5[3QZI4M16C[RY!:2,Z[=)B":Z MY0CS(=+:1XK/1/I('J3 6I//HH#B?WQH5(_2XZ/T=7R1< ?MA,RB=R2.XAG1 M4)E>P0N\L[$D,\<[.\OKF,@66JF0B8K\7.TU*M- OUY*V[/-7V:S0[74+CUODE]NRQ:_:@B"R)&5-[1T;M4 G]DE;/MG!L M=EX/V30)#Z<"PI->:D!5;F(TR64GT+?5N#L.Y5A 60=S7DJ)1\,&&)^J["]02P,$% @ MFSYC5ZJ.<=)A'P I(\! !D !X;"]W;W)K&UL MM9UM<]O(E87_"DI)99*JF1'Q#DQL5\GJZ[%3:X\CSTLJ6_L!0\$2,B"@!2%; M?@D9JW=0>G^Z#Q['/=_+&^SO/6N5N5U?KYR77; MWOQP>KI>7N>K;/U]?9-7W?_SL6Y66=O]M;DZ7=\T>7;Y<-&J//46B^ATE175 MR8MG#__VOGGQK+YMRZ+*WS?.^G:URIK[EWE9?WY^XIYL_^&BN+IN-_]P^N+9 M37:5?\C;7V[>-]W?3K]2+HM57JV+NG*:_./SDS/W!_*2='/%@^37(O^\UKYV M-F/YO:[_V/SES>7SD\7F1\K+?-EN&%GWQZ?\/"_+#:K[0?[WB7KR]9MN+M2_ MWM)?/8R^&\WOV3H_K\O?BLOV^OE)OPSNWOZ)+0+.HY\@?=T@</8W_XX%369B^>-?5GI]FH.]KFBX=/_^'J[O,JJLU, M^= VW?];=->U+]XW]>7MLG6RZM+Y,:^OFNSFNE@Z;ZK'2;BIY7?.AZS,UT[] MT3FO5S=9=?_-VGFZ;NW\5>5M5I3KOW6Z7SXHYZ]__IOS9Z>HG+=%67:7KY^= MMMW/N?ENI\NGG^GEX\_DC?Q,OO.VKMKKM4/597XI7*_LUZ>6ZT^[S^?KA^1M M/Z27GA7X(;_YWO$7WSK>PO.%G^=\_\L]:3C'?75-EI7/^,%7SQOGO_^KTSILV7ZW_1RK](SR0X9N^^,/Z M)EOFST^ZQK?.FT_YR8N__,F-%G^7/GY?? MW91955>G;U:/7SCO_O6S-%@K9^I<0\(4$D8@V* 8T==B1'-V@PA9(21,(6$$ M@@TJ%'^M4'QP-WB\,M1^/3UOP9J!I&$-0YF:,&4:DC2AW F2KT-+K$-[57>W M&.NV6#EG_Y2&9[UZZNQ"PA021B#8H 3IUQ*D<_[^I\@*(6$*"2,0;% A=]'? MXB\.[@!/EPY^+0/6 01-Q+J$$C1NS%O #M%P>)J#<>WW [>?LHNBNA*'9[UT MZ@2#TA241BC:L A>7P1OSC[P1$?5"4E34!JA:,,Z]>;-M3H/>R_PC5]/?M=_ M+FA"HQ>8&M>->2\01+X_T@MZY^/:K<^/654T>5G<.6?+O,W:;LY5_WESM(3*=0,C; M@ZGQ(]X>3$V2\.Y@:M)XI#GT1LBU.Z&W6?=QE75U^C9OED4YTA*LC,E3#4E3 M4!JA:,-J]-[-369M"5!S!Z4I*(U0M&&=>H/G6MV)O26DYJ\[7S^0-"YO":8F M-6X83$TRLG[@]=;(LUNC?V27F30P^V539Q>4IJ T0M&&!>C-F^?.V04\J+^# MTA241BC:L$Z]O_.LOL3:!9XN'=[*LRX@:-B]@Q(DO%&0]*V\D2;0>R+/[HE^ M:J^[J?9;-^&J;];.ZSPKVVMQG-"]*RA-06F$H@T+TKLX+YBU*4!='92FH#1" MT89UZEV=9]^)LS:%T/QMYON,@B;P>%PKA',$5N%(TT@]X&>78;]%/5-K=?LJH5QP?=QX+2%)1&*-HP M>M3[-7\Q9S/PH;8.2E-0&J%HPSKUMLZW[\G9FL'3I8/_ZO-% T%CA X$3^]D&_W0B^;O/IR+X\-NH\%I2DHC5"T80VT$.*\*41L#!&;0\0& M$>>PQ_F'YQ!],QSH>KP3 M"!KN#P2-'_!.( 0:1S)(?F]^?+OY>9U=EL5*W$JP7SEY@D$WJJ T0M&&->@= MFC]K%-&'>C@H34%IA*(-'T[H/5QP>!PQ,!."+!IP+DAXPD"0\%@S"1HWD-M MT-N>P&Y[_IVWA=@$[-=-G5Q0FH+2"$4;5J#W9L&L.<0 ZM^@- 6E$8HVK%/O MWX+#P++;GE_OV[HIQ("1_P 6'9PX#(4_(EP@D#0\8 M"1IW8=P22**Q>X+>]P1VWW/6UE]R<=? ?N'D&0;=FH+2"$4;EJ!W9\&L4<, MZN"@- 6E$8HVK%/OX(+#HX:!&?\S<@#GDFC!]PT$D6^D#261]J##\,'EWOJ$ M.ZQ/O;X=:0;V*R<_K S=FH+2"$4;UJ#W:.&LB<,0ZN2@- 6E$8HVK%/OY,+# M$X>A$ /D3RKMH5&")F3KCB1I1G+'86]_0KO].:^_9%ES^OI^\X M?\2))%$X$B\*>Q,4VDW08P;Y/&LNB_I3ME[>EB-] ;I=!:4I*(U0M&%!>ML6 MSAH[#*'>#DI34!JA:,,Z]=XN/#QV&)I)P( ?;B!H?/YD@J Q,\BB:,PQ])8H MM%NB#T5UU?6"0FX&T"TK*$U!:82B#<\XZGU;-&OL,()Z.RA-06F$H@WKU'N[ MZ/#8823$!=DRX;FDX6DC0>.E?"E1$/GNR$U"U%NBR&Z)WF7KNLKOQ-%!-ZZ@ M- 6E$8HVK$'OW*)9@X<1U-=!:0I*(Q1M6*?>UT6'!P\C(0S(3S(0- %?210T MKG&4@2@:B1Y&O1V*['9(W99Y(T8-[!=.GF'0?2LHC5"T80FTDP_G/?H0>_8A M]O!#[.F''!P\@, _+?\G-)PU<.!(W+K09)(F\D:A#U!BBR&Z#S M,FN*L;L"Z,X5E*:@-$+1AD7H;5HT:_8P@AHY*$U!:82B#8]"[8U'"=W @M(4 ME$8HVK :O5N+9XTBQE!'!Z4I*(U0M&&=>D<7'QY%C(5T('<*DH;GCP1-Q)]; MEC0C2P9Q;X-BNPTZ:Y;UG9Q)ME\Y>8)!MZZ@-$+1AC7HO5H\:Q QAAHZ*$U! M:82B#>O4&[KX\"!B;&8#([Z5L(=&"1K/O#D0@HAC9YW%VCGP=A_TJEYGJTST M"?8K)T\QZ&X5E$8HVK &O5F+9TTBQE _!Z4I*(U0M&&=>C\7'YY$C,UH8, W M$@2-<0ZJH'$]?H"!)')'U@R2W@8E=ANDBINF[CX_\0$%^[53)QF4IJ T0M&& M5>CM6C)K$C&!&CDH34%IA*(-Z]0;N>3P)&*R^]#"9\5U;?.R[J;>IMWPJE\\QJXNJROQ,4$.WSR M'(1N9T%IA*(-R]3[N&36F&("]7I0FH+2"$4;UJGW>LGA,<5$B"!R#R%H^$O5 ME* Q/80D8=#=+"B-4+3AJ]=Z&Y?.&DM,H48/2E-0&J%HPSKU1B\]/):8 M"G%"?O21H.&O65"")N6/,DF:D67%M'='J=T=/1@(<630#2PH34%IA*(-*]!; MN'362&(*]7!0FH+2"$4;UJGW<.GAD<343 G&_.EF06.<>2)H/)Y6(DD4CJPD MI+WU2>W69[P10#>PH#0%I1&*-JQ [\[261.)*=3!06D*2B,4;5BGWL&EAR<2 M4^%X0KY((&CXN49*T+@+XX9 $(T]II#VQB>U&Y]?OO_PO3@TZ.X5E*:@-$+1 MA@70WLD\[TN9L6]EQKZ6&?M>YGE>S*R_F?F85S.;&4&?/[-\+JKX<6E*4KF+ MR'C'FB@+QE[+NM#>T;RP6Z!-3W#^SWF7W]V46557IV]6CU\X[_[ULSQZ[*N; MH3B%Q1$,Q^KC:?69]_W-"^P+G*$XA<41#,>JI;W$>7'$6YP7PIN5 ^XE1%5H MO)=14 6N\;)62;48\1-=.]&&:3=,3TWC55V6Q;HM5L[9/^410W>WL#B%Q1$, MQZJBO*/S0D@C\L5'4<27'201W]LD M433RT(.[T%[KO+#;J>V]Q>VG[**HKN218E_K#,4I+(Y@.%81[=7.BWG?[;S MOMP9BE-8',%PK%K:"YX71[SA>2$$$/E349)(:!&F*.0KDY(H&MFB<%W-9[EV MG_74(G[,JJ+)R^+..5OF;=9VD[#Z3[YLBY%WP=NID^P.(+A6)$TC^C. MFH?VC(KF'#TQR6:W=83WWB']FEF(;: MGI'<7CM\0,KH M#::(YZ4E#<]/T8[OQD:HF2O7;JZ>NL/C8Q:_=7.P^F;MO,ZSLKV6!PW=?,/B M%!9',-RP.I[F"[U9$Y1;/*I:4)S"X@B&8]72#*)W>(YR>^W@]]?8]9!$/#DA MB8Q3X261=N8T&Z+FJCR[JWIJ%Q=Y];',[XJ1H6(WVZ XA<41#,=*HOE ;]9X MY18/JQ;6&D)Q!,.Q:FG6T#L\9+F]=O";S=\;(8KX,0Z2R(W-)B&H@K'E3$]S M5)[=46UO*JJVN?V25>(+978PIL\[[#X;%$JI;E$[_ $YO;:82K2Z!*"R# >@H@? T&B:+1':-;*VYW"['K$RR:OOMR/ M#!2[S0;%*2R.8#A6$,T)>K.F,K=X6+6PSA"*(QAN6"U?TN@.IL;L M#CLY9.>PX6GNR=\K/V_:TL?:0"A. M87$$P[%J:3;0/R)MZ0M!2J,W[-0H26/$I@3-R+$P;J#YIF"OI.6O]VW=%')6 MRDZ8/-^@.(7%$0S'"J(YO6#>5&6 =8%0G,+B"(9CU=)<8'!$JC(0@HZ\.P@: MXZDN06-T!T$S\F"X&VBV*=@K4WG6UE]R>=?"#I@^W;"[95 U.O;T>Z MW26#XA061S <*XCF\X)YLY0!U@9"<0J+(QB.54NS@<$16:W6&G1NVA M(;N_S3<%>0O[S=_R$/%[I-!<0J+(QAN6)90\WOAO G*$&L& MH3B%Q1$,QZJEF<'PB 1E*!PSR7N$H#$6'P2-<62$H'''3HP(-?L4[A6??$Q; MGV?-95%_RM;+VW*D5]AQTV^>;OV#L+T^8;=.(/B"(9C!=$,8#AO?C+$^D(H3F%Q!,,- MJQ5IOC Z(C\9[9&?W*U1>VA(THR=.15I1BK:*S^I;LN\D3,0=L#DZ0;%*2R. M8#A6#\WX1?.F)R.L$83B%!9',!RKEF8$HR/2DY%TFJ31'4P1?^^>DD0N?R:4 M)%4Z=O\0:?8IVBM">5YF33%V V%'3)]UV.TS*(Y@.%81S?%%\V8H(ZP9A.(4 M%DXIVBM#^;A2>9&O;XHF M:^M&?,OF#M;TF8?=2(/B"(9CI=&<7S1OGC+"VD(H3F%Q!,.Q:FFV,#HB3QD) MIU<:#WQ+(O->0GCKM[%2*8C\8*17Q)J7BO?*5)XUR_IN)'%M)TR>9ZM,]AEVPO3YAMTX@^((AF,%T9Q?/&^H,L:Z0BA.87$$P[%J::XP M/B)4&9M!1V.;<[=&21KCYL&J8K+*V+NLK>8'"_DVF3TGLWAH4 M1S#3>3.7"=8L0G$*BR,8CE5+,XO)$9G+Q,Q!&@?E"QHCR5L^RZPTV^'%F]M".F M3SCLSAH41S %NXT1YV:I2D M,9X(MVK8\#1[E>P5LWSP'_(0L;MI4)S"X@B&8^70[& R;\@RP1I!*$YA<03# M#:N5:D8P/2)DF9K!QY#W!D%CO(-+T+C&XH0@\L9N'E+-.Z5[Q2S'NX/]^LGS M#8I36!S!<*P?&?R_E(6+WT: XA<41#,>JH?F\=-YT98KU@%"< MPN((AF/5TCQ@>D2Z,C43CZX;I$9[D&2QL?*[^[*;.JKD[?K!Z_<-[]ZV?Y8\#NLT%Q"HLC&(Z523."Z;RIRQ3K M$Z$XA<41#,>JI?G$](C492J<+&GL:DBBQ.@=TMO'S=L+096.Y"Z]16^O-E_O MWSE>U659K-MBY9S]4QKV#MK4&8C%*2R.8#A6'%5BVH<\3B"(9C MU?*T:AV>P=Q>._A//U_&%$7\<7%)Y"[X2J:L&C$DWL+7!FDW7.Q.X_93=E%4 M5_*0H5ML6)S"X@B&8X4)M,+,FLC_;9P)8FXQ2%1-'+$OK=(M2':O=>P>;S-N@^QK*O3MWFS+,JQE@'= ME\/B%!9',-RP0JYF'-U9 YI;/*I:4)S"X@B&8]72G*1[>$!S>ZVM&YR+(KX. M*HE2XWY#$"4C*0O/U>R7:[=?PY;QC^Q2S&'MH$R?=]#].2R.8#A6%,TNNK/& M-+=X6+6P'A**(QB.54OSD.[A,)KIP.(+A6)$TV^C.FMS@.(7%$0S'*J-Y M0V_64.<6#ZL6UC1"<03#L6IIIM$[/-2YO7;PNYL8G4(X%3,P6H4I"HW%"DDT MVVL'/8"?SR^)/+-1""=H&H$+033>*#2#Y4U)=I[=_UY4 M;5'+ \9NPD%Q"HLC&(X51K.%WJQ9SBT>5BVL583B"(9CU=*LHG=XEG-[[0[S M(8B,M4U!Y!OK%(+(&SFNW_,U?^5/27*^SB[+8B5O@=A!DZ<>%*>P.(+A6%TT M5^C/&^+TL4X1BE-8',%PK%J:4_2/"''ZMA>&;S_?G1HE:5S^L(@H&@M\^YJY M\J<$./^=M_)Y%3LPTZ<==N<-BB,8CE5%\X/^O.E-'^L2H3B%Q1$,QZJEN43_ MB/2F+\0I^4/IDB@)C38A13R-VPE)E8RM9OJ:N?*GY#=_O6_KII"#5W;0],F' MW7*#X@B&8W71'*$_;U;3Q]I$*$YA<03#L6II-M$_(JOI"S%,(ZLIB0SC(8A2 M8XE"$HT%O7W-6_E3LIIG;?TEE_<\[)SI,P^[WP;%$0PW+$N@^<%@WH!F@'6) M4)S"X@B&8]727&)P1$ S$ ZU] SG(:D6*>\4@LHW,YJ2*AR[J0@T>Q5,"6E> MU.O;L69A!TV??M@M-RB.8#A6%\T5!O/F- .L6X3B%!9',!RKEN86@R-RFH&9 MG33>![2/2$FBD!_I+XK&TMR!9K&"*5G-\_I+EC6GK^\W?\BCQFZ\07$*BR,8 MCE5'\X;!O"'- .L8H3B%Q1$,QZJE.<;@B)!F8*8FS>4*2<0/LI!$'F\J)*J" ML77-0#-:P928YF.X^SQK+HOZ4[9>WI9C?0.[#0?%*2R.8#A6),TJ!O,F-@.L M@X3B%!9',-RP6J'F(,,C$INAF:'D+PL\ET1\ 5-)(I>',$A4N6-/FH::\0JG MA#8_%-55URL*N5G849.G'Q2GL#B"X5AE-*\8SAO:#+$.$HI36!S!<*Q:FH,, MCPAMAF:*,C%"FX(HY:=X2R(O,4R)H/(78TN=H6:\PBFQS7?9NAYY[?D.T/3) MA]V0@^((AF-UT=QB.&]L,\2Z1RA.87$$P[%J:>XQ/"*V&0HY2GZPGB3B9W0FAA^15/'(R\^]4#-=X93@IKHM\T8.6M@YT^<>=C\.BB,8CI5%LXGAO+'- M$.L7H3B%Q1$,QZJE^<7PB-AF:.8H^?F]>VB4I.%/E) D\L?V0R+-8D530IOG M9=848W<4=M+DF0?%*2R.8#A6&,T61O.F-B.L583B%!9',!RKEF85HR-2FY$9 MI#0W3R61$<@21.["YZU"4*4C9WQ[D6:PHBG!S<<%SHM\?5,T65LWXCM+=R"G MST+LMAP41S 1.< M$=8Q0G$*BR,8CE5+H+(-VR(('+Y&;\DJMRQ5A%K7BN>$N%4Q4U3=Y^J_&2('35]^F&W MX* X@N%8932'&,\;XHRQ;A&*4U@Q(6HV+)D2Z>P:Q4V^'%GXM),FSSTH3F%Q!,.QPFC6,9DWT9E@[204I[ X M@N%8M30[F1R1Z$R$'*9A4"2185 $46)V"B$;.G9+D6@>+)F2YWPP*/)HL3MS M4)S"X@B&8U71;&,R;YHSP3I%*$YA<03#L6II3C$Y(LV9F.G*V'A*1!#Q%R K M2>3Q)1&25:.-0C-8R90TIZ518+?FH#B%Q1$,QZJB.<)DWC!G@O6)4)S"X@B& M8]72?&)R1)CSZ=I(_\4U-E(%D6_$.061$-*25,;NR.GZ.L];E;79BV?=A+K* MS_.R7#O+^K9J-[-2^U>GR3]NWBG_PYEWGW0W]+_7;3?;'[Z\SK/+ MO-D(NO__8UVWV[]LOL'GNOGC83@O_A]02P,$% @ FSYC5X@#8"3&ULM9IM;^HV%,>_BI5= M3?=*71,G$!X&2)1X6Z=;K6K5[<6T%RXQ$-T\,-N4WF\_YZ$)"<8JW>%-(>%_ M?O;Q.3GXX$[V&?\F-HQ)])K$J9A:&RFW8]L6RPU+J+C.MBQ5GZPRGE"I+OG: M%EO.:%@8);'M.HYO)S1*K=FDN'?/9Y-L)^,H9?<R/R&/9MLZ9H],OFTO>?JRJXI892P5$19BCA;3:TY'A/7S0T*Q9\1VXN# M]RAWY3G+ON47M^'4OG^C_U(X MKYQYIH(MLOBO*)2;J36T4,A6=!?+AVS_&ZL\91:+XB_:5UK'0LN=D%E2 M&:L9)%%:OM+7:B$.#!1';^!6!F[7H'?"P*L,O/>.T*L,>N\=H5\9%*[;I>_% MP@54TMF$9WO$<[6BY6^*U2^LU7I%:9XHCY*K3R-E)V?W/ MW2XEH&J)?6;;F M=+N)EN@V+7,PC^5/Z(&]L'3'!'K^?BB:J\Q$GP,F:12++TKW]!B@SY^^H$\H M2M%=%,?*7$QLJ>:9CV8OJSG=E'-R3\S)0W=9*C<"D31DH<8^,-N/#/:V6I]Z MD=RW1;IQCG3%>P?-.\*ID M0"N>)8B\2L93&J-%D:J,H[^_*CVZE2P1_^A"7\)[>GA>%L=B2Y=L:JFZ)QA_ M8=;LQQ^P[_RL6W=(6 )(T"P5H1Z=81Z)OI;A+1/7FGI%Y;YE\C+#/?Q:&*_ M'"ZK3N0-VJ+@6-3S_7Y;1'2B83-B.W M4PIR\#P]JYH=&YIS22+$2/DDJ]AT;S ['RX"E6GK"1\XG2J@$_E^ MIPQH1-CQ.WL&HE6=*@3XH(?!1A?G(J+HGBZCE>I*\GW![W1+4ZW#1M"Y*0=* M"T!I!(K6#HG;A,2]9&6HZ%!Q@J0%H#0"16O'J6GFL+$3,5<'[^AI=8>];G70 MB;J;!(UHZ'?* 5--X3-[=!7*J,4S57214MZA>ZB,(P9(E3(*_2P$VH3<57L'N:K7*!= M!N, 9^M&:"]'R@M *41*%H[3DW_AXW-B[EFC([+ M@=?]J5$K.FHNCD7^\*BWT(@.?H]L__#?=$^NN7OZ0VX8UWEGMCLWQ4!I 2B- M0-':$6B:.Q=?LA2XH!T?*"T I1$H6CM.3[J9/'R/+N\D-FV.+!]SJ3*\>+MAM&0 M\5R@/E]EF7R[R >H_ZM@]A]02P,$% @ FSYC5VPEVC[ @ U < !D M !X;"]W;W)K&ULQ57?;],P$/Y73F&"36)+FG9M M-]I([09B$D/5JL$#XL%-KHVUQ ZVVZ[\]9R=-!21Y@&!>$G\X^Z[[SN??:.M M5$\Z133PG&="C[W4F.+:]W6<8L[TA2Q0T,Y2JIP9FJJ5KPN%+'%.>>:'0=#W M<\:%%XW<[4;HJ9W(Z]CK=?>."KU-@%/QH5;(5S-(_% M3-',KU$2GJ/07 I0N!Q[D\[U=&CMG<$GCEM], :K9"'EDYW<)6,OL(0PP]A8 M!$:_#=Y@EED@HO&MPO3JD-;Q<+Q'?^>TDY8%TW@CL\\\,>G8&WJ0X)*M,_,@ MM^^QTG-I\6*9:?>%;6D[N/(@7FLC\\J9&.1/"'LK<*-KEY&>BN9'QT_F4="5P(W,Z:\U< MNF89$QK.X2-3BMG,P>DM&L8S?08GP 7<\RPC0SWR#?&P:'Y)?RTBW(N8AJV MW3C-*H->M'+%YU^\*9%7:]6UVM#CR:Y7!-1N82U4!C+E>#? M24!\*#26VC2>< G==]#VXF^BSB 8^9L&/I\0.[) IZ'0@+PNR!PG;Z9;<]FLM_5;DV?SQ56/>6MW^\, '-:G!?R[GP3]0 M-ZS5#=O+QS&DTG"=2L18E4D3SW:DKBN+QC+P#U[:'-7*]1--94F56SZZ]6K= MLB;E2_W3O.QW]TRM.#VQ&2[)-;@84*VJLH>4$R,+]VXOI*$NX(8IM5U4UH#V MEU*:_<0&J!MY] -02P,$% @ FSYC5PYHO:?[ P XQ4 !D !X;"]W M;W)K&ULQ5C;;N,V$/T50ET4N\!N=+-L)[4-Q):* M!F@ (\;N/A1]H*VQ+40B79*VD[\O*2FR+HR0M 3R$HO4F3,\,]2$G,F9LD>^ M!Q#H*4L)GUI[(0XWMLTW>\@POZ('(/+-EK(,"SED.YL?&. X-\I2VW.O>1.Y &>2('PF<>>T9*2EK2A_5X"Z>6HY:$:2P M$8H"RY\3+"!-%9-4B#U' M$8DAUMB'_?;7/?:VC% 5)N\E3'.OEW %AROD.U^1YWB^9CV+MYM[.CG_SWOT MG[TW@N%7>\;/^?S7^/:8@6Y+W#*&R0YD'1%H_8SJN"5^SJ=OSYC%Z*\_)26Z M$Y#QOW6[H_ _T/M7M?.&'_ &II8LCAS8":S9K[^X0^E-/(A3?M2XM!>,P9U3_@4XS;S2Q3_5@=R'NN D)NY#1H F) MNI# JR -N4$E-^B5>T>D2$ "/Z$U$-@F0EN6"I*@YGC8$MA%^"U]783;(HDT M$%>O;UCI&_;J6U N$-TBCE/0*NLU?^\G99(L-$D6&2)KY&!4Y6#TP75Q9#*) M)LE"DV21(;)&$L=5$L?&Z^*X\SD'K:K11;2K1A?AMB!1%W*M+QK7E=;K?JWR M?)Z0W5>TDR61X11A$B,M@]1"A_%:946#"9Q67=%@ M_$!?65SO(MKK%?T@ XG99I_7E!A.D-*#VIQ:L;U4[]Z))ME"HVR1*;9F4BX7 M-_>C;VZNT:N;4;;0*%MDBJV9RLOUS35_?W.[]ZI!NZ9T(>V3B@92N[V4P>EB MQJV*8M>:5AFP7=XMY%++D8BB%U'-5AW)V[P/UYJ?NS<+5S,?J@YFWB2[T!?M MSWO,=@GA*(6M=.5LA;9FLJ!,WRQSW@&)@"R/=;2L7+0#FH M^KJS?P%02P,$% @ FSYC5^Z"$6W6 @ !@@ !D !X;"]W;W)K&ULK551;]HP$/XK5B9-G;22D$#H.H@$M-/V4 T5K7N8 M]F"2@U@X<68;*/]^9R>D4+F(A[XD]OGN\_>=[;OA3LBUR@$T>2YXJ49>KG5U MZ_LJS:&@JB,J*'%E*61!-4[ERE>5!)K9H(+[81#$?D%9Z25#:YO)9"@VFK,2 M9I*H35%0N9\ %[N1U_4.AD>VRK4Q^,FPHBN8@_Y5S23._!8E8P64BHF22%B. MO''W=CHP_M;AB<%.'8V)4;(08FTF/[*1%QA"P"'5!H'B;PM3X-P (8U_#:;7 M;FD"C\<']&]6.VI94 53P7^S3.&A U 9$56C.SLNZHILE0BAV1 MQAO1S,#FQD:C&E::4YQKB:L,XW0RUR)=7T\P$1F9B@(OAZ(VOS-.2T6NB74@ M/RMK?*)\4R^/%9Z[-2IR=0>:,JX^#7V-E RPGS;;3^KMPS>V_T(>1*ES1>[+ M#++3>!^EM'K"@YY)>!9P#E6'1,%G$@9AY. SO3P\/$,G:M,;6;SH+;R<2FC2 M.Z-[O/Z:C*6DY0KL^,]XH;3$N_S7E;L:N^?&-N_[5E4TA9&'#UB!W(*7?/S0 MC8.O+N'O!':2AEZ;AMXY].3^N<)GBSG(V)9E4&9DSX!G+LTUT(T%,B5HFP2= MH'>#A[$]5N-TB[HO;B<\^RW/_EF>CTRMKY<2@+!2 ^9!$TDUN'CVG03Z\2N> M3K>P-W#SC%N>\67YW J.[Y$SO7=QC!V;]\RS.*'H](IZD9OBH*4XN(PB9TL@ M5WN@TET@SL/TB8TDW8 4=:4( Y+1O7)=\7>!JM7Z1R6U +FRG4:15&Q*75>C MUMHVL[&MX:_L$VQR=4]Z@:D[Y .5*X;ED\,2(8/. .^*K+M./=&BLH5[(32V M 3O,L5&#- ZXOA1"'R9F@[;U)_\!4$L#!!0 ( )L^8U:04 # > M 9 >&PO=V]R:W-H965TH+8"?N)I':SLSN/HRF:N?R3&.26/4E R3I2/OA%U]JTMJPMM/VH;[$P)\# MY_PX,#OD[(%O*!7@,4TR/KZ;N"D),ZLQ:Q\=\,6LWPGDCBC-PSP79H2]NN*)OEA;GG6TXO;>+T1 MQ0MG,=N2-;VCXMOVALDGIZDEBE.:\3C/ *.KN77I75SAH"A0?O$]I@=^= ^* MKMSG^4/Q\$\TM]Q"$4WH4A15$'G9TVN:)$5-4L?/NE*K:;,H>'S_5/NGLO.R M,_>$T^L\^1%'8C.WIA:(Z(KL$G&;'_ZF=8?\HKYEGO#R/SC4W[H66.ZXR-.Z ML%20QEEU)8^U(8X*(*@I .L"L-1=-52J_$ $6<9!&?.4*J*]IPEK62JTH)U"@) MP><\$QL./F81C9Z7=V2OFJ[!IZY=06.%=W1K ^2^!]"%"/P.G">=U<70 FJ, MA\H6D,EXX,NVM$=7CZOBN+MXX7 7?$N6=&Y)C^*4[:FU^.,W+W#_-(C#C3AL MJGWQ92>XD$,19^OWX)ZNXRR3MW(*RX%=4O!.CE9EB#/P;Z=)JBY4C?AE(X6+ M[Q=X D/7=6?.OD.=WZCSC>K^DC-)R#G75X;?DN%Y$&ME!(V,P"CC.^52A?/Q MD;)ES ?H"5IZ-$HFC9*)48F,,2L:%V*NB_%)D@%B)BTQYU/]$$T;1=/^$XB6 MU\&S9]I2YD\"_;"%C;30Z'@_RF K+43VE$EX %H/(-BR>$F[E(1OX(J>JZ*L M>ZHS1GF2$,;!EK+*H&>=,;1J9W)D481MA+OMZ1UAP.OMCSV55!6&1TH@LGVH M40*5$CC<)7M*@GV]TE,AWC,&::U?]E2$6D9"@>WIC*1BNS<@N'?X9D]UN*T. MVM#3J%.QW?.'N>>ZF%T@(H*"%8D9V)-DU^FEGI$:8]U4T< SX^#UW#1H679J MASK#*D9X9DB,\-))2TA@^[Y&B$*#9V;#*4[:9H+.214./&/X/M5)PX[!"L)G M?]T*H0( ' " T0X+V]%_:F/<1ZDB 323X%8.K81H,DT* M ,@5-6XK"=%YQC7[\6ARKT0W/H M?XW5.&PG"H$/ [TZQ0,X?2/B0R-HQOJJ(@G"7W",6K# D_UT1@I5J#^:4(O(1U<0 8A"@MH1)K02U'O M) &I4(_&)0F]](1]]6 5V?%I*4&OW5FW:U\4:H<.JVB/O3#%1ZP&0_#B8[;NTB2Z!IZXJ,# C,)3@ Z;F<$NAFG MPCTVYP*GP1RW$P*=(A7G\8 X/QKD=2,O5H;XY9:MIGPF3TYZ#A*YD4;FDD59AU?%D]2#R;7DD>)\+D:?E M[8:2B++B _G[*L_%TT/10'-(O/@/4$L#!!0 ( )L^8U>M6;DA#00 /00 M 9 >&PO=V]R:W-H965T?X M\3&O7SGC+>//8@4@T4N6YF+BK:0L+GU?1"O(J.BP G+U9,%X1J5J\J4O"@XT M-D%9ZI,@&/@937(O')N^&0_';"W3)(<91V*=992_3B%EVXF'O5W'?;)<2=WA MA^."+F$.\J&8<=7RJRQQDD$N$I8C#HN)=X4OIX3H //&8P);T;A'>BI/C#WK MQM=XX@6:"%*(I$Y!U64#UY"F.I/B^%DF]:HQ=6#S?I?]3S-Y-9DG*N":I3^2 M6*XFWH6'8EC0=2KOV?8O*"?4U_DBE@KS'VW+=P,/16LA658&*X(LR>V5OI2% M: 3T#@60,L 4PK<#&3J::+B9#B7 M+'K^,E7SBM$UR]1B"VK*-4MI+M 7=/MSGJ*_ H$8!F/(G ,B#"GUP5$F72PY+*@%]S25/U.86H4>:KD'3 MM4'9[(,&U(%:#BN@X3% ]Z"W;BWG[\ S4[I74(4[;X-Q9Q[:2(1[**:O+B%= M5*P71PCI^XI*I!9OM]ST*84VRHL3*&A4$8].J*#1&P5UN]BI(!S4^WSP/]!0 M";$GHFYG.#I WW I?%(9E>E_04>8U$SDXTIJA7#GZ^_T$Z#,6A_NOJ*_\1JVL7O*Y7CYKTZV8I[ @7'L0[IW./;'3X#[*7OL4=AM5H\A"?QU' M[P!E_N86, B&[BV@MB+L]J+F)U#2':VCMWZ$<>\ 6&U)V.T<;\%^04SNE-B( M"6&\TQ)Y7TNU+6&GAX0SX.8\E*N-\CTQG<*-<&U'>'1",3F][H/LI'8LXG:L M?RVF,O^>F,C(I252&Q)Q&])_H"7RUI,P.3V MB&T;DA7F6/O$I#HDF]L5T!BX?D$]7S F=PT]0/5#1_@/4$L#!!0 ( )L^ M8U?3^&NY@ 0 /8B 9 >&PO=V]R:W-H965TZSL,=23&_HCG) MY#\;RE(LY"/;ZCQG!$>549KHEF$X>HKC3%O,JK1;MIC10B1Q1FX9XD6:8O9S M21*ZGVNF]IQP%V]WHDS0%[,<;\D]$=_R6R:?])82Q2G)>$PSQ,AFKGTRIX'I ME 95CN\QV?.C>U16Y8'2'^7#EVBN&66)2$)"42*PO#R2%4F2DB3+\6\#U5J? MI>'Q_3/=KRHO*_. .5G1Y*\X$KNY=JVAB&QPD8@[NO],F@J-2UY($U[]HGV= M=S324%AP0=/&6)8@C;/ZBI^:AC@RL*P7#*S&P!IJ8#<&]E"#46,P.C&PS1<, MQHW!>*@'IS%PAAI,&H-)U5EUZU9=XV*!%S-&]XB5N26MO*GZM[*6/1)GI13O M!9/_QM).+.X(%ZP(1<'B;(O>NT3@..$?T#L49V@=)XG4"Y_I0KHJ#?2PP2YK MK/4"UD9KFHD=1UX6D:C'WE/;WRCL=5G%MI[69'9!F6C;[= MN^C]NP\]Y5JI,?UB]@.GUH MMUJU*ZX]2*LKR@7"681D,F&/!/W]I\R/O@B2\G_Z%%O#1_WPE:62=ZE<(&$N),RK8>,*5JY;'A>F;T]%)'[T."8"JU6GY2=OR MDPM:OMJ!R*&7]#:_DG1I\T_.V^6T_2']>:_[\R']!>?^K(._3E==MUUUK>PJ MN<:BKVN4EI=V#23,A81YD# ?$A8 P3K"N&F%*,T'I050M*Z&#K%#4QE> M&KKS:RC'RVG'.)UP0(-_H#0/E.:#T@(H6EE!5"TKE0.84)S_*83#FCD$)3F@M(\4)H/2@N@:%T-'2*-)DBHT3R/ MVTW.)AS(>*0+2O- :3XH+8"BU0K0C[ZRIX1MJP,4'%5;VOHC9IO:'M+X5!U- M.$E?FE/7[$GWS*E?'\$XX.L3(6O,MG'&44(VTI5Q-9'29O4AB_I!T+SZQO] MA:!I=;N3VVW"R@SR_PVEXOFA=- >=5G\!U!+ P04 " ";/F-7_0&.MH " M "L!P &0 'AL+W=O07UM[X7>^3VE) TP23A# JJI=Q-.%HFQMP;?"&SEWAJ92):"I)7!'$GB$_UD'2"Y%0/%YW ANZ[V&WB8[>51"OR5:I[(O^!DDTA6[905O +W+06%"Y?O45QIOC/RB0\T<*GH%%:,[ MSE0MT8*54 [H\^/ZZR-Z7X?5QQ;M8IM%1X&/T(Y0''Q 41#% _>9GRZ/AL+Y M/^^+?_9^D(RX+W1L>?$KO*Z^NMXH)[*@7*X%H!\W2ZF$_K?^'*JW(R;#1-/! M)K+%!4P]W:(DB UXV=LWX3CX.)3L<\+R<\(69X(=E"7IRY(+J@+;*Q%Q M!5*Z0 (K&*J'0X6!99D)L,F"4729^IO]1#NKJP.C\'I\:)4/6HW#0ZO%L,?> MR(7L[[6?!L3*]GV)"KYFRGV@_6D_6FYL1WUQ/@LG\W#@/->CR$V.OW@WQ^ZP M6!$F$85*NPI&E[H["C<;W$;QUC:_)5>ZE=IEK<&PO=V]R:W-H965TV"D ML4V4$K4D;:?]]1U*BB)+M-I#+A(IS1N^-R1G9GX0\KO: FCRE/%<+9RMUL65 MZZID"QE5EZ* '/^LA?KN3\5SL-&8V7E*60:Z8R(F$ M]<)YYU]=^R,#*"V^,CBHUI@8*8]"?#>3VW3A>(81<$BT<4'QM8=KX-QX0A[_ MUTZ=9DT#;(^?O=^4XE',(U5P+?@WENKMPHDW-.WA"6DT^,8]O6,[PG*1D(T1JW)#8/3W@B=8@&>567A5\TEK3#Z(. MK[[->&RG-6EH309I?-)$+IBYGLOE<(;3)[WD(A-SGYB"J'JREH+O-=, MEJ_E[5ANJS#Z?[0-)RY:C3X.VMNE*//!&@74#:UNU=)7:W*M>[%Z=[8<( UB8V:QOH2O?A MST[2D+!I!"?W#<2.YS>>?S*.Q\,=%]_D"D"AYS1A%K M8/K.@HN4*-T42U>N!9!Y9I0F;N!Y/3/[?<< M%&^DXFEAK&>04I;_D^="B(I!$+QB$!0&P;$&86$0'FO0+0RZF3)Y*)D.F"@R M'@J^0\*,UC1SD8F96>OP*3//?:J$ODNUG1K?44983$F"[IE48J,?J9+H5_2% M"$',(T'G&!2AB?R WK\;A+WN1T09^DR31#\V>8'.JLVAJ_2<#-F-"__7N?_@ M%?]36'=0Z%V@P M"]#3%Z/SL0P/FYA3,[=,C.B]FVP3#[3 ,L8;Y&2QHGI.K M92ZU#DJM@XP;OLH5=)N+6A'[ OVFTQ.=3[C4&O\]T4;H7D$J_VE2,_?0;?9@ M%HDKN28QC!R]"D@06W#&[]_Y/>]CDZ8V8=@2K*9L6"H;MM''G^*8;\R+*R & MK?$L 8D6>DWA N;H7W36)&6.[&5(LSQNQU$T=+=5@5J]GBK0S_ZZ8>FO%G:W M#+O;&O;M1G"$@7&],!"E(_T#1(HFG# =\Q08Y0)]X0H:\[(5?>J;9!.&+<%J MDD:EI-&;YVAD4UF;,&P)5E.V5RK;:WU9[S08D=3D*>(+_6V>J2;Q6B&GBI?# M?+^2<_[E(*QG.;;DLJ9*OU2EWZK*/F.OD5:()E3].")Y6Z&GJF03ABW!:F(. M2C$';YZ\ YO*VH1A2[":LI>ELI?N_L MM:H2= ;]Z)>79)U"O#';C2QI$=Z V3\.#I)9-[^*)6&ZY,FWWH!\-)G<-.Z< M6[V?*J=5&K9%JRM?J5K\-\_TPH4M>6W2L"U:7=Y]H>*W[M:/3?=VRLD*!@U? MZR#R#E+>EM.Z-/M*PV\O-:8JVVE3ID#C%=)5,C1JDV/\H!*-U]$+0O^PR#AZ M)&Z?VO\-?5]M^.WEQIVNINB2H=OG>$78$I#NV!$Q;PS?:GEAE89MT>HR[BL, M_^U+#-]JC6&5AFW1ZO+NRPR_O<[0GUG*&4E>UJ]7JO^"4BW'?<_S#G/39CF" MFWQ&%9]YQ&[E-,^]/VS 0_5=.&9I 8B1- M0YE8&@G:L2&!AJA@'Z9]<)-K8^'8F>TT[+_?.0E1"P%MTKXT_G'O^;VS[QK7 M2C^8'-'"8R&DF7JYM>6I[YLTQX*9(U6BI)V5T@6S--5KWY0:6=: "N&'03#Q M"\:EE\3-VHU.8E59P27>:#!543#]^QR%JJ?>R'M:N.7KW+H%/XE+ML8%VKOR M1M/,[UDR7J T7$G0N)IZ9Z/36>3BFX![CK79&H-SLE3JP4TNLZD7.$$H,+6. M@=%G@S,4PA&1C%\=I]5DR@S,EOO/,YE/OHP<9KE@E[*VJ MOV+GY]CQI4J8YA?J+C;P(*V,544')@4%E^V7/79YV *,HE< 80<(_Q8P[@#C MQFBKK+$U9Y8EL58U:!=-;&[0Y*9!DQLNW2TNK*9=3CB;7'#)9,J9@$MIK*[H M@JR!#["@YY)5 D&M8#CF%E.E,\R 6?AL+*>4TN2"<0WW3%0(^W.TC MS0'17 MN$$!(8WN%G/8WSN /> 2KKD0=)DF]BUY<8K\M--]WNH.7]&]P/((QL$AA$$X M'H#/WH;/,27XJ(&'NW"?,MBG,>S3 \XU?Y--\P]R*W$ V?X*KYU)0LQ:E'Y6I0;]!+WK\;38)/0_;_$]E.,L9] M,L9OL2=47S73&:1*6DUU:MQ5?[,Y:GK16E-F@!F#=O#:6^I)0^U:T"89G<3^ M9MO;RY!)'[$C..H%1_\N^"Q-=>6>M\Q [8@7G"VYX);CH(/HI8/PF8.7(6'T MS(*_5=.NGUXSO>;2@, 5@8*CDV,/=-NCVHE595/F2V6I:33#G-HZ:A= ^RNE M[-/$=8[^CR+Y U!+ P04 " ";/F-70N0JZFD# Y#0 &0 'AL+W=O M5 FAR MFV=<39Q4Z_6QZZHXA9RJ([$&CF^60N94XU"N7+660!,+RC/7][RAFU/&G>G8 MSEW+Z5AL=,8X7$NB-GE.Y?=3R,1NXO2 M0+F>@>&+1:;L+]F5MIY#XHW2(B_!&$'.>/%/;\L\[ &0IQG@EP#_/J#_"" H M <$]P"!X!- O ?W?!0Q*@%VZ6ZS=)BZDFD['4NR(--;(9AYL]BT:\\6XV2=S M+?$M0YR>GC%.>$L;)%_:L&[F)TJ1?Y=BD[]5L(YK(](X!T2W_.#AGAFOP_WFY;S;]ZC MO_9>2T90[9? \@6/\(4@V9::P[V_#P[).98D'[QD\ KA6&&E!!Y_)RO,DC*%ZYU.09*XEAAF$].D\?_V4A-_ M4(D_:'4;;:3 4LT%WAT(^F-I]*2@G/\@<.$/EWPH-C<6YE?I/%>V2+.R2 M+.J(K*;/L-)G^-]KZ+!+F;HD"[LDBSHBJ\DTJF0:M1ZCOQNYV/\$/37JC8=TF?&CC]^HFT4.3P LJFV*1[EXOB*5[99MP MA:5FPW5QS5>S59]_8MO;>_.GO>-9KV$^Q.^"HHW_15]\5%Q1N3(IRV")KKRC M$1XR633JQ4"+M>U$%T)C7VL?4_RV 6D,\/U28%4J!\9!];4T_0E02P,$% M @ FSYC5_&ULM5=;;],P%/XK5IA0*VU+FMZ@M)'6)8-*FYA6#1X0#UYRVD0X=K'="_^> MXR0-O61E0'AI;.=\W[GF^'2X%O*;B@$TV:2,JY$5:[T8V+8*8TBINA0+X/AF M)F1*-6[EW%8+"33*0"FS7<%JE2@/<76_9;S+? MT9: M>D,IUD0::60SBRSZ&1KCE7!3)U,M\6V"..W=))SR,*&,3+C2FN26Z$4P=SZ(),5-?G=PS1\T#1AJHGHQZE/&F=-%<>/<./<9X]KD3G =*Q+P"*(*O'\:__8$WL9 E=%RM]$: MNR<)I["X)&WGG+B.VZZPY_KE<+?*G7_3'ORU]KU@M,O2:6=\[6?XJNO@G)AJ M(0U3+4WRY19!9*(A55^K\I]KZ%1K,#URH!8TA)&%35"!7('EO7[5ZCGOJH)? M)YE?)UE0$]E>FCIEFCJGV+U@$\:4SX$PS C@=SK'_*AF539RHEY&9"Z8E=?J M#.W5;HR/10XD_&,)M[LO$AR+7+BM4F;/RV[I9?>DEQ]U#)(T)CP4*31)L,&+ M5$&5DR=Y_K3DZB3SZR0+:B+;2T:O3$;OOW>&7IUIJI/,KY,LJ(EL+TW],DW] MNCI#__>=X5CDL#,<2QQUAF.1X\Y@[TP[*KLQ"LK_ ]Y/4$L#!!0 ( )L^8U<.MS@^T < +% M 9 >&PO=V]R:W-H965TJ7><:7D527 M_*$O5IQ%LZ+1,ND3SQOTEU&<]L:GQ7+B/^\YPEV=-9 M#_>>O[B-'Q8R_Z(_/EU%#VS"Y-WJAJNK?HTRBY9D^_L\JA,,>;9HDH_D5/ MU;U>#TW70F;+JK'JP3).R[_1CXJ(1@-"MC0@50.R;P._:N#OVR"H&@0%,Z4K M!0\TDM'XE&=/B.=W*[3\0T%FT5JY'Z?Y?5ITZ+SM%MG3J!'W-4KD0Z',Z8S.S?5\Y6'M)GKT\)U; M"5L=(]\[1,0C/KJ;4'3P]GU'ORY<8#[?W:*#ROTN,&H'HVRJP' !1KK[9/CJ MUT_4+W#]K;C<)_7ZD;T!?)EN*?KD=1H@7=:'G:^2!6T92=]51>$8P_LM[X MW1L\\#YV\0<)1H' #!:#FL7 ACZ^E@O&T<$L%M-LG8_X*)VI?**HC8581^F4 MH6DFI.AZ\.*4^)74VR&GH@]GM@]?N* M"?$!7:PYSZ-GE?%B?E+I<#HE15 M'\K]J5/] M-6!IG'!4QV>F[ M%=5UV("B42@TDU&B&26@ 5C!05$)B4:AT$PJ=4F-K;7F/C'H;Y1@) S\=AB" MUL<56C,,R?!D2_F#=>6+[:7O'I%87*J"@,W0]2/C:2ZNT667>KC';4^9)2C:S5* MBS4;-7A5GF1"HAO&XVS623>D!+@ 1:-0:.93T=(#CV#C'U1[@*)1*#232BT_ ML+4N=XK_$@G[9OQ[& =!6\';K3IS]!K:@FAM0>S:8K\DL!9'^^:!;PO.'#*! MO7NNPQ<4C4*AF8]&ZR&"03,! 15"H&@4"LVD4@LA8E4'+IF@0MK(!&2 ![B5 M">Q6G3EZ#85#M,(A=H4#6PY,XA\.20!T!P(4C4*AF4]%2S$2P"8!4&4%BD:A MT$PJM;(B]NT,ER00=B>!@(Q(>S7;;M69H]>03$1+)F*73)_7/$.4I=E21;54 M<=[,"KO7XNSHSJ,/5&U!H9G,:K5%AK"!#"J10-$H%)I)I99(Q+X]LWLMK@)H MKL4-AVTQ;[?BS,EHDY MZ"9*A89QTZO0,XFD4#;-EQVTA/'M$L8A9ZG+XNZB)KF/TN_H>CYG>3USNV4F ML-MV?CD"5)] H9F\:WWBP^H3'U2?@*)1*#232JU/?#!]4B'M6JFT&W2FYS6D MB=]XG\DN38)C3,+?GB/Y68*4$4W7+']_:K1'=6*WXCP 8=]T>@V9X6N9X$P<2<>@,5 NW8W?=.:N_:2UW7^L*WZPMR/!I" MS*R@J@,4C4*AF2\1:W42>*!Q&H *#E T"H5F4JD%1V!_06SWS%H!-&=6[./V M!I[=C#,I>&-FQ;Z/NV?60$N"P"X)7A"9+C.KW;KS, -5&U!H)O-:;02PQR<" M4%D!BD:AT$PJ&TOX(R:I*D!4.P8U]BS_*C M@FD7%43EB7:"V_=.:N_:2UW7\B&PRX?0D ]WJ>A(HP"QVW$>-Z!" 0K- MY%@+A0!6* 2@0@$4C4*AF51JH1#\WXV'8'/C@7@;TMYNQIF4'39-9[4T".S2 MX$6QZ52"@(H&4#0*A6:>N].B(805#2&H: !%HU!H)I5:-(1VT;#O[%K!M.?, M<%/<[WTGM7?-U?5^XXSWDO&'XJR\0,7IU/*X=_UM?1[_4W$*O:]O+P_S?XWX M0YP*E+"Y:NH=#U49P,OS\>6%S%;%B?'[3,IL67Q'Z#^GV>J6BO+G(# M]?]2,/X/4$L#!!0 ( )L^8U?ME.2!4@( #L% 9 >&PO=V]R:W-H M965TFD :)$W*C[$V$K1#( VIHH-] MF/;!3:ZMA6-GMM/"?[^SDT9%:]$^[$OCL^^]OG>^\V"MS;-=(CIX*:6R0[9T MKKJ,(ILOL>3V1%>HZ&2N3GV+K9]3SY=K:<,OK-O< MF$%>6Z?+%DP*2J&:+W]IZ[ %Z/7W )(6D/PK(&T!H7)1HRS8&G/'LX'1:S ^ MF]C\(M0FH,F-4/X6I\[0J2"PX@;\RK4 M IZXK-$"5P5\M4Y0];" &R[,YH22 _Y.66=JNF5GX7",C@MICXCU<3J&PX,C M. "AX%Y(25=H!Y$C!UY'E+=JKQNUR1ZU4ZQ.((T_01(GZ0[XZ'WX&'."]P(\ M>0N/J&Y=\9*N>$G@2_?RD>6QL+G4MC8(/Z]F9)\Z\]7G]9+6_$< MAXS&T:)9(<[YF""K#+:H,_"WC_CJRR M\XM3NK#5MH6_DRZ2S_TNJ9$6;;6V?U;NN5D(94'BG&#QR?DI ].,:A,X785N MGVE'LQ.62WK=T/@$.I]K[3:!'Z#NOS'EY04Q6YE8@9X M$XL4WY?DH\-#,I.=D%_5&E'#MX)Q-0W66I?78:BR-19$]42)W+Q9"ED0;8IR M%:I2(LDK4<'")(I&84$H#V:3JNY1SB9BHQGE^"A!;8J"R/T%L4I(5+E!_+A^E*86M2TX+Y(H*#A*7T^ FOD[CQ JJ%G]1W*F#9[!3 M>1;BJRW9Z/0W& >2X)!NFG\3N#VPF-+1^F6"J^@N[NNW(])AME!9%(S;E@O+Z MEWQK0!P(XL$)0=((DO\KZ#>"_@^"9'A",&@$@XI,/96*0THTF4VDV(&TK8V; M?:A@5FHS?\%7%Y]0%I#BLX8+^$BD)/9;P-L4-:%,O3.U MGQTM.]'8%#X+KM8+W/,?\6!^: MD;?#3UZ&/T^ ^2^#=(HJ3?,9Y;M_R!R![THY/RU"U?8'E*?C2;?OLQ M^I5?_X1?]0GNN-)R8Y:6AK_O30.XTUBH?SI&-Z_=!MUN-F-B3C[Q&'*R5XY0&[4@1T[K+]6V@OD%:8BV ML69R*%JLIV Z?<^%Z=,LK%QNGU;EL?)JEGLR.$(Y;A&.OF\/8)T6?9JDGLR.*5RW%*V<@/DJ1 M(>8*EE(4YN#Z$I99'99+1UA>_92(QU&[*FI,SK[/Q>3)[ A3'+V>"R,GJ.I, M>"\(AWF[6.$_6""G0L)'H;%S'W6[GAMV7MU27V['1 ].VK'7!=S8^4+ITRWU MY7:,,GE%F3B#\SV1;&]6;W.BLQNMJ@/SU'[K-CP;9O)3+DB&/R2#U%>7-:/P MX(Y7H%Q5=V4%F=AP75_WVMKV/GY3W4+#U^;U9=[<>E;F? P,ET8:]2[-^4G6 M]^.ZH$59W1B?A3;WS^IQC21':1N8]TMAEG]3L!VT_Z68?0=02P,$% @ MFSYC5S9Y)D1> @ /P8 !D !X;"]W;W)K&UL MC95O;]HP$,:_BI554RNM) 1(& N12M'424-"I=U>3'MAPH58=>+,=J#[]CL[ M(6);@+XA_G/W_)YSXB/:"_FB,@!-7G->J*F3:5U.7%14]40)!>ZD0N94 MXU1N755*H!N;E'/7][S S2DKG#BR:TL91Z+2G!6PE$15>4[E[QEPL9\Z?>>P M\,BVF38+;AR5= LKT,_E4N+,;54V+(=",5$0">G4N>M/9F,3;P.^,=BKHS$Q ME:R%>#&3+YNIXQE#P"'11H'B8P?WP+D10AN_&DVG19K$X_%!_;.M'6M94P7W M@G]G&YU-G;%#-I#2BNM'L7^ IIZ1T4L$5_:7[)M8SR%)I;3(FV1TD+.B?M+7 MYAR.$GS_1(+?)/C6=PVR+N=4TSB28D^DB48U,["EVFPTQPKS4E9:XB[#/!U_ M%<7V]@ED3N:PUN26K/"U;RH.1*1D074EF6:@"!Z@#=5MZ/4<-&5,BU6UI?EM M:;[5'9S0M2[G3"5S6,E=CHDJ:P-3!;U^!W($3 MOW_7#[Q/9YP.6J>#<^JQ*;S+4YT5V"QSNW:Q'[F[#M"P!0TO@89=H#IK= 3Z MV T:M:#1)="H"S1Z*RAH0<$E4- %"MX*"EM0> D4=H'"MX+&+6A\%O24 7;7 M%"]:%V[\WR&PO=V]R:W-H965TL6V-!9O5BR)?"YND[69 M;A/J+W.C*#2)93EFY >Q,1WGS^Z2Z9CM>!C$]"Y!Z2Z*_.3GC(9L/S&P\?+@ M/EAO>/; G(ZW_IH^4/YM>Y>(.[-B6081C=. Q2BAJXEQ@Z\]XF0&.>)[0/?I MP37*I#PR]B.[^;R<&%;6(QK2!<\H?/'S1.A %& #4AH0V:!WQ, N#>Q36^B5!KU36^B7!KETL]"> M#YSK)1E:L&47^>CGUF*\@CB;* \\$6\#8<>G-XO%+MJ%/J=+](5O M:(+F+!)3;I/-A2>*/L<+%E%T\2=+TX_HPJ7<#T)Q=8F^/;CHXL-'] $%,;H- MPE#X/1V;7'0JHS8790=F10?(D0[8Z);%?),B+U[2)6#OJNU'"GM3#$8U(N1E M1&9$2?A MU?(MCXA8A$;Z,_\=',"R7E;Z][9K3<&PZZFAYWSV5JFQ]_W+ R1 M^(#W?K+\!YH+16L]N+5L4;Q.M_Z"3@S11DJ3)VI,?_T%.]9OD"-TDKDZR3Q- M9 V7]2J7]53LTQE=!W$ROC9.Z"1S=9)YFL@:KL%6 MG?I9[QK4TKFZN5S=/%UG3<03S=7*YNEB M:SJN+@ZPNCHX;9%LY^ARB@5 +K$MKQIM$):SYPZBILRZ'L#J@N"<(@AWEPO= M$!> 7&)9LQ+3E%P7#5A=-1RI@7 [3V^IZH2XW1 /@!S35)<#6%T/G%\)X7;B MWI+="7$!2-N9*IJF[KH^P.H"X83@/NK^1-L0X!/MY/$Z>)K;B76:3939X'1> MQ(_,HU\3$+K>FXNBP@ZK+@I/A.H&R^)VWPS$&4G/.[,$HN@D"4=62= M)'5E0-25P3EAOJ14;Y)!H-8N&03"-\3M MAGA*2%-3G9N2NNZ(].64#&P*U?0JEHRV?@GO8QWQ:)ZU$G;1V1_V2H'E" M,91/*""4,Y C_TE<7A=7(=4\.&J-:++.S[A3XII=8Y^DY\>2\]G M^'J.@>*E**0KT91U-1!>28IS\.*&LVU^T/O(.&=1 M?KFA_I(F&4"\7S'&7VZR!JK_1IC^#U!+ P04 " ";/F-7RU,E4@ # #J M"0 &0 'AL+W=O^K2--M*Z\C")H6K5X 7BA9M<4FM.'&RG71$?GK.39MW41F*B;Q+;N?O[ MY_/E[-%:R'NU!-#D(>.Y&CM+K8L+UU71$C*J.J* '+\D0F948U>FKBHDT-@Z M9=P-/&_@9I3E3CBR8S,9CD2I.O/4"^H;_0BP95]DG5EVT?CJ%1:9+4S$F0LK][TH0[$CD,0'' ( M:@<;"+>:R%).J:;A2(HUD<8:U4S#+M5Z(QS+S:[,M<2O#/UT.*>9*O.4X*HX M70A);:S>D:]4FO8*R.D4-&5B+A1/=6DFBHX,-4Y MN1&Y7BKR(8\A?NKO(G;#'FS9)T&KX!R*#NEZ;TG@!5UR-Y^2TY,W+;K=)B9= MJ]L[H#N1]#?C^Q;8ZF=^H M5T C&#OXA"N0*G/#U*W_@O6^AZC54/:O>/4 U M98JFJ82TVB*1D%M805X"^?$%3Y[5MU4F%7H=;K]D;O:PS1HF :M3-N< MGS !!=N;R:T"+PS9L,$;'FFCAT>@/FNHSUJ#^K2 4.1O]I>)>!]MNY[OD0U0 MJ5K0SANT\U:IF=!(PB@G2:E+"7B:I"6G6L@-EE0.6&0QK 7=&."]Z5#I#W:R M,#B0@[[W6'B]?\E"\H<&UL MM5EM;]LV$/XKA%8,+=!%[[*=V08:2T(#+%@0M]V'81\8ZRP+E42/I.WVWX]Z MB6Q1C.(XVI=8+_<\=_<<11Z9Z8'0[VP#P-&/+,W93-MPOKW6=;;:0(;9%=E" M+MZL"H:37)M/RV?W=#XE.YXF.=Q3Q'99ANG/ M&TC)8::9VM.#AR3>\.*!/I]N<0Q+X%^W]U3G!CCG>G!K@'LN MP*L!7JE])5:IM(\YGD\I.2!:6 NVXJ(L5XD6 B=Y,;*6G(JWB<#Q^1)G;)?' M2%0FQ8^$XK+>OZ%E-=(06:/;O!K Q8L'2#&'"'$B(=[[P'&2L@\"^W7IH_?O M/J!W*,G179*FPH!-=2["+9SJJSJTFRHTZYG0;'1'T MM)MQ9Y=\]G-\"<-Q3"&NAH\89@^PAWP'Z.\_A"FZY9"Q?U2#IN)UU+S%1'S- MMG@%,TW,M SH'K3YK[^8GO&[JF)#DOE#D@5#DH4#D;4J[325=OK8Q0R3@O+K MKV!>"2L6P/W<=,W)5-^?%DAE9(_:1G[7R/$\MVT4J(S&DKNP-Y4+A7(;H=Q> MH1:$\>)#8,\)5L'=DPP\TY+TZMJXKBG)U;4QQ[9$%"B,1H8AR=6;T(5R>8U< M7O^X$MU(DL>U\ZXYW@,AO08CKKSD3,Z3C6M(HR; M(HQ[BW"/?U85$%V52O\O%$<@>O 5V>60X5'\V3V:E5@TE1@\L(:5:E^DQ#8)LK!W4OPVK9C2#)_2+)@2+)P(+)6 M24WCN+,Q_J<6LR8>J-B#LOF#L@6#LH5#L;4+?K*5-2_K-&M<>[&VI6E1961) M_:&O,+(G\JJO,G(\:=7OS^52K:RC5M;;FLT:?YK$1%[+%39C3U:L:V.-Y&93 M9629LF*]&5VJV''#:O;NDB[M-VO6=B,MZVAWNXJQK&.7Q[5E&;L\GMRR]V=Y MJ8K'S:#9OQL99O]&<[A^ MLW;4&G#RCK0_F%=7X&6/P: >0X7'D=QNZB<'L!G0N#PJ9Z@4L#H3:YXVQ_&? MRD-HZ?F->;TP%<]]\SJH#MN/]-79_QVF<9(SE,):N#*N1B)<6AVG5S><;,OC MWT?".&PO=V]R:W-H965TS@:*D(:R1Z$VP MX3U/? [&F/&6\4>1 $CTE-),3(Q$ROS2-$640(I%C^60J2M+QE,L59>O3)%S MP'$A2JGI6)9OIIAD1C NSDUY,&9K24D&4X[$.DTQ?[X&RK83PS9>3LS(*I'Z MA!F,<[R".&)8>$%"(I"9@==C #5"J06H8?RNF4?^E%NZV7^A?"^_*RP(+N&'T%XEE M,C&&!HIAB==4SMCV&U1^^IH7,2J*7[2M:BT#16LA65J)U0A2DI5'_%3EL".P MO2,"IQ(X;Q6XE$QQ=3S.4SNN(<9RM0-U4*=(&NHHBM=7,&$9 -7E 0Z#P$B0D5 MGU3!PSQ$YV>?T!DB&;HCE*H;*<:F5,/2<#.JAG!=#L$Y,H3OZZR'+/0:Q5RMT$>MLM#B)3<+N3.OMQ46=:!.G6@3L%SC_!F0+&$&)61 MWJM$!2ZG^.\?JA3=2DC%GZ:42J[7S-6/_Z7(<0030SW? O@&C.#C!]NWOC1E MUB4L[ BVEZ=;Y^FVT8-P#6C)68KN@$>/>J;5\Y+7\[(ISE;LJ7&6,+^ Z95T M$]B^-QR;F]V8&HJ\0;\NVK/OU?:]_]J7K,%\CI^/.6\EGNJ\A/5W35G^X)7S MAB+;=9J=]VOG_5;G>P]2D\U6^:DVNX2%'<'V8O/KV/QW6G_\+O/L$A9V!-O+ MP46U^U/G:W4H\U??H MX(7D6_8KWXQ=9?.<$_4$L#!!0 ( )L^8U&PO=V]R:W-H965T0XK%*FT M$YR2X-0)O1<(;DEP7SM"KR3T7CN"5Q)RZV;A/0]<@"7VQYQM$-=HI:9?\NCG M;!6OA.IU,I-1=B@5=BH4=B>TEIU_9H;*YW8]H&<@?[H* )ZO7[WCXH; ,-GX?;\^95WKR#WK;E2KSDL:![.X/V M;:=FL8GQ/+OFL(FQAVY-*&P!#2RKW6&_#@95#@;_J;P-NDQ.EV)!EV)A1V)[R1E6R1F^K;P-&[O1&=9V?A/BUB!! M$S*J%[8FQ+9Z[;M^5)D:O:^NC1K%U*E-:]J$N/6JUH0,:_[#)F1DU[R9.V?2 M%/@ROPP(-&)R&ULM=U;;]LX @7@OT*X1=$!!K%U\25M8J -*;*#-BV:[>X"BWU0 M;#H61A>/)"<=8'[\4K)BBK;,6(.S+TV^Y?.K;%O&42J_Y:38)DF8__E1QMG3]< 9/'_A>_2P+JLO#.=7F_!! MWLGRQ^9;KAX-]\HR2F1:1%E*#V8 LY2KBEKC8%F66-(/5 MXR1*=Q_#G\T/HC7 =4\,<)L![L$ Y_+$ *\9X)V[!+\9X!\.F)X8,&X&C,]= MPJ09,#GW-4R; =-S!\R: 75K7Z% M45IE]Z[,U7S;R)_YY$*?D2Q;&* M6?$K>=U^>#4LU?(K9;AHEO5QMRSWQ+(<\D4M;5T0EB[ETAP_5.N]7WGW>>4_ MNE;PZZ*\()[S*W%'KDO8C^_D;;/>OW2LW8T=^Q+FSYCCDX7Z_]!AT#-6R)G4 M*^21'W>4O'W=M2K,SMS)C5J5DOG,GH?5>HD!A%8@R)!4B,(S$!PHSP^?OP^39]_B')MFE)LA6) MY4,85Y.FFM8E:994D+_(ZZX$6M6^"41B%(FQ'3:IL6HCZG'N>E?#QW:NCI_B M3,VG<.0J"1!FI&6\3\O8FI:[C=J6[(J#=5C?." QBL08$@N0&$=B H09$9OL M(S9!SX839/B0&$5B#(D%2(PC,0'"C/!-]^&;6M_?>/8H\U3MV)9J*EQ5J?OK M>3^B*W@[S'%:[_W>I?G>?V-=8-\\(3&&Q (DQI&8 &%&GF;[/,VL>0JR(E2[ MNEW9L0[L^Z:%Q"@28T@L0&(8D,'Q*C2(PAL0")<20F M0)@1/F>D#[^-K.]QM]OD7N;5'N1&IDN50;*(PRCI/KIFI?H&#ZI1J,8:;=S> M-'"\T<&^(W29'*H)E&;&JG54USEGZE0;8(%,MCD)\G!1;G-)/D=E]!#6M4'U MO:7,P[@S:U:_=]:0&H5J#*H%4(U#-8'2S$RZ.I,N>J9M1%0*D1J%:@RJ!5"- M0S6!TLP4ZKK L1X0[C?A0IL"J$:A&H-J 53CC=;>&+B<^N:V@.A\TGC_)#,L M^O"^8S^^K\.R"PE91D42%<5A>]G$!7I8O]':KV@R/M@$HM!%,J@60#4.U01* M,W.EBP#'W@01N&+\R^T:H!J%*HQ MJ!9 -0[5!$HS_V)6%P[N"#W_NM#> :I1J,:@6@#5.%03*,U,H>XG7'L_T6?^ MM5.]XP>M(J ::[3V_.M.#W;- ^@B.503*,U,E6X87.NQXS.GWZ_E6D6O-?-V MIPY:/4 U"M485 N@&H=J J69\=35@PL_5<&%-A!0C4(U!M4"J,:AFD!I9@IU MI^&>VVF<,?5"&PVH1J$:;7?FA(:%64>+>JS3K^NHZPS8-#* JI1J,:@6@#5.%03*,V, MHJXV7/AY$BZTO8!J%*HQJ!9 -0[5!$HSK_6@VPL/=[J$G>H;/ZA&H1KSCD^7 M.)QDH0OD4$V@-#-3NHOPSNTBMNDJBN72EBEH%P'5*%1CWG$7,9X/CYB9WL'#%H[0#4&U0*HQJ&:0&EF M%%L72,)?(0E[B23L-9*P%TG"7B4)>YDD['62_A^U@Z=K!P]7.]BIWO&#U@Y0 MC7G'M8,S.YQEH;T#5!,HS0R5[AV\%\ZC>)YEU<1ZM[TOY!];F99$/JI_.X,% M;1^@&H5J#*H%4(U#-8'2S CJ]L&#MP\>M'V :A2J,:@60#4.U01*,U.HVP?/ MWC[\W0L1VMG>480V$8W6OC;@X=^B,^@2 ZC&H9I :6; =!/AO7#"1&NF?6D7 M%EH^0#4*U1A4"Z :AVH"I9GIT^6#!R\?/&CY -4H5&-0+8!J'*H)E&9>ZU>7 M#SZN?+!3?>,'U2A48_YQ^7!XG!BZ0 [5!$HS,Z7+!]]>/GS+LXU<1.&0J,^* M19BK^?7'Q=U%9Z:@Y0-4HU"-0;4 JG&H)E":&3]=4_CP:S+YT(8"JE&HQJ!: M -4X5!,HS4RA;BA\W#69[%3O^$&K":C&_.-+&CF'$RNT;X!J J69F6K=F<'> M-W1-K"_LN-K%WM&"U@Y0C4&U *IQJ"90FIE"75#X8_C\"NTHH!J%:@RJ!5"- M0S6!TLP4ZH["MU\6JM?\"BTGH!J%:JS1C/GU\)POZ!(Y5!,HS0R5KAS\OW'" M@WJW"^N;$G9G"]HV0#4*U9A_?-[#X5]D0A?(H9I :6:T=-G@][TZTV9;AM5- M+L_(&+1]@&H4JC'_^&I-1W?7@E8*4$V@M%W&AJU;8"8R?ZAOAUJ0156+[FXH MN?_J_I:K'^H;C1Y\_:/S[F9WXU3-[.[C^B7,'Z*T(+%<*7)T,54_^7QW:]3= M@S+;U#?:O,_*,DOJ3]H+Z_BK+RN<'U0+V-ZB=_P]02P,$% @ MFSYC5V(7?F-1 P MA0 T !X;"]S='EL97,N>&ULW5A=3]LP%/TKD1D3 M2!-I&TB;T5;:*B%-VB8D>-@;0XF>.REL?]GOVJ_9+YQOEHBV_%>!AE MJ2#V/3[G'MLWC6%8Z+5@-PO&M+=*A2Q&9*%U_M[WB]F"I;0XRW(F#9)D*J7: M=-7<+W+%:%P *15^K],)_91R2<9#N4RO4EUXLVPI]8CTFY!G;Y_B$>F&Y\2S MS]Z=W34N3N]W(V?E, I\9VB%T\0/>O@N@;#I,-M MZ7KXL=%JN,<8N>\@MTR4-G!/Y_?/7\@JM#>JKWT'HNP*UA%^5 MQ'B89+*MC(#8@,E!4^;=4S$B$RKX5'%@)33E8FW#/0C,,I$I3YN2-$F[$"D> M+-RU/:C62B?E,E-E;IO!_IY6PW> N@<&N1"-P1ZQ@?$PIUHS):],IQQ?&X5S1=;=W05I">3-)IIF*F6K2=$D=&@\%2\".XO,%W'66^P!JG:6F M$7,ZSR0M/=2,JF%D9TR(&WB4OR5;VJMD8_?*O9--TQBJFE;&=D!_4\UJ;\J> M/TO7R_E]IC\NS71DV8=:9=>*)7Q5]E=)8P!3[^+J-,_%^H/@@L>QTP^ M.G,9>4VGYH^R+7TS/F8)70I]VX CTK:_L)@OTZ@9=0T+48UJVY]A>MVP.5&; M7%S&;,7B2=55\VG9]$S#9*TN(.PB5^7E1C".Q=P(8%@>S '&L2PLS_\TGP$Z M'XMAW@9.9(!R!BC'LES(I/Q@>=R(?OK -O3?16"S12O1&RF^%H#XEXW8$21>[>Q/,# =@&K M'8$ >PJY@U[@G$DBC $:M%=HV&(K$X('_?^8$])$$21&P',[2 ( M, 2>1AS!'( '# F"\CVX\S[RZ_>4W_ZG7BKL< MP !," + 7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$ M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G_#:UJMMMBZ0QFTW0+8Q:J/7!2W1%A&)=$G*:?KK=R3'6-)1!KG,^A#$ M>IC^Q-!D=^*[% _VO^O=(=M+ M*]>RENYQ%O6?:Q&Q1BK9R%^BG$63B-E*/_REC?REE>/ULC"ZKF?1]'#ANS!. M%L].+SO(%5_;_HSCZV\<0&91/H$"-])8U]_1E\^!<2_@YL-1Z_1G63MAYMR) M+T:W.ZFV73'P%&/O,?IZ./X_5.*E>4TUZLU&%F*NB[81RAWJT8BZ U2VDCL; M,<4;,8NN]5Z8[GG@!V[*P[,Y@/)JREQ*N&!NRAZ/$D650EE1,OAD=2U+X"C9 MLL.!KWJ0,0(9GQ'RG]B#3!#(Y"R0'WG-52&8!YDBD.D9(8.:S!#([)S-G7B0 M.0*9GQ,R]2#?()!OS@F9>9!O$7&_A>E8E8S#WU?N6B.8WK"[G3#< M>9#O$,AWU)!6V@YJ882%6_L[_"E\@LWA$UJXJ^)'"S_:G^_K\!:^IRSHC5T9 MPWU,5#7$KOG$C0(FRZ!=V;+BT,H7O_UHM?OSTV)Y^/"[SXH99TJL'(AQRK9P M?6U^$7IK^*Z2!;M1A])\3,PY4V+I+)TN[D?0.?LAWD!)MK^)+6!"MSXE)ITI ML76^">L,U&9KH/E]*$PR4V++K/A/ 2-:09L6NA$^%J:5*;%7;M0>;H"H6 3- MATED2FR1SU)!="!Y#575-61W>P"'R6-*;(];K;:CE3 -FXMU,"XQ6TR)=7%5 MP"UMW=OVSE4PWW6CTXBJFY;W?F>+,7'$Q.)8\L:V8(EK6&+QM3:G5HLQ7<3$ MNEA5TI2C!3?NL=>8VHK3GA>CBQ+Z58F#^4S T C&:HP)(286PH(_LKUE"V'Z MKW\:+ M%OI6KH7U0^@$DTM"+)?!L&&0$K-,0FR9,'X8Q,,DDQ!+!@TDPM07FONB7H<, M!1*#E8EY)R'VSDL1Q1.HCXFI)R%7#Y(0"=L<4T]"K!XTZQ!B8L))B(7S.D/. MA;]V2##U),3JP0WIIS\33#T)L7IP3#\!FF(62HDMA&/Z*= 4TU!*K"$TW@@& M4XKI*"76$8[I]\T4TU%ZSK18V#?1S1AB'^&80=_$?)02^PC'S'U,S$%PO#NG^'=Q[2K-NXW+1U?0WG[M2MYN7Q)<7C"Y8?_@50 M2P,$% @ FSYC5R=EU:4, @ A"4 !H !X;"]?!-T#(HPS= M1Y +Z1 ITA@\%3$D>/D7Q =B^/2K'-IQWYWJ;M_7Q._8^4ZGI7 MCFV]Z_IR.E_9=,.Q'<_+89OZ=OW>;DO2Y3*GX79&\_QT.W/Q^MF7_YG8;3;[ M=?G9K7\?RVG\Q^#TIQO>ZZZ4L5F\ML.VC*LF?1RNIVNZ'.3N/+E9O+RMFN'E M39HT=Y!"D,X?9!!D\PBGHK@=Z*>BN!WHIZ*X'>BGHK M@=Z*>BN!WHIZ*X'>AGH;@=Z&>AN!WH9Z&X'>-MDL(=#;4&\CT-M0;R/0VU!O M(]#;4&\CT-M0;R/0VU!O(]#;46\GT-M1;R?0VU%O)]#;46\GT-LGF]T$>COJ M[01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>@?J M'01ZQ^1G)8'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=X9]F?4.Q/HG5'O3*!W M1KWS=^I=Q\]#J=>>KS4^_SNI'L_WENOC+\NODY-7Y8)SNJVHSW\!4$L#!!0 M ( )L^8U?NU>T8Y@$ /4D 3 6T-O;G1E;G1?5'EP97-=+GAM;,W: M74_",!0&X+]"=FM8Z=?\B'"CWJH7_H&Z'61A6YNV(/Q[NP$F&B4:3'QO6*#M M><]ZDN>*ZZ>MHS#:M$T7IMDB1G?%6"@7U)J06T==6IE;WYJ8OOH7YDRY-"_$ MQ&12L-)VD;HXCGV-;'9]2W.S:N+H;I-^#K7MIIFG)F2CF]W&/FN:&>>:NC0Q MK;-U5WU*&>\3\G1RV!,6M0MG:4/&ODSH5[X/V)][6)/W=46C1^/CO6G3+K9I M6(C;AD)^O,07/=KYO"ZILN6J34?RX#R9*BR(8MODNZ)GQY-CNF':??*3\X00V/$Z_XX\S?J__RSX$2!\2I \%TH<&Z:, Z>,&UL4$L! A0#% @ FSYC5^,:;LKN *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ FSYC5YE&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5Z)S(W7D M!0 FAL !@ ("!#@X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5W-%:+L# P P @ !@ M ("!Z!T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ FSYC5W5*@K[^!@ "!\ !@ ("!GBP 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5V5FK&-" P 1@< !D M ("!S4< 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ FSYC5],F*LU$! : H !D ("!?5H 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5Q8R M7X;-" 1A< !D ("!3&8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5_M.AQ)P!0 PPP !D M ("![WH 'AL+W=O6E8D% "I#0 &0 @(&6@ >&PO M=V]R:W-H965T>EC!4 M #L[ 9 " @5:& !X;"]W;W)K&UL4$L! A0#% @ FSYC5[J;7RQV @ K@< !D ("! M&9P 'AL+W=O&PO=V]R:W-H965TU-#[@:@@ )(5 9 M " @4"A !X;"]W;W)K&UL4$L! A0#% M @ FSYC5SFC@JE: P 40< !D ("!X:D 'AL+W=O&UL4$L! A0#% @ FSYC5ZS)1/H. M P < @ !D ("!JKL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5^VD7>$H P BPD !D M ("!_\< 'AL+W=ORP >&PO=V]R M:W-H965T3;XEW0( &D& M 9 " @8K. !X;"]W;W)K&UL M4$L! A0#% @ FSYC5X;L%:H8 P ? P !D ("!GM$ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MFSYC5UR2,( T @ M@0 !D ("!0MP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5SKW$EYI!0 ,!X !D M ("!C@T! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ FSYC5_T!CK: @ K < !D ("!*1P! 'AL M+W=O&PO=V]R:W-H965T]:L3O'P0 & 6 9 " M@88B 0!X;"]W;W)K&UL4$L! A0#% @ FSYC M5S<6@^20 @ - 8 !D ("!W"8! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5PZW.#[0!P L4 M !D ("!B3 ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5S9Y)D1> @ /P8 !D M ("! 3\! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ FSYC5W0 TC*M! X!@ !D ("!04H! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ FSYC5[%! M;)\^"0 K'8 !D ("!$58! 'AL+W=O&PO7BKL

MC 0!X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " ";/F-7)V75I0P" "$)0 &@ M@ $-:0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "; M/F-7[M7M&.8! #U) $P @ %1:P$ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 1P!' &@3 !H;0$ ! end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 564 259 1 false 90 0 false 11 false false R1.htm 0000001 - Document - Cover Sheet http://www.organon.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Income Sheet http://www.organon.com/role/CondensedConsolidatedStatementsofIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.organon.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.organon.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders' Equity (Deficit) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Background and Nature of Operations Sheet http://www.organon.com/role/BackgroundandNatureofOperations Background and Nature of Operations Notes 9 false false R10.htm 0000010 - Disclosure - Basis of Presentation Sheet http://www.organon.com/role/BasisofPresentation Basis of Presentation Notes 10 false false R11.htm 0000011 - Disclosure - Acquisitions and Licensing Arrangements Sheet http://www.organon.com/role/AcquisitionsandLicensingArrangements Acquisitions and Licensing Arrangements Notes 11 false false R12.htm 0000012 - Disclosure - Earnings per Share ("EPS") Sheet http://www.organon.com/role/EarningsperShareEPS Earnings per Share ("EPS") Notes 12 false false R13.htm 0000013 - Disclosure - Product and Geographic Information Sheet http://www.organon.com/role/ProductandGeographicInformation Product and Geographic Information Notes 13 false false R14.htm 0000014 - Disclosure - Stock-Based Compensation Plans Sheet http://www.organon.com/role/StockBasedCompensationPlans Stock-Based Compensation Plans Notes 14 false false R15.htm 0000015 - Disclosure - Restructuring Sheet http://www.organon.com/role/Restructuring Restructuring Notes 15 false false R16.htm 0000016 - Disclosure - Taxes on Income Sheet http://www.organon.com/role/TaxesonIncome Taxes on Income Notes 16 false false R17.htm 0000017 - Disclosure - Inventories Sheet http://www.organon.com/role/Inventories Inventories Notes 17 false false R18.htm 0000018 - Disclosure - Financial Instruments Sheet http://www.organon.com/role/FinancialInstruments Financial Instruments Notes 18 false false R19.htm 0000019 - Disclosure - Long-Term Debt Sheet http://www.organon.com/role/LongTermDebt Long-Term Debt Notes 19 false false R20.htm 0000020 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 20 false false R21.htm 0000021 - Disclosure - Samsung Collaboration Sheet http://www.organon.com/role/SamsungCollaboration Samsung Collaboration Notes 21 false false R22.htm 0000022 - Disclosure - Third-Party Arrangements Sheet http://www.organon.com/role/ThirdPartyArrangements Third-Party Arrangements Notes 22 false false R23.htm 0000023 - Disclosure - Contingencies Sheet http://www.organon.com/role/Contingencies Contingencies Notes 23 false false R24.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Basis of Presentation (Policies) Sheet http://www.organon.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 26 false false R27.htm 9954472 - Disclosure - Earnings per Share ("EPS") (Tables) Sheet http://www.organon.com/role/EarningsperShareEPSTables Earnings per Share ("EPS") (Tables) Tables http://www.organon.com/role/EarningsperShareEPS 27 false false R28.htm 9954473 - Disclosure - Product and Geographic Information (Tables) Sheet http://www.organon.com/role/ProductandGeographicInformationTables Product and Geographic Information (Tables) Tables http://www.organon.com/role/ProductandGeographicInformation 28 false false R29.htm 9954474 - Disclosure - Stock-Based Compensation Plans (Tables) Sheet http://www.organon.com/role/StockBasedCompensationPlansTables Stock-Based Compensation Plans (Tables) Tables http://www.organon.com/role/StockBasedCompensationPlans 29 false false R30.htm 9954475 - Disclosure - Inventories (Tables) Sheet http://www.organon.com/role/InventoriesTables Inventories (Tables) Tables http://www.organon.com/role/Inventories 30 false false R31.htm 9954476 - Disclosure - Financial Instruments (Tables) Sheet http://www.organon.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.organon.com/role/FinancialInstruments 31 false false R32.htm 9954477 - Disclosure - Long-Term Debt (Tables) Sheet http://www.organon.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.organon.com/role/LongTermDebt 32 false false R33.htm 9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLoss 33 false false R34.htm 9954479 - Disclosure - Samsung Collaboration (Tables) Sheet http://www.organon.com/role/SamsungCollaborationTables Samsung Collaboration (Tables) Tables http://www.organon.com/role/SamsungCollaboration 34 false false R35.htm 9954480 - Disclosure - Third-Party Arrangements (Tables) Sheet http://www.organon.com/role/ThirdPartyArrangementsTables Third-Party Arrangements (Tables) Tables http://www.organon.com/role/ThirdPartyArrangements 35 false false R36.htm 9954481 - Disclosure - Background and Nature of Operations (Details) Sheet http://www.organon.com/role/BackgroundandNatureofOperationsDetails Background and Nature of Operations (Details) Details http://www.organon.com/role/BackgroundandNatureofOperations 36 false false R37.htm 9954482 - Disclosure - Acquisitions and Licensing Arrangements (Details) Sheet http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails Acquisitions and Licensing Arrangements (Details) Details http://www.organon.com/role/AcquisitionsandLicensingArrangements 37 false false R38.htm 9954483 - Disclosure - Earnings per Share ("EPS") (Details) Sheet http://www.organon.com/role/EarningsperShareEPSDetails Earnings per Share ("EPS") (Details) Details http://www.organon.com/role/EarningsperShareEPSTables 38 false false R39.htm 9954484 - Disclosure - Product and Geographic Information - Narrative (Details) Sheet http://www.organon.com/role/ProductandGeographicInformationNarrativeDetails Product and Geographic Information - Narrative (Details) Details 39 false false R40.htm 9954485 - Disclosure - Product and Geographic Information - Sales of Company's Products (Details) Sheet http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails Product and Geographic Information - Sales of Company's Products (Details) Details 40 false false R41.htm 9954486 - Disclosure - Product and Geographic Information - Revenues by Geographic Area (Details) Sheet http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails Product and Geographic Information - Revenues by Geographic Area (Details) Details 41 false false R42.htm 9954487 - Disclosure - Stock-Based Compensation Plans - Narrative (Details) Sheet http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails Stock-Based Compensation Plans - Narrative (Details) Details 42 false false R43.htm 9954488 - Disclosure - Stock-Based Compensation Plans - Stock-based Compensation Expenses (Details) Sheet http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails Stock-Based Compensation Plans - Stock-based Compensation Expenses (Details) Details 43 false false R44.htm 9954489 - Disclosure - Stock-Based Compensation Plans - Stock Option Valuation Assumptions (Details) Sheet http://www.organon.com/role/StockBasedCompensationPlansStockOptionValuationAssumptionsDetails Stock-Based Compensation Plans - Stock Option Valuation Assumptions (Details) Details 44 false false R45.htm 9954490 - Disclosure - Stock-Based Compensation Plans - Equity Award Transactions (Details) Sheet http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails Stock-Based Compensation Plans - Equity Award Transactions (Details) Details 45 false false R46.htm 9954491 - Disclosure - Stock-Based Compensation Plans - Equity Awards Outstanding (Details) Sheet http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails Stock-Based Compensation Plans - Equity Awards Outstanding (Details) Details 46 false false R47.htm 9954492 - Disclosure - Restructuring (Details) Sheet http://www.organon.com/role/RestructuringDetails Restructuring (Details) Details http://www.organon.com/role/Restructuring 47 false false R48.htm 9954493 - Disclosure - Taxes on Income (Details) Sheet http://www.organon.com/role/TaxesonIncomeDetails Taxes on Income (Details) Details http://www.organon.com/role/TaxesonIncome 48 false false R49.htm 9954494 - Disclosure - Inventories (Details) Sheet http://www.organon.com/role/InventoriesDetails Inventories (Details) Details http://www.organon.com/role/InventoriesTables 49 false false R50.htm 9954495 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.organon.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 50 false false R51.htm 9954496 - Disclosure - Financial Instruments - Schedule of Financial Instruments Recorded at Estimated Fair Value (Details) Sheet http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails Financial Instruments - Schedule of Financial Instruments Recorded at Estimated Fair Value (Details) Details 51 false false R52.htm 9954497 - Disclosure - Financial Instruments - Schedule of Long-term Debt Instruments (Details) Sheet http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails Financial Instruments - Schedule of Long-term Debt Instruments (Details) Details 52 false false R53.htm 9954498 - Disclosure - Financial Instruments - Schedule of (Gain) Loss on Derivative Instruments (Details) Sheet http://www.organon.com/role/FinancialInstrumentsScheduleofGainLossonDerivativeInstrumentsDetails Financial Instruments - Schedule of (Gain) Loss on Derivative Instruments (Details) Details 53 false false R54.htm 9954499 - Disclosure - Long-Term Debt - Summary of Long-term Debt Instruments (Details) Sheet http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails Long-Term Debt - Summary of Long-term Debt Instruments (Details) Details 54 false false R55.htm 9954500 - Disclosure - Long-Term Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) Sheet http://www.organon.com/role/LongTermDebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails Long-Term Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) Details 55 false false R56.htm 9954501 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://www.organon.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 56 false false R57.htm 9954502 - Disclosure - Long-Term Debt - Schedule of Maturities on Long-term Debt (Details) Sheet http://www.organon.com/role/LongTermDebtScheduleofMaturitiesonLongtermDebtDetails Long-Term Debt - Schedule of Maturities on Long-term Debt (Details) Details 57 false false R58.htm 9954503 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossTables 58 false false R59.htm 9954504 - Disclosure - Samsung Collaboration - Narrative (Details) Sheet http://www.organon.com/role/SamsungCollaborationNarrativeDetails Samsung Collaboration - Narrative (Details) Details 59 false false R60.htm 9954505 - Disclosure - Samsung Collaboration - Summary of Information Related to Collaboration (Details) Sheet http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails Samsung Collaboration - Summary of Information Related to Collaboration (Details) Details 60 false false R61.htm 9954506 - Disclosure - Third-Party Arrangements - Accounts Receivables (Details) Sheet http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails Third-Party Arrangements - Accounts Receivables (Details) Details 61 false false R62.htm 9954507 - Disclosure - Third-Party Arrangements - Sales and Cost of Sales Resulting from the Manufacturing and Supply Agreements (Details) Sheet http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails Third-Party Arrangements - Sales and Cost of Sales Resulting from the Manufacturing and Supply Agreements (Details) Details 62 false false R63.htm 9954508 - Disclosure - Contingencies (Details) Sheet http://www.organon.com/role/ContingenciesDetails Contingencies (Details) Details http://www.organon.com/role/Contingencies 63 false false All Reports Book All Reports ogn-20230930.htm ogn-20230930.xsd ogn-20230930_cal.xml ogn-20230930_def.xml ogn-20230930_lab.xml ogn-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ogn-20230930.htm": { "nsprefix": "ogn", "nsuri": "http://www.organon.com/20230930", "dts": { "inline": { "local": [ "ogn-20230930.htm" ] }, "schema": { "local": [ "ogn-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "ogn-20230930_cal.xml" ] }, "definitionLink": { "local": [ "ogn-20230930_def.xml" ] }, "labelLink": { "local": [ "ogn-20230930_lab.xml" ] }, "presentationLink": { "local": [ "ogn-20230930_pre.xml" ] } }, "keyStandard": 230, "keyCustom": 29, "axisStandard": 21, "axisCustom": 0, "memberStandard": 30, "memberCustom": 60, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 564, "entityCount": 1, "segmentCount": 90, "elementCount": 548, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1035, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.organon.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "longName": "0000002 - Statement - Condensed Consolidated Statements of Income", "shortName": "Condensed Consolidated Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R3": { "role": "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R4": { "role": "http://www.organon.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.organon.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-33", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-33", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical", "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.organon.com/role/BackgroundandNatureofOperations", "longName": "0000009 - Disclosure - Background and Nature of Operations", "shortName": "Background and Nature of Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.organon.com/role/BasisofPresentation", "longName": "0000010 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.organon.com/role/AcquisitionsandLicensingArrangements", "longName": "0000011 - Disclosure - Acquisitions and Licensing Arrangements", "shortName": "Acquisitions and Licensing Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.organon.com/role/EarningsperShareEPS", "longName": "0000012 - Disclosure - Earnings per Share (\"EPS\")", "shortName": "Earnings per Share (\"EPS\")", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.organon.com/role/ProductandGeographicInformation", "longName": "0000013 - Disclosure - Product and Geographic Information", "shortName": "Product and Geographic Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.organon.com/role/StockBasedCompensationPlans", "longName": "0000014 - Disclosure - Stock-Based Compensation Plans", "shortName": "Stock-Based Compensation Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.organon.com/role/Restructuring", "longName": "0000015 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.organon.com/role/TaxesonIncome", "longName": "0000016 - Disclosure - Taxes on Income", "shortName": "Taxes on Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.organon.com/role/Inventories", "longName": "0000017 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.organon.com/role/FinancialInstruments", "longName": "0000018 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.organon.com/role/LongTermDebt", "longName": "0000019 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ogn:DebtDisclosureAndLesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ogn:DebtDisclosureAndLesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLoss", "longName": "0000020 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "shortName": "Accumulated Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.organon.com/role/SamsungCollaboration", "longName": "0000021 - Disclosure - Samsung Collaboration", "shortName": "Samsung Collaboration", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.organon.com/role/ThirdPartyArrangements", "longName": "0000022 - Disclosure - Third-Party Arrangements", "shortName": "Third-Party Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.organon.com/role/Contingencies", "longName": "0000023 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.organon.com/role/BasisofPresentationPolicies", "longName": "9954471 - Disclosure - Basis of Presentation (Policies)", "shortName": "Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.organon.com/role/EarningsperShareEPSTables", "longName": "9954472 - Disclosure - Earnings per Share (\"EPS\") (Tables)", "shortName": "Earnings per Share (\"EPS\") (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.organon.com/role/ProductandGeographicInformationTables", "longName": "9954473 - Disclosure - Product and Geographic Information (Tables)", "shortName": "Product and Geographic Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.organon.com/role/StockBasedCompensationPlansTables", "longName": "9954474 - Disclosure - Stock-Based Compensation Plans (Tables)", "shortName": "Stock-Based Compensation Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.organon.com/role/InventoriesTables", "longName": "9954475 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.organon.com/role/FinancialInstrumentsTables", "longName": "9954476 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.organon.com/role/LongTermDebtTables", "longName": "9954477 - Disclosure - Long-Term Debt (Tables)", "shortName": "Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.organon.com/role/SamsungCollaborationTables", "longName": "9954479 - Disclosure - Samsung Collaboration (Tables)", "shortName": "Samsung Collaboration (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.organon.com/role/ThirdPartyArrangementsTables", "longName": "9954480 - Disclosure - Third-Party Arrangements (Tables)", "shortName": "Third-Party Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.organon.com/role/BackgroundandNatureofOperationsDetails", "longName": "9954481 - Disclosure - Background and Nature of Operations (Details)", "shortName": "Background and Nature of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-6", "name": "ogn:NumberOfMedicinesAndProducts", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "ogn:NumberOfMedicinesAndProducts", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails", "longName": "9954482 - Disclosure - Acquisitions and Licensing Arrangements (Details)", "shortName": "Acquisitions and Licensing Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-52", "name": "ogn:CollaborativeArrangementRightsAndObligationsUpfrontPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "ogn:CollaborativeArrangementRightsAndObligationsUpfrontPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.organon.com/role/EarningsperShareEPSDetails", "longName": "9954483 - Disclosure - Earnings per Share (\"EPS\") (Details)", "shortName": "Earnings per Share (\"EPS\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R39": { "role": "http://www.organon.com/role/ProductandGeographicInformationNarrativeDetails", "longName": "9954484 - Disclosure - Product and Geographic Information - Narrative (Details)", "shortName": "Product and Geographic Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails", "longName": "9954485 - Disclosure - Product and Geographic Information - Sales of Company's Products (Details)", "shortName": "Product and Geographic Information - Sales of Company's Products (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-60", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R41": { "role": "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails", "longName": "9954486 - Disclosure - Product and Geographic Information - Revenues by Geographic Area (Details)", "shortName": "Product and Geographic Information - Revenues by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-438", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R42": { "role": "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails", "longName": "9954487 - Disclosure - Stock-Based Compensation Plans - Narrative (Details)", "shortName": "Stock-Based Compensation Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails", "longName": "9954488 - Disclosure - Stock-Based Compensation Plans - Stock-based Compensation Expenses (Details)", "shortName": "Stock-Based Compensation Plans - Stock-based Compensation Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.organon.com/role/StockBasedCompensationPlansStockOptionValuationAssumptionsDetails", "longName": "9954489 - Disclosure - Stock-Based Compensation Plans - Stock Option Valuation Assumptions (Details)", "shortName": "Stock-Based Compensation Plans - Stock Option Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails", "longName": "9954490 - Disclosure - Stock-Based Compensation Plans - Equity Award Transactions (Details)", "shortName": "Stock-Based Compensation Plans - Equity Award Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails", "longName": "9954491 - Disclosure - Stock-Based Compensation Plans - Equity Awards Outstanding (Details)", "shortName": "Stock-Based Compensation Plans - Equity Awards Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.organon.com/role/RestructuringDetails", "longName": "9954492 - Disclosure - Restructuring (Details)", "shortName": "Restructuring (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "unitRef": "position", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "unitRef": "position", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.organon.com/role/TaxesonIncomeDetails", "longName": "9954493 - Disclosure - Taxes on Income (Details)", "shortName": "Taxes on Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.organon.com/role/InventoriesDetails", "longName": "9954494 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "longName": "9954495 - Disclosure - Financial Instruments - Narrative (Details)", "shortName": "Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails", "longName": "9954496 - Disclosure - Financial Instruments - Schedule of Financial Instruments Recorded at Estimated Fair Value (Details)", "shortName": "Financial Instruments - Schedule of Financial Instruments Recorded at Estimated Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-481", "name": "us-gaap:FairValueHedgeAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-481", "name": "us-gaap:FairValueHedgeAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails", "longName": "9954497 - Disclosure - Financial Instruments - Schedule of Long-term Debt Instruments (Details)", "shortName": "Financial Instruments - Schedule of Long-term Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "ogn:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ogn:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.organon.com/role/FinancialInstrumentsScheduleofGainLossonDerivativeInstrumentsDetails", "longName": "9954498 - Disclosure - Financial Instruments - Schedule of (Gain) Loss on Derivative Instruments (Details)", "shortName": "Financial Instruments - Schedule of (Gain) Loss on Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-490", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R54": { "role": "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails", "longName": "9954499 - Disclosure - Long-Term Debt - Summary of Long-term Debt Instruments (Details)", "shortName": "Long-Term Debt - Summary of Long-term Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.organon.com/role/LongTermDebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails", "longName": "9954500 - Disclosure - Long-Term Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details)", "shortName": "Long-Term Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.organon.com/role/LongTermDebtNarrativeDetails", "longName": "9954501 - Disclosure - Long-Term Debt - Narrative (Details)", "shortName": "Long-Term Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "ogn:DebtInstrumentInterestPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ogn:DebtInstrumentInterestPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.organon.com/role/LongTermDebtScheduleofMaturitiesonLongtermDebtDetails", "longName": "9954502 - Disclosure - Long-Term Debt - Schedule of Maturities on Long-term Debt (Details)", "shortName": "Long-Term Debt - Schedule of Maturities on Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954503 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-25", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R59": { "role": "http://www.organon.com/role/SamsungCollaborationNarrativeDetails", "longName": "9954504 - Disclosure - Samsung Collaboration - Narrative (Details)", "shortName": "Samsung Collaboration - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-537", "name": "ogn:CollaborationArrangementProfitSharingArrangementPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-537", "name": "ogn:CollaborationArrangementProfitSharingArrangementPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails", "longName": "9954505 - Disclosure - Samsung Collaboration - Summary of Information Related to Collaboration (Details)", "shortName": "Samsung Collaboration - Summary of Information Related to Collaboration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-539", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R61": { "role": "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails", "longName": "9954506 - Disclosure - Third-Party Arrangements - Accounts Receivables (Details)", "shortName": "Third-Party Arrangements - Accounts Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-543", "name": "ogn:SeparationAndDistributionAgreementProvisionOfServicesExtensionPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R62": { "role": "http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails", "longName": "9954507 - Disclosure - Third-Party Arrangements - Sales and Cost of Sales Resulting from the Manufacturing and Supply Agreements (Details)", "shortName": "Third-Party Arrangements - Sales and Cost of Sales Resulting from the Manufacturing and Supply Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-546", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "unique": true } }, "R63": { "role": "http://www.organon.com/role/ContingenciesDetails", "longName": "9954508 - Disclosure - Contingencies (Details)", "shortName": "Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LitigationReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LitigationReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "ogn-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails", "http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Sales", "netLabel": "Sales", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r152", "r159", "r199", "r200", "r204", "r208", "r209", "r215", "r217", "r219", "r223", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r369", "r417", "r707" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r335", "r336", "r420" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Income Before Income Taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r89", "r114", "r198", "r205", "r210", "r213", "r417", "r427", "r560" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.organon.com/role/LongTermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r79" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r134", "r228", "r413", "r562", "r581", "r697", "r698" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r283", "r291", "r321", "r322", "r323", "r397", "r398", "r439", "r460", "r461", "r521", "r523", "r525", "r526", "r534", "r548", "r549", "r561", "r568", "r579", "r583", "r586", "r699", "r709", "r733", "r734", "r735", "r736", "r737" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other (discounts and debt issuance costs)", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r70", "r266", "r278", "r564", "r565" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 255,606 in 2023 and 254,370 in 2022", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r79", "r422", "r581" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r291", "r398", "r439", "r460", "r461", "r521", "r523", "r525", "r526", "r534", "r548", "r549", "r561", "r568", "r579", "r583", "r709", "r732", "r733", "r734", "r735", "r736", "r737" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "presentation": [ "http://www.organon.com/role/LongTermDebtScheduleofMaturitiesonLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r163", "r710" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r79", "r470" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r283", "r291", "r321", "r322", "r323", "r397", "r398", "r439", "r460", "r461", "r521", "r523", "r525", "r526", "r534", "r548", "r549", "r561", "r568", "r579", "r583", "r586", "r699", "r709", "r733", "r734", "r735", "r736", "r737" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r79", "r470", "r488", "r743", "r744" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r291", "r398", "r439", "r460", "r461", "r521", "r523", "r525", "r526", "r534", "r548", "r549", "r561", "r568", "r579", "r583", "r709", "r732", "r733", "r734", "r735", "r736", "r737" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r107", "r125", "r346", "r347", "r687" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseMember", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income) Expense", "label": "Other Operating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other operating income (expense)." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r164", "r165", "r166", "r193", "r399", "r446", "r455", "r462", "r463", "r464", "r465", "r466", "r467", "r470", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r483", "r484", "r485", "r486", "r487", "r489", "r492", "r493", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r515", "r587" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r40", "r133", "r552" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails", "http://www.organon.com/role/LongTermDebtNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r28" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "verboseLabel": "Less: Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r136" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Background and Nature of Operations", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r118", "r127" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.organon.com/role/LongTermDebtScheduleofMaturitiesonLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r163", "r271" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r306" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r684" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested/Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r307" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.organon.com/role/LongTermDebtScheduleofMaturitiesonLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r163", "r271" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": [ "http://www.organon.com/role/LongTermDebtScheduleofMaturitiesonLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r163", "r271" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.organon.com/role/EarningsperShareEPS" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share (\"EPS\")", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r178", "r189", "r190", "r191" ] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationReserve", "crdr": "credit", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of legal defense reserves", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r30", "r702" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://www.organon.com/role/LongTermDebtScheduleofMaturitiesonLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r163", "r271" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation plans and other (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r14", "r78", "r79", "r105" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r636" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails", "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails", "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "PSU's", "terseLabel": "Performance Share Units", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r637" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Consolidated Revenues by Geographic Area", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r18" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r663" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r635" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r637" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r644" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r635" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.organon.com/role/CondensedConsolidatedBalanceSheets", "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders' Deficit", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r79", "r81", "r82", "r100", "r472", "r488", "r516", "r517", "r581", "r593", "r686", "r696", "r722", "r743" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r664" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r62", "r63", "r64", "r65", "r459", "r461", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r483", "r484", "r485", "r486", "r502", "r503", "r504", "r505", "r508", "r509", "r510", "r511", "r528", "r529", "r532", "r533", "r557", "r584", "r586" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r638" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CN", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "China", "label": "CHINA" } } }, "auth_ref": [] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r635" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r664" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.organon.com/role/Contingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r102", "r243", "r244", "r537", "r701" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r640" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r639" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies (Note 15)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r30", "r74", "r421", "r469" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "ogn_CostsExpensesAndOther", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r93" ] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableOtherPayablesMember", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable, Other Payables", "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r643" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "presentation": [ "http://www.organon.com/role/SamsungCollaborationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Information Related to Collaboration", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r716" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r665" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r641" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r636" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r642" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r664" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r642" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r232", "r233", "r234", "r235", "r239", "r240", "r241" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r666" ] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of positions", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r665" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r636" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards That are Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Sales of Company's Products", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r94" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock dividends declared (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r105" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r637" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.organon.com/role/BasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Accounting", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r636" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails", "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $9 in 2023 and $9 in 2022)", "verboseLabel": "Receivables from Samsung included in Other current assets", "netLabel": "Due from Merck in Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r220", "r221" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails", "http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r290", "r389", "r390", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r463", "r464", "r465", "r466", "r467", "r487", "r489", "r520", "r729" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r667" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails", "http://www.organon.com/role/LongTermDebtNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Equity Awards Outstanding", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r16", "r17", "r57" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Vested and Expected to Vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Weighted Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r319" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r245", "r246", "r247", "r250", "r703", "r704" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net income", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r61", "r91", "r98", "r169", "r170", "r171", "r172", "r185", "r188" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Flows Used in Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r157" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r636" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r636" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Flows Used in Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r157" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Awards (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r318" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r644" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Flows Provided by Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r96", "r97", "r98" ] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "crdr": "credit", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivables factored", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r319" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r637" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r318" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r644" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r637" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r637" ] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of pending claims", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r703", "r704" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Weighted Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Awards (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r319" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CA", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CANADA", "label": "CANADA" } } }, "auth_ref": [] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r609", "r617", "r627", "r644", "r652", "r656", "r664" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r637" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r644" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r609", "r617", "r627", "r644", "r652", "r656", "r664" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r597" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.organon.com/role/TaxesonIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Income", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r160", "r334", "r339", "r340", "r341", "r344", "r348", "r351", "r352", "r450" ] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTextBlock", "presentation": [ "http://www.organon.com/role/AcquisitionsandLicensingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions and Licensing Arrangements", "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r715" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r98" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r418", "r426", "r581" ] }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Shares Outstanding:", "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Governmental fine", "label": "Loss Contingency, Damages Sought, Value", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r702", "r703", "r704" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r630" ] }, "us-gaap_FairValueHedgeAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgeAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward contracts in Other current assets", "label": "Fair Value Hedge Assets", "documentation": "Fair value of all derivative assets designated as fair value hedging instruments." } } }, "auth_ref": [ "r63" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r177", "r292", "r670", "r671", "r692" ] }, "us-gaap_FairValueHedgeLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgeLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward contracts in Accrued and other current liabilities", "label": "Fair Value Hedge Liabilities", "documentation": "Fair value of all derivative liabilities designated as fair value hedging instruments." } } }, "auth_ref": [ "r63" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Int\u2019l", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r745", "r746", "r747", "r748" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r41" ] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Headcount reductions, percent", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent", "documentation": "Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r37", "r447" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r669" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r131", "r142", "r159", "r223", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r353", "r355", "r369", "r581", "r707", "r708", "r730" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from revolving credit facility", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquired in-process research and development and milestones", "label": "Payments to Acquire in Process Research and Development", "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination." } } }, "auth_ref": [ "r36" ] }, "ogn_ClarinexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ClarinexMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clarinex", "label": "Clarinex [Member]", "documentation": "Clarinex" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "ogn_CostsExpensesAndOther", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails", "http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "verboseLabel": "Cost of sales", "netLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r92", "r399" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of product rights and asset acquisition, net of cash acquired", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r95" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ogn_ProscarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ProscarMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proscar", "label": "Proscar [Member]", "documentation": "Proscar" } } }, "auth_ref": [] }, "ogn_NexplanonImplanonNXTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NexplanonImplanonNXTMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nexplanon/Implanon NXT", "label": "Nexplanon/Implanon NXT [Member]", "documentation": "Nexplanon/Implanon NXT" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "terseLabel": "Other comprehensive loss, net of taxes", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r14", "r21", "r144", "r147", "r153", "r375", "r376", "r381", "r414", "r429", "r680", "r681" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share:", "verboseLabel": "EPS:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "ogn_LossContingencyPendingClaimsNumberOfPendingPutativeClassActions": { "xbrltype": "integerItemType", "nsuri": "http://www.organon.com/20230930", "localname": "LossContingencyPendingClaimsNumberOfPendingPutativeClassActions", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of pending putative class actions", "label": "Loss Contingency, Pending Claims, Number of Pending Putative Class Actions", "documentation": "Loss Contingency, Pending Claims, Number of Pending Putative Class Actions" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of unrecognized compensation costs period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r328" ] }, "ogn_CollaborationArrangementProfitSharingArrangementPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.organon.com/20230930", "localname": "CollaborationArrangementProfitSharingArrangementPercentage", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross profit sharing arrangement percentage", "label": "Collaboration Arrangement, Profit Sharing Arrangement, Percentage", "documentation": "Collaboration Arrangement, Profit Sharing Arrangement, Percentage" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r268", "r284", "r285", "r286", "r287", "r288", "r289", "r368", "r394", "r395", "r396", "r564", "r565", "r576", "r577", "r578" ] }, "ogn_JadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "JadaMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jada", "label": "Jada [Member]", "documentation": "Jada" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ogn_OtherOperatingAndNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherOperatingAndNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "ogn_CostsExpensesAndOther", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense, net", "label": "Other Operating and Nonoperating Income (Expense)", "documentation": "Other Operating and Nonoperating Income (Expense)" } } }, "auth_ref": [] }, "ogn_EuroInterbankOfferedRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "EuroInterbankOfferedRateMember", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro Interbank Offered Rate", "label": "Euro Interbank Offered Rate [Member]", "documentation": "Euro Interbank Offered Rate" } } }, "auth_ref": [] }, "ogn_ImplanonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ImplanonMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Implanon", "label": "Implanon [Member]", "documentation": "Implanon" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r41" ] }, "ogn_OtherRespiratoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherRespiratoryMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Respiratory", "label": "Other Respiratory [Member]", "documentation": "Other Respiratory" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Information [Line Items]", "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.organon.com/role/LongTermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities on Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r11" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ogn_InventoryNetAndInventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "InventoryNetAndInventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.organon.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Inventory", "label": "Inventory Net And Inventory Noncurrent", "documentation": "Inventory Net And Inventory Noncurrent" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares excluded from the calculation of EPS (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r189" ] }, "ogn_OntruzantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OntruzantMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ontruzant", "label": "Ontruzant [Member]", "documentation": "Ontruzant" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "calculation": { "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r6", "r148", "r153", "r337", "r349", "r350", "r375", "r379", "r381", "r414", "r429" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r595" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r132", "r159", "r223", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r354", "r355", "r356", "r369", "r581", "r707", "r730", "r731" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.organon.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r675" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r95" ] }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalEntityTypeOfCounterpartyDomain", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity Type of Counterparty [Domain]", "label": "Legal Entity Type of Counterparty [Domain]", "documentation": "Nature of the other party participating in a financial transaction." } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r657" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r659" ] }, "ogn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award performance period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period" } } }, "auth_ref": [] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.organon.com/role/InventoriesDetails": { "parentTag": "ogn_InventoryNetAndInventoryNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total (approximates current cost)", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r679" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r662" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity of Counterparty, Type [Axis]", "label": "Legal Entity of Counterparty, Type [Axis]", "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction." } } }, "auth_ref": [ "r32" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r41" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r656" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r330", "r331", "r332", "r454", "r689", "r690", "r691", "r721", "r743" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested/Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r78", "r79", "r105", "r307" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r261" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Information [Table]", "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarlyRepaymentOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarlyRepaymentOfSeniorDebt", "crdr": "credit", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Early repayment of senior debt", "label": "Early Repayment of Senior Debt", "documentation": "The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity." } } }, "auth_ref": [ "r39" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r663" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r141", "r581" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Remaining Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r319" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r658" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Employee withholding taxes related to stock-based awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r156" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r595" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.organon.com/role/ThirdPartyArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r663" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash dividends declared on common stock", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r105" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r660" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Remaining Term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r318" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails", "http://www.organon.com/role/LongTermDebtNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r28", "r163", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r384", "r563", "r564", "r565", "r566", "r567", "r685" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r632" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r320" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r661" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r662" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.organon.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails", "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "verboseLabel": "Payables to Samsung included in Trade accounts payable", "netLabel": "Due to Merck in Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24", "r581" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "ogn_CostsExpensesAndOther", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r70", "r116", "r151", "r201", "r383", "r499", "r592", "r741" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r695" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r594" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "ogn_EuroDenominatedTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "EuroDenominatedTermLoansMember", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro Denominated Term Loan", "label": "Euro Denominated Term Loans [Member]", "documentation": "Euro Denominated Term Loans" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r662" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.organon.com/role/SamsungCollaboration" ], "lang": { "en-us": { "role": { "terseLabel": "Samsung Collaboration", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r119", "r121", "r128" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.organon.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r674" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.organon.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r338" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r598", "r668" ] }, "us-gaap_LIFOInventoryAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LIFOInventoryAmount", "crdr": "debit", "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories valued under the last in, first out (\"LIFO\") method", "label": "LIFO Inventory Amount", "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods." } } }, "auth_ref": [ "r554" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r164", "r165", "r166", "r193", "r399", "r446", "r455", "r462", "r463", "r464", "r465", "r466", "r467", "r470", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r483", "r484", "r485", "r486", "r487", "r489", "r492", "r493", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r515", "r587" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r663" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r596" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r25", "r159", "r223", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r354", "r355", "r356", "r369", "r468", "r559", "r593", "r707", "r730", "r731" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails", "http://www.organon.com/role/ContingenciesDetails", "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "verboseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r163", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r384", "r563", "r564", "r565", "r566", "r567", "r685" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r595" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails", "http://www.organon.com/role/LongTermDebtNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r22", "r76", "r77", "r110", "r112", "r163", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r384", "r563", "r564", "r565", "r566", "r567", "r685" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r663" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited/Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r315" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r310", "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r313" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r595" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r313" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails", "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails", "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r155", "r169", "r170", "r171", "r172", "r173", "r181", "r186", "r187", "r188", "r192", "r365", "r366", "r416", "r431", "r558" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r310", "r311" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails", "http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r290", "r389", "r390", "r463", "r464", "r465", "r466", "r467", "r487", "r489", "r520" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r232", "r233", "r234", "r235", "r239", "r240", "r241" ] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails", "http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Affiliated Entity [Member]" } } }, "auth_ref": [ "r489", "r547", "r587", "r712", "r727", "r728", "r729" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of unrecognized compensation costs", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r328" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r9", "r47" ] }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average interest rate of debt", "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time." } } }, "auth_ref": [] }, "us-gaap_InventoryLIFOReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLIFOReserve", "crdr": "credit", "calculation": { "http://www.organon.com/role/InventoriesDetails": { "parentTag": "ogn_InventoryNetAndInventoryNoncurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease to LIFO costs", "label": "Inventory, LIFO Reserve", "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods." } } }, "auth_ref": [ "r678" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r595" ] }, "ogn_LossContingencyClaimsOnAppealNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.organon.com/20230930", "localname": "LossContingencyClaimsOnAppealNumber", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of claims on appeal", "label": "Loss Contingency, Claims on Appeal, Number", "documentation": "Loss Contingency, Claims on Appeal, Number" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r459", "r461", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r483", "r484", "r485", "r486", "r502", "r503", "r504", "r505", "r508", "r509", "r510", "r511", "r528", "r529", "r532", "r533", "r584", "r586" ] }, "ogn_DuleraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "DuleraMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dulera", "label": "Dulera [Member]", "documentation": "Dulera" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r720" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested/Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested/Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r314" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r595" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited/Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r713" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r77", "r111" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited/Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r713" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r325", "r333" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.organon.com/role/LongTermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r28", "r51", "r52", "r68", "r69", "r71", "r75", "r103", "r104", "r564", "r566", "r688" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash flows provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefits", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of (Gain) Loss on Derivative Instruments", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r62", "r64", "r357" ] }, "ogn_HadlimaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "HadlimaMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hadlima", "label": "Hadlima [Member]", "documentation": "Hadlima" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets", "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories (excludes inventories of $95 in 2023 and $148 in 2022 classified in Other assets)", "verboseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r140", "r553", "r581" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofGainLossonDerivativeInstrumentsDetails", "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r229", "r234", "r498" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofGainLossonDerivativeInstrumentsDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r357" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofGainLossonDerivativeInstrumentsDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r15", "r62", "r64", "r65", "r66", "r67", "r357" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTable", "presentation": [ "http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Table]", "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r715" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofGainLossonDerivativeInstrumentsDetails", "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r234", "r498" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetAbstract", "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized as:", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r80", "r105", "r424", "r443", "r445", "r449", "r471", "r581" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r715" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.organon.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r676" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r382", "r393" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r715" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-based Compensation Expenses", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r316" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r302", "r303" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r302", "r303" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r33", "r34", "r88", "r138", "r423", "r444", "r445" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenueAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Costs, Expenses and Other", "label": "Cost of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation Plans", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r293", "r298", "r326", "r327", "r329", "r580" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested/Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited/Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Revenue from External Customers by Products and Services [Table]", "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r322" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r177", "r292", "r670", "r692" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories classified in other assets", "verboseLabel": "Other assets", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r673" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r321" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r595" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails", "http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r72", "r73", "r494", "r495", "r498" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.organon.com/role/ThirdPartyArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Third-Party Arrangements", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r386", "r387", "r388", "r390", "r392", "r451", "r452", "r453", "r496", "r497", "r498", "r518", "r519" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r323" ] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Line Items]", "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r715" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate Changes on Cash and Cash Equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r374" ] }, "us-gaap_OtherInventorySupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInventorySupplies", "crdr": "debit", "calculation": { "http://www.organon.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplies", "label": "Other Inventory, Supplies, Gross", "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r677" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails", "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails", "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r101", "r400" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Decrease in Cash and Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r96" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails", "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails", "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r294", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails", "http://www.organon.com/role/ThirdPartyArrangementsSalesandCostofSalesResultingfromtheManufacturingandSupplyAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r494", "r495", "r498" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails", "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails", "http://www.organon.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r294", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and Cash Equivalents, Beginning of Period", "periodEndLabel": "Cash and Cash Equivalents, End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r40", "r96", "r158" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains on derivatives", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r719" ] }, "ogn_FemurFractureLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "FemurFractureLitigationMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Femur Fracture Litigation", "label": "Femur Fracture Litigation [Member]", "documentation": "Femur Fracture Litigation" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r51", "r52", "r68", "r69", "r71", "r75", "r103", "r104", "r163", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r384", "r563", "r564", "r565", "r566", "r567", "r685" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.organon.com/role/LongTermDebtScheduleofMaturitiesonLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r163", "r271" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 }, "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "terseLabel": "Total Long-term debt, net of current portion", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r137" ] }, "ogn_NetFinancingTransfers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NetFinancingTransfers", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net transfers to Merck & Co., Inc.", "label": "Net Financing Transfers", "documentation": "Net Financing Transfers" } } }, "auth_ref": [] }, "ogn_DebtInstrumentInterestPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "DebtInstrumentInterestPayments", "crdr": "debit", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument interest payments", "label": "Debt Instrument, Interest Payments", "documentation": "Debt Instrument, Interest Payments" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r22", "r112", "r277" ] }, "ogn_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments", "crdr": "credit", "presentation": [ "http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial milestone payments", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments", "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r689", "r690", "r721", "r740", "r743" ] }, "ogn_OtherCardiovascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherCardiovascularMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Cardiovascular", "label": "Other Cardiovascular [Member]", "documentation": "Other Cardiovascular" } } }, "auth_ref": [] }, "country_ES": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "ES", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spain", "label": "SPAIN" } } }, "auth_ref": [] }, "ogn_NumberOfMedicinesAndProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NumberOfMedicinesAndProducts", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of medicines and products", "label": "Number Of Medicines And Products", "documentation": "Number Of Medicines And Products" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r282", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r382", "r393" ] }, "ogn_NasonexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NasonexMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nasonex", "label": "Nasonex [Member]", "documentation": "Nasonex" } } }, "auth_ref": [] }, "ogn_NorthernDistrictOfOhioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NorthernDistrictOfOhioMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Northern District of Ohio", "label": "Northern District of Ohio [Member]", "documentation": "Northern District of Ohio" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividend payments", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r38" ] }, "ogn_GanirelixAcetateInjectionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "GanirelixAcetateInjectionMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ganirelix Acetate Injection", "label": "Ganirelix Acetate Injection [Member]", "documentation": "Ganirelix Acetate Injection" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r282", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "ogn_AybintioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "AybintioMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aybintio", "label": "Aybintio [Member]", "documentation": "Aybintio" } } }, "auth_ref": [] }, "ogn_CollaborationAgreementPotentialContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "CollaborationAgreementPotentialContractualObligation", "crdr": "credit", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential future regulatory milestone payments", "label": "Collaboration Agreement, Potential Contractual Obligation", "documentation": "Collaboration Agreement, Potential Contractual Obligation" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Instruments Recorded at Estimated Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r367", "r368" ] }, "ogn_LossContingencyUnfiledClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.organon.com/20230930", "localname": "LossContingencyUnfiledClaimsNumber", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of unfiled claims", "label": "Loss Contingency, Unfiled Claims, Number", "documentation": "Loss Contingency, Unfiled Claims, Number" } } }, "auth_ref": [] }, "ogn_NuvaRingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NuvaRingMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NuvaRing", "label": "NuvaRing [Member]", "documentation": "NuvaRing" } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r598", "r668" ] }, "ogn_FederalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "FederalMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Federal [Member]", "documentation": "Federal" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on income", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r117", "r126", "r175", "r176", "r202", "r337", "r345", "r432" ] }, "ogn_PropeciaProscarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "PropeciaProscarMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Propecia/ Proscar", "label": "Propecia/ Proscar [Member]", "documentation": "Propecia/ Proscar" } } }, "auth_ref": [] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r717", "r718" ] }, "ogn_EuroDenominatedTermLoanBFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "EuroDenominatedTermLoanBFacilityMember", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan B Facility", "label": "Euro Denominated Term Loan B Facility [Member]", "documentation": "Euro Denominated Term Loan B Facility" } } }, "auth_ref": [] }, "ogn_AtozetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "AtozetMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Atozet", "label": "Atozet [Member]", "documentation": "Atozet" } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total principal long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r22", "r112", "r267", "r279", "r564", "r565", "r738" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ogn_LatinAmericaMiddleEastRussiaAndAfricaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "LatinAmericaMiddleEastRussiaAndAfricaMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Latin America, Middle East, Russia, and Africa", "label": "Latin America, Middle East, Russia and Africa [Member]", "documentation": "Latin America, Middle East, Russia and Africa" } } }, "auth_ref": [] }, "ogn_A2875SeniorSecuredNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "A2875SeniorSecuredNotesDue2028Member", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.875% Senior Secured Notes Due 2028", "label": "2.875% Senior Secured Notes Due 2028 [Member]", "documentation": "2.875% Senior Secured Notes Due 2028" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r49" ] }, "ogn_SamsungBioepisCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "SamsungBioepisCoLtdMember", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Samsung Bioepis", "label": "Samsung Bioepis Co., Ltd. [Member]", "documentation": "Samsung Bioepis Co., Ltd." } } }, "auth_ref": [] }, "ogn_VytorinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "VytorinMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vytorin", "label": "Vytorin [Member]", "documentation": "Vytorin" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face amount of debt", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r69", "r71", "r260", "r384", "r564", "r565" ] }, "ogn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock, Remaining Term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.organon.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r23", "r84", "r85", "r86" ] }, "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryNoncurrentTableTextBlock", "presentation": [ "http://www.organon.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Noncurrent", "label": "Schedule of Inventory, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs." } } }, "auth_ref": [] }, "ogn_OncologyBiosimilarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OncologyBiosimilarMember", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oncology Biosimilar", "label": "Oncology Biosimilar [Member]", "documentation": "Oncology Biosimilar" } } }, "auth_ref": [] }, "ogn_CozaarHyzaarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "CozaarHyzaarMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cozaar/Hyzaar", "label": "Cozaar/Hyzaar [Member]", "documentation": "Cozaar/Hyzaar" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation plans and other", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r59", "r60", "r295" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss, pretax", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r108" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Forfeited/Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r315" ] }, "ogn_FosamaxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "FosamaxMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fosamax", "label": "Fosamax [Member]", "documentation": "Fosamax" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "ogn_CostsExpensesAndOther", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/FinancialInstrumentsScheduleofGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exchange losses (gains)", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r370", "r371", "r372", "r373", "r512" ] }, "ogn_LossContingencyPendingClaimsNumberOfPendingClassActions": { "xbrltype": "integerItemType", "nsuri": "http://www.organon.com/20230930", "localname": "LossContingencyPendingClaimsNumberOfPendingClassActions", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of pending class actions", "label": "Loss Contingency, Pending Claims, Number of Pending Class Actions", "documentation": "Loss Contingency, Pending Claims, Number of Pending Class Actions" } } }, "auth_ref": [] }, "ogn_SecuredOvernightFinancingRateSOFRSixMonthInterestPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "SecuredOvernightFinancingRateSOFRSixMonthInterestPeriodMember", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Six Month Interest Period", "label": "Secured Overnight Financing Rate (SOFR) Six Month Interest Period [Member]", "documentation": "Secured Overnight Financing Rate (SOFR) Six Month Interest Period" } } }, "auth_ref": [] }, "ogn_CollaborativeArrangementRightsAndObligationsUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment", "crdr": "credit", "presentation": [ "http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payments", "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment", "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment" } } }, "auth_ref": [] }, "ogn_OtherSundryEstablishedBrandsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherSundryEstablishedBrandsMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Established Brands [Member]", "documentation": "Other Sundry Established Brands" } } }, "auth_ref": [] }, "ogn_NumberOfCountriesProductSoldIn": { "xbrltype": "integerItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NumberOfCountriesProductSoldIn", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of countries product sold in", "label": "Number Of Countries Product Sold In", "documentation": "Number Of Countries Product Sold In" } } }, "auth_ref": [] }, "ogn_ConsiderationPaidInConnectionWithTheSeparation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ConsiderationPaidInConnectionWithTheSeparation", "crdr": "debit", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net transfers to Merck & Co., Inc. including Separation Adjustments", "label": "Consideration Paid in Connection With the Separation", "documentation": "Consideration Paid in Connection With the Separation" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r245", "r246", "r247", "r250", "r703", "r704" ] }, "ogn_DebtDisclosureAndLesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.organon.com/20230930", "localname": "DebtDisclosureAndLesseeOperatingLeasesTextBlock", "presentation": [ "http://www.organon.com/role/LongTermDebt" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt", "label": "Debt Disclosure and Lessee, Operating Leases [Text Block]", "documentation": "Debt Disclosure and Lessee, Operating Leases" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r268", "r284", "r285", "r286", "r287", "r288", "r289", "r394", "r395", "r396", "r564", "r565", "r576", "r577", "r578" ] }, "us-gaap_LossContingencyClaimsDismissedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyClaimsDismissedNumber", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of claims dismissed", "label": "Loss Contingency, Claims Dismissed, Number", "documentation": "Number of claims dismissed." } } }, "auth_ref": [ "r703", "r704" ] }, "ogn_SingulairMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "SingulairMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Singulair", "label": "Singulair [Member]", "documentation": "Singulair" } } }, "auth_ref": [] }, "ogn_NexplanonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NexplanonMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nexplanon", "label": "Nexplanon [Member]", "documentation": "Nexplanon" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.organon.com/role/BasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ogn_AsiaPacificAndJapanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "AsiaPacificAndJapanMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific and Japan", "label": "Asia Pacific and Japan [Member]", "documentation": "Asia Pacific and Japan" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r245", "r246", "r247", "r250", "r703", "r704" ] }, "ogn_OtherSundryProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherSundryProductsMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Products [Member]", "documentation": "Other Sundry Products" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Organon & Co. Stockholders' Deficit:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "ogn_FollistimAQMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "FollistimAQMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Follistim AQ", "label": "Follistim AQ [Member]", "documentation": "Follistim AQ" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r245", "r246", "r247", "r250", "r703", "r704" ] }, "ogn_OrganonFinance1LLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OrganonFinance1LLCMember", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organon Finance 1 LLC", "label": "Organon Finance 1 LLC [Member]", "documentation": "Organon Finance 1 LLC" } } }, "auth_ref": [] }, "ogn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "ogn_OtherStateCourtsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherStateCourtsMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other State Courts", "label": "Other State Courts [Member]", "documentation": "Other State Courts" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income, Net of Taxes:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "ogn_ArcoxiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ArcoxiaMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arcoxia", "label": "Arcoxia [Member]", "documentation": "Arcoxia" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive loss, net of taxes", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r108", "r144", "r147" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.organon.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r227" ] }, "ogn_A4125SeniorSecuredNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "A4125SeniorSecuredNotesDue2028Member", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.125% Senior Secured Notes Due 2028", "label": "4.125% Senior Secured Notes Due 2028 [Member]", "documentation": "4.125% Senior Secured Notes Due 2028" } } }, "auth_ref": [] }, "ogn_RenflexisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "RenflexisMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renflexis", "label": "Renflexis [Member]", "documentation": "Renflexis" } } }, "auth_ref": [] }, "ogn_ClariaMedicalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ClariaMedicalIncMember", "presentation": [ "http://www.organon.com/role/AcquisitionsandLicensingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Claria Medical, Inc.", "label": "Claria Medical, Inc. [Member]", "documentation": "Claria Medical, Inc." } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r598", "r668" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r155", "r169", "r170", "r171", "r172", "r173", "r179", "r181", "r186", "r187", "r188", "r192", "r365", "r366", "r416", "r431", "r558" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r108" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.organon.com/role/EarningsperShareEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock awards and equity units (share equivalent) (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r182", "r183", "r184", "r188", "r297" ] }, "ogn_RosuzetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "RosuzetMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rosuzet", "label": "Rosuzet [Member]", "documentation": "Rosuzet" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefit plan net loss and prior service cost, net of amortization", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r5", "r12", "r88", "r108" ] }, "ogn_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherCountriesMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Countries [Member]", "documentation": "Other Countries" } } }, "auth_ref": [] }, "ogn_PropeciaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "PropeciaMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Propecia", "label": "Propecia [Member]", "documentation": "Propecia" } } }, "auth_ref": [] }, "ogn_ImmunologyBiosimilarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ImmunologyBiosimilarMember", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Immunology Biosimilar", "label": "Immunology Biosimilar [Member]", "documentation": "Immunology Biosimilar" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Equity Award Transactions", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.organon.com/role/EarningsperShareEPSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Earnings Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r693" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r607", "r618", "r628", "r653" ] }, "ogn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Vested and Expected to Vest", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest [Abstract]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r655" ] }, "ogn_NewJerseyStateCourtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NewJerseyStateCourtMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Jersey State Court", "label": "New Jersey State Court [Member]", "documentation": "New Jersey State Court" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Class of Treasury Stock [Line Items]", "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r655" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r129", "r164", "r165", "r166", "r168", "r174", "r176", "r224", "r225", "r330", "r331", "r332", "r342", "r343", "r358", "r360", "r361", "r363", "r364", "r440", "r442", "r454", "r743" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r79" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r607", "r618", "r628", "r653" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefit Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r13", "r34", "r680", "r681", "r682" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r87", "r153", "r414", "r429" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders' Deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r83", "r113", "r425", "r581", "r686", "r696", "r722" ] }, "ogn_ZetiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ZetiaMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zetia", "label": "Zetia [Member]", "documentation": "Zetia" } } }, "auth_ref": [] }, "ogn_DebtInstrumentAverageMaturity": { "xbrltype": "durationItemType", "nsuri": "http://www.organon.com/20230930", "localname": "DebtInstrumentAverageMaturity", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average maturity of long-term debt", "label": "Debt Instrument, Average Maturity", "documentation": "Debt Instrument, Average Maturity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r139", "r222", "r226" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Translation Adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3", "r13", "r34", "r149", "r150", "r377", "r378", "r379", "r380", "r381", "r680" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r476", "r480", "r485", "r504", "r510", "r530", "r531", "r532", "r586" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r129", "r148", "r149", "r150", "r164", "r165", "r166", "r168", "r174", "r176", "r193", "r224", "r225", "r281", "r330", "r331", "r332", "r342", "r343", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r375", "r377", "r378", "r379", "r380", "r381", "r385", "r440", "r441", "r442", "r454", "r515" ] }, "ogn_NumberOfManufacturingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NumberOfManufacturingFacilities", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of manufacturing facilities", "label": "Number of Manufacturing Facilities", "documentation": "Number of Manufacturing Facilities" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r13", "r34", "r359", "r362", "r385", "r440", "r441", "r680", "r681", "r682", "r689", "r690", "r691" ] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Plans", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r694" ] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Treasury Stock [Table]", "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r53", "r54", "r55", "r56" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r306" ] }, "ogn_EuropeAndCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "EuropeAndCanadaMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe and Canada", "label": "Europe and Canada [Member]", "documentation": "Europe and Canada" } } }, "auth_ref": [] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r608", "r619", "r629", "r654" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardTransactionsDetails", "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r41" ] }, "ogn_DiprospanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "DiprospanMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diprospan", "label": "Diprospan [Member]", "documentation": "Diprospan" } } }, "auth_ref": [] }, "ogn_UsSecuredOvernightFinancingRateSOFRThreeMonthInterestPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "UsSecuredOvernightFinancingRateSOFRThreeMonthInterestPeriodMember", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "us-Secured Overnight Financing Rate (SOFR) Three Month Interest Period", "label": "us-Secured Overnight Financing Rate (SOFR) Three Month Interest Period [Member]", "documentation": "us-Secured Overnight Financing Rate (SOFR) Three Month Interest Period" } } }, "auth_ref": [] }, "ogn_CollaborationArrangementAgreementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.organon.com/20230930", "localname": "CollaborationArrangementAgreementPeriod", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement period", "label": "Collaboration Arrangement Agreement Period", "documentation": "Collaboration Arrangement Agreement Period" } } }, "auth_ref": [] }, "ogn_SeparationAndDistributionAgreementProvisionOfServicesExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.organon.com/20230930", "localname": "SeparationAndDistributionAgreementProvisionOfServicesExtensionPeriod", "presentation": [ "http://www.organon.com/role/ThirdPartyArrangementsAccountsReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision of services extension period", "label": "Separation And Distribution Agreement, Provision Of Services Extension Period", "documentation": "Separation And Distribution Agreement, Provision Of Services Extension Period" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.organon.com/role/EarningsperShareEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r180", "r188" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r35", "r145", "r147", "r154", "r415", "r430" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "ogn_CostsExpensesAndOther", "weight": 1.0, "order": 6.0 }, "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Acquired in-process research and development and milestones", "terseLabel": "Acquired in-process research and development and milestones", "label": "Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired", "documentation": "The fair value of capitalized costs of a research and development nature that were acquired during the period in a transaction other than a business combination." } } }, "auth_ref": [ "r46" ] }, "ogn_SecuredOvernightFinancingRateSOFROneMonthInterestPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "SecuredOvernightFinancingRateSOFROneMonthInterestPeriodMember", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) One Month Interest Period", "label": "Secured Overnight Financing Rate (SOFR) One Month Interest Period [Member]", "documentation": "Secured Overnight Financing Rate (SOFR) One Month Interest Period" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ogn_A5125SeniorUnsecuredNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "A5125SeniorUnsecuredNotesDue2031Member", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.125% Senior Unsecured Notes Due 2031", "label": "5.125% Senior Unsecured Notes Due 2031 [Member]", "documentation": "5.125% Senior Unsecured Notes Due 2031" } } }, "auth_ref": [] }, "ogn_NumberOfBiosimilarProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NumberOfBiosimilarProducts", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of biosimilar products", "label": "Number Of Biosimilar Products", "documentation": "Number Of Biosimilar Products" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails", "http://www.organon.com/role/ContingenciesDetails", "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails", "http://www.organon.com/role/SamsungCollaborationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r217", "r218", "r456", "r457", "r458", "r522", "r524", "r527", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r551", "r570", "r586", "r711", "r739" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r106" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r632" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r655" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.organon.com/role/EarningsperShareEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/EarningsperShareEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted average number of shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r179", "r188" ] }, "ogn_EuroDenominatedSeniorSecuredTrancheBTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "EuroDenominatedSeniorSecuredTrancheBTermLoanMember", "presentation": [ "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro Denominated Term Loan B", "label": "Euro Denominated Senior Secured Tranche B Term Loan [Member]", "documentation": "Euro Denominated Senior Secured Tranche B Term Loan" } } }, "auth_ref": [] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r632" ] }, "ogn_OtherWomensHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherWomensHealthMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Women's Health", "label": "Other Womens Health [Member]", "documentation": "Other Womens Health" } } }, "auth_ref": [] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r655" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r635" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r634" ] }, "ogn_CostsExpensesAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "CostsExpensesAndOther", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total, costs expenses and other", "label": "Costs Expenses And Other", "documentation": "Costs Expenses And Other" } } }, "auth_ref": [] }, "ogn_BrenzysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "BrenzysMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brenzys", "label": "Brenzys [Member]", "documentation": "Brenzys" } } }, "auth_ref": [] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r655" ] }, "country_BR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "BR", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brazil", "label": "BRAZIL" } } }, "auth_ref": [] }, "ogn_CaliforniaStateCourtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "CaliforniaStateCourtMember", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California State Court", "label": "California State Court [Member]", "documentation": "California State Court" } } }, "auth_ref": [] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r633" ] }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts." } } }, "auth_ref": [ "r63" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r39", "r448" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r655" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for restructuring", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r233", "r683" ] }, "ogn_MarvelonMercilonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "MarvelonMercilonMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marvelon/Mercilon", "label": "Marvelon/Mercilon [Member]", "documentation": "Marvelon/Mercilon" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofFinancialInstrumentsRecordedatEstimatedFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r268", "r284", "r289", "r368", "r395", "r564", "r565", "r576", "r577", "r578" ] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.organon.com/role/Restructuring" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r230", "r231", "r233", "r236", "r242" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of assets", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r9", "r48" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r633" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "ogn_CostsExpensesAndOther", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9", "r237", "r239", "r700" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "ogn_CostsExpensesAndOther", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r714" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r109", "r135", "r159", "r198", "r206", "r211", "r223", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r353", "r355", "r369", "r419", "r482", "r581", "r593", "r707", "r708", "r730" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r655" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r634" ] }, "ogn_NetTransfersInConnectionWithSeparation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "NetTransfersInConnectionWithSeparation", "crdr": "credit", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Net transfers from Merck & Co., Inc., including Separation Adjustments", "label": "Net Transfers in Connection with Separation", "documentation": "Net Transfers in Connection with Separation" } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails", "http://www.organon.com/role/ContingenciesDetails", "http://www.organon.com/role/ProductandGeographicInformationRevenuesbyGeographicAreaDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails", "http://www.organon.com/role/SamsungCollaborationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r217", "r218", "r456", "r457", "r458", "r522", "r524", "r527", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r551", "r570", "r586", "r711", "r739" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring activities", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r233", "r238" ] }, "ogn_OtherNonOpiodPainBoneAndDermatologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "OtherNonOpiodPainBoneAndDermatologyMember", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Non-Opiod Pain, Bone and Dermatology", "label": "Other Non-Opiod Pain, Bone and Dermatology [Member]", "documentation": "Other Non-Opiod Pain, Bone and Dermatology" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.organon.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.organon.com/role/LongTermDebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "ogn_TermLoanBFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.organon.com/20230930", "localname": "TermLoanBFacilityMember", "presentation": [ "http://www.organon.com/role/LongTermDebtNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan B Facility", "label": "Term Loan B Facility [Member]", "documentation": "Term Loan B Facility" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r656" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.organon.com/role/RestructuringDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r292", "r692" ] }, "ogn_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://www.organon.com/20230930", "localname": "DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Gain Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "documentation": "DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized foreign exchange loss (gain)", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r98", "r490", "r592", "r723", "r724", "r742" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r606", "r617", "r627", "r652" ] }, "ogn_AccruedAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.organon.com/20230930", "localname": "AccruedAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Accrued and Other Liabilities, Current", "documentation": "Accrued and Other Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r606", "r617", "r627", "r652" ] }, "ogn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.organon.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansEquityAwardsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock, Awards (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r600", "r611", "r621", "r646" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r631" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails", "http://www.organon.com/role/ContingenciesDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r215", "r399", "r433", "r434", "r435", "r436", "r437", "r438", "r550", "r569", "r582", "r672", "r705", "r706", "r711", "r739" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.organon.com/role/StockBasedCompensationPlansStockbasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r599", "r610", "r620", "r645" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.organon.com/role/FinancialInstrumentsNarrativeDetails", "http://www.organon.com/role/FinancialInstrumentsScheduleofLongtermDebtInstrumentsDetails", "http://www.organon.com/role/LongTermDebtNarrativeDetails", "http://www.organon.com/role/LongTermDebtSummaryofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r50" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r31", "r129", "r148", "r149", "r150", "r164", "r165", "r166", "r168", "r174", "r176", "r193", "r224", "r225", "r281", "r330", "r331", "r332", "r342", "r343", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r375", "r377", "r378", "r379", "r380", "r381", "r385", "r440", "r441", "r442", "r454", "r515" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.organon.com/role/BackgroundandNatureofOperationsDetails", "http://www.organon.com/role/ContingenciesDetails", "http://www.organon.com/role/ProductandGeographicInformationSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r215", "r399", "r433", "r434", "r435", "r436", "r437", "r438", "r550", "r569", "r582", "r672", "r705", "r706", "r711", "r739" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r601", "r612", "r622", "r647" ] }, "us-gaap_BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccounting", "presentation": [ "http://www.organon.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting [Text Block]", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r99" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r599", "r610", "r620", "r645" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.organon.com/role/BasisofPresentationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r42", "r43", "r44", "r120", "r122", "r123", "r124" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r161", "r162", "r263", "r280", "r391", "r555", "r557" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r605", "r616", "r626", "r651" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r602", "r613", "r623", "r648" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r8" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.organon.com/role/SamsungCollaborationNarrativeDetails", "http://www.organon.com/role/SamsungCollaborationSummaryofInformationRelatedtoCollaborationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r161", "r162", "r263", "r280", "r391", "r556", "r557" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r602", "r613", "r623", "r648" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r603", "r614", "r624", "r649" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.organon.com/role/CondensedConsolidatedStatementsofIncome", "http://www.organon.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit", "http://www.organon.com/role/EarningsperShareEPSDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income", "terseLabel": "Net income", "verboseLabel": "Net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r90", "r98", "r115", "r130", "r143", "r146", "r150", "r159", "r167", "r169", "r170", "r171", "r172", "r175", "r176", "r185", "r198", "r205", "r210", "r213", "r223", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r366", "r369", "r428", "r491", "r513", "r514", "r560", "r592", "r707" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r604", "r615", "r625", "r650" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.organon.com/role/ProductandGeographicInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Geographic Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r203", "r207", "r211", "r212", "r213", "r214", "r215", "r216", "r219" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r606", "r617", "r627", "r652" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r606", "r617", "r627", "r644", "r652" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.organon.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r34", "r725", "r726" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.organon.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net changes in assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r606", "r617", "r627", "r652" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r606", "r617", "r627", "r652" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.organon.com/role/ContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r382", "r393" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r670": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r671": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 81 0001821825-23-000013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001821825-23-000013-xbrl.zip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Ð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end